

An ISO 9001:2015 Certified Hospital



MOI TEACHING AND REFERRAL HOSPITAL P.O. BOX 3-30100 ELDORET

TENDER NO. MTRH/T/94/2023-2024

TENDER FOR SUPPLY AND DELIVERY OF HUMAN DRUGS (PHARMACEUTICALS)

(FRAMEWORK CONTRACT)

CLOSING DATE: 11TH APRIL, 2024

AT: 10.00 AM

TABLE OF CONTENTS

| OPEN NATIONAL TENDER NOTICE | 4 |
|---|-----|
| INVITATION TO TENDER | 4 |
| Date: 26 th March, 2024 | 5 |
| SECTION I - INSTRUCTIONS TO TENDERERS | 1 |
| SECTION II - TENDER DATA SHEET (TDS) | 17 |
| The contact person in the Procuring Entity able to provide additional information about registration is | 19 |
| PHARMACEUTICALS | 22 |
| SECTION III - EVALUATION AND QUALIFICATION CRITERIA | 23 |
| FORM OF TENDER | 32 |
| (Amended and issued pursuant to PPRA CIRCULAR No. 02/2022) | 32 |
| TENDERER'S ELIGIBILITY- CONFIDENTIAL BUSINESS QUESTIONNAIRE | 35 |
| CERTIFICATE OF INDEPENDENT TENDER DETERMINATION | 38 |
| SELF- DECLARATION FORMS | 39 |
| FORM SD1 | 39 |
| FORM SD2 | 40 |
| SELF DECLARATION THAT THE PERSON/TENDERER WILL NOT ENGAGE IN ANY CORRUPT OR FRAUDULENT PRACTICE | 40 |
| DECLARATION AND COMMITMENT TO THE CODE OF ETHICS | 41 |
| APPENDIX 1- FRAUD AND CORRUPTION | 42 |
| TENDERER INFORMATION FORM | 44 |
| FORM ELI - 1.1 (continued) Tenderer Information Form | 47 |
| TENDERER'S JV MEMBERS INFORMATION FORM | 49 |
| FORM FIN – 3.1 | 50 |
| 3. FINANCIAL DOCUMENTS | 51 |
| FORM FIN - 3.2 | 52 |
| FORM - EXP - 1 - EXPERIENCE | 53 |
| TENDER - SECURING DECLARATION FORM | 129 |
| MANUFACTURER'S AUTHORIZATION | 130 |
| SPECIMEN CERTIFICATE OFA PHARMACEUTICAL PRODUCT | 131 |
| SECTION VII - SCHEDULE OF REQUIREMENTS CONTENTS | 135 |
| 1. LIST OF GOODS AND DELIVERY SCHEDULE | 137 |
| 1. TECHNICALSPECIFICATIONS | 68 |
| SAMPLE TECHNICAL SPECIFICATIONS PHARMACEUTICALS | 69 |
| SAMPLE TECHNICAL SPECIFICATION VACCINES | 71 |
| 3. INSPECTIONS ANDTESTS | 76 |
| APPENDIX TO GENERAL CONDITIONS | 90 |
| Special Conditions of Contract PHARMACEUTICALS | 96 |
| Special Conditions of Contract | 96 |

| CONDOMS | 9′ | 7 |
|---|-----|---|
| Amended and issued pursuant to PPRA CIRCULAR No. 02/2022) | 10′ | 7 |

OPEN NATIONAL TENDER NOTICE

INVITATION TO TENDER

1. PROCURING ENTITY: MOI TEACHING AND REFERRAL HOSPITAL OF P.O. BOX 3-30100 ELDORET CONTRACT NAME AND DESCRIPTION: MTRH/T/94/2023-2024 TENDER FOR SUPPLY AND DELIVERY OF HUMAN DRUGS (PHARMACEUTICALS)

The **Moi Teaching and Referral Hospital** invites sealed tenders for Supply and Delivery of Human drugs (Pharmaceuticals) under framework contract for a period of three years (3).

- 2. Tendering will be conducted under open competitive method (National) using a standardized tender document. Tendering is open to all qualified and interested Tenderers.
- 3. Qualified and interested tenderers may obtain further information and inspect the Tender Document during office hours from 8.30 a.m to 4.30 p.m at Supply Chain Department.
- 4. A complete set of tender documents may be obtained by interested tenderers by electronically from www.mtrh.go.ke or www.tenders.go.ke under tender portals. Tender documents obtained electronically will be free of charge.
- 5. Tenderers who download the tender document must forward their particulars immediately to supplies@mtrh.go.ke to facilitate any further clarification or addendum.
- 6. Tenders shall be quoted in Kenya Shillings and shall include all applicable taxes. Tenders shall remain valid for 120 days from the date of opening of the tenders.
- 7. All Tenders must be accompanied by a Tender Security of **Kshs. 100,000/-** in form of Bankers cheque, Bank or insurance guarantee issued by company registered and licensed by the Insurance Regulatory Authority listed and listed by the Public Procurement Regulatory Authority valid for **150** days after the date of tender opening.
- 8. Completed tenders must be delivered to the address below on or before 11th April, 2024 at 10.00 a.m. Electronic Tenders *will not* be permitted.
- 9. Tenders will be opened immediately after the deadline date and time specified above or any deadline date and time specified later. Tenders will be publicly opened in the presence of the Tenderers' designated representatives who choose to attend at the address below.
- 10. Tenderers shall chronologically serialize all pages of the tender documents submitted
- 11. Late tenders will be rejected.
- 12. The addresses referred to above are:

A Address for obtaining further information and for purchasing tender documents

- i. Name of Procuring Entity: Moi Teaching and Referral Hospital,
- ii. Physical address for hand Courier Delivery to an office or Tender Box

Eldoret, Nandi Road, Moi Teaching and Referral Hospital,

Supply Chain Department.

iii. Postal Address: P. O. Box 3-30100, ELDORET,

ELDORET.

iv. Insert name, telephone number and e-mail address of the officer to be contacted

Ag.Manager, Supply Chain.

Email: msc@mtrh.go.ke Telephone number 0532033473 or 0722209795 extension 3318.

B. Address for Submission of Tenders.

- 1. Name of Procuring Entity: Moi Teaching and Referral Hospital
- 2. Postal Address (include Designation of Officer to be intentioned):

The Ag. Chief Executive Officer

P. O. Box 3-30100, ELDORET

Tender Box "A" is located at Ground Floor, left wing of Chandaria Cancer and Chronic diseases

Centre (CCCDC) Building.

3. Physical address for hand Courier Delivery to another office or Tender Box A (City, Street Name, Building, Floor Number and Room) – *There is no alternative delivery office or tender box*.

NOTE: Bulky tenders shall be received at Supply Chain Department.

C. Address for Opening of Tenders.

1. Name of Procuring Entity

Moi Teaching and Referral Hospital

P.O. BOX 3-30100,

ELDORET.

2. Physical address for the location (City, Street Name, Building, Floor Number and Room):

Eldoret, Nandi Road Moi Teaching and Referral Hospital is situated along Nandi Road in Eldoret.


Tenderers shall converge at 2nd Floor, left wing of old administration block.

Venue for opening shall be advised by the Tender Opening Committee

Ag. MANAGER, SUPPLY CHAIN

FOR: Ag. CHIEF EXECUTIVE OFFICER

Date: 26th March, 2024



SECTION I - INSTRUCTIONS TO TENDERERS

A General

1. Scope of Tender

1.1 In connection with this Invitation to Tenderer (ITT), the Procuring Entity issues this tendering document for the supply of Health Goods (pharmaceuticals, vaccines, and condoms and Related Services incidental thereto as specified in Section V, Schedule of Requirements. The name, identification and number of items or lots (contracts) of this ITT are specified in the TDS.

2 Definitions

Throughout this tendering document:

- a) The term "in writing" means communicated in written form (e.g. by mail, e-mail, fax, including if specified **in the TDS**, distributed or received through the electronic-procurement system used by the Procuring Entity) with proof of receipt;
- b) if the context so requires, "singular" means "plural" and vice versa; and "Day" mean scale day, unless otherwise specified as "Business Day." A Business Day is any day that is an official working day of the Procuring Entity. It excludes the Procuring Entity's official public holidays.

3. Fraud and Corruption

- 3.1 The Procuring Entity requires compliance with the provisions of the Public Procurement and Asset Disposal Act, 2015, Section 62 "Declaration not to engage in corruption". The tender submitted by a person shall include a declaration that the person shall not engage in any corrupt or fraudulent practice and a declaration that the person or his or her sub-contractors are not debarred from participating in public procurement proceedings.
- 3.2 The Procuring Entity requires compliance with the provisions of the Competition Act 2010, regarding collusive practices in contracting. Any tenderer found to have engaged in collusive conduct shall be disqualified and criminal and/or civil sanctions may be imposed to this effect, Tenders shall be required to complete and sign the "Certificate of Independent Tender Determination" annexed to the Form of Tender.
- 3.3 Unfair Competitive Advantage-Fairness and transparency in the tender process require that the firms or their Affiliates competing for a specific assignment do not derive a competitive advantage from having provided consulting services related to the assignment in question. To that end, the Procuring Entity shall indicate in the **Data Sheet** and make available to all the firms together with this tender document all information that would in that respect give such firm any unfair competitive advantage over competing firms.
- 3.4 Tenderers shall permit and shall cause their agents (where declared or not), subcontractors, sub-consultants, service providers, suppliers, and their personnel, to permit the Procuring Entity to inspect all accounts, records and other documents relating to any initial selection process, prequalification process, tender submission, proposal submission, and contract performance (in the case of award), and to have them audited by auditors appointed by the Procuring Entity.

4. Eligible Tenderers

- 4.1 A Tenderer may be a firm that is a private entity, a state-owned enterprise or institution subject to ITT4.6 or any combination of such entities in the form of a joint venture (JV) under an existing agreement or with the intent to enter in to such an agreement supported by a Form of intent. In the case of a joint venture, all members shall be jointly and severally liable for the execution of the entire Contract in accordance with the Contract terms. The JV shall nominate a Representative who shall have the authority to conduct all business for and on behalf of any and all the members of the JV during the Tendering process and, in the event the JV is awarded the Contract, during contract execution. Members of a joint venture may not also make an individual tender, be a subcontractor in a separate tender or be part of another joint venture for the purposes of the same Tender. The maximum number of JV members shall be specified in the **TDS**.
- 4.2 Public Officers of the Procuring Entity, their spouse, child, parent, brother, sister, child, parent or sister of a spouse their business associates or agents and firms/organizations in which they have a substantial or controlling interest shall not be eligible to tender or be awarded a contract. Public Officers are also not allowed to participate in any procurement proceedings.

- 4.3 A Tenderer shall not have a conflict of interest. Any Tenderer found to have a conflict of interest shall be disqualified. A Tenderer may be considered to have a conflict of interest for the purpose of this Tendering process, if the Tenderer:
 - a Directly or indirectly controls, is controlled by or is under common control with another Tenderer; or
 - b Receives or has received any direct or indirect subsidy from another Tenderer; or
 - c has the same legal representative as another Tenderer; or
 - d has a relationship with another Tenderer, directly or through common third parties, that puts it in a position to influence the Tender of another Tenderer, or influence the decisions of the Procuring Entity regarding this Tendering process; or
 - e or any of its affiliates participated as a consultant in the preparation of the design or technical specifications of the goods that are the subject of the Tender; or
 - f or any of its affiliates has been hired (or is proposed to be hired) by the Procuring Entity or Procuring Entity for the Contract implementation; or
 - g would be providing goods, works, or non-consulting services resulting from or directly related to consulting services for the preparation or implementation of the project specified in the TDS ITT 2.1 that it provided or were provided by any affiliate that directly or indirectly controls, is controlled by, or is under common control with that firm; or
 - h has a close business or family relationship with a professional staff of the Procuring Entity who: (i) are directly or indirectly involved in the preparation of the tendering document or specifications of the Contract, and/or the Tender evaluation process of such Contract; or (ii) would be involved in the implementation or supervision of such contract unless the conflict stemming from such relationship has been resolved in a manner acceptable to the Procuring Entity throughout the Tendering process and execution of the Contract.

A firm that is a Tenderer (either individually or as a JV member) shall not participate in more than one Tender, except for permitted alternative Tenders. This includes participation as a subcontractor. Such participation shall result in the disqualification of all Tenders in which the firm is involved. A firm that is not a Tenderer or a JV member may participate as a subcontractor in more than one Tender.

- 4.4 A Tenderer may have the nationality of any country, subject to the restrictions pursuant to ITT4.9. A Tenderer shall be deemed to have the nationality of a country if the Tenderer is constituted, incorporated or registered in and operates in conformity with the provisions of the laws of that country, as evidenced by its articles of incorporation (or equivalent documents of constitution or association) and its registration documents, as the case may be. This criterion also shall apply to the determination of the nationality of proposed subcontractors or sub-consultants for any part of the Contract including related Services.
- 4.5 A tenderer that has been debarred from participating in public procurement shall be in eligible to be prequalified for, initially selected for, tender for, propose for, or be awarded a contract during such period of time as the PPRA shall have determined. The list of debarred firms and individuals is available at **PPRA's** website info@ppra.go.ke or complaints@ppra.go.ke.
- 4.6 Tenderers that are state-owned enterprises or institutions in Kenya may be eligible to compete and be awarded a Contract(s) only if they can establish, in a manner acceptable to the Procuring Entity, that they (i) are legally and financially autonomous (ii) operate under commercial law, and (iii) are not under supervision of the Procuring Entity.
- 4.7 A tenderer shall not be under suspension from tendering by the Procuring Entity as the result of the operation of a Tender–Securing Declaration or Proposal-Securing Declaration.
- 4.8 Firms and individuals may be ineligible if (a) as a matter of law or official regulations, Kenya prohibits commercial relations with that country, or (b) by an act of compliance with a decision of the United Nations Security Council taken under Chapter VII of the Charter of the United Nations, Kenya prohibits any import of goods or contracting of works or services from that country, or any payments to any country, person, or entity in that country.
- 4.9 Foreign tenderers are required to source at least forty (40%) percent of their contract inputs (in supplies, subcontracts and labor) from national suppliers and contractors. To this end, a foreign tenderer shall provide in its tender documentary evidence that this requirement is met. Foreign tenderers not meeting this criterion will be automatically disqualified. Information required to enable the Procuring Entity determine if this

condition is met shall be provided in for this purpose is be provided in "SECTION III - EVALUATION AND QUALIFICATION CRITERIA, item 9".

- 4.10 Pursuant to the eligibility requirements of ITT 4.10, a tender is considered a foreign tenderer, if the tenderer is not registered in Kenya or if the tenderer is registered in Kenya and has <u>less than 51 percent</u> ownership by Kenyan citizens. JVs are considered as foreign tenderers if the individual member firms are not registered in Kenya or if are registered in Kenya and have less than 51 percent ownership by Kenyan citizens. The JV shall not subcontract to foreign firms more than 10 percent of the contract price, excluding provisional sums.
- 4.11 The Competition Act of Kenya requires that firms wishing to tender as Joint Venture undertakings which may prevent, distort or lessen competition in provision of services are prohibited unless they are exempt in accordance with the provisions of Section 25 of the Competition Act, 2010. JVs will be required to seek for exemption from the Competition Authority. Exemption shall not be a condition for tender, but it shall be a condition of contract award and signature. A JV tenderer shall be given opportunity to seek such exemption as a condition of award and signature of contract. Application for exemption from the Competition Authority of Kenya may be accessed from the website www.cak.go.ke.
- 4.12 A Kenyan tenderer shall provide evidence of having fulfilled his/her tax obligations by producing a valid tax compliance clearance certificate or tax exemption certificate issued by the Kenya Revenue Authority.

5. Eligible Goods and Related Services

- 5.1 All the Goods and Related Services to be supplied under the Contract may have their origin in any eligible country.
- 5.2 For purposes of this ITT, the term "goods" includes any goods that are the subject of this Invitation to Tender, and "Related Services" includes services such as transportation, insurance, commissioning and training.
- 5.3 The term "origin" means the country where the goods have been mined, grown, cultivated, produced, manufactured or processed; or, through manufacture, processing, or assembly, another commercially recognized article results that differs substantially in its basic characteristics from its components.
- 5.4 Any goods, works and production processes with characteristic that have been declared by the relevant national environmental protection agency or by other competent authority as harmful to human beings and to the environment shall not be eligible for procurement.

B. Contents of Tendering Document

6. Sections of Tendering Document

6.1 The tendering document consists of Parts1,2, and 3, which includes all the sections indicated below, and should be read in conjunction with any Addenda issued in accordance with ITT 8.

PART 1 - Tendering Procedures

Section I - Instructions to Tenderers (ITT)

Section II - Tendering Data Sheet (TDS)

Section III - Evaluation and Qualification Criteria

Section IV - Tendering Forms

PART 2 - Supply Requirements

Section V - Schedule of Requirements

PART 3 - Contract

Section VI - General Conditions of Contract

Section VII - Special Conditions of Contract

Section VIII - Contract Forms

6.2 The Specific Procurement Notice-Invitation to Tender (ITT) notice issued by the Procuring Entity is not part of this tendering document.

- 6.3 Unless obtained directly from the Procuring Entity, the Procuring Entity is not responsible for the completeness of the document, responses to requests for clarification, or Addenda to the tendering document in accordance with ITT10. In case of any contradiction, documents obtained directly from the Procuring Entity shall prevail.
- 6.4 The Tenderer is expected to examine all instructions, forms, terms, and specifications in the tendering document and to furnish with its Tender all information or documentation as is required by the tendering document.

7. Clarification of Tendering Document

7.1 A Tenderer requiring any clarification of the tendering document shall contact the Procuring Entity in writing at the Procuring Entity's address specified **in the TDS**. The Procuring Entity will respond in writing to any Invitation to clarification, provided that such request is received prior to the deadline for submission of Tenders within a period specified **in the TDS**. The Procuring Entity shall forward copies of its response to all Tenderers who have acquired the tendering document in accordance with ITT 6.3, including a description of the inquiry but without identifying its source. If so specified **in the TDS**, the Procuring Entity shall also promptly publish its response at the web page identified **in the TDS**. Should the clarification result in changes to the essential elements of the tendering document, the Procuring Entity shall amend the tendering document following the procedure under ITT 8 and ITT 22.2.

8. Amendment of Tendering Document

- 8.1 At any time prior to the deadline for submission of Tenders, the Procuring Entity may amend the tendering document by issuing addenda.
- 8.2 Any addendum issued shall be part of the tendering document and shall be communicated in writing to all who have obtained the tendering document from the Procuring Entity in accordance with ITT 6.3. The Procuring Entity shall also promptly publish the addendum on the Procuring Entity's web page in accordance with ITT 7.1.
- 8.3 To give prospective Tenderers reasonable time in which to take an addendum into account in preparing their Tenders, the Procuring Entity may, at its discretion, extend the deadline for the submission of Tenders, pursuant to ITT 22.2.

C. Preparation of Tenders

9. Cost of Tendering

9.1 The Tenderer shall bear all costs associated with the preparation and submission of its Tender, and the Procuring Entity shall not be responsible or liable for those costs, regardless s of the conduct or outcome of the Tendering process.

10. Language of Tender

10.1The Tender, as well as all correspondence and documents relating to the Tender exchanged by the Tenderer and the Procuring Entity, shall be written in the English Language. Supporting documents and printed literature that are part of the Tender may be in another language provided they are accompanied by an accurate translation of the relevant passages into the English Language, in which case, for purposes of interpretation of the Tender, such translation shall govern.

11. Documents Comprising the Tender

- 11.1 The Tender shall comprise the following:
- a) Form of Tender prepared in accordance with ITT 12;
- b) Price Schedules: completed in accordance with ITT 12 and ITT 14;
- c) **Tender Security** or **Tender-Securing Declaration**, in accordance with ITT 19.1;
- d) Alternative Tender, if permissible, in accordance with ITT 13;
- e) **Authorization**: written confirmation authorizing the signatory of the Tender to commit the Tenderer, in accordance with ITT20.3;
- f) **Tenderer's Qualifications**: documentary evidence in accordance with ITT 17 establishing the Tenderer's qualifications to perform the Contract if its Tender is accepted;

- g) **Tenderer's Eligibility**: documentary evidence in accordance with ITT 17 establishing the Tenderer's eligibility to Tender;
- h) **Eligibility of Goods and Related Services**: documentary evidence in accordance with ITT 16, establishing the eligibility of the Goods and Related Services to be supplied by the Tenderer;
- i) **Conformity**: documentary evidence in accordance with ITT 16, that the Goods and Related Services conform to the tendering document; and
- j) Any other document required in the TDS.
- 11.2In addition to the requirements under ITT 11.1, Tenders submitted by a JV shall include a copy of the Joint Venture Agreement entered into by all members. Alternatively, a Form of intent to execute a Joint Venture Agreement in the event of a successful Tender shall be signed by all members and submitted with the tender, together with a copy of the proposed Agreement. The Tenderer shall chronologically serialize pages of all tender documents submitted.
- 11.3The Tenderer shall furnish in the Form of Tender information on commissions and gratuities, if any, paid or to be paid to agents or any other party relating to this Tender.

12. Form of Tender and Price Schedules

12.1The Form of Tender and Price Schedules shall be prepared using the relevant forms furnished in Section IV, Tendering Forms. The forms must be completed without any alterations to the text, and no substitutes shall be accepted except as provided under ITT 20.3. All blank spaces shall be filled in with the information requested.

13 Alternative Tenders

13.1 Unless otherwise specified in the TDS, alternative Tenders shall not be considered.

14 Tender Prices and Discounts

- 14.1The prices and discounts quoted by the Tenderer in the Form of Tender and in the Price Schedules shall conform to the requirements specified below.
- 14.2All lots (contracts) and items must be listed and priced separately in the Price Schedules.
- 14.3The price to be quoted in the Form of Tender in accordance with ITT 11.1 shall be the total price of the Tender, including any discounts offered.
- 14.4The Tenderer shall quote any discounts and indicate the methodology for their application in the Form of Tender, in accordance with ITT 14.1.
- 14.5Prices quoted by the Tenderer shall be fixed during the Tenderer's performance of the Contract and not subject to variation on any account, unless otherwise specified in the TDS. A Tender submitted with an adjustable price quotation shall be treated as non-responsive and shall be rejected, pursuant to ITT 29. However, if in accordance with the TDS, prices quoted by the Tenderer shall be subject to adjustment during the performance of the Contract, a Tender submitted with a fixed price quotation shall not be rejected, but the price adjustment shall be treated as zero.
- 14.6If so specified in ITT 1.1, Tenders are being invited for individual lots(contracts) or any combination of lots (packages). Unless otherwise specified in the TDS, prices quoted shall correspond to 100 % of the items specified for each lot and to 100% of the quantities specified for each item of a lot. Tenderers wishing to offer discounts for the award of more than one Contract shall specify in their Tender the price reductions applicable to each package, or alternatively, to individual Contracts within the package. Discounts shall be submitted in accordance with ITT 14.4 provided the Tenders for all lots (contracts) are opened at the same time.
- 14.7The terms EXW, CIP, and other similar terms shall be governed by the rules prescribed in the current edition of Incoterms, published by The International Chamber of Commerce, as specified in the TDS.
- 14.8Prices shall be quoted as specified in each Price Schedule included in Section IV, Tendering Forms. The dis-aggregation of price components is required solely for the purpose of facilitating the comparison of Tenders by the Procuring Entity. This shall not in any way limit the Procuring Entity's right to contract on any of the terms offered. In quoting prices, the Tenderer shall be free to use transportation through carriers registered in any eligible country, in accordance with Section V, Eligible Countries. Similarly,

the Tenderer may obtain insurance services from any eligible country in accordance with Section V, Eligible Countries. Prices shall be entered in the following manner:

- a) For Goods manufactured in Kenya:
 - i) the price of the Goods quoted EXW (ex-works, ex-factory, ex warehouse, ex showroom, or offthe- shelf, as applicable), including all customs duties and sales and other taxes already paid or payable on the components and raw material used in the manufacture or assembly of the Goods;
 - ii) any Kenya sales tax and other taxes which will be payable on the Goods if the Contract is awarded to the Tenderer; and
 - iii) the price for inland transportation, insurance, and other local services required to convey the Goods to their final destination (Project Site) **specified in the TDS**;
- b) for Goods manufactured outside Kenya, to be imported:
 - i) the price of the Goods, quoted CIP named place of destination, in Kenya, as **specified in the TDS**; and
 - ii) the price for inland transportation, insurance, local taxes payable on the goods and other local services required to convey the Goods from the named place of destination to their final destination (Project Site) specified in the TDS;
- c) for Goods manufactured outside Kenya, already imported:
 - i) the price of the Goods, including the original import value of the Goods; plus, any mark-up (or rebate); plus, any other related local cost, and custom duties and other import taxes already paid or to be paid on the Goods already imported;
 - ii) the custom duties and other import taxes already paid (need to be supported with documentary evidence) or to be paid on the Goods already imported;
 - iii) the price of the Goods, obtained as the difference between (i) and (ii) above;
 - iv) any Kenya sales and other taxes which will be payable on the Goods if the Contract is awarded to the Tenderer; and
 - v) the price for inland transportation, insurance, and other local services required to convey the Goods from the named place of destination to their final destination (Project Site) specified in the TDS.
- d) for Related Services, other than inland transportation and other services required to convey the Goods to their final destination, whenever such Related Services are specified in the Schedule of Requirements:
 - i) the price of each item comprising the Related Services (inclusive of any applicable taxes).

15 Currencies of Tender and Payment

- 15.1The currency(ies) of the Tender and the currency(ies) of payments shall be the same. The Tenderer shall quote in the currency of Kenya the portion of the Tender price that corresponds to expenditures incurred in Kenya Shillings, unless otherwise specified in the TDS.
- 15.2The Tenderer may express the Tender price in any currency. If the Tenderer wishes to be paid in a combination of amounts in different currencies; it may quote its price accordingly but shall use no more than two foreign currencies in addition to the currency of Kenya.
- 15.3The rates of exchange to be used by the Tenderer shall be based on the exchange rate provided by the Central Bank of Kenya on the date 30 days prior to the actual date of tender opening. Such exchange rate shall apply for all foreign payments under the foreign payments under the contract.

16 Documents Establishing the Eligibility and Conformity of the Goods and Related Services

- 16.1To establish the eligibility of the Goods and Related Services in accordance with ITT 5, Tenderers shall complete the country of origin declarations in the Price Schedule Forms, included in Section IV, Tendering Forms.
- 16.2To establish the conformity of the Health Sector Goods and Related Services to the tendering document, the Tenderer shall furnish as part of its Tender the documentary evidence that the Goods conform to the technical specifications and standards specified in Section VII, Schedule of Requirements.
- 16.3The documentary evidence may be in the form of literature, drawings or data, and shall consist of:
- e) an item-by-item commentary on the provisions of Section VII, Schedule of Requirements demonstrating substantial responsiveness of the Goods and Services to the specifications, or a statement of deviations and exceptions to the provisions of the specifications; and

f) any other procurement-specific documentation requirement as stated in the TDS.

Unless the **TDS** stipulates otherwise, the Goods to be supplied under the Contract shall be registered with the relevant authority in Kenya. A Tenderer who has already registered its Goods by the time of Tendering should submit a copy of the Registration Certificate with its Tender. Otherwise, the successful Tenderer, by the time of Contract signing, shall submit to the Procuring Entity either:

- a) A copy of the Registration Certificate of the Goods for use in Kenya; or
- **b)** If such Registration Certificate has not yet been obtained, evidence establishing to the Procuring Entity's satisfaction that the Tenderer has complied with all the documentary requirements for registration as specified **in the TDS.**
- 16.4The Procuring Entity shall at all times cooperate with the successful Tenderer to facilitate the registration process within Kenya. The agency and contact person to provide additional information about registration are identified in the TDS.
- 16.5If the Goods of the successful Tenderer have not been registered in Kenya at the time of Contract signing, then the Contract shall become effective upon such date as the Certificate of Registration is obtained.
- 16.6Standards for workmanship, process, material, and equipment, as well as references to brand names or catalogue numbers specified by the Procuring Entity in the Schedule of Requirements, are intended to be descriptive only and not restrictive. The Tenderer may offer other standards of quality, brand names, and/or catalogue numbers, provided that it demonstrates, to the Procuring Entity's satisfaction, that the substitutions ensure substantial equivalence or are superior to those specified in the Section VII, Schedule of Requirements.

17 Documents Establishing the Eligibility and Qualifications of the Tenderer

- 17.1To establish Tenderer's eligibility in accordance with ITT 4, Tenderers shall complete the Form of Tender, included in Section IV, Tendering Forms.
- 17.2The documentary evidence of the Tenderer's qualifications to perform the Contract if its Tender is accepted shall establish to the Procuring Entity's satisfaction:
 - a) that a Tenderer that does not manufacture or produce the Health Sector Goods it offers to supply shall submit the Manufacturer's Authorization using the form included in Section IV, Tendering Forms to demonstrate that it has been duly authorized by the manufacturer or producer of the Goods to supply these Goods in Kenya;
 - b) that in case of a Tenderer not doing business within Kenya (or for other reasons will not itself carry out service obligations), the Tenderer is or will be (if awarded the Contract) represented by a local service provider in Kenya equipped and able to carry out the Tenderer's warranty obligations prescribed in the Conditions of Contract and/or Technical Specifications; and
 - c) that the Tenderer meets each of the qualification criterion specified in Section III, Evaluation and Qualification Criteria (see additional ITT for pharmaceuticals and vaccines).
- 17.3Tenderers shall be asked to provide, as part of the data for qualification, such information, including details of ownership, as shall be required to determine whether, according to the classification established by the Procuring Entity a supplier or group of suppliers' qualifies for a margin of preference. Further the information will enable the Procuring Entity identify any actual or potential conflict of interest in relation to the procurement and/or contract management processes, or a possibility of collusion between tenderers, and thereby help to prevent any corrupt influence in relation to the procurement process or contract management.
- 17.4The purpose of the information described in ITT 17.2 above overrides any claims to confidentiality which a tenderer may have. There can be no circumstances in which it would be justified for a tenderer to keep information relating to its ownership and control confidential where it is tendering to undertake public sector work and receive public sector funds. Thus, confidentiality will not be accepted by the Procuring Entity as a justification for a Tenderer's failure to disclose, or failure to provide required information on its ownership and control.
- 17.5The Tenderer shall provide further documentary proof, information or authorizations that the Procuring Entity may request in relation to ownership and control which information on any changes to the information which wasprovided by the tenderer under ITT 17.3. The obligations to require this information shall continue for the duration of the procurement process and contract performance and after

- completion of the contract, if any change to the information previously provided may reveal a conflict of interest in relation to the award or management of the contract.
- 17.6 All information provided by the tenderer pursuant to these requirements must be complete, current and accurate as at the date of provision to the Procuring Entity. In submitting the information required pursuant to these requirements, the Tenderer shall warrant that the information submitted is complete, current and accurate as at the date of submission to the Procuring Entity.
- 17.7If a tenderer fails to submit the information required by these requirements, its tenderer will be rejected. Similarly, if the Procuring Entity is unable, after taking reasonable steps, to verify to a reasonable degree the information submitted by a tenderer pursuant to these requirements, then the tender will be rejected.
- 17.8 If information submitted by a tenderer pursuant to these requirements, or obtained by the Procuring Entity (whether through its own enquiries, through notification by the public or otherwise), shows any conflict of interest which could materially and improperly benefit the tenderer in relation to the procurement or contract management process, then:
- i) If the procurement process is still ongoing, the tenderer will be disqualified from the procurement process,
- ii) If the contract has been awarded to that tenderer, the contract award will be set aside,
- iii) the tenderer will be referred to the relevant law enforcement authorities for investigation of whether the tenderer or any other persons have committed any criminal offence.
- 17.9 If a tenderer submits information pursuant to these requirements that is in complete, in accurate or outof-date, or attempts to obstruct the verification process, then the consequences ITT 17.7 will ensue unless the tenderer can show to the reasonable satisfaction of the Procuring Entity that any such act was not material, or was due to genuine error which was not attributable to the intentional act, negligence or recklessness of the tenderer.

18 Period of Validity of Tenders

- 18.1Tenders shall remain valid for the Tender Validity period specified in the TDS. The Tender Validity period starts from the date fixed for the Tender submission deadline (as prescribed by the Procuring Entity in accordance with ITT22.1). A Tender valid for a shorter period shall be rejected by the Procuring Entity as non-responsive.
- 18.2In exceptional circumstances, prior to the expiration of the Tender validity period, the Procuring Entity may request Tenderers to extend the period of validity of their Tenders. The request and the responses shall be made in writing. If a Tender Security is requested in accordance with ITT 19, it shall also be extended for a corresponding period. A Tenderer may refuse the request without forfeiting its Tender Security. A Tenderer granting the request shall not be required or permitted to modify its Tender.

19 Tender Security

- 19.1The Tenderer shall furnish as part of its Tender, either a Tender-Securing Declaration or a Tender Security, as specified in the TDS, in original form and, in the case of a Tender Security, in the amount and currency specified in the TDS.
- 19.2A Tender-Securing Declaration shall use the form included in Section IV, Tendering Forms. If a Tender is specified pursuant to ITT 19.1, the Tender Security shall be a:
- i) cash;
- ii) a bank guarantee;
- iii) a guarantee by an insurance company registered and licensed by the Insurance Regulatory Authority listed by the Authority; or
- iv) a guarantee issued by a financial institution approved and licensed by the Central Bank of Kenya.
- v) Any other Form specified in the **TDS**.
- 19.3 If a Tender Security is specified pursuant to ITT 19.1, any Tender not accompanied by a substantially responsive Tender Security shall be rejected by the Procuring Entity as non-responsive.
- 19.4 If a Tender Security is specified pursuant to ITT 19.1, the Tender Security of unsuccessful Tenderers shall be returned as promptly as possible upon the successful Tenderer's signing the Contract and

furnishing the Performance Security pursuant to ITT 45. The Procuring Entity shall also promptly return the tender security to the tenderers where the procurement proceedings are terminated, all tenders were determined non-responsive or abider declines to extend tender validity period.

- 19.5 The Tender Security of the successful Tenderer shall be returned as promptly as possible once the successful Tenderer has signed the Contract and furnished the required Performance Security.
- 19.6 The Tender Security may be forfeited or the Tender-Securing Declaration executed:
- c) if a Tenderer withdraws its Tender during the period of Tender validity specified by the Tenderer on the Form of Tender, or any extension thereto provided by the Tenderer; or
- d) if the successful Tenderer fails to:
 - i) sign the Contract in accordance with ITT 44; or
 - ii) furnish a Performance Security in accordance with ITT 45.
- 19.7Where tender securing declaration is executed, the Procuring Entity shall recommend to the PPRA that PPRA debars the Tenderer from participating in public procurement as provided in the law.
- 19.8The Tender Security or Tender-Securing Declaration of a JV must be in the name of the JV that submits the Tender. If the JV has not been legally constituted into a legally enforceable JV at the time of Tendering, the Tender Security or Tender-Securing Declaration shall be in the names of all future members as named in the Form of intent referred to in ITT 4.1and ITT 11.2.

20 Format and Signing of Tender

- 20.1 The Tenderer shall prepare one original of the documents comprising the Tender as described in ITT 11 and clearly mark it "ORIGINAL." Alternative Tenders, if permitted in accordance with ITT 13, shall be clearly marked "ALTERNATIVE" In addition, the Tenderer shall submit copies of the Tender, in the number specified **in the TDS** and clearly mark them "COPY." In the event of any discrepancy between the original and the copies, the original shall prevail.
- 20.2Tenderers shall mark as "CONFIDENTIAL" information in their Tenders which is confidential to their business. This may include proprietary information, trade secrets or commercial or financially sensitive information.
- 20.3 The original and all copies of the Tender shall be typed or written in indelible ink and shall be signed by a person duly authorized to sign on behalf of the Tenderer. This authorization shall consist of a written confirmation as specified in the TD Sand shall be attached to the Tender. The name and position held by each person signing the authorization must be typed or printed below the signature. All pages of the Tender where entries or amendments have been made shall be signed or initialed by the person signing the Tender.
- 20.4 In case the Tenderer is a JV, the Tender shall be signed by an authorized representative of the JV on behalf of the JV, and so as to be legally binding on all the members as evidenced by a power of attorney signed by their legally authorized representatives.
- 20.5Any inter-lineation, erasures, or overwriting shall be valid only if they are signed or initialed by the person signing the Tender.

D. Submission and Opening of Tenders

21 Sealing and Marking of Tenders

- 21.1The Tenderer shall deliver the Tender in a single, sealed envelope (one-envelope Tendering process). Within the single envelope the Tenderer shall place the following separate, sealed envelopes:
 - a) In an envelope marked "ORIGINAL", all documents comprising the Tender, as described in ITB11; and
 - b) in an envelope marked "COPIES", all required copies of the Tender; and
 - c) if alternative Tenders are permitted in accordance with ITB13, and if relevant:
 - i) in an envelope marked "ORIGINAL-ALTERNATIVE", the alternative Tender; hand
 - ii) in the envelope marked "COPIES-ALTERNATIVE TENDER" all required copies of the alternative Tender.

- 21.2The outer envelopes, shall:
- d) Be addressed to the Procuring Entity in accordance with ITT 22.1;
- e) Bear the specific identification of this Tendering process indicated in ITT 1.1; and
- f) bear a warning not to open before the time and date for Tender opening.

 The inner envelopes shall bear the name and address (include email and telephone number) of the Tenderer and all the information above ITT21.2 (a) to (c).
- 21.3If all envelopes are not sealed and marked as required, the Procuring Entity will assume no responsibility for the misplacement or premature opening of the Tender. Tenders that are misplaced or opened prematurely will not be accepted

22 Deadline for Submission of Tenders

- 22.1 Tenders must be received by the Procuring Entity at the address and no later than the date and time specified in the TDS. When so specified in the TDS, Tenderers shall have the option of submitting their Tenders electronically. Tenderers submitting Tenders electronically shall follow the electronic Tender submission procedures specified in the TDS.
- 22.2 The Procuring Entity may, at its discretion, extend the deadline for the submission of Tenders by amending the tendering document in accordance with ITT8, in which case all rights and obligations of the Procuring Entity and Tenderers previously subject to the deadline shall thereafter be subject to the deadline as extended.

23 Late Tenders

23.1The Procuring Entity shall not consider any Tender that arrives after the deadline for submission of Tenders, in accordance with ITT 22. Any Tender received by the Procuring Entity after the deadline for submission of Tenders shall be declared late, rejected, and returned unopened to the Tenderer.

Withdrawal, Substitution, and Modification of Tenders

- 24.1A Tenderer may withdraw, substitute, or modify its Tender after it has been submitted by sending a written notice, duly signed by an authorized representative, and shall include a copy of the authorization (the power of attorney) in accordance with ITT 20.3, (except that withdrawal notices do not require copies). The corresponding substitution or modification of the Tender must accompany the respective written notice. All notices must be:
 - a) prepared and submitted in accordance with ITT 20 and 21 (except that withdrawal notices do not require copies), and in addition, the respective envelopes shall be clearly marked "WITHDRAWAL," "SUBSTITUTION," or "MODIFICATION;" and
 - b) received by the Procuring Entity prior to the dead line prescribed for submission of Tenders, in accordance with ITT 22.1.
- 24.2 Tenders requested to be withdrawn in accordance with ITT24. 1shallbereturnedunopenedtotheTenderers.
- 24.3No Tender may be withdrawn, substituted, or modified in the interval between the deadline for submission of Tenders and the expiration of the period of Tender validity specified by the Tenderer on the Form of Tender or any extension thereof.

25 Tender Opening

- 25.1Except as in the cases specified in ITT23 and ITT24.2, the Procuring Entity shall publicly open and read out in accordance with this ITT all Tenders received by the deadline at the date, time and place specified in the TDS in the presence of Tenderers' designated representatives and anyone who choose to attend. All Tenderers, or their representatives and any interested party may attend a public opening. Any specific electronic Tender opening procedures required if electronic Tendering is permitted in accordance with ITT22. 1, shall be as specified in the TDS.
- 25.2First, envelopes marked "WITHDRAWAL" shall be opened and read out and the envelope with the corresponding Tender shall not be opened, but returned to the Tenderer. If the withdrawal envelope does not contain a copy of the "power of attorney" confirming the signature as a person duly authorized to sign on behalf of the Tenderer, the corresponding Tender will be opened. No Tender withdrawal shall

- be permitted unless the corresponding withdrawal notice contains a valid authorization to request the withdrawal and is read out at Tender opening.
- 25.3Next, envelopes marked "SUBSTITUTION" shall be opened and read out and exchanged with the corresponding Tender being substituted, and the substituted Tender shall not be opened, but returned to the
 - Tenderer. No Tender substitution shall be permitted unless the corresponding substitution notice contains a valid authorization to request the substitution and is readout at Tenderopening.
- 25.4Next, envelopes marked "MODIFICATION" shall be opened and read out with the corresponding Tender. No Tender modification shall be permitted unless the corresponding modification notice contains a valid authorization to request the modification and is read out at Tender opening.
- 25.5Next, all remaining envelopes shall be opened one at a time, reading out: the name of the Tenderer and whether there is a modification; the total Tender Prices, per item or lot (contract) if applicable, including any discounts and alternative Tenders; the presence or absence of a Tender Security, if required; and any other details as the Procuring Entity may consider appropriate.
- 25.6 Only Tenders, alternative Tenders and discounts that are opened and read out at Tender opening shall be considered further for evaluation. The Form of Tender and the Price Schedules are to be initialed by representatives of the Procuring Entity attending Tender opening in the manner specified in the TDS.
- 25.7The Procuring Entity shall neither discuss the merits of any Tender nor reject any Tender (except for late Tenders, in accordance with ITT 23.1).
- 25.8The Procuring Entity shall prepare a record of the Tender opening that shall include, as a minimum:
 - a) The name of the Tenderer and whether there is a withdrawal, substitution, or modification;
 - b) The Tender Price, per lot(contract)if applicable, including any discounts;
 - c) any alternative Tenders; and
 - d) the presence or absence of a Tender Security or Tender Securing Declaration, if one was required.
 - e) Number of pages of each tender document submitted
- 25.9The Tenderers' representatives who are present shall be requested to sign the record. The omission of a Tenderer's signature on the record shall not invalidate the contents and effect of the record. A copy of the tender opening register shall be issued to a tenderer upon request.

E. Evaluation and Comparison of Tenders

26 Confidentiality

- 26.1Information relating to the evaluation of Tenders and recommendation of contract award, shall not be disclosed to Tenderers or any other persons not officially concerned with the Tendering process until the Notification of Intention to Award the Contract is transmitted to all Tenderers in accordance with ITT 40.
- 26.2Any effort by a Tenderer to influence the Procuring Entity in the evaluation or contract award decisions may result in the rejection of its Tender.
- 26.3Notwithstanding ITT 26.2, from the time of Tender opening to the time of Contract Award, if any Tenderer wishes to contact the Procuring Entity on any matter related to the Tendering process, it should do so in writing.

27 Clarification of Tenders

27.1To assist in the examination, evaluation, comparison of the Tenders, and qualification of the Tenderers, the Procuring Entity may, at its discretion, ask any Tenderer for a clarification of its Tender. Any clarification submitted by a Tenderer in respect to its Tender and that is not in response to a request by the Procuring Entity shall not be considered. The Procuring Entity's Invitation to clarification and the response shall be in writing. No change, including any voluntary increase or decrease, in the prices or substance of the Tender shall be sought, offered, or permitted, except to confirm the correction of arithmetic errors discovered by the Procuring Entity in the Evaluation of the Tenders, in accordance with ITT 31.

27.2If a Tenderer does not provide clarifications of its Tender by the date and time set in the Procuring Entity's Invitation to clarification, its Tender may be rejected.

28 Deviations, Reservations, and Omissions

- 28.1During the evaluation of Tenders, the following definitions apply:
 - a) "Deviation" is a departure from the requirements specified in the tendering document;
 - b) "Reservation" is the setting of limiting conditions or withholding from complete acceptance of the requirements specified in the tendering document; and
 - c) "Omission" is the failure to submit part or all of the information or documentation required in the tendering document.

29 Determination of Responsiveness

- 29.1The Procuring Entity's determination of a Tender's responsiveness is to be based on the contents of the Tender itself, as defined in ITT 11.
- 29.2A substantially responsive Tender is one that meets the requirements of the tendering document without material deviation, reservation, or omission. A material deviation, reservation, or omission is one that:
 - a) If accepted, would:
 - i) affect in any substantial way the scope, quality, or performance of the Goods and Related Services specified in the Contract; or
 - ii) limit in any substantial way, inconsistent with the tendering document, the Procuring Entity's rights or the Tenderer's obligations under the Contract; or
 - b) if rectified, would unfairly affect the competitive position of other Tenderers presenting substantially responsive Tenders.
- 29.3The Procuring Entity shall examine the technical aspects of the Tender submitted in accordance with ITT 16 and ITT 17, in particular, to confirm that all requirements of Section VII, Schedule of requirements have been met without any material deviation or reservation, or omission.
- 29.4If a Tender is not substantially responsive other requirements of tendering document, it shall be rejected by the Procuring Entity and may not subsequently be made responsive by correction of the material deviation, reservation, or omission.

30 Non-conformities, Error sand Omissions

- 30.1 Provided that a Tender is substantially responsive, the Procuring Entity may waive any non-conformity in the Tender.
- 30.2 Provided that a Tender is substantially responsive, the Procuring Entity may request that the Tenderer submit the necessary information or documentation, within a reasonable period of time, to rectify nonmaterial non- conformities or omissions in the Tender related to documentation requirements. Such omission shall not be related to any aspect of the price of the Tender. Failure of the Tenderer to comply with the request may result in the rejection of its Tender.
- 30.3 Provided that a Tender is substantially responsive, the Procuring Entity shall rectify quantifiable nonmaterial non-conformities related to the Tender Price. To this effect, the Tender Price shall be adjusted, for comparison purposes only, to reflect the price of a missing or n on-conforming item or component in the manner specified in the TDS.

31 Arithmetical Errors

- 31.1The tenders submitted and read out during the tender opening shall be absolute and final and shall not be the subject of correction, adjustment or amendment in any way by any person or entity.
- 31.2Provided that the Tender is substantially responsive, the Procuring Entity shall handle errors on the following basis:
 - a) Any error detected if considered a major deviation that affects the substance of the tender, shall lead to disqualification of the tender as non-responsive.

- b) Any errors in the submitted tender arising from a miscalculation of unit price, quantity, and subtotal and total bid price shall be considered as a major deviation that affects the substance of the tender and shall lead to disqualification of the tender as non-responsive. and
- c) If there is a discrepancy between words and figures, the amount in words shall prevail
- 31.3 Tenderers shall be notified of any error detected in their bid during the notification of award.

32 Conversion to Single Currency

32.1 For evaluation and comparison purposes, the currency(ies) of the Tender shall be converted in a single currency as specified **in the TDS.**

33 Margin of Preference and Reservations

- 33.1A margin of preference may be allowed on locally manufactured Health goods only when the contract is open to international tendering, where the tender is likely to attract foreign goods and where the contract exceeds the threshold specified in the Regulations. A margin of preference shall not be allowed unless it is specified so in the **TDS**.
- 33.2Contracts procured on basis of international competitive tendering shall not be subject to reservations to specific groups as provided in ITT 33.3.
- 33.3Where it is intended to reserve a contract to a specific group of businesses (these groups are Small and Medium Enterprises, Women Enterprises, Youth Enterprises and Enterprises of persons living with disability, as the case maybe), and who are appropriately registered as such by a competent authority, a procuring entity shall ensure that the invitation to tender specifically indicates that only businesses or firms belonging to the group are eligible to tender. No tender shall be reserved to more than one group. If not so stated in the Tender documents, the invitation to tender will be open to all interested tenderers.

34 Evaluation of Tenders

- 34.1The Procuring Entity shall use the criteria and methodologies listed in this ITT and Section III, Evaluation and Qualification criteria. No other evaluation criteria or methodologies shall be permitted. By applying the criteria and methodologies, the Procuring Entity shall determine the Lowest Evaluated Tender. This is the Tender of the Tenderer that meets the qualification criteria and whose Tender has been determined to be:
 - a) Substantially responsive to the tendering document; and
 - b) The lowest evaluated cost.
- 34.2To evaluate a Tender, the Procuring Entity shall consider the following:
 - a) Price adjustment due to discounts offered in accordance with ITT 14.4;
 - b) Price adjustment due to quantifiable non material non-conformities in accordance with ITT 30.3; and
 - c) converting the amount resulting from applying (a) and (b) above, if relevant, to a single currency in accordance with ITT 32;
 - d) any additional evaluation factors specified in Section III, Evaluation and Qualification Criteria.
- 34.3 The estimated effect of the price adjustment provisions of the Conditions of Contract, applied over the period of execution of the Contract, shall not be taken in to account in Tender evaluation.
- 34.4 In the case of multiple contracts or lots, Tenderers are allowed to tender for one or more lots and the methodology to determine the lowest evaluated cost of the lot (contract) and for combinations, including any discounts offered in the Form of Tender, is specified in Section III, Evaluation and Qualification Criteria.
- 34.5The Procuring Entity's evaluation of a Tender will exclude and not taken to account:
 - a) in the case of Goods manufactured in Kenya, sales and other similar taxes, which will be payable on the goods if a contract is awarded to the Tenderer;
 - b) in the case of Goods manufactured outside Kenya, already imported or to be imported, customs duties and other import taxes levied on the imported Good, sales and other similar taxes, which will be payable on the Goods if the contract is awarded to the Tenderer;
 - c) any allowance for price adjustment during the period of execution of the contract, if provided in the

Tender.

34.6The Procuring Entity's evaluation of a Tender may require the consideration of other factors, in addition to the Tender Price quoted in accordance with ITT 14. These factors may be related to the characteristics, performance, and terms and conditions of purchase of the Goods and Related Services. The effect of the factors selected, if any, shall be expressed in monetary terms to facilitate comparison of Tenders, unless otherwise specified in the TDS from amongst those set out in Section III, Evaluation and Qualification Criteria. The criteria and methodologies to be used shall be as specified in ITT 34.2

35 Comparison of Tenders

35.1The Procuring Entity shall compare the evaluated costs of all substantially responsive Tenders established in accordance with ITT 34.2 to determine the Tender that has the lowest evaluated cost. The comparison shall be on the basis of CIP (place of final destination) prices for imported goods and EXW prices, plus cost of inland transportation and insurance to place of destination, for goods manufactured within Kenya, together with prices for any required installation, training, commissioning and other services. The evaluation of prices shall not take into account custom duties and other taxes levied on imported goods quoted CIP and sales and similar taxes levied in connection with the sale or delivery of goods.

36 Abnormally Low Tenders and Abnormally

High Tenders Abnormally Low Tenders

- 36.1 An Abnormally Low Tender is one where the Tender price in combination with other constituent elements of the Tender, appears unreasonably low to the extent that the Tender price raises material concerns with the Procuring Entity as to the capability of the Tenderer to perform the Contract for the offered Tender price.
- 36.2 In the event of identification of a potentially Abnormally Low Tender by the evaluation committee, the Procuring Entity shall seek written clarification from the Tenderer, including a detailed price analyses of its Tender price in relation to the subject matter of the contract, scope, delivery schedule, allocation of risks and responsibilities and any other requirements of the tendering document.
- 36.3 After evaluation of the price analyses, in the event that the Procuring Entity determines that the Tenderer has failed to demonstrate its capability to perform the contract for the offered Tender price, the Procuring Entity shall reject the Tender.

Abnormally High Tenders

- An abnormally high tender price is one where the tender price, in combination with other constituent elements of the Tender, appears unreasonably too high to the extent that the Procuring Entity is concerned that it (the Procuring Entity) may not be getting value for money or it may be paying too high a price for the contract compared with market prices or that genuine competition between Tenderers is compromised.
- 36.5In case of an abnormally high price, the Procuring Entity shall make a survey of the market prices, check if the estimated cost of the contract is correct and review the Tender Documents to check if the specifications, scope of work and conditions of contract are contributory to the abnormally high tenders. The Procuring Entity may also seek written clarification from the tenderer on the reason for the high tender price. The Procuring Entity shall proceed as follows:
- (i) If the tender price is abnormally high based on wrong estimated cost of the contract, the Procuring Entity <u>may accept or not accept</u> the tender depending on the Procuring Entity's budget considerations.
- (ii) If specifications, scope of work and/or conditions of contract are contributory to the abnormally high tender prices, scope of work and conditions of contract, as the case may be.
- 36.6 If the Procuring Entity determines that the Tender Price is abnormally too high because <u>genuine</u> <u>competition between tenderers is compromised</u> (often due to collusion, corruption or other manipulations), the Procuring Entity shall reject all Tenders and shall institute or cause competent

Government Agencies to institute an investigation on the cause of the compromise, before retendering.

37 Qualification of the Tenderer

- 37.1The Procuring Entity shall determine to its satisfaction whether the Tenderer that is selected a shaving submitted the lowest evaluated cost and substantially responsive Tender is eligible and meets the qualifying criteria specified in ITT 11.1 as applicable, and Section III, Evaluation and Qualification Criteria.
- 37.2 The determination shall be based upon an examination of the documentary evidence of the Tenderer's qualifications submitted by the Tenderer, pursuant to ITT 17. The determination shall not take into consideration the qualifications of other firms such as the Tenderer's subsidiaries, parent entities, affiliates, sub-contractors or any other firm (s) different from the Tenderer.
- 37.3An affirmative determination shall be a prerequisite for award of the Contract to the Tenderer. A negative determination shall result in disqualification of the Tender, in which event the Procuring Entity shall proceed to the Tenderer who offers a substantially responsive Tender with the next lowest evaluated cost to make a similar determination of that Tenderer's qualification stopper form satisfactorily.

38 Procuring Entity's Right to Accept Any Tender, and to Reject Any or All Tenders

38.1 The Procuring Entity reserves the right to accept or reject any tender, and to annul the Tendering process and reject all Tenders at any time prior to Contract Award, without thereby incurring any liability to Tenderers. In case of annulment, all Tenderers shall be notified with reasons and all Tenders submitted and specifically, tender securities, shall be promptly returned to the Tenderers.

F. Award of Contract

39 Award Criteria

39.1The Procuring Entity shall award the Contract to the successful tenderer whose tender has been determined to be the Lowest Evaluated Tender.

40 Procuring Entity's Right to Vary Quantities at Time of Award

40.1 The Procuring Entity reserves the right at the time of Contract award to increase or decrease, by the percentage (s) for items as indicated **in the TDS.**

Notice of Intention to enter into a Contract

- 41.1 Upon award of the contract and Prior to the expiry of the Tender Validity Period the Procuring Entity shall issue a Notification of Intention to Enter in to a Contract/Notification of award to all tenderers which shall contain, at a minimum, the following information:
- a) The name and address of the Tenderer submitting the successful tender;
- b) The Contract price of the successful tender;
- c) a statement of the reason(s) the tender of the unsuccessful tenderer to whom the letter is addressed was unsuccessful, unless the price information in (c) above already reveals the reason;
- d) the expiry date of the Stands till Period; and
- e) instructions on how to request a de briefing and/or submit a complaint during the stand still period;

42 Standstill Period

- 42.1The Contract shall not be signed earlier than the expiry of a Standstill Period of 14 days to allow any dissatisfied tender to launch a complaint. Where only one Tender is submitted, the Standstill Period shall not apply.
- 42.2Where a Standstill Period applies, it shall commence when the Procuring Entity has transmitted to each Tenderer the Notification of Intention to enter in to a Contract with the successful Tenderer.

43 Debriefing by the Procuring Entity

43.1 On receipt of the Procuring Entity's <u>Notification of Intention to Enter into a Contract</u> referred to in ITT 40, an unsuccessful tenderer may make a written request to the Procuring Entity for a debriefing on specific issues or concerns regarding their tender. The Procuring Entity shall provide the debriefing within five days of receipt of the request. Debriefings of unsuccessful full Tenderers may be done in writing or verbally. The Tenderer shall bear its own costs of attending such a debriefing meeting.

44 Letter of Award

44.1 Prior to the expiry of the Tender Validity Period and upon expiry of the Standstill Period specified in ITT 41.1, upon addressing a complaint that has been filed within the Standstill Period; the Procuring Entity shall transmit the <u>Letter of Award</u> to the successful Tenderer. The letter of award shall request the successful tenderer to furnish the Performance Security within 21days of the date of the letter.

45 Signing of Contract

- 45.1Upon the expiry of the fourteen days of the Notification of Intention to enter in to contract and upon the parties meeting their respective statutory requirements, the Procuring Entity shall send the successful Tenderer the Contract Agreement.
- 45.2Within fourteen (14) days of receipt of the Contract Agreement, the successful Tenderer shall sign, date, and return it to the Procuring Entity.
- 45.3The written contract shall be entered into within the period specified in the notification of award and before expiry of the tender validity period

46 Performance Security

- 46.1Within twenty-one (21) days of the receipt of the Letter of Award from the Procuring Entity, the successful Tenderer shall furnish the Performance Security and, any other documents required in the **TDS**, in accordance with the General Conditions of Contract, subject to ITT 38.2 (b), using the Performance Security and other Forms included in Section X, Contract Forms, or another form acceptable to the Procuring Entity. A foreign institution providing a bank guarantee shall have a correspondent financial institution located in Kenya, unless the Procuring Entity has agreed in writing that a correspondent bank is not required.
- 46.2Failure of the successful Tenderer to submit the above-mentioned Performance Security and other documents required in the TDS or sign the Contract shall constitute sufficient grounds for the annulment of the award and forfeiture of the Tender Security. In that event the Procuring Entity may award the Contract to the Tenderer offering the next Best Evaluated Tender.
- 46.3Performance security shall not be required for contracts estimated to cost less than the amount specified in the Regulations.

47 Publication of Procurement Contract

- 47.1Within fourteen days after signing the contract, the Procuring Entity shall publish the awarded contract at its noticeboards and websites; and on the Website of the Authority. At the minimum, the notice shall contain the following information:
 - a) Name and address of the Procuring Entity;
 - b) Name and reference number of the contract being awarded, a summary of its scope and the selection method used;
 - c) the name of the successful Tenderer, the final total contract price, the contract duration.
 - d) Dates of signature, commencement and completion of contract;
 - e) names of all Tenderers that submitted Tenders, and their Tender prices as read out at Tender opening.

48 Procurement Related Complaint and Administrative Review

- 48.1 The procedures for making a Procurement-related Complaint are as specified in the TDS.
- 48.2 A request for administrative review shall be made in the form provided under contract forms.

SECTION II - TENDER DATA SHEET (TDS)

The following specific data for the Maintenance Services to be procured shall complement, supplement, or amend the provisions in the Instructions to Tenderers (ITT). Whenever there is a conflict, the provisions here in shall prevail over those in ITT.

[Where an e-procurement system issued, modify the relevant parts of the TDS accordingly to reflect thee-procurement process].

[Instructions for completing the Tender Data Sheet are provided, as needed, in the notes in italics mentioned for the relevant ITT].

Section II - Tender Data Sheet (TDS)

The following specific data for the goods to be procured shall complement, supplement, or amend the provisions in the Instructions to Tenderers (ITT). Whenever there is a conflict, the provisions herein shall prevail over those in ITT.

Where an e-procurement system is used, modify the relevant parts of TDS to reflect the e-procurement process

| Reference to ITC Clause | PARTICULARS OF APPENDIX TO INSTRUCTIONS TO TENDERS |
|-------------------------|--|
| A. General | |
| ITB 1.1 | Name of the Tender: For Supply and Delivery of Human Drugs (Pharmaceuticals) |
| | The reference Number: MTRH/T/94/2023-2024. |
| | The Procuring Entity is: Moi Teaching and Referral Hospital |
| ITB2.1(a) | Electronic -Procurement System |
| | The Procuring Entity shall use the following electronic-procurement system to manage this Tendering process: N/A |
| | The electronic-procurement system shall be used to manage the following aspects of the Tendering process: N/A |
| ITT 3.3 | The firms that provided consulting services are N/A |
| ITB 4.1 | Maximum number of members in the Joint Venture (JV) shall be: N/A |
| B. Contents o | f Tendering Document |
| ITB 7.1 | Contact Address is; |
| | Attention: Chief Executive Officer. |
| | Moi Teaching and Referral Hospital |
| | P.O. BOX, 3-30100, |
| | ELDORET. |
| | Moi Teaching and Referral Hospital situated is along Nandi Road in Eldoret, |
| | Tender Box "A" is located at Ground floor left wing of Chandaria Cancer and Chronic Diseases Centre (CCCDC) Building. Electronic email Address: ceo@mtrh.go.ke |
| | Bulky tenders shall be received at Supply Chain Department. |
| | The deadline for submission is 11 th April, 2024 at 10:00am |
| | The electronic tender procedure shall not be allowed |
| | Requests for clarification should be received by the Procuring Entity no later than: [13.11.2023]. |
| | The Procuring Entity shall publish its response at the website www.mtrh.go.ke |
| C. Preparatio | on of Tenders |
| ITB 11.1 (j) | The Tenderer shall submit the following additional documents in its Tender: |

| Reference to ITC Clause | PARTICULARS OF APPENDIX TO INSTRUCTIONS TO TENDERS |
|--|---|
| | I. Manufacturer Authorization |
| | II. Annual Practicing License for Superintendent Pharmacist from Pharmacy and Poisons |
| | Board of Kenya III. Current and valid wholesale dealer's license from Pharmacy and Poisons Board of Kenya |
| | IV. Registration or retention Certificate for each product from Pharmacy and Poisons Board |
| ITB 13.1 | Alternative Tenders <i>shall not be</i> considered. |
| ITB 14.5 | The prices quoted by the Tenderer <i>shall not be</i> subject to adjustment during the performance of the Contract. |
| ITB 14.6 | Prices quoted for each lot (contract) shall correspond at least to percent of the items specified for each lot (contract). |
| | Prices quoted for each item of a lot shall correspond at least to 15% percent of the quantities specified for this item of a lot. |
| ITB 14.7 | The Incoterms edition is: 2023 Edition |
| ITB 14.8 (a) iii, (b) (i) and (c) (v) | Place of destination: Moi Teaching and Referral Hospital-Eldoret |
| ITB 14.8 (a) (iii), (b) (ii) and c (v) | Final destination (Project Site): Moi Teaching and Referral Hospital |
| ITB 15.1 | The Tenderer "is" required to quote in Kenya shillings the portion of the Tender price that corresponds to expenditures incurred in that currency. |
| ITT 16.3(b) | Other procurement-specific documentation requirements are manufacturers Authorization letter, Annual practicing license for superintendent Pharmacist, current valid wholesale dealers license and Registration or retention Certificate for each product from Pharmacy and Poisons Board |
| ITT 16.4 | Goods to be supplied under the Contract shall be registered with Kenya Poisons Board of Kenya in Kenya. |
| 16.5 | The contact person in the Procuring Entity able to provide additional information about registration is |
| | Manager, Supply Chain. |
| | Email: msc@mtrh.go.ke |
| | Telephone number 0532033473 or 0722209795 extension 3318. |
| ITB 18.1 | The Tender validity period shall be 120 days. |
| ITB 18.3 (a) | The tender price shall not be adjusted for comparison purposes |
| ITB 19.1 | A Tender Security <i>shall be</i> required. |
| | A Tender-Securing Declaration shall not be required. |
| | Tender Security of Kshs.100,000/- in form of Banker's cheque, Bank or Insurance guarantee issued by insurance company registered and licensed by the Insurance Regulatory Authority and listed by the Public Procurement Regulatory Authority valid for 150 days after the date of tender opening |
| ITB 19.2 (v) | Other types of acceptable securities: bank guarantee, a guarantee by an insurance company registered |
| | |

| Reference to ITC Clause | PARTICULARS OF APPENDIX TO INSTRUCTIONS TO TENDERS |
|-------------------------|---|
| | and licenced by Insurance Regulatory Authority listed by the Authority or guarantee issued by financial institutions approved and licenced by the Central Bank of Kenya |
| ITB 20.1 | In addition to the original of the Tender, the number of copies is: One (1) Note: Original bid and a copy MUST be submitted |
| ITB 20.3 | The written confirmation of authorization to sign on behalf of the Tenderer shall consist of: Power of Attorney document duly signed and witnessed. |
| D. Submissi | on and Opening of Tenders |
| ITB 22.1 | For <u>Tender submission purposes</u> only, the procuring Entity's address is: |
| | Attention: Chief Executive Officer. |
| | Moi Teaching and Referral Hospital |
| | P.O. BOX, 3-30100, |
| | ELDORET. |
| | Physical address for hand courier delivery. |
| | Moi Teaching and Referral Hospital situated is along Nandi Road in Eldoret, |
| | Tender Box "A" is located at Ground Floor, left wing of Chandaria Cancer and Chronic Diseases Centre (CCCDC) Building. |
| | Bulky tenders shall be received at Supply Chain Department. |
| | The deadline for submission is 11 th April, 2024 at 10:00 am |
| | The electronic tender procedure shall not be allowed |
| ITB 25.1 | The Tender opening shall take place at: |
| | Attention: Manager, Supply Chain. |
| | Moi Teaching and Referral Hospital |
| | P.O. BOX, 3-30100, |
| | ELDORET. |
| | Physical Address: |
| | Moi Teaching and Referral Hospital situated along Nandi Road in Eldoret, |
| | Tender Box "A" is located at Ground floor left wing of Chandaria Cancer and Chronic Diseases Centre (CCCDC) Building |
| | Date: 11 th April, 2024 |
| | Time: 10:00 a.m. |
| | Venue of opening shall be advised by Tender Opening Committee |
| ITB 25.1 | The electronic Tender opening procedures shall NOT: N/A |
| ITB 25.6 | The Form of Tender and Price Schedules shall be initialed by three representatives of the Procuring Entity conducting Tender opening. |
| E. Evaluatio | on and Comparison of Tenders |

| Reference to ITC Clause | PARTICULARS OF APPENDIX TO INSTRUCTIONS TO TENDERS |
|-------------------------|---|
| ITB 30.3 | The adjustment shall be based on the comparison purposes only for price of the item or component as quoted in other substantially responsive Tenders. If the price of the item or component cannot be derived from the price of other substantially responsive Tenders, the Procuring Entity shall use its lowest estimate. |
| ITB 32.1 | The currency that shall be used for Tender evaluation and comparison purposes to convert (at the selling exchange rate) all Tender prices expressed in various currencies into a single currency is: Kenya Shillings |
| | The source of exchange rate shall be: Central Bank exchange rates prevailing at the date of Tender opening |
| | The date for the exchange rate shall be on: 11 th April, 2024 |
| ITB 33.1 | A margin of preference shall not be allowed. |
| ITT 33.3 | The specific group of businesses is the invitation to tender will be open to all interested tenderers. |
| ITB 34.6 | The adjustments shall be determined using the following criteria, from amongst those set out in Section III, Evaluation and Qualification Criteria: |
| | (a) Deviation in Time for Completion: <i>No</i> . |
| | (b) Life cycle costs: the projected operating and maintenance costs during the life of the goods or equipment <i>No</i> . |
| | (c) Functional Guarantees of the Facilities <i>No</i> . |
| | Work, services, facilities, etc., to be provided by the Procuring Entity <i>No</i> . |
| F. Award of | Contract |
| ITB 40.1 | The maximum percentage by which quantities may be increased is: N/A |
| | The maximum percentage by which quantities may be decreased is: N/A |
| ITT 40.1 | Procuring Entity may vary Quantities at a percentage not exceed 15% |
| ITT 46 | Performance security of 5% of total contract value shall be required for contract whose value is kshs.5,000,000 and above |
| ITB 48.1 | The procedures for making a Procurement-related Complaint are available from the PPRA website www.ppra.go.ke or email complaints@ppra.go.ke . If a Tenderer wishes to make a Procurement-related Complain, the Tenderer should submit its complaint following these procedures, in writing (by the quickest means available, that is either by hand delivery or email to: For the attention: Ag. Chief Executive Officer |
| | Title/position : Ag. Chief Executive Officer Procuring Entity: Moi Teaching and Referral Hospital Email address: ceo@mtrh.go.ke |
| | In summary, a Procurement-related Complaint may challenge any of the following: (i) The terms of the Tender Documents; and |
| | (ii) The Procuring Entity's decision to award the contract. |

PHARMACEUTICALS

(Additional TDS for Pharmaceuticals)

All products must

- Be manufactured in accordance with Good Manufacturing Practice (GMP).
- Have clear direction for reconstitution, dilution, storage and stability of the resulting product where applicable

NOTE: The successful tenderer shall be required to stamp MTRH-ELDORET on the outer pack of drugs supplied using indelible and conspicuous ink. This shall be a Mandatory deliver requirement

ITT 16.3 (b)

[Sample ITT]

The pharmaceuticals offered should meet the specified pharmacopoeia standards as stated in the Technical Specification. If the Goods offered are not included in one of the specified pharmacopoeias (e.g., the case of a new drug), the Tenderer will provide testing protocols and alternative reference standards.

Tender Data Sheet (continued) Vaccines--(Additional TDS for Vaccines)

[Note: The below data should be included in the Tender Data Sheet tendering document for the procurement of vaccines.]

ITT 11.1 (f)

Documentary evidence of the Tenderer's qualifications to perform the Contract if its Tender is accepted:

a) is certified by a competent authority in the country of manufacture according to resolution WHA 28 65 of the World Health Organization's Certificate Scheme on the Quality of Pharmaceutical Products Moving in International Commerce.

The Tenderer will submit the following additional information:

b) list of vaccines being manufactured by the Tenderer with product registration / license number and date.

ITT 16.3 (b)

[Sample ITT]

- (i) The vaccines to be supplied under the Contract must be licensed both in the country of manufacture and in Kenya by the time of Contract signing by a recognized National Control Authority (NCA). An NCA is an organization that performs all six critical functions for control of biological products as defined by the World Health Organization, namely: licensing based on published set of requirements; surveillance of vaccine field performance; system of lot release for vaccines; use of laboratory when needed; regular inspections for good manufacturing practice and evaluation of clinical performance. The license from country of manufacture must state that the Tenderer is licensed to manufacture the Goods by the NCA in the manufacturing country. Documentary evidence in the form of a certified copy of the license and a copy of the vaccine license/registration that the offered vaccine has been licensed by the NCA s of the manufacturer's country shall accompany the Tender and a copy of the license issued by an NCA in Kenya must be submitted by Contract signing. If there is no NCA with specific biologics expertise in Kenya, the Tenderer shall furnish evidence that the Goods meet the qualification criteria in the Technical Specifications.
- (ii) If the Goods offered do not meet the specified pharmacopoeia standards as stated in the Technic a Specification, the Tenderer will provide Specification; the Tenderer will provide testing protocols and alternative reference standards.

SECTION III - EVALUATION AND QUALIFICATION CRITERIA

1. General Provision

- 1.1 Wherever a Tenderer is required to state a monetary amount, Tenderers should indicate the Kenya Shilling equivalent using the rate of exchange determined as follows:
 - a) For construction turn over or financial data required for each Year-Exchange rate prevailing on the last day of the respective calendar year (in which the amounts for that year is to be converted) was originally established.
 - b) Value of single Contract-Exchange rate prevailing on the date of the contract signature.
 - c) Exchange rates shall be taken from the publicly available source identified in the ITT. Any error in determining the exchange rates in the Tender may be corrected by the Procuring Entity.
- 1.2 This section contains the criteria that the Employer shall use to evaluate tender and qualify tenderers. No other factors, method s or criteria shall be used other than specified in this tender document. The Tenderer shall provide all the information requested in the forms included in Section IV, Tendering Forms. The Procuring Entity should use **the Standard Tender Evaluation Report for Goods and Works** for evaluating Tenders.

2. Evaluation and contract award Criteria

2.1 The Procuring Entity shall use the criteria and methodologies listed in this Section to evaluate tenders and arrive at the Lowest Evaluated Tender. The tender that (i) meets the qualification criteria, (ii) has been determined to be substantially responsive to the Tender Documents, and (iii) is determined to have the Lowest Evaluated Tender price shall be selected for award of contract.

3. Preliminary examination for Determination of Responsiveness

3.1 The Procuring Entity will start by examining all tenders to ensure they meet in all respects the eligibility criteria and other mandatory requirements in the ITT, and that the tender is complete in all aspects in meeting the requirements provided for in the preliminary evaluation criteria outlined below. The Standard Tender Evaluation Report Document for Goods and Works for evaluating Tenders provides very clear guide on how to deal with review of these requirements. Tenders that do not pass the Preliminary Examination will be considered non-responsive and will not be considered further.

A. EVALUATION CRITERIA

Preliminary / Mandatory Evaluation Criteria

Tenderers are required to submit the under listed documents: -

- 1. A copy of certificate of Registration or Incorporation.
- 2. A copy of valid Tax Compliance Certificate
- 3. Submission audited accounts for the 2020, 2021 and 2022.
- 4. Submission of original bid bond of **Ksh. 100,000/-** a in form of Bankers cheque,Bank or Insurance guarantee or guarantee issued by insurance company registered and licensed by the Insurance Regulatory Authority and listed by the Public Procurement Regulatory Authority valid for **150 days** after the date of tender opening.
- 5. Submission of original and one copy of the tender document shall be required.
- 6. Tenderer to submit Manufacturers Authorization letter.

- 7. Tenderers to submit valid annual practicing license for Superintendent Pharmacist from Pharmacy and Poisons Board
- 8. Tenderers to provide registration or retention certificate for each product/ drug from Pharmacy and Poisons Board. For products not registered in Kenya, provide special import permit from Pharmacy and Poisons Board.
- 9. Tenderers to submit annual Wholesalers' License from Pharmacy and Poisons Board.
- 10. Tenderers to provide reference letters from at least five (5) organizations where you have supplied pharmaceutical products subject to confirmation.
- 11. Tenderers to provide maximum accumulative volume of business handled (Must attach LPO's/Contracts signed and stamped) (Subject to confirmation) Business handled in the last three years above 3 million
- 12. All pages of the tender documents (including attachments) MUST be chronologically serialized.
- 13. Copy of Certificate of Confirmation of Directors (CR12) in case for a Limited company and in case of a sole proprietorship Photostat copy of National Identity Card for each of the consulting firms.
- 14. Letter from the firm giving authority the person signing the tender to represent the firm (Power of Attorney), without material deviation, reservation, or omission. The document shall be duly signed and witnessed.
- 15. Submission of duly filled and signed form of Tender, the document must be prepared on tenderers letter head letter head (**Refer to Page 37-39**)
- 16. Form ELI 1.1; Tenderer Information Form (**Refer to page 58**)
- 17. Submission of duly filled, signed and stamped Tenderers Eligibility Confidential Business Questionnaire. (Refer to Page 52-54)
- 18. Form **FIN 3.1**; Financial situation and Performance (**Refer to page 53**)
- 19. Submission of duly filled FORM PER -Historical Contracts Non-Performance, Pending Litigation and Litigation History. (Refer to Page 54)
- 20. Submission of duly filled, signed and stamped Certificate of Independent Tender Determination.

 (Refer to Page 40)
- 21. Submission of duly filled and signed Self-declaration forms SD1 and SD2. (Refer to Page 42-43)
- 22. Submission of duly filled, signed and witnessed Declaration and Commitment to the Code of Ethics. (Refer to Page 44)
- 23. Duly filled Price Schedule in the format provided. (**Refer to Page 57**)

4. Tender Evaluation (ITT 34)

a) In addition to the criteria listed in ITT 34.2(a)–(c) the additional evaluation factors as per ITT 34.2 is specified as follows:

STAGE 2 TECHNICAL EVALUATIONS

The tenderer shall be required to submit Manufacturers authorization registration or retention certificate for each product quoted issued by Pharmacy and Poisons Board

STAGE THREE FINANCIAL EVALUATION

- Financial Evaluation will be carried out on lowest cost basis per item
- ➤ If there is a tie on the lowest quoted price between two firms; the contract quantities may be equally shared or the proceeding may be subjected to competitive negotiation.
- Unrealistic low or high prices shall be rejected as may be guided by prevailing market price
- 4.1 To evaluate Items or Lots that include at least the percentages of items per lot and quantity per item as specified in ITT 14.6, if applicable. Tender evaluation of such tenders will be carried out as per the following procedures. The average price (or highest price as specified in TDS 30.3) of an item quoted by substantially responsive Tenders will be added to the Tender price of those who did not quote for that item and the equivalent total cost of the tender so determined will be used for Tender comparison, evaluation, and award.

b) Delivery schedule. (As specified in the TDS)

The Goods specified in the List of Goods are required to be delivered within the acceptable time range (after the earliest and before the final date, both dates inclusive) specified in Section VII, Schedule of Requirements. No credit will be given to deliveries before the earliest date, and Tenders offering delivery after the final date shall be treated as non-responsive. Within this acceptable period, an adjustment of[insert he adjustment factor], will be added, for evaluation purposes only, to the Tender price of Tenders offering deliveries later than the "Earliest Delivery Date" specified in Section VII, Schedule of Requirements.

c) **Deviation in payment schedule**.[insert tone of the following]N/A

i) Tenderers shall state their Tender price for the payment schedule outlined in the SCC. Tenders shall be evaluated on the basis of this base price, tenderers are, however, permitted to state an alternative payment schedule and indicate the reduction in Tender price they wish to offer for such alternative payment schedule. The Procuring Entity may consider the alternative payment schedule and the reduced Tender price offered by the tenderer selected on the basis of the base price for the payment schedule out lined in the SCC.

Or

i) The SCC stipulates the payment schedule specified by the Procuring Entity. If a Tender deviate from the schedule and if such deviation is considered acceptable to the Procuring Entity ,the Tender will be evaluated by calculating interest earned for any earlier payments involved in the terms outlined in the Tender as compared with those stipulated in the SCC, at the rate per annum [insert adjustment rate].

d) Specific additional criteria N/A

[Other specific additional criteria to be considered in the evaluation, and the evaluation method shall be detailed in TDS34.6][If specific sustainable procurement technical requirements have been specified in Section VII- Specification, either state that (i) those requirements will be evaluated on a pass/fail (compliance basis) or otherwise (ii)in addition to evaluating those requirements on a pass s/fail (compliance basis), if applicable, specify the monetary adjustments to be applied to Tender Prices for comparison purposes on account of Tenders that exceed the specified minimum sustainable procurement technical requirements.]

5. Multiple Contracts (ITT 34.4) N/A

5.1 Multiple contracts will be permitted in accordance with ITT 34.4. Tenderers are evaluated on basis of Lots and the lowest evaluated tenderer identified for each Lot. The Procuring Entity will select one Option of the two Options listed below for award of Contracts.

OPTION 1

- i) If a tenderer wins only one Lot, the tenderer will be awarded a contract for that Lot, provided the tenderer meets the Eligibility and Qualification Criteria for that Lot.
- ii) If a tenderer wins more than one Lot, the tender will be awarded contracts for all won Lots, provided the tenderer meets the aggregate Eligibility and Qualification Criteria for all the Lots. The tenderer will be awarded the combination of Lots for which the tenderer qualifies and the others will be considered for award to second lowest the tenderers.

OPTION 2

5.2 The Procuring Entity will consider all possible combinations of won Lots [contract(s)] and determine the combinations with the lowest evaluated price. Tenders will then be awarded to the Tenderer or Tenderers in the combinations provided the tenderer meets the aggregate Eligibility and Qualification Criteria for all the won Lots.

6. Alternative Tenders (ITT13.1)

6.1 An alternative if permitted under ITT 13, will be evaluated as follows: The Procuring Entity shall consider Tenders offered for alternatives as specified in Part II Section II, Schedule of Requirements. Only the technical alternatives, if any, of the Tenderer with the Lowest Evaluated Tender conforming to the basic technical shall be considered by the Procuring Entity.

7. MARGIN OF PREFERENCE N/A

- 7.1 If the TDS so specifies, the Procuring Entity will grant a margin of preference of 15% (fifteen percent) to Tenderers offering goods manufactured, mined, extracted, grown, assembled or semi-processed in Kenya. Goods assembled or semi-processed in Kenya shall have a local content of not less than 40%.
- 7.2 The margin of preference will be applied in accordance with, and subject to, the following provisions:
 - a) Tenderers applying for such preference on goods offered shall be asked to provide, as part of the data forqualification, such information, including details of the goods produced in Kenya, so as to determine whether, according to the classification established by the Procuring Entity, a particular category of goods or group of goods qualifies for a margin of preference.
 - b) After Tenders have been received and reviewed by the Procuring Entity, goods offered in the responsive Tenders shall be assessed to ascertain they are manufactured, mined, extracted, grown, assembled or semi- processed in Kenya. Responsive tenders shall be classified into the following groups:
 - i) **Group A:** Tenders offering goods manufactured in Kenya, for which (a) labor, raw materials, and components from within Kenya account for more than forty (40) percent of the Ex-Works price; and (b) the production facility in which they will be manufactured or assembled has been engaged in manufacturing or assembling such goods at least since the date of Tender submission date:
 - ii) Group B: All other Tenders offering Goods manufactured in Kenya;
 - *iii)* **Group C:** Tenders offering Goods manufactured outside Kenya that have been already imported or that will be imported.
 - a) To facilitate this classification by the Procuring Entity, the tenderer shall complete whichever version of the Price Schedule furnished in the Tendering document is appropriate, provided however, that the completion of an incorrect version of the Price Schedule by the Tenderer shall not result in rejection of its Tender, but merely in the Procuring Entity's reclassification of the Tender in to its appropriate Tender group.
 - b) The Tenders in each group will then be compared to determine the Tender with the lowest evaluated cost in that group. The lowest evaluated cost Tender from each group shall then be compared with each other and if as a result of this comparison a Tender from Group A or Group B is the lowest, it shall be selected for the award.
 - c) If as a result of the preceding comparison, a Tender from Group C is the lowest evaluated cost, an amount equal to or 15% of the respective tender price, including unconditional discounts and excluding provisional sums, if any, shall be added to the evaluated price offered in each tender from Group C. If the tender from Group C is still the lowest tender, it shall be selected for award. If not, the lowest evaluated tender from Group A or B based on the first evaluation price shall be selected.

8. Post qualification and Contract ward (ITT37), more specifically,

- 8.1 After determining the substantially responsive tender which offers the lowest-evaluated price, whether the tenderer is a manufacturer on or just a supplier: The Procuring Entity shall carry out the post-qualification, if no prequalification was done using the following criteria:
 - a) In case the tender <u>was subject to post-qualification</u>, the contract shall be awarded to the lowest evaluated tenderer, subject to confirmation of prequalification data, if so required.
 - b) In case the tender <u>was not subject to post-qualification</u>, the tender that has been determined to be the lowest evaluated tenderer shall be considered for contract award, subject to meeting each of the following conditions.
 - i) The Tenderer shall demonstrate that it has access to, or has available, liquid assets, unencumbered real assets, lines of credit, and other financial means (independent of any contractual advance payment) sufficient to meet the construction cash flow of Kenya Shillings____.
 ii) Minimum average annual construction turnover of Kenya Shillings_______[insert amount], equivalentcalculatedastotalcertifiedpaymentsreceivedforcontractsinprogressand/orcompleted within the last_______[insert of year] years.
 iii) At least_______(insertnumber)ofcontract(s)ofasimilarnatureexecutedwithinKenya,ortheEast African Community or abroad, that have been satisfactorily and substantially completed as a prime contractor,orjointventurememberorsub-contractoreachofminimumvalueKenyashillings equivalent.
 - iv) Other conditions depending on their seriousness.

a) History of non-performing contracts:

Tenderer and each member of JV in case the Tenderer is a JV, shall demonstrate that Non-performance of a contract did not occur because of the default of the Tenderer, or the member of aJV in the last _____(specify years). The required information shall be furnished in the appropriate form.

b) Pending Litigation

Financial position and prospective long-term profitability of the Single Tenderer, and in the case the Tenderer is a JV, of each member of the JV, shall remain sound according to criteria established with respect to Financial Capability under Paragraph (i) above if all pending litigationwillberesolvedagainsttheTenderer.Tenderershallprovideinformationonpending litigations in the appropriate form.

c) Litigation History

There shall be no consistent history of court/arbitral award decisions against the Tenderer, in the last______(specify years). All parties to the contract shall furnish the information in the appropriate form about any litigation or arbitration resulting from contracts

completedorongoingunderitsexecutionovertheyearsspecified. Aconsistenthistoryofawards against the Tenderer or any member of a JV may result in rejection of the tender.

| Eligibility and Qualification Criteria | | Compliance Requirements | | | | Documentation | |
|--|--|--|------------------------|--------------------------------------|------------------------------------|---------------|----------------------------------|
| No. Subject | | Requirement | Single Entity | Joint Venture (existing or intended) | | | Submission |
| | | | | All Members Combined | Each Member | One Member | Requirements |
| 1. El | ligibility | | | | | | |
| 1.1 | Nationality | Nationality in accordance with ITT 4.5 | Must meet requirement | Must meet requirement | Must meet requirement | N/A | Forms ELI – 1.1 with attachments |
| 1.2 | Conflict of Interest | No conflicts of interest in accordance with ITT 4.3 | Must meet requirement | Must meet requirement | Must meet requirement | N/A | Tender Submission Letter |
| 1.3 | Bank Eligibility | Not having been declared ineligible by the PPRA as described in ITT 4.6 and 5.1 | Must meet requirement | Must meet requirement | Must meet requirement | N/A | Tender Submission Letter |
| 1.4 | State-owned enterprise of Kenya | Meet conditions of ITT 4.7 | Must meet requirement | Must meet requirement | Must meet requirement | N/A | Forms ELI – 1.1 with attachments |
| 1.5 | United Nations resolution or Kenya law | Not having been excluded as a result of prohibition in Kenya laws or official regulations against commercial relations with the Tenderer's country, or by an act of compliance with UN Security Council resolution, both in accordance with ITT 4.9 and Section V. | Must meet requirement | Must meet requirement | Must meet requirement | N/A | Forms ELI – 1.1 with attachments |
| 2. H | istorical Contract Non-P | 1 | 1 | 1 | 1 | 1 | 1 |
| 2.1 | History of Non- Performing Contracts | Non-performance of a contract ¹ did not occur as a result of Supplier's default since 1 st January [insert year]. | Must meet requirement2 | Must meet requirements | Must meet requirement ² | N/A | Form PER-1 |
| 2.2 | Suspension Based on Execution of Tender/Proposal Securing Declaration by the Procuring Entity | Not under suspension based on execution of a Tender/Proposal Securing Declaration pursuant to ITT 4.8 | Must meet requirement | Must meet requirement | Must meet requirement | N/A | Tender Submission Letter |
| 2.3 | Pending Litigation | Tenderer's financial position and prospective long- term profitability still sound according to criteria established in 3.1 below and assuming that all pending litigation will be resolved against the Tenderer | Must meet requirement | N/A | Must meet requirement | N/A | Form PER-1 |
| 2.4 | Litigation History | No consistent history of court/arbitral award decisions | Must meet | Must meet | Must meet | N/A | Form PER-1 |

requirement

requirement

requirement

against the Tenderer since 1st January 2020

Nonperformance, as decided by the Procuring Entity, shall include all contracts where (a) nonperformance was not challenged by the Supplier, including through referral to the dispute resolution mechanism under the respective contract, and (b) contracts that were so challenged but fully settled against the Supplier. Nonperformance shall not include contracts where Procuring Entity's decision was overruled by the dispute resolution mechanism. Nonperformance must be based on all information on fully settled disputes or litigation, i.e. dispute or litigation that has been resolved in accordance with the dispute resolution mechanism under the respective contract and where all appeal instances available to the Tenderer have been exhausted.

² This requirement also applies to contracts executed by the Tenderer as JV member.

| Eligibility and Qualification Criteria | | Compliance Requirements | | | | Documentation | |
|--|----------------------------|---|--|--|-----------------------|--|----------------|
| No. Subject | | Requirement | Single Entity | Joint Venture (existing or intended) | | | Submission |
| | | • | | All Members Combined | Each Member | One Member | Requirements |
| | | | | | | | |
| 3. Fi | nancial Situation and Pe | rformance | | | | | |
| 3.1 | Financial Capabilities | The audited balance sheets or, if not required by the laws of the Tenderer's country, other financial statements acceptable to the Procuring Entity, for the last [insert number] years shall be submitted and must demonstrate the current soundness of the Tenderer's financial position and indicate its prospective long-term profitability. | Must meet requirement | N/A | Must meet requirement | N/A | |
| 3.2 | Average Annual Turnover | Average annual turnover (Average Annual Sales Revenue) from supply of Health Sector Goods of US\$ [insert amount in US\$ equivalent in words and figures], calculated as total certified payments received for contracts in progress and/or completed during the last three years. [Insert a figure which is at least five times the estimated contract amount] | Must meet requirement | Must meet requirement | N/A | N/A | Form FIN – 3.2 |
| 3.3 | Current Commitments | The Tenderer shall also demonstrate, to the satisfaction of the Procuring Entity, that it has adequate sources of finance to meet the cash flow requirements on contracts currently in progress and for future contract commitments. | | | | | Form CON -1 |
| | kperience | Every in an in averalty of Health Contag Conda for at | Maratanasat | NT/A | Most mast | NT/A | Form EVD 1 |
| 4.1 | General Experience | Experience in supply of Health Sector Goods for at least the last three years | Must meet requirement | N/A | Must meet requirement | N/A | Form EXP –1 |
| 4.2 (a) | Specific Experience | (i) Documentary evidence of the Tenderer's qualifications to perform the Contract in accordance with 4.2 (b)(i) below (ii) Technical and Production Capability in accordance with 4.2(b)(ii) as below. (iii) Experience on Packaging, Distribution in accordance with 4.2(b)(iii) below. | Must meet requirement Must meet requirement | Must meet requirement Must meet requirement | N/A | Must meet requirement Must meet requirement | |
| 4.2 | See below for details | | Must meet requirement | Must meet requirement | N/A | Must meet requirement | |

| | | | | | | | | ı |
|-----|--|-------------|---------------|--------------------------------------|--------|--------|--------------|---|
| Eli | Eligibility and Qualification Criteria | | | Compliance Requirements | | | | ı |
| No | . Subject | Requirement | Single Entity | Joint Venture (existing or intended) | | | Submission | ı |
| | | | | All Members | Each | One | Requirements | ı |
| | | | | Combined | Member | Member | | ı |
| (b) | | | | | | | | ı |

Specific Experience Requirements

The Specific Experience Requirements under 4.2 (b) (from the table above) are as follows:

4.2(b)(i) Documentary evidence in accordance with TDS ITT 11.1 4.2(b)

(ii) Technical and Production Capability.

The Tenderer shall provide evidence that it has the technical, and production capability necessary to perform the Contract:

(i) That it has successfully completed or substantially completed at least [insert number] similar contracts for supply ofthegoodsandwithinthelastfiveyears.[Thenumberofsimilarcontractsrequiredshouldbenotlessthanthree andnotmorethanfive(normallyfour),dependingonthesizeandcomplexityofthesubjectcontract].]Similar contractsarethoseofapproximatelythesamesizeandthatincludescomparableproducts, e.g., capsules, tablets, vaccines.

The goods may have been supplied by the Tenderer as a manufacturer or by its agent, with references being submitted to confirm satisfactory performance.

(ii) That it has achieved an annual average production rate of ______[The annual production rate required should be at least three times the quantities specified under the contract] during the last three years.

4.2 (b) (iii) Experience on Packaging, Distribution and Transportation

The Tenderer should provide proof of experience with and knowledge of modes of packing, distribution, and transportationofpharmaceuticalssimilartothosesubjecttoTenderingunderlogisticalandclimaticconditions similar to the ones in Kenya. It should provide names of countries to which the Tenderer has supplied (including packaged, distributed, and transported) products worth at least the amount [insert the amount] within the past three years.

[Note to the Procuring Entity: If Tenders for individual lots are permitted; the qualification criteria for each lot should be given separately].

FORM OF TENDER

(Amended and issued pursuant to PPRA CIRCULAR No. 02/2022)

INSTRUCTIONS TO TENDERERS

- i) All italicized text is to help the Tenderer in preparing this form.
- ii) The Tenderer must prepare this Form of Tender on stationery with its letterhead clearly showing the Tenderer's complete name and business address. Tenderers are reminded that this is a mandatory requirement.
- iii) Tenderer must complete and sign CERTIFICATE OF INDEPENDENT TENDER DETERMINATION and the SELF DECLARATION FORMS OF THE TENDERER as listed under (s) below.

| Date of this | Tender submission: | [insert date | (as day, month and y | year) of Tender | submission] | Tender |
|--------------|--------------------|----------------------|-------------------------|------------------|---------------|-----------|
| Name | and | Identification: | [insert | identį | fication] Alt | ternative |
| No.: | [inser | t identification No | if this is a Tender for | r an alternative | 1 | |
| То: | [Insert con | inlete name of Procu | ring Entityl | | | |

- a) **No reservation:** We have examined and have no reservations to the tendering document, including Add and issued in accordance with Instructions to Tenderers (ITT 8);
- b) **Eligibility:** We meet the eligibility requirements and have no conflict of interest in accordance with ITT 4;
- c) We have not been suspended nor declared in eligible by the Procuring Entity based on execution of a Tender-Securing Declaration or Proposal-Securing Declaration in Kenya in accordance with ITT 4.8;
- d) **Conformity:** We offer to supply in conformity with the tendering document and in accordance with the Delivery Schedules specified in the Schedule of Requirements the following Goods: [insert a brief description of the Goods and Related Services];
- *e)* **Tender Price:** The total price of our Tender, excluding any discounts offered in item(f) below is: [Insert one of the options below as appropriate]
 - **Option 1**, in case of one lot: Total price is: [insert the total price of the Tender in words and figures, indicating the various amounts and the respective currencies];

or

Option 2, in case of multiple lots: (a) Total price of each lot [insert the total price of each lot in words and figures, indicating the various amounts and the respective currencies]; and (b) Total price of all lots (sum of all lots) [insert the total price of all lots in words and figures, indicating the various amounts and the respective currencies];

- f) **Discounts:** The discounts offered and the methodology for their application are:
 - i) The discounts offered are:[Specify in detail each discount offered.]
 - ii) The exact method of calculations to determine the net price after application of discounts is shown below: [Specify in detail the method that shall be used to apply the discounts];
- g) **Tender Validity Period**: Our Tender shall be valid for the period specified in TDS 18.1 (as amended if applicable) from the date fixed or the Tender submission deadline specified in TDS 22.1 (as a mended if applicable), and it shall remain binding upon us and may be accepted at any time before the expiration of that period;

- h) **Performance Security**: I four Tender is accepted, we commit to obtain a Performance Security in accordance with the tendering document;
- i) **One Tender per Tenderer**: We are not submitting any other Tender(s) as an individual Tenderer, and we are not participating in any other Tender(s) as a Joint Venture partner or as a sub-contractor, and meet the requirements of ITT 4.4, other than alternative Tenders submitted in accordance with ITT 13:
- j) **Suspension and Debarment:** We, along with any of our sub-contractors, suppliers, consultants, manufacturers, or service providers for any part of the contract, are not subject to, and not controlled by any entity or individual that is subject to, a temporary suspension or a debarment imposed by the PPRA. Further, we are not ineligible under Kenya laws or official regulations or pursuant to a decision of the United Nations Security Council;
- *State-owned enterprise or institution:* [select the appropriate option and delete the other] [We are not a state-owned enterprise or institution]/ [We are a state-owned enterprise or institution but meet the requirements of ITT 4.7];
- l) Commissions, gratuities, fees: We have paid, or will pay the following commissions, gratuities, or fees with respect to the Tendering process or execution of the Contract: [insert complete name of each Recipient, its full address, the reason for which each commission or gratuity was paid and the amount and currency of each such commission or gratuity]

| Name of Recipient | Address | Reason | Amount |
|-------------------|---------|--------|--------|
| | | | |
| | | | |
| | | | |
| | | | |

(If none has been paid or is to be paid, indicate "none.")

- m) **Binding Contract:** We understand that this Tender, together with your written acceptance thereof included in your notification of award, shall constitute a binding contract between us, until a formal contract is prepared and executed;
- n) **Procuring Entity Not Bound to Accept:** We understand and that you are not bound to accept the lowest evaluated cost Tender, the Lowest Evaluated Tender or any other Tender that you may receive; and
- p) **Fraud and Corruption:** We here by certify that we have taken steps to ensure that no person acting for us or on our behalf engages in any type of Fraud and Corruption.
- p) Collusive practices: We hereby certify and confirm that the tender is genuine, non-collusive and made with the intention of accepting the contract if awarded. To this effect we have signed the "Certificate of Independent tender Determination" attached below.
- (q) We undertake to adhere by the Code of Ethics for Persons Participating in Public Procurement and Asset Disposal, copy available from ______(specify website) during the procurement process and the execution of any resulting contract.
- (r) **Beneficial Ownership Information:** We commit to provide to the procuring entity the Beneficial Ownership Information in conformity with the Beneficial Ownership Disclosure Form upon receipt of notification of intention to enter into a contract in the event we are the successful tenderer in this subject procurement proceeding.
- (s) We, the Tenderer, have duly completed, signed and stamped the following Forms as part of our Tender:
 - a) Tenderer's Eligibility; Confidential Business Questionnaire to establish we are not in any conflict to interest.
 - b) Certificate of Independent Tender Determination to declare that we completed the tender without

- colluding with other tenderers.
- c) Self-Declaration of the Tenderer–to declare that we will, if awarded a contract, not engage in any form of fraud and corruption.
- d) Declaration and commitment to the Code of Ethics for Persons Participating in Public Procurement and Asset Disposal.

Further, we confirm that we have read and understood the full content and scope of fraud and corruption as in formed in "Appendix 1-Fraud and Corruption" attached to the Form of Tender. Name of the Tenderer:*[insert complete name of the Tenderer]

Name of the person duly authorized to sign the Tender on behalf of the Tenderer: **[insert complete name of person duly authorized to sign the Tender]

Title of the person signing the Tender: [insert complete title of the person signing the Tender]

Signature of the person named above: [insert signature of person whose name and capacity are shown

above] Date signed [insert date of signing] day of [insert month],[insert year]

^{*:} In the case of the Tender submitted by a Joint Venture specify the name of the Joint Venture as Tenderer.

^{**:} Person signing the Tender shall have the power of attorney given by the Tenderer. The power of attorney shall be attached with the Tender Schedules.

TENDERER'S ELIGIBILITY- CONFIDENTIAL BUSINESS QUESTIONNAIRE

Instruction to Tenderer

Tender is instructed to complete the particulars required in this Form, *one form for each entity if Tender is a JV*. Tenderer is further reminded that it is an offence to give false information on this Form.

a) Tenderer's details

| | ITEM | DESCRIPTION |
|----|--|---|
| 1 | Name of the Procuring Entity | |
| 2 | Reference Number of the Tender | |
| 3 | Date and Time of Tender Opening | |
| 4 | Name of the Tenderer | |
| 5 | Full Address and Contact Details of the Tenderer. | Country City Location Building Floor Postal Address Name and email of contact person. |
| 6 | Current Trade License Registration Number and Expiring date | • |
| 7 | Name, country and full address (postal and physical addresses, email, and telephone number) of Registering Body/Agency | |
| 8 | Description of Nature of Business | |
| 9 | Maximum value of business which the Tenderer handles. | |
| 10 | State if Tenders Company is listed in stock exchange, | |
| | give name and full address (postal and physical | |
| | addresses, email, and telephone number) of | |
| | state which stock exchange | |

General and Specific Details

| b) | Sole Proprietor, provide the following details. | |
|------------|--|--|
| b) | Sole Proprietor, provide the following details. | |

Name in full ______Age___

| | - |
|-------------|-------------------|
| Nationality | Country of Origin |
| Citizenshin | |

c) **Partnership,** provide the following details.

| | Names of Partners | Nationality | Citizenship | % Shares owned |
|---|-------------------|-------------|-------------|----------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |

| d) | Keg | istered Company, provide the | | | | |
|------------------------------|--|--|--|--------------------|---------|--|
| | i) | Private or public Company | | | | |
| | ii) | State the nominal and issued c | capital of the Compar | ny:- | | |
| | | Nominal Kenya Shillings (Equ | uivalent) | | | |
| | | Issued Kenya Shillings (Equiv | | | | |
| | | | | •••••• | •••••• | |
| | iii) | Give details of Directors as fo | llows. | | | |
| | | Names of Director | Nationality | Citi | izenshi | p % Shares owned |
| | 2 | | | | | |
| | 3 | | | | | |
| Na | ames | firm?Yes/No of Person | Designation in the | | | est or Relationship with |
| | | | Procuring Entity | | Tend | erer |
| | | | | | | |
| | | | | | | |
|) | Con | flict of interest disclosure | | | | |
| Ту | pe of | Conflict | | Disclosu YES OF | | If YES provide details of the relationship with Tenderer |
| | ender | : : | | I LO OI | R NO | relationship with renderer |
| | ic un | | ols, is controlled by | 125 01 | R NO | relationship with Tenderer |
| 16 | | der common control with another receives or has received any | er tenderer. | 125 01 | R NO | relationship with Tenderer |
| su | endero bsidy | der common control with another receives or has received any a from another tenderer. | er tenderer. direct or indirect | | RNO | relationship with Tenderer |
| su Te | endero bsidy | der common control with another receives or has received any of from another tenderer. The receives are legal representations of the same legal representation. | er tenderer. direct or indirect | | RNO | relationship with Tenderer |
| Te ter | endere bsidy endere ndere | der common control with another receives or has received any of from another tenderer. The receives or has received any of from another tenderer. The receives or has received any of from another tenderer. The receives or has received any of from another tenderer. The receives or has received any of from another tenderer. | direct or indirect tive as another tenderer, directly | | RNO | relationship with Tenderer |
| Te ten | endere bsidy endere ndere ender throu | der common control with another receives or has received any of from another tenderer. The receives or has received any of from another tenderer. The relationship with another has a relationship with another has common third parties, that processes the received any of the received an | direct or indirect tive as another tenderer, directly buts it in a position | | RNO | relationship with Tenderer |
| Te ten Te or to the | endere bsidy endere ndere throu influe e deci | der common control with another receives or has received any of from another tenderer. The receives or has received any of from another tenderer. The receives or has received any of the received any of the received any of the received another tender of another tender is is on the received another tender of the received any of the receiv | tive as another tenderer, directly outs it in a position erer, or influence | | RNO | Telationship with Tenderer |
| Te ten Te or to the ten | enderenderender throu influenderinderinderinderinderinderinderinder | der common control with another receives or has received any of from another tenderer. The has the same legal representation in the relationship with another right common third parties, that prence the tender of another tender isions of the Procuring Entity reng process. | tive as another tenderer, directly turn tenderer, directly outs it in a position erer, or influence egarding this | | RNO | Telationship with Tenderer |
| Tee tee Tee or to the tee An | endere bsidy endere ndere ender throu influ- e deci- nderin ny of | der common control with another receives or has received any of from another tenderer. The receives or has received any of from another tenderer. The receives or has received any of the received any of the received any of the received another tender of another tender is is on the received another tender of the received any of the receiv | tive as another tenderer, directly buts it in a position berer, or influence begarding this pated as a lign or technical | | RNO | Telationship with Tenderer |

8

Document.

Tenderer would be providing goods, works, nonconsulting services or consulting services during implementation of the contract specified in this Tender

Tenderer has a close business or family relationship with a professional staff of the Procuring Entity who are directly or indirectly involved in the preparation of the Tender document or specifications of the Contract, and/or the Tender evaluation process of such contract.

Tenderer has a close business or family relationship with

| | Type of Conflict | Disclosure YES OR NO | If YES provide details of the relationship with Tenderer |
|---|--|-------------------------|--|
| | a professional staff of the Procuring Entity who would | | |
| | be involved in the implementation or supervision of the such Contract. | | |
| 9 | Has the conflict stemming from such relationship stated in item 7 and 8 above been resolved in a manner acceptable to the Procuring Entity throughout the tendering process and execution of the Contract. | | |

| e | | | | C | | | | |
|---|-----|--------|---|---|----|-----|----|---|
| f | 1 (| PI | ш | h | ca | tı. | n | n |
| | , , | | | | | u | ٧, | |

| On behalf of the Tenderer, I certify that the information given above is complete, current and accurate as at the date of submission. | | | | |
|---|--------|--|--|--|
| Full Name | | | | |
| Title or Designation | | | | |
| | | | | |
| (Signature) | (Date) | | | |

CERTIFICATE OF INDEPENDENT TENDER DETERMINATION

| of Pro | ocuri | rsigned, in submitting the accompanying Letter of Tender to the |
|---------|--------------|--|
| I certi | fy, o | n behalf of [Name of Tenderer] that: |
| 1. | I ha | ve read and I understand the contents of this Certificate; |
| 2. | Iunc | lerstandthattheTenderwillbedisqualifiedifthisCertificateisfoundnottobetrueandcompleteinevery respect; |
| 3. | | the authorized representative of the Tenderer with authority to sign this Certificate, and to submit the der on behalf of the Tenderer; |
| 4. | | the purposes of this Certificate and the Tender, I understand that the word "competitor" shall include any vidual or organization, other than the Tenderer, whether or not affiliated with the Tenderer, who: |
| | a) | has been requested to submit a Tender in response to this request for tenders; |
| | b) | could potentially submit a tender in response to this request for tenders, based on their qualifications, abilities or experience; |
| 5. | The | Tenderer discloses that [check one of the following, as applicable]: |
| | a) | The Tenderer has arrived at the Tender independently from, and without consultation, communication, agreement or arrangement with, any competitor; |
| | b) | the Tenderer has entered into consultations, communications, agreements or arrangements with one or more competitors regarding this request for tenders, and the Tenderer discloses, in the attached document(s), complete details thereof, including the names of the competitors and the nature of, and reasons for, such consultations, communications, agreements or arrangements; |
| 6. | | articular, without limiting the generality of paragraphs (5) (a) or (5) (b) above, there has been no sultation, communication, agreement or arrangement with any competitor regarding: |
| | a) | prices; |
| | b) | methods, factors or formulas used to calculate prices; |
| | c) | the intention or decision to submit, or not to submit, a tender; or |
| | d) | the submission of a tender which does not meet the specifications of the request for Tenders; except as specifically disclosed pursuant to paragraph (5)(b) above; |
| 7. | rega requ | ddition, there has been no consultation, communication, agreement or arrangement with any competitor arding the quality, quantity, specifications or delivery particulars of the works or services to which this test for tenders relates, except as specifically authorized by the procuring authority or as specifically losed pursuant to paragraph(5)(b) above; |
| 8. | indi the | terms of the Tender have not been, and will not be, knowingly disclosed by the Tenderer, directly or rectly, to any competitor, prior to the date and time of the official tender opening, or of the awarding of Contract, whichever comes first, unless otherwise required by law or as specifically disclosed pursuant to graph (5)(b) above. |
| Name | <u> </u> | |
| Title_ | | |
| Date_ | | |
| [Nam | e, titi | le and signature of authorized agent of Tenderer and Date] |

SELF- DECLARATION FORMS

FORM SD1

SELF DECLARATION THAT THE PERSON / TENDERER IS NOT DEBARRED IN THE MATTER OF THE PUBLIC PROCUREMENT AND ASSET DISPOSAL ACT 2015

| | | , of Post Office Boxhe Republic of | |
|--------|---|---|---|
| follo | | no respuesto es minimos | do norody make a statement as |
| 1. | No | | y) who is a Bidder in respect of Tender / description) for |
| 2. | THAT the aforesaid Bidder, its procurement proceeding under | Directors and subcontractors have not Part IV of the Act. | been debarred from participating in |
| 3. | THAT what is deponed to here | in above is true to the best of my know | ledge, information and belief. |
| | | | |
| (Title | e) | (Signature) | (Date) |
| D: 11 | 0.00 1.1.0 | | |

Bidder Official Stamp

FORM SD2

SELF DECLARATION THAT THE PERSON/TENDERER WILL NOT ENGAGE IN ANY CORRUPT OR FRAUDULENT PRACTICE

| I, | of P. O. Boxbeing a resident of |
|------------|---|
| ••••• | do hereby make a statement as follows:- |
| 1. | THAT I am the Chief Executive / Managing Director /Principal Officer/Director of |
| | |
| 2. | THAT the aforesaid Bidder, it's servants and/or agents/sub-contractors will not engage in any corrupt or fraudulent practice and has not been requested to pay any inducement to any member of the Board, Management, Staff and/or employees and/or agents of(insert name of the Procuring entity) which is the procuring entity. |
| 3. | THAT the aforesaid Bidder, its servants and/or agents /subcontractors have not offered any inducement to any member of the Board, Management, Staff and/or employees and/or agents of(name of the procuring entity). |
| 4. | THAT the aforesaid Bidder will not engage /has not engaged in any corrosive practice with other bidders participating in the subject tender |
| 5. | THAT what is deponed to herein above is true to the best of my knowledge information and belief. |
| (Title | e) (Signature) (Date) |
| | |

Bidder's Official Stamp

DECLARATION AND COMMITMENT TO THE CODE OF ETHICS

| I, (person) on behalf of (<i>Name of the Business/Company / Firm</i>) |
|---|
| Disposal Act, 2015, Regulations and the Code of Ethics for persons participating in Public Procurement and Asset Disposal and my responsibilities under the Code. |
| I do here by commit to abide by the provisions of the Code of Ethics for persons participating in Public Procuremen and Asset Disposal. |
| Name of Authorized signatory |
| Sign |
| Position |
| Office address |
| E-mail |
| Name of the Firm/Company. |
| Date |
| (Company Seal/ Rubber Stamp where applicable) |
| Witness Name |
| |
| Sign. |
| Date |

APPENDIX 1- FRAUD AND CORRUPTION

(Appendix 1 shall not be modified)

1. Purpose

1.1 The Government of Kenya's Anti-Corruption and Economic Crime laws and their sanction's policies and procedures, Public Procurement and Asset Disposal Act (no. 33 of 2015) and its Regulation, and any other Kenya's Acts or Regulations related to Fraud and Corruption, and similar offences, shall apply with respect to Public Procurement Processes and Contracts that are governed by the laws of Kenya.

2. Requirements

- 2.1 The Government of Kenya requires that all parties including Procuring Entities, Tenderers, (applicants/proposers), Consultants, Contractors and Suppliers; any Sub-contractors, Sub-consultants, Service providers or Suppliers; any Agents (whether declared or not); and any of their Personnel, involved and engaged in procurement under Kenya's Laws and Regulation, observe the highest standard of ethics during the procurement process, selection and contract execution of all contracts, and refrain from Fraud and Corruption and fully comply with Kenya's laws and Regulations as per paragraphs 1.1 above.
- 2.2 Kenya's public procurement and asset disposal act (no. 33 of 2015) under Section 66 describes rules to be followed and actions to be taken in dealing with Corrupt, Coercive, Obstructive, Collusive or Fraudulent practices, and Conflicts of Interest in procurement including consequences for offences committed. A few of the provisions noted below high light Kenya's policy of no tolerance for such practices and behavior:
 - 1) A person to whom this Act applies shall not be involved in any corrupt, coercive, obstructive, collusive or fraudulent practice; or conflicts of interest in any procurement or asset disposal proceeding;
 - 2) A person referred to under subsection (1) who contravenes the provisions of that sub-section commits an offence;
 - 3) Without limiting the generality of the subsection (1) and (2), the person shall be—
 a) disqualified from entering into a contract for a procure mentor asset disposal proceeding; or
 b) if a contract has already been entered into with the person, the contract shall be voidable;
 - 4) The voiding of a contract by the procuring entity under subsection (7) does not limit any legal remedy the procuring entity may have;
 - 5) An employee or agent of the procuring entity or a member of the Board or committee of the procuring entity who has a conflict of interest with respect to a procurement:
 - a) Shall not take part in the procurement proceedings;
 - b) shall not, after a procurement contract has been entered into, take part in any decision relating to the procurement or contract; and
 - c) shall not be a subcontractor for the tenderer to whom was awarded contract, or a member of the group of tenderers to whom the contract was awarded, but the subcontractor appointed shall meet all the requirements of this Act.
 - 6) An employee, agent or member described in subsection (1) who refrains from doing anything prohibited under that subsection, but for that subsection, would have been within his or her duties shall disclose the conflict of interest to the procuring entity;
 - 7) If a person contravenes subsection (1) with respect to a conflict of interest described in sub section (5)(a) and the contract is awarded to the person or his relative or to another person in whom one of them had a direct or indirect pecuniary interest, the contract shall be terminated and all costs incurred by the public entity shall be made good by the awarding officer. Etc.
- 2.3 In compliance with Kenya's laws, regulations and policies mentioned above, the Procuring Entity:
 - a) Defines broadly, for the purposes of the above provisions, the terms set forth below as follows:

- ii) "fraudulent practice" is any act or omission, including misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, aparty to obtain financial or other benefit or to avoid an obligation;
- "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;
- "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any iv) partyorthepropertyofthepartytoinfluenceimproperlytheactionsofaparty;
- "obstructive practice" is:

i)

- deliberatelydestroying, falsifying, altering, or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede investigation by Public Procurement Regulatory Authority (PPRA) or any other appropriate authority appointed by GovernmentofKenyaintoallegationsofacorrupt, fraudulent, coercive, or collusive practice; and/or threatening, harassing, or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or
- acts intended to materially impede the exercise of the PPRA's or the appointed authority's inspectionandauditrightsprovidedforunderparagraph2.3e.below.
- Defines more specifically, in accordance with the above procurement Act provisions set forth for b) fraudulent and collusive practices as follows:

"fraudulent practice" includes a misrepresentation of fact in order to influence a procurement or disposal process or the exercise of a contract to the detriment of the procuring entity or the tenderer or the contractor, and includes collusive practices amongst tenderers prior to or after tender submission designed to establish tender prices at artificial non-competitive levels and to deprive the procuring entity of the benefits of free and open competition.

- Rejects a proposal for award of a contract if PPRA determines that the firm or individual recommended for award, any of its personnel, or its agents, or its sub-consultants, sub-contractors, service providers, suppliers and/ or their employees, has, directly or indirectly, engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices in competing for the contract in question;
- Pursuant to the Kenya's above stated Acts and Regulations, may sanction or recommend to appropriate authority(ies) for sanctioning and debarment of a firm or individual, as applicable under the Acts and Regulations;
- Requires that a clause be included in Tender documents and Request for Proposal documents requiring (i) Tenderers(applicants/proposers), Consultants, Contractors, and Suppliers, and their Sub-contractors, Sub- consultants, Service providers, Suppliers, Agents personnel, permit the PPRA or any other appropriate authority appointed by Government of Kenya to inspect²all accounts, records and other documents relating to the procurement process, selection and/or contract execution, and to have them audited by auditors appointed by the PPRA or any other appropriate authority appointed by Government of Kenya; and
- Pursuant to Section 62 of the above Act, requires Applicants/Tenderers to submit along with their Applications/Tenders/Proposals a "Self-Declaration Form" as included in the procurement document declaring that they and all parties involved in the procurement process and contract execution have not engaged/will not engage in any corrupt or fraudulent practices.

For the a voidance of doubt, a party's ineligibility to be awarded a contract shall include, without limitation,(i) applying for pre-qualification expressing interest in A consultancy, and tendering, either directly or as a nominated sub-contractor, nominated consultant, nominated manufacturer or supplier, or nominated service provider, in respect of such contract, and (ii) entering into an addendum or amendment introducing a material modification to any existing contract.

² Inspections in this context usually are investigative (i.e., forensic) in nature. They involve fact-finding activities undertaken by the Investigating Authority or persons appointed by the Procuring Entity to address specific matters related to investigations/audits, such as evaluating the veracity of an allegation of possible Fraud and Corruption, through the appropriate mechanisms. Such activity includes but is not limited to: accessing and examining a firm's or individual's financial records and information, and making copies thereof as relevant; accessing and examining any other documents, data and information (whether in hard copy or electronic format) deemed relevant for the investigation/audit, and making copies there of as relevant; interviewing staff and other relevant individuals; performing physical inspections and site visits; and obtaining third party verification of information.

TENDERER INFORMATION FORM

shall be permitted and no substitutions shall be accepted.] Date:.....[insertdate(asday,monthandyear)ofTendersubmission] ITT No:.....[insert number of tendering process] Page of pages 1. Tenderer's Name [insert Tenderer's legal name] 2. In case of JV, legal name of each member: [insert legal name of each member in JV] 3. Tenderer's actual or intended country of registration: [insert actual or intended country of registration] 4. Tenderer's year of registration: [insert Tenderer's year of registration] 5. Tenderer's Address in country of registration: [insert Tenderer's legal address in country of registration] 6. Tenderer's Authorized Representative Information Name: [insert Authorized Representative's name] Address: [insert Authorized Representative's Address] Telephone/Fax numbers: [insert Authorized Representative's telephone/fax numbers] Email Address: [insert Authorized Representative's email address] 7. Attached are copies of original documents of [check the box(es) of the attached original documents] Articles of Incorporation (or equivalent documents of constitution or association), and/or documents of registration of the legal entity named above, in accordance with ITT 4.4. In case of JV, Form of intent to form JV or JV agreement, in accordance with ITT 4.1. In case of state-owned enterprise or institution, in accordance with ITT 4.7 documents establishing: Legal and financial autonomy Operation under commercial law Establishing that the Tenderer is not under the supervision of the Procuring Entity 2. Included are the organizational chart and a list of Board of Directors.

[The Tenderers hall fill in this Form in accordance with the instructions indicated below. No alterations to its format

FORM ELI - 1.1 (continued)

Tenderer Information Form

Date: [insert day, month, year]

ITT No. and title: [insert ITT number and title]

Page [insert page number] of [insert total number] pages

| 1. | Tenderer's name | | | | | | | | |
|-----|--|------------------|-----------|---------------|--|--|--|--|--|
| 2. | 2. Street Address: | Postal Code: | | City: | Country: | | | | |
| 3. | P.O. Box and Mailing Address: | | | | • | | | | |
| 4. | Telephone Number: | | | | | | | | |
| 5. | Fax Number: | | | | | | | | |
| 6. | E-mail Address: | | | | | | | | |
| 7. | Web Site: | | | | | | | | |
| 8. | Contact Name: | | | | | | | | |
| 9. | Contact Title: | | | | | | | | |
| 10. | Type of Business: | | | | | | | | |
| 11. | If Other, specify: | | | | | | | | |
| 12. | Nature of Business: | | | | | | | | |
| 13. | Year Established: | | | | | | | | |
| 14. | Dates, Numbers, and Expiration Da | tes of Current I | Licenses | and Permits | : | | | | |
| 15. | Current health authority registration | information: | | | | | | | |
| 16. | Proof of product and facility regist WHO Certification Scheme, GMP) | trations with K | enya reg | ulatory auth | nority and international agencies (e.g | | | | |
| | of the raw material and or processing | • | | g and licensi | ing of facilities in the country of original | | | | |
| | ate of last inspection: | | | | | | | | |
| | Quality Assurance Certification | | | | | | | | |
| (P | lease include a copy of your latest ce | ertificate): | | | | | | | |
| 19. | Production capacity: [insert peak a units/month, etc.] | and average pro | oduction | capacity ov | ver the last three years in units/day o | | | | |
| 20. | List of names and addresses of sour | ces of raw mate | erial and | what produc | cts they will be used in: | | | | |
| 21. | 21. Proof of raw material product and facility registrations with Kenya regulatory authority and international agencies (e.g., WHO Certification Scheme, GMP): | | | | | | | | |

| 22. Raw materials tested prior to use: |
|---|
| 23. Presence and characteristics of in-house quality control laboratory |
| 24. Names and addresses of external quality control laboratories used: |
| 25. Are all finished products tested and released by quality control prior to release for sale? Yes No, If not, why? |
| 26. List control tests done during production? If so list. |
| 27. Procedures for dealing with rejected batches: |
| 28. List tests conducted after production and prior to release of product on market: |
| 29. List product recalls linked to defects during the last 36 months. Include reason and date of recall. |
| 30. Are technical documents available in: [Procuring Entity should insert language] Yes or No |
| |

TENDERER'S JV MEMBERS INFORMATION FORM

filled in for the Tenderer and for each member of a Joint Venture]]. Date:..... [insert date (as day, month and year) of Tender submission] tendering process] Alternative No.: [insert No.:[insert number of identification No .if this is a Tender for an alternative] Page___of____pages Tenderer's Name: [insert Tenderer's legal name] Tenderer's JV Member's name: [insert JV's Member legal name] Tenderer's JV Member's country of registration: [insert JV's Member country of registration] Tenderer's JV Member's year of registration: [insert JV's Member year of registration] 4. Tenderer's JV Member's legal address in country of registration: [insert JV's Member legal address in country of registration] Tenderer's JV Member's authorized representative information Name: [insert name of JV's Member authorized representative] Address: [insert address of JV's Member authorized representative] Telephone/Fax numbers: [insert telephone/fax numbers of JV's Member authorized representative] Email Address: [insert email address of JV's Member authorized representative] Attached are copies of original documents of [check the box(es) of the attached original documents] 7. Articles of Incorporation (or equivalent documents of constitution or association), and/or registration documents of the legal entity named above, in accordance with ITT4.4 ☐ Tax Obligations for Kenyan Tenderers, attach copy of current tax clearance certificate or tax exemption certificate issued by the Kenya Revenue Authority in accordance with ITT 4.13. In case of a state-owned enterprise or institution, documents establishing legal and financial autonomy, operation in accordance with commercial law, and not under the supervision of the Procuring Entity, in accordance with ITT4.7. 2. Included are the organizational chart and a list of Board of Directors.

[The Tenderer shall fill in this Form in accordance with the instructions indicated below. The following table shall be

FORM FIN – 3.1

FINANCIAL SITUATION AND PERFORMANCE

[The following table shall be filled in for the Tenderer and for each member of a Joint Venture]

Tenderer's Name: [insert full name]

Date: [insert day, month, year]

Joint Venture Member Name: [insert full name]

ITT No. and title: [insert ITT number and title]

Page [insert page number] of [insert total number] pages

1. Financial data

| Type of Financial information in (currency) Historic information for previous _ [insert number] years, [insert in words] (amount in currency, currency, exchange rate, USD equivalent) | | | | | | | | | | |
|--|--------------|-----------------|--------|--|--|--|--|--|--|--|
| | Year 1 | Year 2 | Year 3 | | | | | | | |
| Statement of Financial Position | (Information | from Balance Sl | neet) | | | | | | | |
| Total Assets (TA) | | | | | | | | | | |
| Total Liabilities (TL) | | | | | | | | | | |
| Total Equity/Net Worth (NW) | | | | | | | | | | |
| Current Assets (CA) | | | | | | | | | | |
| Current Liabilities (CL) | | | | | | | | | | |
| Working Capital (WC) | | | | | | | | | | |
| Information from Income Stater | nent | | | | | | | | | |
| Total Revenue (TR) | | | | | | | | | | |
| Profits Before Taxes (PBT) | | | | | | | | | | |
| Cash Flow Information | | | | | | | | | | |
| Cash Flow from Operat Activities | ing | | | | | | | | | |

3. FINANCIAL DOCUMENTS

requirements

The Tenderer and its parties shall provide copies of financial statements for [number] years pursuant Section III, Qualifications Criteria and Requirements, Sub-factor 3.1. The financial statements shall:

| a) | reflect the financial situation of the Tenderer or in case of JV member, and not an affiliated entity(such as parent company or group member). |
|----|--|
| b) | Be independently audited or certified in accordance with local legislation. |
| c) | Be complete, including all notes to the financial statements. |
| d) | Correspond to accounting periods already completed and audited. |

Attached are copies of financial statements for the [number] years required above; and complying with the

⁴If the most recent set of financial statements is for a period earlier than 12 months from the date of tendering, the reason for this should be justified.

FORM FIN - 3.2

AVERAGE ANNUAL TURNOVER (ANNUAL SALES VALUE)

[The following table shall be filled in for the Tenderer and for each member of a Joint Venture]

Tenderer's Name: [insert full name]

Date: [insert day, month, year]

Joint Venture Member Name: [insert full name]

ITT No. and title: [insert ITT number and title]

Page [insert page number] of [insert total number] pages

| Annual turnov | Annual turnover data | | | | | | | | | | | |
|-----------------------------|---------------------------------------|------------------------------|----------------|--|--|--|--|--|--|--|--|--|
| Year | Amount Currency | Exchange rate | USD equivalent | | | | | | | | | |
| [indicate calendar year] | [insert amount and indicate currency] | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | Average Annual Turnover * | | | | | | | | | | |

^{*} Total USD equivalent for all years divided by the total number of years.

FORM CON-1 CURRENT CONTRACT COMMITMENTS / CONTRACTS IN PROGRESS FORM

| 1. | Name of Contract(s) |
|----|---|
| 2. | Procuring Entity Contact Information [insert address, telephone, fax, e-mail address] |
| 3. | Value of outstanding contracts [current US\$ equivalent] |
| 4. | Estimated delivery date |
| 5. | Average monthly invoices over the last six months (US\$/mon.) |

FORM - EXP - 1 - EXPERIENCE

| Contracts over [insert amount] during the last three years: | | | | | | | | | | |
|---|-------|------|-------------------------|------------------------|--|--|--|--|--|--|
| Procuring Entity | Value | Year | Goods/Services Supplied | Country of Destination | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

FORM - PER 1

HISTORICAL CONTRACT NON-PERFORMANCE, AND PENDING LITIGATION AND LITIGATION HISTORY

| [The fol | lowing table shal | l be filled | in for the Tenderer and for each member of a Joi | int Venture | 7 | | | | | | |
|------------------|---|-------------|---|--|------------|----------------|--|--|--|--|--|
| Tenderer | 's Name: | | [insert full name] | | | | | | | | |
| Date: | [insert do | ay, month | , year] | | | | | | | | |
| Joint Ver | nture Member Na | me: | [insert full name] | | | | | | | | |
| ITT No. | and title: | [inser | t ITT number and title] | | | | | | | | |
| Page | [insert page | number] | of[insert total number] pages. | | | | | | | | |
| Non-Perfor | med Contracts in a | accordanc | e with Section III, Qualification Criteria and Requir | rements | | | | | | | |
| | ract non-performa Requirements, Sub- | | t occur since 1 st January [insert year] specified in S | Section III, | Qualifica | ation Criteria | | | | | |
| | ract(s) not perfor nirements, requirer | | e 1st January [insert year] specified in Section | III, Qualif | ication | Criteria and | | | | | |
| Year | Non- performed portion of contract | | Contract Identification | Total Contr value, curre and US\$ eq | ency, excl | | | | | | |
| [insert year] | [insert amount and percentage] | | Identification: [indicate complete contract name/and any other identification] | [insert amo | unt] | | | | | | |
| | | Name of | Procuring Entity: [insert full name] | | | | | | | | |
| | | Address | of Procuring Entity: [insert street/city/country] | | | | | | | | |
| | | Reason(s |) for nonperformance: [indicate main reason(s)] | | | | | | | | |
| Pending Lit | igation, in accordar | nce with Se | ection III, Qualification Criteria and Requirements | | | | | | | | |
| □ No p | ending litigation in | accordan | ce with Section III, Qualification Criteria and Requi | irements, Su | ıb-Facto | r 2.3 | | | | | |
| □ Pend below | | ordance w | ith Section III, Qualification Criteria and Requirement | ents, Sub-Fa | actor 2.3 | as indicated | | | | | |
| Year | of Amount in | dispute | Contract Identification | | Contract | Amount | | | | | |
| dispute | (currency) | | | (exchange | rate) | Equivalent | | | | | |
| [insert year] | [insert amou | | Contract Identification: [indicate complete contract name, number, and any other identification] Name of Procuring Entity: [insert full name] Address of Procuring Entity: [insert street/city/country] Matter in dispute: [indicate main issues in dispute] Party who initiated the dispute: [indicate "Procuring Entity" or "Supplier"] Status of dispute: [Indicate if it is being treated by the Adjudicator, under Arbitration or being dealt with by the Judiciary] /arbitral award decisions in accordance with Sectio | n III, Quali | | Criteria and | | | | | |
| Requirem | ents, Sub-Factor 2 | .4. | | | | | | | | | |
| | Consistent history of | of_court/ar | bitral award decisions in accordance with Section | III. Qualif | ication (| Criteria and | | | | | |

| Requirements | s, Sub-Factor 2.4 as indic | ated below. | |
|------------------|------------------------------------|--|--|
| Year of award | Outcome as percentage of Net Worth | Contract Identification | Total Contract Amount (currency), USD Equivalent (exchange rate) |
| [insert year] | [insert percentage] | Contract Identification: [indicate complete contract name, number, and any other identification] Name of Procuring Entity: [insert full name] Address of Procuring Entity: [insert street/city/country] Matter in dispute: [indicate main issues in dispute] Party who initiated the dispute: [indicate "Procuring Entity" or "Supplier"] Court/ arbitral award decision: [Indicate if the award decision was against the Tenderer or any member of a joint venture.] | [insert amount] |

PRICE SCHEDULE FORMS

PRICE SCHEDULE: GOODS MANUFACTURED OUTSIDE KENYA, TO BE IMPORTED PLEASE QUOTE FOR THE EXACT NUMBER OF CAPS/TABLETS AS INDICATED IN THE PRICE SCHEDULE TO AVOID INCONVENIENCES. PRICES QUOTED MUST INCLUDE ALL THE TRANSPORTATION COSTS AND ALL LEVIES APPLICABLE TAXES/LEVIES

| | | | | | | | | | Date | : | | | | | |
|------------------|------------------------------------|----------|---|---|-----------------|--|---|---|---------------|--|--|--------------------------------|---------------------------|---|----|
| | | | | (Group C Tenders, goods to be imported) | | | | | | | | | _ | | |
| | | | | | 1 | •.1 | TOTO 1.5 | | | | o: | | | | |
| | T | T | T | Currencies in | | | 111 15 | | Page | | of | ı | T | 1 | |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | | | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| Produc t code | Product | Strength | Dosage form | Unit pack size | Qty. offered | Unit prices | | Total Total unit price per | | Local agent's commissio n as a % of CIP price included | Shi pm ent wei ght and vol | Name of Manufa cturer | Cnty. Of origi n | Phar ma- copo eial stand ard | |
| | | | | | | | | | | | in quoted price | um e | | | |
| | | | | | | [a] CIP nam ed place of desti natio n (spec ify one) | [b] Inland transp., insurance & other local costs incidental to delivery if specified | [c] Other incident al costs as defined in the SCC | price [a+b+c] | item [6 x 8] | price | C | | | |
| | ITEM DESCRIPTION/CONT RACT PACKAGE | PACK | ESTIMATE D ANNUAL CONSUMP TION | | | | | | | | | | | | |
| | ANTIBIOTICS | | | | | | | | | | | | | | |
| 1. | Africef 1gm | | | Vial | 30,000 | | | | | | | | | | |

| 2. | Africef SB 1.5gm | Vial | 30,000 |
|-----|---|-------------|--------|
| 3. | Amoxicillin/Clavulanic | 70ml Bottle | 3710 |
| | Acid Syrup 457mg/5ml | <u> </u> | |
| 4. | Ampicillin/Sulbactum Injection 1.5g | Vial | 5000 |
| 5. | Ceftaroline Injection 600mg | Vial | 3000 |
| 6. | Cefoperazone/Sulbactam Injection 2g | Vial | 3000 |
| 7. | Clarithromycin Injection 500mg | Ampoule | 40000 |
| 8. | Clindamycin Capsule 300mg | 1x10s | 20000 |
| 9. | Colistin Injection 1MU | Vial | 100 |
| 10. | Gemifloxacin Capsule 320mg | 1x5 | 3000 |
| 11. | Merado 1 gm | Vial | 30,000 |
| 12. | Minocycline Injection 100mg | Vial | 300 |
| 13. | Telavancin Injection 250mg | Vial | 300 |
| | Vancomycin Capsule 250mg | 2x10s | 300 |
| | ANTIFUNGALS | | |
| 16. | Clotrimazole Vaginal Tablet 500mg | 1x1s | 3000 |
| 17. | Micafungin Injection 50mg | Vial | 100 |
| 18. | Flucytosine Capsule 500mg | 1x30s | 200 |
| 19. | Flucytosine Injection 2.5g/250ml | Vial | 200 |
| 20. | Posaconazole Tablet Delayed Release 100mg | 1x100s | 300 |
| 21. | Posaconazole Injection 300mg | Vial | 200 |
| 22. | Luliconazole cream 1% | 30gm | 1200 |

| T | 4 3 700 20 21 21 21 21 21 21 21 21 21 21 21 21 21 | | | 1 | I | ı | 1 | ı | |
|-----|---|---------------|-------------|---|---|---|---|---|------|
| | ANTIRHEUMATIC DRUGS | | | | | | | | l |
| 23. | Everolimus Tablet 0.25mg | 1x10s | 6000 | | | | | | |
| 24. | Everolimus Tablet 0.5mg | 1x10s | 6000 | | | | | | |
| 25. | Everolimus 10mg | 1x10s | 6000 | | | | | | |
| 26. | Everolimus Tablet 1mg | 1x10s | 15000 | | | | | | |
| 27. | Tofacitinib Citrate Tablet 5mg | Tablet | 6000 | | | | | | |
| | GASTROINTESTINAL DRUGS | | | | | | | | |
| 28. | Chlolestyramine Satchet 4gm | Satchet | 6000 | | | | | | |
| 29. | Domperidone Syrup 5mg/5mls | Bottle | 6000 | | | | | | |
| 30. | Dexlansoprazole 30mg | 1x10 | 6000 | | | | | | |
| 31. | Emitino 8mg | 1x10 | 6000 | | | | | | i |
| 32. | Sodium Phosphates Enema 100ml | Bottle | 3000 | | | | | | |
| 33. | Glycerin Infant Suppositories | Supposit y | tor 1000 | | | | | | |
| 34. | Anusol Cream | 25g | 10000 | | | | | | l |
| 35. | B- Complex/Carnitine/Lysi ne/Cyproheptadine Orotate Syrup | 250ml | 3000 | | | | | | |
| 36. | Ondansetron Tablet 8mg | 1x10s | 10000 | | | | | | |
| 37. | Hyoscine-N-Butyl Bromide/Paracetamol Tablet 10mg/500mg | 1x100s | 1000 | | | | | | |
| 38. | Otilonium Bromide Tablet 40mg | 1x100s | 1000 | | | | | | |
| 39. | Polyethylene Glycol with Electrolytes for Oral Solution Satchet 118g | Satchet | 1000 | | | | | | |

| - | | | | | | 1 | 1 | | |
|-----|---|------------|-------------|----------|------|---|-------|-------|--|
| 40. | Rabeprazole Sodium/Itopride Sustained Release Tablet 20mg/150mg | 1x10s | 2000 | | | | | | |
| 41. | Rabeprazole/Clarithromy cin/Amoxicillin 20/500/1000 mg | Kit | 1000 | | | | | | |
| 42. | Octreotide Long Acting Release Injection 30mg | Vial | 500 | | | | | | |
| 43. | Sulfasalazine Tablet 500mg | 1x10s | 50 | <u> </u> | | | | | |
| 44. | Senna Tablet 7.5mg | 1x100s | 3000 | <u></u> | | | | l | |
| | ANTIDIABETIC | | | | | | | | |
| 45. | Diazoxide Suspension 50mg/ml | Bottle | 50 | | | | | | |
| 46. | Empagliflozin Tablet 25mg | 1x28s | 8000 | | | | | | |
| 47. | Empaglifozin/Metformin Tablet IR 12.5mg/500mg | 1x60s | 4000 | | | | | | |
| 48. | Empaglifozin/Metformin Tablet IR 12.5mg/1000mg | 1x60s | 3000 | | | | | | |
| 49. | Empaglifozin/Metformin Tablet IR 5mg/500mg | 1x60s | 3000 | | | | | | |
| | Empaglifozin/Metformin Tablet IR 5mg/1000mg | 1x60s | 3000 | | | | | | |
| 51. | Pioglitazone/Metformin Tablet 15mg/500mg | 1x28s | 3000 | | | | | | |
| 52. | Pioglitazone/Metformin Tablet 15mg/850mg | 1x28s | 3000 | | | | | | |
| 53. | Human Insulin Long Acting Basal (Glargine) Injection, 100IU/ml | Vial | 800 | | | | | | |
| 54. | Human Insulin, Long Acting Basal (Glargine) Injection, Pre-filled Pen, 100IU/ml, 3ml | VIal | 800 | | | | | | |

| 1 | | | | | | ı | 1 | 1 | | 1 | |
|-----|--|-------------|--------------------|-------|------|---|---|---|------|---|------|
| 55. | Human Insulin, Premixed (Ultra-Short Acting + Intermediate Acting) Injection | | Vial | 600 | | | | | | | |
| 56. | Human Insulin, Ultra Short Acting Injection 100IU/ml | | Vial | 600 | | | | | | | |
| 57. | Novorapid, Pen Fill 3ml | | VIal | 200 | | | | | | | |
| 58. | Novomix Pen 100IU/ml | | Vial | 200 | | | | | | | |
| 59. | Levemir Pen 100Units/ml 3ml | | Vial | 200 | | | | | | | |
| 60. | Repaglinide Tablet 0.5mg | | 1x100s | 500 | | | | | | | |
| | ANALGESICS/ANTIPY RETICS | | | | | | | | | | |
| 61. | Celecoxib /Paracetamol Tablet 200mg/500mg | | 1x10s | 10000 | | | | | | | |
| 62. | Celecoxib/Paracetamol/ Chlorzoxazone Tablet 200mg/325mg/250mg | | 1x10s | 10000 | | _ | | | | | |
| | Celecoxib /Paracetamol Tablet 200mg/325mg | | 1x10s | 6000 | | | | | | | |
| 64. | Erenumab Pre Filled Syringe Injection 70mg | | Pre- Filled Pen | 100 | | | | | | | |
| 65. | S-Etodolac/Paracetamol Tablet 400mg/325mg | | 1x10s | 6000 | | | | | | | |
| 66. | Ibuprofen Injection 20mg | | Vial | 5000 | | | | | | | |
| 67. | Paracetamol/Ibuprofen Injection 1000mg/300mg | | Vial | 10000 | | | | | | | |
| 68. | Ibuprofen/Paracetamol Suspension 125mg/100mg | | 100mls | 20000 | | | | | | | |
| 69. | Lornoxicam Injection 8mg | | Vial | 6000 | | | | | | | |
| 70. | Morphine Powder 100g | | 100g | 100 | | | _ | | | | |
| 71. | Morphine Oral Liquid 10mg/ml | | 100mls | 2000 | | | | | | | |
| 72. | Morphine Tablet 30mg | | 1x60 | 60000 | | | | | | | |
| | | | | | | | | | | | |

| | | | | | | • | | | |
|-----|--|---------|-------|-------------|------|---|--|----------|-------|
| 73. | Naproxen/Esomeprazole 500mg/20mg | 1x10 | 1200 | | | | | <u> </u> | _ |
| 74. | Oxycodone Tablet IR 5mg | 1x10 | 4000 | | | | | | |
| 75. | Probenecid Tablet 250mg | 1x100s | 1000 | | | | | | |
| 76. | Tramadol/Paracetamol Tablet 37.5mg/325mg | 1x20s | 50000 | | | | | | |
| | RESPIRATORY DRUGS | | | | | | | | |
| 77. | Beclomethasone Inhaler 200mcg/Dose | Inhaler | 100 | | | | | | |
| 78. | Beclomethasone/Salbuta mol Inhaler 50/100mg | Inhaler | 100 | | | | | | |
| 79. | Budesonide Inhaler 200mcg | Inhaler | 100 | | | | | | |
| 80. | Caffeine Citrate Injection 10mg/ml | Vial | 11000 | | | | | | |
| 81. | Formoterol/Budesonide Inhaler 4.5mcg/160mcg per Dose | Inhaler | 1000 | | | | | | |
| 82. | Formoterol/Budesonide Inhaler 6mcg/100mcg per Dose | Inhaler | 1000 | | | | | | |
| 83. | Glycopyrronium Bromide Injection 200mcg | Vial | 4000 | | | | | | |
| 84. | Ipratropium Inhaler 20mcg/Dose (200 Doses) | Inhaler | 300 | | | | | | |
| 85. | Ipratropium/ Salbutamol Inhaler 20mcg/100mcg per Dose | Inhaler | 300 | _ | | | | | |
| 86. | Ipratropium/Levosalbuta mol Inhaler 20mcg/50mcg per Dose | Inhaler | 300 | | | | | | |
| 87. | Ipratropium/Salbutamol Nebulizer 500mcg/2.5mg | Respule | 30000 | | | | | | |
| 88. | Levosalbutamol Syrup 1mg/5mls | Bottle | 3000 | | | | | | |

| | | | $\overline{}$ | | 1 | 1 | 1 | I | | | | | |
|---|---|---|--|-------|--------------|-------|-------|--|--|----------|-------|-------------|-------|
| 150mg | | 1x10s | 400 | | | | | | | | | | |
| Prostaglandin E1 Injection 500mcg | | Vial | 20 | | | | | | | | | | |
| Salbutamol Injection 500mcg/ml | | Vial | 100 | | | | | | | | | | |
| Salmeterol/Fluticasone Inhaler 25/50mcg per Dose | | Inhaler | 100 | | | | | | | | | | |
| Salmeterol/Fluticasone Inhaler 50/100mcg per Dose | | Inhaler | 100 | | | | | | | | | | |
| Tiotropium Bromide Respimat Inhaler 2.5 mcg/dose | | Inhaler | 300 | | | | | | | | | | |
| 200mg | | 1x100s | 100 | | | | | | | | | | 1 |
| CARDIOVASCULAR/ RENAL | | | | | | | | | | | | | 1 |
| Apixaban Tablet 2.5mg | | 1x10s | 1000 | | | | | | | <u> </u> | | <u> </u> | |
| Aliskiren Tablet 150mg | | 1x30s | 1000 | | | | | | | | | | 1 |
| Alteplase Injection 100mg | | vial | 20 | | | | | | | | | | |
| Alteplase Injection 50mg | | vial | 20 | | | | | | | | | | |
| Amiodarone Injection 150mg | | Ampoule | 1200 | | | | | | | | | | |
| Amlodipine/Hydrochloro thiazide Tablet 5mg/12.5mg | | 1x100s | 10000 | | | | | | | | | | |
| Amlodipine/Indapamide Tablet 5mg/1.25mg | | 1x30s | 900 | | | | | | | | | | 1 |
| Bempedoic acid 180mg | | 1x30s | 1200 | | | | | | | <u> </u> | | | |
| Bempedoic acid/Ezetimibe 180mg/10mg | | 1x30s | 1200 | | | | | | | | | | |
| S-Amlodipine Tablet 5mg | | 1x100s | 1000 | | | | | | | | | | 1 |
| S-Amlodipine Tablet 2.5mg | | 1x100s | 2000 | | | | | | | | | | |
| | Prostaglandin E1 Injection 500mcg Salbutamol Injection 500mcg/ml Salmeterol/Fluticasone Inhaler 25/50mcg per Dose Salmeterol/Fluticasone Inhaler 50/100mcg per Dose Tiotropium Bromide Respimat Inhaler 2.5 mcg/dose Pirfenidone Tablets 200mg CARDIOVASCULAR/ RENAL Apixaban Tablet 2.5mg Aliskiren Tablet 150mg Alteplase Injection 100mg Alteplase Injection 50mg Amiodarone Injection 150mg Amiodipine/Hydrochloro thiazide Tablet 5mg/12.5mg Amlodipine/Indapamide Tablet 5mg/1.25mg Bempedoic acid/Ezetimibe 180mg/10mg S-Amlodipine Tablet 5mg S-Amlodipine Tablet | Prostaglandin E1 Injection 500mcg Salbutamol Injection 500mcg/ml Salmeterol/Fluticasone Inhaler 25/50mcg per Dose Salmeterol/Fluticasone Inhaler 50/100mcg per Dose Tiotropium Bromide Respimat Inhaler 2.5 mcg/dose Pirfenidone Tablets 200mg CARDIOVASCULAR/ RENAL Apixaban Tablet 2.5mg Aliskiren Tablet 150mg Alteplase Injection 100mg Alteplase Injection 150mg Amiodarone Injection 150mg Amiodipine/Hydrochloro thiazide Tablet 5mg/12.5mg Amlodipine/Indapamide Tablet 5mg/1.25mg Bempedoic acid 180mg Bempedoic acid/Ezetimibe 180mg/10mg S-Amlodipine Tablet 5mg S-Amlodipine Tablet 5mg S-Amlodipine Tablet | Prostaglandin E1 Injection 500mcg Salbutamol Injection 500mcg/ml Salmeterol/Fluticasone Inhaler 25/50mcg per Dose Salmeterol/Fluticasone Inhaler 50/100mcg per Dose Tiotropium Bromide Respimat Inhaler 2.5 mcg/dose Pirfenidone Tablets 200mg CARDIOVASCULAR/ RENAL Apixaban Tablet 2.5mg Aliskiren Tablet 150mg Alteplase Injection 100mg Amiodarone Injection 150mg Amiodipine/Hydrochloro thiazide Tablet 5mg/12.5mg Amlodipine/Indapamide Tablet 5mg/1.25mg Bempedoic acid/Ezetimibe 180mg/10mg S-Amlodipine Tablet 5mg S-Amlodipine Tablet | 150mg | 150mg | 150mg | 150mg | 150mg 1810s 400 400 1810s 400 40 | 150mg 1810s 400 1810s 400 1810s 400 1810s 1810s 400 1810s 1810 | 150mg | 150mg | 150mg | 150mg |

| | | 1 | | | | | | |
|------|--|---------|------|------|---|--|-------|--|
| 107. | Calcium Polystyrene Sulphonate Satchet 15g | Satchet | 1000 | | _ | | _ | |
| 108. | Cardioplegia Solution | Vial | 100 | | | | | |
| | Chlorthalidone Tablet 12.5mg | 1x100s | 1000 | | | | | |
| 110. | Chlorthalidone Tablet 6.25mg | 1x100s | 1000 | | | | | |
| 111. | Cilnidipine Tablet 5mg | 1x10s | 5000 | | | | | |
| 112. | Clonidine Tablet 0.1mg | 1x10s | 500 | | | | | |
| 113. | Clopidogrel Tablet 75mg | 1x10s | 1000 | | | | | |
| 114. | Dabapoietin Alfa Injection 25mcg | Vial | 1000 | | | | | |
| 115. | Dabapoietin Alfa Injection 40mcg | Vial | 1000 | | | | | |
| 116. | Desmopressin Nasal Spray 10mcg/spray | Spray | 50 | | | | | |
| | Desmopressin Tablet 0.1mg | 1x100s | 100 | | | | | |
| 118. | Digoxin Injection 500mcg | Ampoule | 100 | | | | | |
| 119. | Diltiazem Gel 2% | Tube | 100 | | | | | |
| 120. | Diltiazem Injection 5mg/ml | Vial | 100 | | | | | |
| 121. | Doxazocin Tablet 2mg | 1x10s | 100 | | | | | |
| 122. | Esmolol Injection 100mg | Vial | 100 | | | | | |
| 123. | Glyceryl Trinitrate Injection 50mg Vial | Vial | 50 | | | | | |
| 124. | Hydrochlorothiazide Tablet 12.5mg | 1x100s | 5000 | | | | | |
| 125. | Isoproterenol (Isoprenaline) Injection 2mg | Vial | 100 | | | | | |
| 126. | Isosorbide Dinitrate Tablet 20mg | 1x10s | 100 | | | | | |
| 127. | Isosorbide Mononitrate Tablet 60mg | 1x10s | 100 | | | | | |
| 128. | Milrinone Injection 10mg Vial | Vial | 200 | | | | | |

| 129. | Nicardipine Injection 25mg Vial | Vial | 200 | | | | | | | |
|------|--|----------|-------|--|-------|---|--|---|---|--|
| 130. | Perindopril/Amlodipine Tablet 5mg/5mg | 1x10s | 300 | | | | | | | |
| 131. | Perindopril/Amlodipine Tablet 5mg/10mg | 1x10s | 300 | | | | | | | |
| 132. | Perindopril/Amlodipine/I ndapamide 5mg/5mg/1.25mg | 1x10s | 300 | | | | | | | |
| 133. | Perindopril/Amlodipine/I ndapamide 10mg/10mg/2.5mg | 1x10s | 400 | | | | | | | |
| 134. | Phenoxybenzamine Capsule 10mg | 1x10s | 200 | | | | | | | |
| 135. | Phenylephrine Injection 10mg/Ml | Vial | 100 | | | | | | | |
| 136. | Prazocin Tablet 1mg | 1x10s | 100 | | | | | | | |
| 137. | Sildenafil PFOL 10mg/ml | Bottle | 100 | | | | | | | |
| 138. | Sodium Nitroprusside Injection 50mg | Vial | 100 | | | | | | | |
| 139. | Sodium Polysytrene Sulphonate 450g | Tin | 100 | | | | | | | |
| 140. | Terazocin Tablet 2mg | 1x10s | 100 | | | | | | | |
| 141. | Torsemide/Eplerenone Tablet 10mg/25mg | 1x30s | 3000 | | | | | | | |
| 142. | Vasopressin Injection 20 units/ml | Vial | 150 | | | | | | | |
| 143. | Warfarin Tablet 1mg | 1x10s | 10000 | | | | | | _ | |
| 144. | Warfarin Tablet 3 mg | 1x10s | 10000 | | | | | | | |
| 145. | Warfarin Tablet 5mg | 1x10s | 10000 | | | | | | | |
| | ANAESTHESIA AND CRITICAL CARE | | | | _ | _ | | _ | | |
| 146. | Botulinum Toxin Injection | Vial | 10 | | | | | | | |
| 147. | Dantrolene Injection 20mg | Vial | 10 | | | | | | | |

| _ | | | | | | 1 | | | | |
|------|--|---------|------|----------|------|---|------|---|--|--|
| 148. | Etomidate Injection 20mg | Vial | 500 | | | | | | | |
| 149. | Glycopyrronium Injection 200mcg/ml | Ampoule | 3000 | | | | | | | |
| 150. | Glycopyrronium + Neostigmine Injection 500mcg/2.5mg | Ampoule | 1000 | | | | | | | |
| 151. | Lignocaine Topical spray 2% | Spray | 300 | | | | | | | |
| 152. | Tetracaine Topical spray 2% | Spray | 300 | | | | | _ | | |
| 153. | Lignocaine/Adrenaline Injection 2%/1:200000 vial | Vial | 300 | | | | | | | |
| 154. | Pyridostigmine Tablet 60mg | 1x10 | 500 | | | | | | | |
| 155. | Pyridostigmine Oral solution 60mg/5ml, 240ml | 240ml | 100 | | | | | | | |
| 156. | Pyridostigmine Injection 10mg | vial | 100 | | | | | | | |
| 157. | Remifentanyl Injection 2mg | Vial | 500 | | | | | | | |
| 158. | Rocuronium Bromide Injection 10mg | Vial | 500 | | | | | | | |
| 159. | Vecuronium Bromide Injection 10mg | Vial | 200 | | | | | | | |
| | REPRODUCTIVE HEALTH | | | | | | | | | |
| 160. | Carboprost Tromethamine Injection 250mcg | Vial | 10 | | | | | | | |
| 161. | Danazol Capsule 50mg | 1x10s | 300 | <u> </u> | | | | | | |
| 162. | Ergometrine Injection 500mcg | Vial | 100 | | | | | | | |
| 163. | Human Menopausal Gonadotrophin (HMG) Injection 75 IU | Vial | 10 | | | | | | | |
| 164. | Terbutaline Injection 2.5mg | Vial | 10 | | | | | | | |

| 10 | | | | | | | | • | | | | |
|--|------|--|---------|-------|------|---|----------|----------|----------|-----------|-------|-------|
| Note | 165. | | Vial | 10 | | | | | | | | |
| 167. | | ENTS | | | | | | | | | | |
| 167. Potassium Chloride Tab | 166. | 600mg | 1x500s | 5000 | | | | | | | | |
| D3/Magnesium sulphate Zine Sulphae Syrup | 167. | Potassium Chloride Tab 600mg | 1x100s | 5000 | | | | | | | | |
| 170. Vitamin A Capsule 1x10s 10000 | 168. | D3/Magnesium sulphate, Zinc Sulphate Syrup | 1x10s | 4000 | | | | | | | | |
| 170. Vitamin A Capsule 1x100s 10000 | 169. | • | Satchet | 3000 | | | | | | Г <u></u> | | , |
| Tablet 60000iu | | 100,000 i.u. | 1x100s | 10000 | | | | | | | | |
| 173. Nanocalcium 500mg/ Vit D3 | 171. | Vitamin D3 Capsule or Tablet 60000iu | 1x10s | 2000 | | | | | | | | |
| D3 | 172. | | 1x10s | 3000 | · | | | | | | ı | |
| 174. Adapalene Gel 1% 15g 400 <td>173.</td> <td>D3</td> <td>1x10</td> <td>1200</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | 173. | D3 | 1x10 | 1200 | | | | | | | | |
| 175. Calcium dobesilate 30g 200 | | DERMATOLOGICALS | | | | Ī | [| | <u> </u> | [! | | |
| 173. | 174. | _ | 15g | 400 | | | | | | | | |
| 170 100 | 175. | cream | 30g | 200 | | | | | | | | 1 |
| 178. Collagenase clostriopeptidase A + Proteases Ointment 1.2units + 0.24 units (15g) 15g 300 30g 300 30g 300 30g 300 30g 30g <td< td=""><td>176.</td><td>200ml</td><td>100ml</td><td>1000</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<> | 176. | 200ml | 100ml | 1000 | | | | | | | | |
| Clostriopeptidase A + Proteases Ointment 1.2 units + 0.24 units 15g 300 179. Crotamiton Cream 10% 30g 300 180. Desonide cream 15g 200 181. Dexpanthenol Cream 5% 20g 300 180. 180 | 177. | | Pencil | 100 | | | | <u> </u> | | | | |
| 180. Desonide cream 15g 200 | 178. | clostriopeptidase A + Proteases Ointment 1.2units + 0.24 units | 15g | 300 | | | | | | | | |
| 181. Dexpanthenol Cream 5% 20g 300 | 179. | Crotamiton Cream 10% | 30g | 300 | | | <u> </u> | | | | | , |
| 181. Dexpanthenol Cream 5% 20g 300 | 180. | Desonide cream | 15g | 200 | | | | | | | | 1 |
| | | Dexpanthenol Cream 5% | 20g | 300 | | | | | | | | |
| | 182. | Dithranol Paste 2% | 30g | 300 | | | | | | | | |

| 183. | Ketoconazole Shampoo | 100ml | 500 | | | | | |
|------|--|----------|------|--|--|--|--|---|
| | 2% | | | | | | | |
| 184. | Miconazole cream 2% | 30g | 400 | | | | | |
| 185. | Podophyllin Resin Solution 15% | 15ml | 200 | | | | | |
| 186. | Sertaconazole Cream 2% | 20g | 300 | | | | | 1 |
| 187. | Salicylic acid Cream or ointment 2% | 50g | 100 | | | | | |
| 188. | Sun screen SPF >50% | 50ml | 1000 | | | | | |
| 189. | Tretinoin Cream 0.05% | 30g | 300 | | | | | |
| 190. | Imiquimoid Cream 5% | Satchets | 1000 | | | | | |
| 191. | Zinc Hyaluronate Gel | 15g | 300 | | | | | |
| 192. | Zinc Oxide Paste | 500g | 200 | | | | | · |
| 193. | White soft Paraffin (Petroleum Jelly) | 100g | 300 | | | | | |
| | COMPOUNDING VEHICLES | | | | | | | |
| 194. | Distilled Water | Bottle | 200 | | | | | 1 |
| 195. | Simple Syrup | Bottle | 200 | | | | | |
| 196. | Aqueous cream | Bottle | 200 | | | | | |
| | OPTHALMOLOGY DRUGS | | | | | | | |
| 197. | Aflibercept Injection 2mg | Vial | 50 | | | | | |
| 198. | Azelastine Eye Drops 0.05% | 5ml | 200 | | | | | |
| 199. | Bimatoprost Eye drops 0.01% | 5ml | 100 | | | | | |
| 200. | Bimatoprost Eye drops 0.03% | 5ml | 100 | | | | | |
| 201. | Bimatoprost/Timolol Eye drops 0.03%/0.5% | 5ml | 100 | | | | | |
| 202. | Brimonidine/Timolol Eye drops 0.2%/0.5% | 5ml | 100 | | | | | |
| 203. | Diclofenac Opthalmic Solution 0.1% | 5ml | 200 | | | | | |

| | | | | | | | | |
|------|---|---------|-----|------|------|------|------|------|
| 204. | Fluorescein Test Strip 0.6 mg | 5ml | 10 | | | | | |
| 205. | Ganciclovir Intraocular Implant | Implant | 10 | | | | | |
| 206. | Hypertonic Saline Eye Drops 5% | 5ml | 100 | | | | | |
| 207. | Moxifloxacin Eye Drops 0.5% | 5ml | 300 | | | | | |
| | Natamycin Eye Drops 5% | 5ml | 200 | | | | | |
| 209. | Pilocarpine Eye Drops 4% | 5ml | 100 | | | | | |
| 210. | Proparacaine Opthalmic Solution 0.5% | 5ml | 100 | | | | | |
| 211. | Polyacrylic Acid Eye Gel 0.2% | 5ml | 100 | | | | | |
| 212. | Ranibizumab Injection 6mg/ml, | 5ml | 100 | | | | | |
| 213. | Ranibizumab Injection 10mg/ml, | 5ml | 100 | | | | | |
| 214. | Riboflavin Solution 0.1% (with Dextran) | 5ml | 100 | | | | | |
| 215. | Riboflavin Solution 0.1% (without Dextran) | 5ml | 100 | | | | | |
| 216. | Epinastine Eye Drops 0.5mg/ml | 5ml | 100 | | | | | |
| 217. | Sodium Cromoglycate Eye Drops 2% | 5ml | 100 | | | | | |
| 218. | Sodium Hyaluronate Eye Drops 1% Preservative free | 5ml | 800 | | | | | |
| 219. | Tetracaine Eye Drops 0.5% | 5ml | 100 | | | | | |
| 220. | Tobramycin 0.3%/Dexamethasone 0.1% | 5ml | 150 | | | | | |
| 221. | Timolol Eye Drops 0.5% | 5ml | 150 | | | | | |
| 222. | Tropicamide Eye Drops 1% | 5ml | 100 | | | | | |

| | | - | | | | | | | |
|------|--|--------|-------|--|------|--|------|---|--|
| 223. | Tryptan Blue Intracameral Solution 0.06% | 5ml | 200 | | | | | | |
| 224. | Voriconazole Powder for eye drops 1% | 5ml | 100 | | | | | | |
| | ANTIMALARIALS | | | | | | | | |
| 225. | Artemether/Lumefantrin e Tablet 80/480mg | 1x6 | 10000 | | | | | | |
| 226. | Artemether/Lumefantrin e Tablet 20/120mg (dispersible) | 1x6 | 10000 | | | | | | |
| 227. | Dihydroartemesinin/Pipe raquine Tablet 20/160mg | 1x24 | 2000 | | | | | | |
| 228. | Proguanil Tablet 100mg | 1x10s | 1000 | | | | | | |
| | NEUROLOGICAL AND PSYCHOTHERAPEUT IC DRUGS | | | | | | | | |
| 229. | Baclofen Tablet 5mg | 1x10s | 20000 | | | | | | |
| 230. | Benztropine Injection 2mg/2ml | Vial | 100 | | | | | | |
| 231. | Biperiden injection 5mg | Vial | 200 | | | | | | |
| 232. | Biperiden Tablet 2mg | 1x10s | 300 | | | | | | |
| 233. | Bupropion Tablet 150mg | 1x10s | 2000 | | | | | | |
| 234. | Carbidopa/Levodopa Tablet 100mg/10mg | 1x10s | 1000 | | | | | _ | |
| | Carbidopa/Levodopa Tablet 250/25mg | 1x10s | 900 | | | | | | |
| 236. | Citicoline Tablet 500mg | 1x10s | 300 | | | | | | |
| 237. | Clomipramine Capsule 25mg | 1x10s | 200 | | | | | | |
| 238. | Clozapine Tablet 100mg (scored) | 1x10s | 400 | | | | | | |
| 239. | Clozapine Tablet 25mg (scored) | 1x10s | 400 | | | | | | |
| 240. | Disalfirum Tablet 200mg | 1x100s | 200 | | | | | | |

| | · · · · · · · · · · · · · · · · · · · | | | | | 1 | | |
|------|--|--------|-------|------|--|---|--|--|
| 241. | Flupenthixol Decanoate Injection 40mg | Vial | 1000 | | | | | |
| 242. | Flupenthixol Decanoate Injection 20mg | Vial | 1000 | | | | | |
| 243. | Gabapentin Tablet 300mg | 1x10s | 500 | | | | | |
| 244. | Haloperidol Accuphase Injection 5mg | Vial | 500 | | | | | |
| 245. | Haloperidol Oral Solution 2mg/ml | 100ml | 200 | | | | | |
| 246. | Lithium Carbonate MR Tablet 200mg | 1x100s | 300 | | | | | |
| 247. | Lorazepam Tablet 1mg | 1x100s | 300 | | | | | |
| 248. | Lorazepam Injection 4mg/ml | Vial | 300 | | | | | |
| | Meclizine Tablet 12.5mg | 1x100s | 200 | | | | | |
| 250. | Melatonin Tablet 10 mg | 1x100s | 1000 | | | | | |
| 251. | Memantine Tablet 5 mg | 1x10s | 200 | | | | | |
| 252. | Metadoxine 500mg | 1x30 | 6000 | | | | | |
| 253. | Methylphenidate Tablet 10mg | 1x10s | 300 | | | | | |
| 254. | Naltrexone Tablet 50mg | 1x10s | 400 | | | | | |
| 255. | Nicotine Chewing gum 2mg | Gum | 600 | | | | | |
| 256. | Nicotine Chewing gum 4mg | Gum | 600 | | | | | |
| 257. | Nicotine Transdermal Patch 21mg/24h | Patch | 1000 | | | | | |
| 258. | Nicotine Transdermal Patch 14mg/24h | Patch | 1000 | | | | | |
| 259. | Nicotine Transdermal Patch 7mg/24h | Patch | 1000 | | | | | |
| 260. | Olanzapine Tablet 20mg | 1x100s | 60000 | | | | | |
| 261. | Olanzapine Tablet 15mg | 1x100s | 60000 | | | | | |
| 262. | Olanzapine Injection 10mg | Vial | 500 | | | | | |
| 263. | Oxcarbazepine 60mg/ml | 100ml | 300 | | | | | |
| 263. | Oxcarbazepine 60mg/mi | 100ml | 300 | | | | | |

| | | | 1 | | | ı | | | 1 | | | |
|------|---|-----------|-------|---|---|---|---|---|-------|---|---|--|
| 264. | Oxcarbazepine Tablet 150mg | 1x50 | 1000 | | | | | | | | | |
| 265. | Oxcarbazepine Tablet 300mg | 1x50 | 1000 | | | | | | | | | |
| 266. | Phenobarbital Syrup 20mg/ml | 100ml | 500 | | | | | | | | | |
| 267. | Phenytoin Tablet 50 mg | 1x100s | 6000 | | | | | | | | | |
| 268. | Pramipexole tab scored 180mcg base | 1x100 | 120 | | | | _ | _ | _ | | _ | |
| 269. | Pramipexole Tab 700mcg base | 1x30 | 100 | | | | | | | | | |
| 270. | Pregabalin Tablet 150mg | 1x10s | 300 | | | | | | | | | |
| 271. | Pregabalin/Methylcobala min Tablet 75mg/750mcg | 1x10s | 600 | | | | | | | | | |
| 272. | Pyridostigmine Tablet 60mg | 1x30s | 900 | | | | | | | | | |
| 273. | Rivastigmine Capsules 1.5mg | 1x30s | 900 | | | | | | | | | |
| 274. | Riluzole Tablet 50mg | 1x56 | 600 | _ | _ | | | | | | | |
| 275. | Sodium Valproate Tablet 750mg | 5x10s | 9000 | | | | | | | _ | | |
| 276. | Topiramate Tablets 25mg | 1x10s | 1000 | | | | | | | | | |
| 277. | Vigabatrin Tablet 500mg | 1x100s | 500 | | | | | | | | | |
| | STEROIDS/ ANTIHISTAMINES | | | | | | | | | | | |
| 278. | Bilastine Tablet 20mg | 1x50s | 15000 | | | | | | | | | |
| 279. | Chlorpheniramine Syrup 2mg/5mls | 100ml | 1000 | | | | | | | | | |
| 280. | Rupatadine Syrup 5mg/5ml 60ml | 100mls | 2000 | | | | | | | | | |
| 281. | Methyl Prednisolone Sodium Acetate Injection 40mg | Vial | 400 | | | | | | | | | |
| 282. | Triamcinolone Injection 40mg | Vial | 400 | | | | | | | | | |

| | THYROID AND PARATHYROID DRUGS | | | | | | | |
|------|---|---------|------|--|--|--|--|--|
| 283. | Cinacalcet Tablet 30mg | 1x10s | 2000 | | | | | |
| 284. | Methimazole Tablet 5mg | 1x10s | 2000 | | | | | |
| 285. | Iodine 5% (Lugol's Iodine) | 60ml | 100 | | | | | |
| 286. | Propylthiouracil Tablet 50mcg | 1x56s | 1200 | | | | | |
| | ANTIDOTES | | | | | | | |
| 287. | Acetylcysteine Injection 200mg/ml | Ampoule | 100 | | | | | |
| 288. | Fomepizole Injection 1.5g | Vial | 100 | | | | | |
| 289. | Deferoxamine Injection 500mg | Vial | 50 | | | | | |
| 290. | Edetate Calcium Disodium Injection 1g/5ml | Vial | 50 | | | | | |
| 291. | Dimercaprol Injection 100mg | Vial | 50 | | | | | |
| 292. | Flumazenil Injection 1mg | Ampoule | 50 | | | | | |
| 293. | Succimer Capsules 100mg | 1x10s | 50 | | | | | |
| 294. | Physostigmine Injection 2mg | Ampoule | 50 | | | | | |
| 295. | Glucagon Injection 1mg | Vial | 50 | | | | | |
| 296. | Penicillamine Capsules 250mg | 1x10s | 50 | | | | | |
| 297. | Pralidoxime Injection 1g | Vial | 2400 | | | | | |
| 298. | Protamine Sulphate Injection 50mg | Ampoule | 1000 | | | | | |
| | VACCINES and IMMUNOGLOBULINS | | | | | | | |
| 299. | Antithymocyte globulin (rabbit) | Vial | 200 | | | | | |
| 300. | Hepatitis A Vaccine | Vial | 100 | | | | | |

| | E.N.T. | | $\overline{}$ | $\overline{}$ | | $\overline{\top}$ | \top | | \top | \Box | |
|---------|---|--------|---------------|---------------|---------------|-------------------|----------|------|----------|--------------|---|
| | Liquid Paraffin 100% | | | | · | | | | + | <u> </u> | + |
| 301. | Nasal Drops | 100ml | 300 | | | | | | <u> </u> | <u> </u> | |
| 302. | Hydrogen Peroxide Ear Drops 3% | 10ml | 100 | | <u> </u> | | | | ' | ! | |
| 303. | Sodium Chloride Nasal Drops B.P. 0.9% W/V | 10ml | 3000 | | L | | | | | <u>'</u> | |
| 304. | Lignocaine Nasal Spray 10mg/Metered dose | Spray | 300 | | <u></u> | | | | | | |
| | DENTAL | | T | | - | | T | | Ţ ' | · [' | |
| 305. | Chlorhexidine Mouth Gel 1% | 15g | 500 | | | | | | | | |
| 306. | Teething gel 15g | 15g | 1000 | | | | T | | | Ţ ' | |
| 307. | Triamcinolone Dental Paste 0.1% | 5g | 200 | | | | T | | | | |
| 308. | Miconazole Oral Gel | 40g | 300 | | | | 1 | | | , | |
| | HEMATOLOGY/ONCO LOGY DRUGS | | | | | | † | | <u> </u> | | |
| 309. | 6 Mercaptopurine Tablet 50mg | 1x10s | 3000 | | | | | | | | |
| 310. | Abatacept PFI 250mg | Vial | 100 | | · | T | Τ | | Γ_' | ' | |
| 311. | Abiraterone 500mg | 1x60 | 1200 | | | | | | | , | |
| 312. | All-Trans-Retinoic-Acid (ATRA) Tablet 10mg | 1x100s | 20 | | | | † | | <u> </u> | | |
| 313. | Arsenic Trioxide Infusion 1mg/ml | Vial | 100 | | | | | | | | |
| 314. | Azathioprine Injection 100mg | Vial | 100 | | <u> </u> | | | | | <u> </u> | |
| 315. | Busulphan Tablet 2mg | 1x100s | 30 | | · | T | Τ | | Γ_' | ' | |
| 316. | Cabazitaxel Injection 60mg | Vial | 100 | | | | | | | | |
| 317. | Carfilzomib Injection 60mg | Vial | 100 | | | | | | | <u> </u> | |
| 318. | Chlorambucil Tablet 2mg | 1x25s | 250 | | | | | | | <u> </u> | |
| 319. | Cyclophosphamide Tablet 25mg | 1x10s | 1000 | | <u> </u> | | \prod | | | | |

| | | | | | | | | |
|------|--|-----------|------|---|-------|------|------|------------|
| 320. | Dacarbazine Injection 200mg | Vial | 2500 | | | | | |
| 321. | Danazol Capsule 100mg | 1x30s | 100 | | | | | |
| 322. | Daratumumab Injection 400mg | Vial | 100 | | | | | |
| 323. | Dasatinib Tablets 100mg | 1x60 | 100 | | | | | |
| 324. | Daunorubicin Injection 50mg | Vial | 200 | | | | | |
| 325. | Eculizumab Injection 300mg | Vial | 50 | | | | | |
| 326. | Eltrombopag Tablet 50mg | 2x7s | 100 | | | | | |
| 327. | Etoposide Capsule 100mg | 1x12 | 100 | | | | | |
| 328. | Fludarabine Injection 50mg | Vial | 500 | | | | | |
| 329. | Folinic Acid Injection 50mg | Vial | 5000 | | | | | |
| 330. | Folinic Acid Tablet 15mg | 1x10s | 500 | | | | | |
| 331. | Hydroxyurea Capsule 250mg | 1x10s | 300 | | | | | |
| 332. | Ibrutinib Capsule 140mg | 1x90s | 400 | | | | | 1 |
| 333. | Idarubicin Injection 20mg | Vial | 100 | | | | | |
| 334. | Infliximab Injection 100mg | Vial | 50 | | | | | |
| 335. | L-Asparaginase Injection 10000 I.U. | Vial | 400 | | | | | |
| 336. | Lenalidomide Capsule 10mg | 1x10s | 400 | | | | | |
| 337. | Leuprolide Injection 11.25mg | Injection | 300 | | | | | |
| 338. | Melphalan PFI 50mg | Vial | 100 | | T | | |] |
| 339. | Melphalan Tablet 2mg | 1x25s | 100 | | | | | |
| 340. | Methotrexate Injection (pre-filled injection) 25mg/ml, 0.4ml | Vial | 200 | _ | | | | |

| 341. Methotrexate Injection 1g 3000 3000 3000 3000 342. Mitomycin C Injection 10mg Vial 100 343. Mitoxantrone Injection 20mg Vial 400 320mg 344. NAB Paclitaxel Injection 100mg 1x30s 900 345. Osimertinib film coated Tablet 80mg 346. Palbociclib Capsule 150mg 347. Palbociclib Capsule 150mg 348. Palbociclib Capsule 1x21s 300 348. Palbociclib Capsule 1x21s 300 348. Palbociclib Capsule 1x21s 300 349. Palbociclib Capsule 1x21s 300 350. Pazopanib Tablet 200mg 1x10s 400 351. Pazopanib Tablet 400mg 1x10s 500 352. PEG Asparaginase Asparaginase Asparaginase Asparaginase Syringe Sy | |
|--|--|
| 342. Mitomycin C Injection 10mg 100 10mg 343. Mitoxantrone Injection 20mg 344. NAB Paclitaxel Injection 100mg 1x30s 900 345. Osimertinib film coated Tablet 80mg 1x30s 900 346. Palbociclib Capsule 100mg 1x21s 300 347. Palbociclib Capsule 150mg 1x21s 300 348. Palbociclib capsule 125mg 1x21s 300 349. Palbociclib Capsule 1x21s 300 349. Palbociclib Capsule 1x21s 300 350. Pazopanib Tablet 200mg 1x10s 400 351. Pazopanib Tablet 400mg 1x10s 500 352. PEG Asparaginase Injection 3750IU Syringe Syringe Syringe 200 Syringe Syringe | |
| 20mg Vial 400 | |
| 100mg | |
| Tablet 80mg | |
| 100mg | |
| 150mg | |
| 125mg | |
| 75mg 1x21s 300 | |
| 351. Pazopanib Tablet 400mg 1x10s 500 352. PEG Asparaginase Injection 3750IU Vial 100 353. PEG Filgrastim Prefilled Syringe 6mg Syringe 200 | |
| 351. Pazopanib Tablet 400mg 1x10s 500 352. PEG Asparaginase Injection 3750IU Vial 100 353. PEG Filgrastim Prefilled Syringe 6mg Syringe 200 | |
| 352. PEG Asparaginase Injection 3750IU Injection 3750IU Syringe Syringe | |
| Syringe 6mg Syringe 1 Syringe 200 | |
| | |
| 354. Pemetredex Injection 500mg Vial 100 | |
| 355. Pomalidomide Capsule 1x21s 490 | |
| 356. Procarbazine Capsule 50mg 1x100s 100 | |
| 357. Rasburicase Injection 1.5mg Vial 300 | |
| 358. Regorafenib Tablet 40mg 1x28s 100 | |
| 359. Ruxolitinib Tablet 10mg 1x24s 300 | |
| 360. Ruxolitinib Tablet 20mg 1x24s 300 | |
| 361. Ruxolitinib Tablet 5mg 1x24s 300 | |
| 362. Sorafenib Tablet 200mg 1x120 300 | |

| | | | 1 | 1 | П | 1 | 1 | 1 | ı | 1 | 1 |
|------|--|---------|------|---|---|---|---|---|---|---|---|
| 363. | Sunitinib Capsule 50mg | 1x28s | 200 | | | | | | | | |
| 364. | Tacrolimus Injection 5mg | Vial | 100 | | | | | | | | |
| 365. | Tioguanine SODF 40mg | Vial | 100 | | | | | | | | |
| 366. | Topotecan Injection 2.5mg | Vial | 100 | | | | | | | | |
| 367. | Venetoclax Tablet 100mg | 1x120 | 100 | | | | | | | | |
| 368. | Vinorelbine Injection 10mg | Vial | 100 | | | | | | | | |
| | MONOCLONAL ANTIBODIES | | | | | | | | | | |
| 369. | Pembrolizumab Injection 100mg | Vial | 30 | | | | | | | | |
| | UROLOGY DRUGS | | | | | | | | | | |
| 370. | Dutasteride Capsule 0.5mg | 1x10s | 3000 | | | | | | | | |
| 371. | Finasteride/Tamsulosin Capsule 400mcg/5mg | 1x10s | 3000 | | | | | | | | |
| 372. | Mirabegron 50mg | 1x10 | 1200 | | | | | | | | |
| 373. | Mirabegron/Solifenacin 25mg/5mg | 1x10 | 1200 | | | | | | | | |
| 374. | Oxybutynin Tablet 5mg | 1x100s | 1500 | | | | | | | | |
| 375. | Papaverine Injection 60mg | Ampoule | 300 | | | | | | | | |
| 376. | Tolterodine Capsule 2mg | 1x14s | 3000 | | | | | | | | |
| | NUTRACEUTICALS | | | | | | | | | | |
| 377. | Infant formula with iron for term babies-Bidders to bring samples | 400g | 1000 | | | | | | | | |
| 378. | Infant formula with iron for premature babies-Bidders to bring samples | 400g | 800 | | | | | | | | |

| 379. | Human Breast milk fortifier for premature babies and low birth weight infants fed on breast milk- Bidders to bring samples | 1gm x24 | 600 | | | | | |
|------|---|----------------|------|--|--|--|--|--|
| 380. | Human Breast milk fortifier for preterm and low birth weight infants fed on breast milk- Bidders to bring samples | 1gmx 72 | 600 | | | | | |
| 381. | Amino acids Solution for IV infusion 5% for pediatrics | 250mls | 1000 | | | | | |
| 382. | Fat-soluble vitamins (for infants and children) Solution for IV infusion | 10mls | 800 | | | | | |
| 383. | Specialized sip feed for hepatic patients Liquid | 200mls | 800 | | | | | |
| 384. | Specialized hypercaloric liquid formula feed Liquid | 500mls | 600 | | | | | |
| 385. | Low fat formula Powder | 200- 500gms | 800 | | | | | |
| 386. | Specialized Renal formula enriched with vitamins and minerals in Powder form for renal patients | 21gmx 6 | 1000 | | | | | |
| 387. | Nutritional complete feed enriched with MCT and BCAA for hepatic patients | 25gmx6 | 1000 | | | | | |
| 388. | Specialized Semi- elemental peptide formula in Powder form | 400gms | 600 | | | | | |
| 389. | Therapeutic diet feed (F-75) PFOL (for approx. 600mL) Standard formula | 400gms | 1500 | | | | | |

| | | | | | | | | | 1 | | | | |
|---|--|---|---|--|--|--|--|--|---|--|---------------------------|----------------------------------|--|
| 75) PFOL Standard formula | | 400gms | 400 | | | | | | | | | | |
| Breastfeeding stimulator in granules or powder form for lactating mothers | | 250gm | 700 | | | | | | | | | | |
| Specialized semi- elemental peptide formula in powder form | | 400g | 600 | | | | | | | | | | |
| ORIGINAL AND BRANDED DRUGS | | | | | | | | | | | | | |
| Andolex C Spray | | 30mls | 2400 | | | | | | | | | | |
| Biogaia tablets | | 1x30s | 3000 | | | | | | | | | | |
| Coloprep Bowel Preparation Kit 2x177ml | | Bottle | 500 | | | | | | | | | | |
| Cytotec Tablet 200mg | | 1x10s | 3000 | | | | | | | - | | | |
| Epimax Baby and Junior Cream 400g | | Bottle | 300 | | | | | | | | | | |
| Cream 400g | | Bottle | 300 | | | | | | | | | | |
| Flarex Eye Drops | | 5ml | 600 | | | | | | | Ī | | | |
| Heparin Rotex Injection 25000 I.U. | | Vial | 3000 | | | | | | | | | | |
| Herceptin 600mg/5ml | | Vial | 2400 | | | | | | | - | | _ | - |
| Herceptin 440mg | | Vial | 2400 | | | | | | | | | | |
| Infacol Colic Relief Drops 55ml | | Bottle | 300 | | | | | | | | | | |
| Keppra Tablet 250mg | | 1x30s | 2000 | | | | | | | | | | 1 |
| Lantus Solostar Injection 100U/ml | | Syringe | 500 | | | | | | | | | | |
| Mabthera 500mg/50ml | | Vial | 1200 | | | | | | | - | | _ | |
| Marcaine Heavy Injection 0.5% | | Vial | 2000 | | | | | | | | | | <u> </u> |
| Marcain Injection 0.5% | | Vial | 2000 | | | | | | | | | | <u>. </u> |
| Movicol Pediatric Oral Solution 6.9g | | Satchet | 500 | | | | | | | | | | <u> </u> |
| | Breastfeeding stimulator in granules or powder form for lactating mothers Specialized semi-elemental peptide formula in powder form ORIGINAL AND BRANDED DRUGS Andolex C Spray Biogaia tablets Coloprep Bowel Preparation Kit 2x177ml Cytotec Tablet 200mg Epimax Baby and Junior Cream 400g Epimax Plus Adult Cream 400g Flarex Eye Drops Heparin Rotex Injection 25000 I.U. Herceptin 600mg/5ml Herceptin 440mg Infacol Colic Relief Drops 55ml Keppra Tablet 250mg Lantus Solostar Injection 100U/ml Mabthera 500mg/50ml Marcaine Heavy Injection 0.5% Movicol Pediatric Oral | 75) PFOL Standard formula Breastfeeding stimulator in granules or powder form for lactating mothers Specialized semi-elemental peptide formula in powder form ORIGINAL AND BRANDED DRUGS Andolex C Spray Biogaia tablets Coloprep Bowel Preparation Kit 2x177ml Cytotec Tablet 200mg Epimax Baby and Junior Cream 400g Epimax Plus Adult Cream 400g Flarex Eye Drops Heparin Rotex Injection 25000 I.U. Herceptin 600mg/5ml Herceptin 440mg Infacol Colic Relief Drops 55ml Keppra Tablet 250mg Lantus Solostar Injection 100U/ml Mabthera 500mg/50ml Marcaine Heavy Injection 0.5% Movicol Pediatric Oral | 75) PFOL Standard formula Breastfeeding stimulator in granules or powder form for lactating mothers Specialized semi-elemental peptide formula in powder form ORIGINAL AND BRANDED DRUGS Andolex C Spray Biogaia tablets Coloprep Bowel Preparation Kit 2x177ml Cytotec Tablet 200mg Epimax Baby and Junior Cream 400g Epimax Plus Adult Cream 400g Flarex Eye Drops Heparin Rotex Injection 25000 I.U. Herceptin 600mg/5ml Herceptin 640mg Infacol Colic Relief Drops 55ml Keppra Tablet 250mg Lantus Solostar Injection 100U/ml Mabthera 500mg/50ml Marcaine Heavy Injection 0.5% Marcain Injection 0.5% Movicol Pediatric Oral | 75) PFOL Standard formula 400gms 400 | 75) PFOL Standard formula 400gms 400 8 400 8 8 8 8 8 8 8 8 8 | 75) PFOL Standard formula 400gms 400 | 75) PFOL Standard formula 400gms 400 50m 50m | 75 PFOL Standard formula 400gms 400 50 | 75 PFOL Standard formula Streasfeeding stimulator in granules or powder form for lactating mothers Specialized semi-elemental peptide formula in powder form 400g 600 | 75) PFOL Standard 400gms 400 400gms 400 60 | 250 pFOL Standard 250gm | 75) PFOL Standard 400gms 400 | Total Tota |

| 410. | Survanta 25mg/ml | Vial | 3000 | | | | | |
|------|-------------------------------|------|-------|---|--|--|--|--|
| 411. | Syntocinon Injection 10mg | Vial | 3000 | | | | | |
| 412. | Ultiva Injection 2mg | Vial | 500 | | | | | |
| 413. | Tear Naturale II Eye Drops | 15ml | 600 | | | | | |
| 414. | Venofer 100mg/5ml | Vial | 12000 | | | | | |
| | | | | Total Tend Currency: In figures: In words: | | | | |

Name of Tenderer [insert complete name of Tenderer] Signature of Tenderer [signature of person signing the Tender] Date [Insert Date]

In the capacity of: [insert: title or other appropriate designation]

PRICE SCHEDULE: GOODS MANUFACTURED OUTSIDE KENYA, ALREADY IMPORTED*

| 55 | | • | ders, Goods a | • • | ted) | | | | | | | Date: ITT No: Alternat Page No | ive No: of _ | | | - |
|---------|--|----------|---------------|----------------|---------|--|--|--|---|---|----------------------------------|---|--|------------------------------|------------------------|------------------------------------|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | | | | | 8 | 9 | 10 | 11 | 12 | 13 |
| Product | Product | Strength | Dosage | Unit | Qty. | Unit prices | | | | | Tota | Total | Sales and | Nam | Ctr | Pharm |
| code | | | form | pack size | offered | [a] Unit price including Custom Duties and Import Taxes paid and | [b] Custom Duties and Import Taxes paid and payable per unit | [c]=a-b Unit Price net of custom duties and import taxes | [d] Inland transp., insuranc e & other local costs incidenta l to | [e] Other incide nt-al costs as define d in the SCC | Unit pric e [c+d +e] | price per line item [6x8] | other taxes payable per item if Contract is awarded | e of man ufac ture- | y. of orig in | a- copoei al standar d |
| | | | | | | payable | | | delivery | | | | | | | |
| | ANTIBIOTICS | | | | | | | | | | | | | | | |
| 1. | Africef 1gm | | | Vial | 30,000 | | | | | | | | | | | |
| 2. | Africef SB 1.5gm | | | Vial | 30,000 | | | | | | | | | | | |
| 3. | Amoxicillin/Clavulanic Acid Syrup 457mg/5ml | | | 70ml Bottle | 3710 | | | | | | | | | | | |
| 4. | Ampicillin/Sulbactum Injection 1.5g | | | Vial | 5000 | | | | | | | | | | | |
| 5. | Ceftaroline Injection 600mg | | | Vial | 3000 | | | | | | | | | | | |
| 6. | Cefoperazone/Sulbactam Injection 2g | | | Vial | 3000 | | | | | | | | | | | |
| 7. | Clarithromycin Injection 500mg | | | Ampoul e | 40000 | | | | | | | | | | | |
| 8. | Clindamycin Capsule 300mg | | | 1x10s | 20000 | | | | | | | | | | | |
| 9. | Colistin Injection 1MU | | | Vial | 100 | | | | | | | | | | | |
| 10. | Gemifloxacin Capsule 320mg | | | 1x5 | 3000 | | | | | | | | | | | |

| 11. | Merado 1 gm | Vial | 30,000 |
|-----|---|---------|--------|
| 12. | Minocycline Injection 100mg | Vial | 300 |
| 13. | Telavancin Injection 250mg | Vial | 300 |
| 14. | Vancomycin Capsule 250mg | 2x10s | 300 |
| | ANTIFUNGALS | | |
| 15 | Clotrimazole Vaginal Tablet 500mg | 1x1s | 3000 |
| 16 | Micafungin Injection 50mg | Vial | 100 |
| 17. | Flucytosine Capsule 500mg | 1x30s | 200 |
| 18. | Flucytosine Injection 2.5g/250ml | Vial | 200 |
| 19. | Posaconazole Tablet Delayed Release 100mg | 1x100s | 300 |
| 20. | Posaconazole Injection 300mg | Vial | 200 |
| 21. | Luliconazole cream 1% | 30gm | 1200 |
| 22. | ANTIRHEUMATIC DRUGS | | |
| 23. | Everolimus Tablet 0.25mg | 1x10s | 6000 |
| 24. | Everolimus Tablet 0.5mg | 1x10s | 6000 |
| 25. | Everolimus 10mg | 1x10s | 6000 |
| 26. | Everolimus Tablet 1mg | 1x10s | 15000 |
| 27. | Tofacitinib Citrate Tablet 5mg | Tablet | 6000 |
| | GASTROINTESTINAL DRUGS | | |
| 30. | Chlolestyramine Satchet 4gm | Satchet | 6000 |
| 31. | Domperidone Syrup 5mg/5mls | Bottle | 6000 |
| 32. | Dexlansoprazole 30mg | 1x10 | 6000 |

| 33. | Emitino 8mg | 1x10 | 6000 | | | | | | |
|-----|--|--------------|--------|--|--|--|--|--|--|
| 34. | Sodium Phosphates Enema 100ml | Bottle | 3000 | | | | | | |
| 35. | Glycerin Infant Suppositories | Supposit ory | 1000 | | | | | | |
| 36. | Anusol Cream | 25g | 10000 | | | | | | |
| 37. | B- Complex/Carnitine/Lysin e/Cyproheptadine Orotate Syrup | 250ml | 3000 | | | | | | |
| 38. | Ondansetron Tablet 8mg | 1x10s | 100000 | | | | | | |
| 39. | Hyoscine-N-Butyl Bromide/Paracetamol Tablet 10mg/500mg | 1x100s | 1000 | | | | | | |
| 40. | Otilonium Bromide Tablet 40mg | 1x100s | 1000 | | | | | | |
| 41. | Polyethylene Glycol with Electrolytes for Oral Solution Satchet 118g | Satchet | 1000 | | | | | | |
| 42. | Rabeprazole Sodium/Itopride Sustained Release Tablet 20mg/150mg | 1x10s | 2000 | | | | | | |
| 43. | Rabeprazole/Clarithromy cin/Amoxicillin 20/500/1000 mg | Kit | 1000 | | | | | | |
| 44. | Octreotide Long Acting Release Injection 30mg | Vial | 500 | | | | | | |
| 45. | Sulfasalazine Tablet 500mg | 1x10s | 50 | | | | | | |
| 46. | Senna Tablet 7.5mg | 1x100s | 3000 | | | | | | |
| | ANTIDIABETIC | | | | | | | | |
| 47. | Diazoxide Suspension 50mg/ml | Bottle | 50 | | | | | | |
| 48. | Empagliflozin Tablet 25mg | 1x28s | 8000 | | | | | | |
| 49. | Empaglifozin/Metformin Tablet IR 12.5mg/500mg | 1x60s | 4000 | | | | | | |

| | E1:6:-/N/46: | 1 | | | | I | | 1 | 1 |
|-----|---|--------|-------|--|--|---|--|---|---|
| 50. | Empaglifozin/Metformin Tablet IR 12.5mg/1000mg | 1x60s | 3000 | | | | | | |
| 51. | Empaglifozin/Metformin Tablet IR 5mg/500mg | 1x60s | 3000 | | | | | | |
| 52. | Empaglifozin/Metformin Tablet IR 5mg/1000mg | 1x60s | 3000 | | | | | | |
| 53. | Pioglitazone/Metformin Tablet 15mg/500mg | 1x28s | 3000 | | | | | | |
| 54. | Pioglitazone/Metformin Tablet 15mg/850mg | 1x28s | 3000 | | | | | | |
| 55. | Human Insulin Long Acting Basal (Glargine) Injection, 100IU/ml | Vial | 800 | | | | | | |
| 56. | Human Insulin, Long Acting Basal (Glargine) Injection, Pre-filled Pen, 100IU/ml, 3ml | VIal | 800 | | | | | | |
| 57. | Human Insulin, Premixed (Ultra-Short Acting + Intermediate Acting) Injection | Vial | 600 | | | | | | |
| 58. | Human Insulin, Ultra Short Acting Injection 100IU/ml | Vial | 600 | | | | | | |
| 59. | Novorapid, Pen Fill 3ml | VIal | 200 | | | | | | |
| 60. | Novomix Pen 100IU/ml | Vial | 200 | | | | | | |
| 61. | Levemir Pen 100Units/ml 3ml | Vial | 200 | | | | | | |
| 62. | Repaglinide Tablet 0.5mg | 1x100s | 500 | | | | | | |
| | ANALGESICS/ANTIPY RETICS | | | | | | | | |
| 63. | Celecoxib /Paracetamol Tablet 200mg/500mg | 1x10s | 10000 | | | | | | |
| 64. | Celecoxib/Paracetamol/C hlorzoxazone Tablet 200mg/325mg/250mg | 1x10s | 10000 | | | | | | |

| 65. | Celecoxib /Paracetamol Tablet 200mg/325mg | 1x10s | 6000 | | | | | | |
|-----|--|-----------------------|-------|--|------|--|--|--|--|
| 66. | Erenumab Pre Filled Syringe Injection 70mg | Pre- Filled Pen | 100 | | | | | | |
| 67. | S-Etodolac/Paracetamol Tablet 400mg/325mg | 1x10s | 6000 | | | | | | |
| 68. | Ibuprofen Injection 20mg | Vial | 5000 | | | | | | |
| 69. | Paracetamol/Ibuprofen Injection 1000mg/300mg | Vial | 10000 | | | | | | |
| 70. | Ibuprofen/Paracetamol Suspension 125mg/100mg | 100mls | 20000 | | | | | | |
| 71. | Lornoxicam Injection 8mg | Vial | 6000 | | | | | | |
| 72. | Morphine Powder 100g | 100g | 100 | | | | | | |
| 73. | Morphine Oral Liquid 10mg/ml | 100mls | 2000 | | | | | | |
| 74. | Morphine Tablet 30mg | 1x60 | 60000 | | | | | | |
| 75. | Naproxen/Esomeprazole 500mg/20mg | 1x10 | 1200 | | | | | | |
| 78 | Oxycodone Tablet IR 5mg | 1x10 | 4000 | | | | | | |
| 79. | Probenecid Tablet 250mg | 1x100s | 1000 | | | | | | |
| 80. | Tramadol/Paracetamol Tablet 37.5mg/325mg | 1x20s | 50000 | | | | | | |
| | RESPIRATORY DRUGS | | | | | | | | |
| 81. | Beclomethasone Inhaler 200mcg/Dose | Inhaler | 100 | | | | | | |
| 82. | Beclomethasone/Salbuta mol Inhaler 50/100mg | Inhaler | 100 | | | | | | |
| 83. | Budesonide Inhaler 200mcg | Inhaler | 100 | | | | | | |
| 84. | Caffeine Citrate Injection 10mg/ml | Vial | 11000 | | | | | | |
| 85. | Formoterol/Budesonide Inhaler 4.5mcg/160mcg per Dose | Inhaler | 1000 | | | | | | |

| 86. | Formoterol/Budesonide Inhaler 6mcg/100mcg per | Inhaler | 1000 | | | | | | |
|------|--|---------|-------|--|--|--|--|--|--|
| | Dose | | | | | | | | |
| 87. | Glycopyrronium Bromide Injection 200mcg | Vial | 4000 | | | | | | |
| 88. | Ipratropium Inhaler 20mcg/Dose (200 Doses) | Inhaler | 300 | | | | | | |
| 89. | Ipratropium/ Salbutamol Inhaler 20mcg/100mcg per Dose | Inhaler | 300 | | | | | | |
| 90. | Ipratropium/Levosalbuta mol Inhaler 20mcg/50mcg per Dose | Inhaler | 300 | | | | | | |
| 91. | Ipratropium/Salbutamol Nebulizer 500mcg/2.5mg | Respule | 30000 | | | | | | |
| 92. | Levosalbutamol Syrup 1mg/5mls | Bottle | 3000 | | | | | | |
| 93. | Nintendanib Capsule 150mg | 1x10s | 400 | | | | | | |
| 94. | Prostaglandin E1 Injection 500mcg | Vial | 20 | | | | | | |
| 95. | Salbutamol Injection 500mcg/ml | Vial | 100 | | | | | | |
| 96. | Salmeterol/Fluticasone Inhaler 25/50mcg per Dose | Inhaler | 100 | | | | | | |
| 97. | Salmeterol/Fluticasone Inhaler 50/100mcg per Dose | Inhaler | 100 | | | | | | |
| 98. | Tiotropium Bromide Respimat Inhaler 2.5 mcg/dose | Inhaler | 300 | | | | | | |
| 99. | Pirfenidone Tablets 200mg | 1x100s | 100 | | | | | | |
| | CARDIOVASCULAR/ RENAL | | | | | | | | |
| 100. | Apixaban Tablet 2.5mg | 1x10s | 1000 | | | | | | |
| 101. | Aliskiren Tablet 150mg | 1x30s | 1000 | | | | | | |

| 102. | Alteplase Injection 100mg | vial | 20 | | | | | | |
|------|---|-------------|-------|--|--|--|--|--|--|
| 103. | Alteplase Injection 50mg | vial | 20 | | | | | | |
| 104. | Amiodarone Injection 150mg | Ampoul e | 1200 | | | | | | |
| 105. | Amlodipine/Hydrochloro thiazide Tablet 5mg/12.5mg | 1x100s | 10000 | | | | | | |
| 106. | Amlodipine/Indapamide Tablet 5mg/1.25mg | 1x30s | 900 | | | | | | |
| 107. | Bempedoic acid 180mg | 1x30s | 1200 | | | | | | |
| 108. | Bempedoic acid/Ezetimibe 180mg/10mg | 1x30s | 1200 | | | | | | |
| 109. | S-Amlodipine Tablet 5mg | 1x100s | 1000 | | | | | | |
| 110. | S-Amlodipine Tablet 2.5mg | 1x100s | 2000 | | | | | | |
| 111. | Calcium Polystyrene Sulphonate Satchet 15g | Satchet | 1000 | | | | | | |
| 112. | Cardioplegia Solution | Vial | 100 | | | | | | |
| 113. | Chlorthalidone Tablet 12.5mg | 1x100s | 1000 | | | | | | |
| 114. | Chlorthalidone Tablet 6.25mg | 1x100s | 1000 | | | | | | |
| 115. | Cilnidipine Tablet 5mg | 1x10s | 5000 | | | | | | |
| 116. | Clonidine Tablet 0.1mg | 1x10s | 500 | | | | | | |
| 117. | Clopidogrel Tablet 75mg | 1x10s | 1000 | | | | | | |
| 118. | Dabapoietin Alfa Injection 25mcg | Vial | 1000 | | | | | | |
| 119. | Dabapoietin Alfa Injection 40mcg | Vial | 1000 | | | | | | |
| 120. | Desmopressin Nasal Spray 10mcg/spray | Spray | 50 | | | | | | |
| 121. | Desmopressin Tablet 0.1mg | 1x100s | 100 | | | | | | |
| 122. | Digoxin Injection 500mcg | Ampoul e | 100 | | | | | | |

| 123. | Diltiazem Gel 2% | Tube | 100 | | | | | | |
|------|--|--------|------|--|--|--|--|--|--|
| 124. | Diltiazem Injection 5mg/ml | Vial | 100 | | | | | | |
| 125. | Doxazocin Tablet 2mg | 1x10s | 100 | | | | | | |
| 126. | Esmolol Injection 100mg | Vial | 100 | | | | | | |
| 127 | Glyceryl Trinitrate Injection 50mg Vial | Vial | 50 | | | | | | |
| 128. | Hydrochlorothiazide Tablet 12.5mg | 1x100s | 5000 | | | | | | |
| 129. | Isoproterenol (Isoprenaline) Injection 2mg | Vial | 100 | | | | | | |
| 130. | Isosorbide Dinitrate Tablet 20mg | 1x10s | 100 | | | | | | |
| 131. | Isosorbide Mononitrate Tablet 60mg | 1x10s | 100 | | | | | | |
| 132. | Milrinone Injection 10mg Vial | Vial | 200 | | | | | | |
| 133. | Nicardipine Injection 25mg Vial | Vial | 200 | | | | | | |
| 134. | Perindopril/Amlodipine Tablet 5mg/5mg | 1x10s | 300 | | | | | | |
| 135. | Perindopril/Amlodipine Tablet 5mg/10mg | 1x10s | 300 | | | | | | |
| 136. | Perindopril/Amlodipine/I ndapamide 5mg/5mg/1.25mg | 1x10s | 300 | | | | | | |
| 137. | Perindopril/Amlodipine/I ndapamide 10mg/10mg/2.5mg | 1x10s | 400 | | | | | | |
| 138. | Phenoxybenzamine Capsule 10mg | 1x10s | 200 | | | | | | |
| 139. | Phenylephrine Injection 10mg/Ml | Vial | 100 | | | | | | |
| 140. | Prazocin Tablet 1mg | 1x10s | 100 | | | | | | |
| 141. | Sildenafil PFOL 10mg/ml | Bottle | 100 | | | | | | |
| 142. | Sodium Nitroprusside Injection 50mg | Vial | 100 | | | | | | |

| 143. | Sodium Polysytrene Sulphonate 450g | 1 | Гіп | 100 | | | | | | |
|------|---|---------------------------------------|-----------|-------|--|--|--|--|--|--|
| 144. | Terazocin Tablet 2mg | 1 | x10s | 100 | | | | | | |
| 145. | Torsemide/Eplerenone Tablet 10mg/25mg | 1 | x30s | 3000 | | | | | | |
| 146. | Vasopressin Injection 20 units/ml | 1 | Vial | 150 | | | | | | |
| 147. | Warfarin Tablet 1mg | 1 | x10s | 10000 | | | | | | |
| 148. | Warfarin Tablet 3 mg | 1 | x10s | 10000 | | | | | | |
| 149. | Warfarin Tablet 5mg | 1 | x10s | 10000 | | | | | | |
| | ANAESTHESIA AND CRITICAL CARE | | | | | | | | | |
| 150. | Botulinum Toxin Injection | 1 | Vial | 10 | | | | | | |
| 151. | Dantrolene Injection 20mg | \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ | Vial | 10 | | | | | | |
| 152. | Etomidate Injection 20mg | | Vial | 500 | | | | | | |
| 153 | Glycopyrronium Injection 200mcg/ml | A e | Ampoul | 3000 | | | | | | |
| 154. | Glycopyrronium + Neostigmine Injection 500mcg/2.5mg | A e | Ampoul | 1000 | | | | | | |
| 155. | Lignocaine Topical spray 2% | S | Spray | 300 | | | | | | |
| 156. | Tetracaine Topical spray 2% | S | Spray | 300 | | | | | | |
| 157. | Lignocaine/Adrenaline Injection 2%/1:200000 vial | V | √ial | 300 | | | | | | |
| 158. | Pyridostigmine Tablet 60mg | 1 | x10 | 500 | | | | | | |
| 159. | Pyridostigmine Oral solution 60mg/5ml, 240ml | 2 | 240ml | 100 | | | | | | |
| 160. | Pyridostigmine Injection 10mg | · | rial rial | 100 | | | | | | |
| 161. | Remifentanyl Injection 2mg | | Vial | 500 | | | | | | |

| 162. | Rocuronium Bromide Injection 10mg | Vial | 500 | | | | | | |
|------|--|---------|-------|--|--|--|--|--|--|
| 163. | Vecuronium Bromide Injection 10mg | Vial | 200 | | | | | | |
| | REPRODUCTIVE HEALTH | | | | | | | | |
| 164. | Carboprost Tromethamine Injection 250mcg | Vial | 10 | | | | | | |
| 165. | Danazol Capsule 50mg | 1x10s | 300 | | | | | | |
| 166. | Ergometrine Injection 500mcg | Vial | 100 | | | | | | |
| 167. | Human Menopausal Gonadotrophin (HMG) Injection 75 IU | Vial | 10 | | | | | | |
| 168. | Terbutaline Injection 2.5mg | Vial | 10 | | | | | | |
| 169. | Terbutaline Injection 0.5mg | Vial | 10 | | | | | | |
| | VITAMINS/SUPPLEM ENTS | | | | | | | | |
| 170. | Sodium Chloride Tablet 600mg | 1x500s | 5000 | | | | | | |
| 171. | Potassium Chloride Tab 600mg | 1x100s | 5000 | | | | | | |
| 172. | Calcium Citrate/Vitamin D3/Magnesium sulphate, Zinc Sulphate Syrup 250mg/100IU 200ml | 1x10s | 4000 | | | | | | |
| 173. | Collajoint Satchet | Satchet | 3000 | | | | | | |
| 174. | Vitamin A Capsule 100,000 i.u. | 1x100s | 10000 | | | | | | |
| 175. | Vitamin D3 Capsule or Tablet 60000iu | 1x10s | 2000 | | | | | | |
| 176. | Vitamin C Tablet 1g | 1x10s | 3000 | | | | | | |
| 177. | Nanocalcium 500mg/ Vit D3 | 1x10 | 1200 | | | | | | |
| | DERMATOLOGICALS | | | | | | | | |

| 178. | Adapalene Gel 1% | 15g | 400 | | | | | | |
|------|--|----------|------|--|--|--|--|--|--|
| 179. | Calcium dobesilate cream | 30g | 200 | | | | | | |
| 180. | Calamine Lotion 100- 200ml | 100ml | 1000 | | | | | | |
| 181. | Caustic Pencil 40% | Pencil | 100 | | | | | | |
| 182. | Collagenase clostriopeptidase A + Proteases Ointment 1.2units + 0.24 units (15g) | 15g | 300 | | | | | | |
| 183. | Crotamiton Cream 10% | 30g | 300 | | | | | | |
| 184. | Desonide cream | 15g | 200 | | | | | | |
| 185. | Dexpanthenol Cream 5% | 20g | 300 | | | | | | |
| 186. | Dithranol Paste 2% | 30g | 300 | | | | | | |
| 187. | Ketoconazole Shampoo 2% | 100ml | 500 | | | | | | |
| 188. | Miconazole cream 2% | 30g | 400 | | | | | | |
| 189. | Podophyllin Resin Solution 15% | 15ml | 200 | | | | | | |
| 190. | Sertaconazole Cream 2% | 20g | 300 | | | | | | |
| 191. | Salicylic acid Cream or ointment 2% | 50g | 100 | | | | | | |
| 192. | Sun screen SPF >50% | 50ml | 1000 | | | | | | |
| 193. | Tretinoin Cream 0.05% | 30g | 300 | | | | | | |
| 194. | Imiquimoid Cream 5% | Satchets | 1000 | | | | | | |
| 195. | Zinc Hyaluronate Gel | 15g | 300 | | | | | | |
| 196. | Zinc Oxide Paste | 500g | 200 | | | | | | |
| 197. | White soft Paraffin (Petroleum Jelly) | 100g | 300 | | | | | | |
| | COMPOUNDING VEHICLES | | | | | | | | |
| 198. | Distilled Water | Bottle | 200 | | | | | | |
| 199. | Simple Syrup | Bottle | 200 | | | | | | |
| 200. | Aqueous cream | Bottle | 200 | | | | | | |

| | OPTHALMOLOGY DRUGS | | | | | | | | |
|------|--|--------|-------|--|--|--|--|--|--|
| 201. | Aflibercept Injection 2mg | Vial | 50 | | | | | | |
| 202. | Azelastine Eye Drops 0.05% | 5ml | 200 | | | | | | |
| 203. | Bimatoprost Eye drops 0.01% | 5ml | 100 | | | | | | |
| 204. | Bimatoprost Eye drops 0.03% | 5ml | 100 | | | | | | |
| 205. | Bimatoprost/Timolol Eye drops 0.03%/0.5% | 5ml | 100 | | | | | | |
| 206. | Brimonidine/Timolol Eye drops 0.2%/0.5% | 5ml | 100 | | | | | | |
| 207. | Diclofenac Opthalmic Solution 0.1% | 5ml | 200 | | | | | | |
| 208. | Fluorescein Test Strip 0.6 mg | 5ml | 10 | | | | | | |
| 209. | Ganciclovir Intraocular Implant | Implar | nt 10 | | | | | | |
| 210. | Hypertonic Saline Eye Drops 5% | 5ml | 100 | | | | | | |
| 211. | Moxifloxacin Eye Drops 0.5% | 5ml | 300 | | | | | | |
| 212. | Natamycin Eye Drops 5% | 5ml | 200 | | | | | | |
| 213. | Pilocarpine Eye Drops 4% | 5ml | 100 | | | | | | |
| 214. | Proparacaine Opthalmic Solution 0.5% | 5ml | 100 | | | | | | |
| 215. | Polyacrylic Acid Eye Gel 0.2% | 5ml | 100 | | | | | | |
| 216. | Ranibizumab Injection 6mg/ml, | 5ml | 100 | | | | | | |
| 217. | Ranibizumab Injection 10mg/ml, | 5ml | 100 | | | | | | |
| 218. | Riboflavin Solution 0.1% (with Dextran) | 5ml | 100 | | | | | | |
| 219. | Riboflavin Solution 0.1% (without Dextran) | 5ml | 100 | | | | | | |

| | E: (: E D | | | | 1 | | | | | 1 |
|------|---|----------|-------|-----|---|---|---|--|--|---|
| 220. | Epinastine Eye Drops 0.5mg/ml | 5ml | 100 | | | | | | | |
| 221. | Sodium Cromoglycate Eye Drops 2% | 5ml | 100 | | | | | | | |
| 222. | Sodium Hyaluronate Eye Drops 1% Preservative free | 5ml | 800 | | | | | | | |
| 223. | Tetracaine Eye Drops 0.5% | 5ml | 100 | | | | | | | |
| 224. | Tobramycin 0.3%/Dexamethasone 0.1% | 5ml | 150 | | | | | | | |
| 225. | Timolol Eye Drops 0.5% | 5ml | 150 | | | | | | | |
| 226. | Tropicamide Eye Drops 1% | 5ml | 100 | | | | | | | |
| 227. | Tryptan Blue Intracameral Solution 0.06% | 5ml | 200 | | | | | | | |
| 228. | Voriconazole Powder for eye drops 1% | 5ml | 100 | | | | | | | |
| | ANTIMALARIALS | | | | | | | | | |
| 229. | Artemether/Lumefantrine Tablet 80/480mg | 1x6 | 10000 | | | | | | | |
| 230. | Artemether/Lumefantrine Tablet 20/120mg (dispersible) | 1x6 | 10000 | | | | | | | |
| 231. | Dihydroartemesinin/Pipe raquine Tablet 20/160mg | 1x24 | 2000 | | | | | | | |
| 232. | Proguanil Tablet 100mg | 1x10s | 1000 | | | | | | | |
| | NEUROLOGICAL AND PSYCHOTHERAPEUTI C DRUGS | | | | | | | | | |
| 233. | Baclofen Tablet 5mg | 1x10s | 20000 | | | | | | | |
| 234. | Benztropine Injection 2mg/2ml | Vial | 100 | | | | | | | |
| 235. | Biperiden injection 5mg | Vial | 200 | | | | | | | |
| 236. | Biperiden Tablet 2mg | 1x10s | 300 | | | | | | | |
| 237. | Bupropion Tablet 150mg | 1x10s | 2000 | | | | | | | |
| | - 1 | <u> </u> | | I . | | • | • | | | |

| 238. | Carbidopa/Levodopa Tablet 100mg/10mg | 1x10s | 1000 |
|------|--|--------|------|
| 239. | Carbidopa/Levodopa Tablet 250/25mg | 1x10s | 900 |
| 240. | Citicoline Tablet 500mg | 1x10s | 300 |
| 241. | Clomipramine Capsule 25mg | 1x10s | 200 |
| 242. | Clozapine Tablet 100mg (scored) | 1x10s | 400 |
| 243. | Clozapine Tablet 25mg (scored) | 1x10s | 400 |
| 244. | Disalfirum Tablet 200mg | 1x100s | 200 |
| 245. | Flupenthixol Decanoate Injection 40mg | Vial | 1000 |
| 246. | Flupenthixol Decanoate Injection 20mg | Vial | 1000 |
| 247. | Gabapentin Tablet 300mg | 1x10s | 500 |
| 248. | Haloperidol Accuphase Injection 5mg | Vial | 500 |
| 249. | Haloperidol Oral Solution 2mg/ml | 100ml | 200 |
| 250. | Lithium Carbonate MR Tablet 200mg | 1x100s | 300 |
| 251. | Lorazepam Tablet 1mg | 1x100s | 300 |
| 252. | Lorazepam Injection 4mg/ml | Vial | 300 |
| 253. | Meclizine Tablet 12.5mg | 1x100s | 200 |
| 254. | Melatonin Tablet 10 mg | 1x100s | 1000 |
| 255. | Memantine Tablet 5 mg | 1x10s | 200 |
| 256. | Metadoxine 500mg | 1x30 | 6000 |
| 257. | Methylphenidate Tablet 10mg | 1x10s | 300 |
| 258. | Naltrexone Tablet 50mg | 1x10s | 400 |
| 259. | Nicotine Chewing gum 2mg | Gum | 600 |

| 260. | Nicotine Chewing gum 4mg | Gum | 600 | | | | | | |
|------|--|--------|-------|--|--|--|------|--|--|
| 261. | Nicotine Transdermal Patch 21mg/24h | Patch | 1000 | | | | | | |
| 262. | Nicotine Transdermal Patch 14mg/24h | Patch | 1000 | | | | | | |
| 263. | Nicotine Transdermal Patch 7mg/24h | Patch | 1000 | | | | | | |
| 264. | Olanzapine Tablet 20mg | 1x100s | 60000 | | | | | | |
| 265. | Olanzapine Tablet 15mg | 1x100s | 60000 | | | | | | |
| 266. | Olanzapine Injection 10mg | Vial | 500 | | | | | | |
| 267. | Oxcarbazepine 60mg/ml | 100ml | 300 | | | | | | |
| 268. | Oxcarbazepine Tablet 150mg | 1x50 | 1000 | | | | | | |
| 269. | Oxcarbazepine Tablet 300mg | 1x50 | 1000 | | | | | | |
| 270. | Phenobarbital Syrup 20mg/ml | 100ml | 500 | | | | | | |
| 271. | Phenytoin Tablet 50 mg | 1x100s | 6000 | | | | | | |
| 272. | Pramipexole tab scored 180mcg base | 1x100 | 120 | | | | | | |
| 273. | Pramipexole Tab 700mcg base | 1x30 | 100 | | | | | | |
| 274. | Pregabalin Tablet 150mg | 1x10s | 300 | | | | | | |
| 275. | Pregabalin/Methylcobala min Tablet 75mg/750mcg | 1x10s | 600 | | | | | | |
| 276. | Pyridostigmine Tablet 60mg | 1x30s | 900 | | | | | | |
| 277. | Rivastigmine Capsules 1.5mg | 1x30s | 900 | | | | | | |
| 278. | Riluzole Tablet 50mg | 1x56 | 600 | | | | | | |
| 279. | Sodium Valproate Tablet 750mg | 5x10s | 9000 | | | | | | |
| 280. | Topiramate Tablets 25mg | 1x10s | 1000 | | | | | | |
| 281. | Vigabatrin Tablet 500mg | 1x100s | 500 | | | | | | |

| | STEROIDS/ ANTIHISTAMINES | | | | | | | | |
|------|---|-----------|--------|--|--|--|--|--|--|
| 282. | Bilastine Tablet 20mg | 1x50s | 15000 | | | | | | |
| 283. | Chlorpheniramine Syrup 2mg/5mls | 100ml | 1000 | | | | | | |
| 284. | Rupatadine Syrup 5mg/5ml 60ml | 100ml | s 2000 | | | | | | |
| 285. | Methyl Prednisolone Sodium Acetate Injection 40mg | Vial | 400 | | | | | | |
| 286. | Triamcinolone Injection 40mg | Vial | 400 | | | | | | |
| | THYROID AND PARATHYROID DRUGS | | | | | | | | |
| 287. | Cinacalcet Tablet 30mg | 1x10s | 2000 | | | | | | |
| 288. | Methimazole Tablet 5mg | 1x10s | 2000 | | | | | | |
| 289. | Iodine 5% (Lugol's Iodine) | 60ml | 100 | | | | | | |
| 290. | Propylthiouracil Tablet 50mcg | 1x56s | 1200 | | | | | | |
| | ANTIDOTES | | | | | | | | |
| 291. | Acetylcysteine Injection 200mg/ml | Ampo e | ıl 100 | | | | | | |
| 292. | Fomepizole Injection 1.5g | Vial | 100 | | | | | | |
| 293. | Deferoxamine Injection 500mg | Vial | 50 | | | | | | |
| 294. | Edetate Calcium Disodium Injection 1g/5ml | Vial | 50 | | | | | | |
| 295. | Dimercaprol Injection 100mg | Vial | 50 | | | | | | |
| 296. | Flumazenil Injection 1mg | Ampo e | ıl 50 | | | | | | |
| 297. | Succimer Capsules 100mg | 1x10s | 50 | | | | | | |
| 298. | Physostigmine Injection 2mg | Ampo e | ıl 50 | | | | | | |

| 299. | Glucagon Injection 1mg | Vial | 50 |
|------|---|-------------|------|
| 300. | Penicillamine Capsules 250mg | 1x10s | 50 |
| 301. | Pralidoxime Injection 1g | Vial | 2400 |
| 302. | Protamine Sulphate Injection 50mg | Ampoul e | 1000 |
| | VACCINES and IMMUNOGLOBULINS | | |
| 303. | Antithymocyte globulin (rabbit) | Vial | 200 |
| 304. | Hepatitis A Vaccine | Vial | 100 |
| 305. | | | |
| 306. | Liquid Paraffin 100% Nasal Drops | 100ml | 300 |
| 307. | Hydrogen Peroxide Ear Drops 3% | 10ml | 100 |
| 308. | Sodium Chloride Nasal Drops B.P. 0.9% W/V | 10ml | 3000 |
| 309. | Lignocaine Nasal Spray 10mg/Metered dose | Spray | 300 |
| | DENTAL | | |
| 310. | Chlorhexidine Mouth Gel 1% | 15g | 500 |
| 311. | Teething gel 15g | 15g | 1000 |
| 312. | Triamcinolone Dental Paste 0.1% | 5g | 200 |
| 313. | Miconazole Oral Gel | 40g | 300 |
| | HEMATOLOGY/ONCO LOGY DRUGS | | |
| 314. | 6 Mercaptopurine Tablet 50mg | 1x10s | 3000 |
| 315. | Abatacept PFI 250mg | Vial | 100 |
| 316. | | 1x60 | 1200 |
| 317. | All-Trans-Retinoic-Acid (ATRA) Tablet 10mg | 1x100s | 20 |
| 318. | Arsenic Trioxide Infusion 1mg/ml | Vial | 100 |

| 319. | Azathioprine Injection 100mg | Vial | 100 |
|------|------------------------------|--------|------|
| 320. | Busulphan Tablet 2mg | 1x100s | 30 |
| 321. | Cabazitaxel Injection 60mg | Vial | 100 |
| 322. | Carfilzomib Injection 60mg | Vial | 100 |
| 323. | Chlorambucil Tablet 2mg | 1x25s | 250 |
| 324. | Cyclophosphamide Tablet 25mg | 1x10s | 1000 |
| 325. | Dacarbazine Injection 200mg | Vial | 2500 |
| 326. | Danazol Capsule 100mg | 1x30s | 100 |
| 327. | Daratumumab Injection 400mg | Vial | 100 |
| 328. | Dasatinib Tablets 100mg | 1x60 | 100 |
| 329. | Daunorubicin Injection 50mg | Vial | 200 |
| 330. | Eculizumab Injection 300mg | Vial | 50 |
| 331. | Eltrombopag Tablet 50mg | 2x7s | 100 |
| 332. | Etoposide Capsule 100mg | 1x12 | 100 |
| 333. | Fludarabine Injection 50mg | Vial | 500 |
| 334. | Folinic Acid Injection 50mg | Vial | 5000 |
| 335. | Folinic Acid Tablet 15mg | 1x10s | 500 |
| 336. | Hydroxyurea Capsule 250mg | 1x10s | 300 |
| 337. | Ibrutinib Capsule 140mg | 1x90s | 400 |
| 338. | Idarubicin Injection 20mg | Vial | 100 |
| 339. | Infliximab Injection 100mg | Vial | 50 |

| 340. | L-Asparaginase Injection 10000 I.U. | V | ial | 400 | | | | | | |
|------|--|------|---------|------|--|--|--|--|--|--|
| 341. | Lenalidomide Capsule 10mg | 12 | x10s | 400 | | | | | | |
| 342. | Leuprolide Injection 11.25mg | In n | ijectio | 300 | | | | | | |
| 343. | Melphalan PFI 50mg | V | ial | 100 | | | | | | |
| 344. | Melphalan Tablet 2mg | 12 | x25s | 100 | | | | | | |
| 345. | Methotrexate Injection (pre-filled injection) 25mg/ml, 0.4ml | V | ial | 200 | | | | | | |
| 346. | Methotrexate Injection 1g | V | ial | 3000 | | | | | | |
| 347. | Mitomycin C Injection 10mg | v | ial | 100 | | | | | | |
| 348. | Mitoxantrone Injection 20mg | V | ial | 400 | | | | | | |
| 349. | NAB Paclitaxel Injection 100mg | v | ial | 500 | | | | | | |
| 350. | Osimertinib film coated Tablet 80mg | 12 | x30s | 900 | | | | | | |
| 351. | Palbociclib Capsule 100mg | 12 | x21s | 300 | | | | | | |
| 352. | Palbociclib Capsule 150mg | 12 | x21s | 300 | | | | | | |
| 353. | Palbociclib capsule 125mg | 12 | x21s | 300 | | | | | | |
| 354. | Palbociclib Capsule 75mg | 12 | x21s | 300 | | | | | | |
| 355. | Pazopanib Tablet 200mg | 12 | x10s | 400 | | | | | | |
| 356. | Pazopanib Tablet 400mg | 12 | x10s | 500 | | | | | | |
| 357. | PEG Asparaginase Injection 3750IU | V | ial | 100 | | | | | | |
| 358. | PEG Filgrastim Prefilled Syringe 6mg | S | yringe | 200 | | | | | | |
| 359. | Pemetredex Injection 500mg | V | ial | 100 | | | | | | |
| 360. | Pomalidomide Capsule 1mg | 12 | x21s | 490 | | | | | | |

| 361. | Procarbazine Capsule 50mg | 1x100s | 100 |
|------|---|-------------|------|
| 362. | Rasburicase Injection 1.5mg | Vial | 300 |
| 363. | Regorafenib Tablet 40mg | 1x28s | 100 |
| 364. | Ruxolitinib Tablet 10mg | 1x24s | 300 |
| 365. | Ruxolitinib Tablet 20mg | 1x24s | 300 |
| 366. | Ruxolitinib Tablet 5mg | 1x24s | 300 |
| 367. | Sorafenib Tablet 200mg | 1x120 | 300 |
| 368. | Sunitinib Capsule 50mg | 1x28s | 200 |
| 369. | Tacrolimus Injection 5mg | Vial | 100 |
| 370. | Tioguanine SODF 40mg | Vial | 100 |
| 371. | Topotecan Injection 2.5mg | Vial | 100 |
| 372. | Venetoclax Tablet 100mg | 1x120 | 100 |
| 373. | Vinorelbine Injection 10mg | Vial | 100 |
| | MONOCLONAL ANTIBODIES | | |
| 374. | Pembrolizumab Injection 100mg | Vial | 30 |
| | UROLOGY DRUGS | | |
| 375. | Dutasteride Capsule 0.5mg | 1x10s | 3000 |
| 376. | Finasteride/Tamsulosin Capsule 400mcg/5mg | 1x10s | 3000 |
| 377. | Mirabegron 50mg | 1x10 | 1200 |
| 378. | Mirabegron/Solifenacin 25mg/5mg | 1x10 | 1200 |
| 379. | Oxybutynin Tablet 5mg | 1x100s | 1500 |
| 380. | Papaverine Injection 60mg | Ampoul e | 300 |
| 381. | Tolterodine Capsule 2mg | 1x14s | 3000 |
| | NUTRACEUTICALS | | |

| | T | 1 | 1 | 1 | 1 | | ı | | | |
|------|--|--------------------------------------|---------------------------|---|---|--|---|--|--|--|
| 382. | Infant formula with iron | | | | | | | | | |
| | for term babies-Bidders | 400g | 1000 | | | | | | | |
| | to bring samples | | | | | | | | | |
| 383. | Infant formula with iron | | | | | | | | | |
| 303. | for premature babies- | 400g | 800 | | | | | | | |
| | Bidders to bring samples | | | | | | | | | |
| 384. | Human Breast milk | | | | | | | | | |
| 304. | fortifier for premature | | | | | | | | | |
| | babies and low birth | 1gm | | | | | | | | |
| | weight infants fed on | x24 | 600 | | | | | | | |
| | breast milk- Bidders to | 12. | | | | | | | | |
| | bring samples | | | | | | | | | |
| 20.7 | Human Breast milk | | | | | | | | | |
| 385. | fortifier for preterm and | | | | | | | | | |
| | low birth weight infants | 1gmx | 600 | | | | | | | |
| | fed on breast milk- | 72 | 000 | | | | | | | |
| | Bidders to bring samples | | | | | | | | | |
| | Amino acids Solution for | | | | | | | | | |
| 386. | IV infusion 5% for | 250mls | 1000 | | | | | | | |
| | | 250mis | 1000 | | | | | | | |
| | pediatrics | | | | | | | | | |
| 387. | Fat-soluble vitamins (for | 10 1 | 000 | | | | | | | |
| | infants and children) | 10mls | 800 | | | | | | | |
| | Solution for IV infusion | | | | | | | | | |
| 388. | | 200mls | 800 | | | | | | | |
| | | | | | | | | | | |
| 389. | Specialized hypercaloric | | | | | | | | | |
| | | 500mls | 600 | | | | | | | |
| | Liquid | | | | | | | | | |
| 390. | Low fat formula Powder | | 800 | | | | | | | |
| | | 500gms | 300 | | | | | | | |
| 391. | | | | | | | | | | |
| | | 21 amy | | | | | | | | |
| | vitamins and minerals in | | 1000 | | | | | | | |
| | Powder form for renal | U | | | | | | | | |
| | patients | | | | | | | | | |
| 392 | Nutritional complete feed | | | | | | | | | |
| 3,2. | enriched with MCT and | 25 amy 6 | 1000 | | | | | | | |
| | BCAA for hepatic | 23giiix6 | 1000 | | | | | | | |
| | patients | | | | | | | | | |
| 389. | Specialized sip feed for hepatic patients Liquid Specialized hypercaloric liquid formula feed Liquid Low fat formula Powder Specialized Renal formula enriched with vitamins and minerals in Powder form for renal patients Nutritional complete feed enriched with MCT and BCAA for hepatic | 200mls 500mls 200- 500gms 21gmx 6 | 800 600 800 1000 | | | | | | | |

| | | T | 1 | 1 | | ı | | 1 | 1 | | | |
|------|--|---|---------|------|---|---|---|---|---|---|--|---|
| 393. | Specialized Semi- elemental peptide formula in Powder form | | 400gms | 600 | | | | | | | | |
| 394. | Therapeutic diet feed (F-75) PFOL (for approx. 600mL) Standard formula | | 400gms | 1500 | | | | | | | | |
| 395. | Therapeutic diet feed (F-75) PFOL Standard formula | | 400gms | 400 | | | | | | | | |
| 396. | Breastfeeding stimulator in granules or powder form for lactating mothers | | 250gm | 700 | | | | | | | | |
| 397. | Specialized semi- elemental peptide formula in powder form | | 400g | 600 | | | | | | | | |
| | ORIGINAL AND BRANDED DRUGS | | | | | | | | | | | |
| 398. | Andolex C Spray | | 30mls | 2400 | | | | | | | | |
| 399. | Biogaia tablets | | 1x30s | 3000 | | | | | | | | |
| 400. | Coloprep Bowel Preparation Kit 2x177ml | | Bottle | 500 | | | | | | | | |
| 401. | Cytotec Tablet 200mg | | 1x10s | 3000 | | | | | | | | |
| 402. | Epimax Baby and Junior Cream 400g | | Bottle | 300 | | | | | | | | |
| 403. | Epimax Plus Adult Cream 400g | | Bottle | 300 | | | | | | | | |
| 404. | Flarex Eye Drops | | 5ml | 600 | | | | | | | | |
| 405. | Heparin Rotex Injection 25000 I.U. | | Vial | 3000 | _ | | _ | | | _ | | _ |
| 406. | Herceptin 600mg/5ml | | Vial | 2400 | | | | | | | | |
| 407. | Herceptin 440mg | | Vial | 2400 | | | | | | | | |
| | T C 1 C 1' D 1' C | | Bottle | 300 | | | | | | | | |
| 409. | Keppra Tablet 250mg | | 1x30s | 2000 | | | | | | | | |
| 410. | Lantus Solostar Injection 100U/ml | | Syringe | 500 | | | | | | | | |

| 411. | Mabthera 500mg/50ml | | Vial | 1200 | | | | | | | | |
|-------------------|---|--------------------------|-------------|------------|--------------|----|---|-------|------|--------|--|--|
| 412. | Marcaine Heavy Injection 0.5% | | Vial | 2000 | | | | | | | | |
| 413. | Marcain Injection 0.5% | | Vial | 2000 | | | | | | | | |
| 414. | Movicol Pediatric Oral Solution 6.9g | | Satchet | 500 | | | | | | | | |
| 415. | Survanta 25mg/ml | | Vial | 3000 | | | | | | | | |
| 416. | Syntocinon Injection 10mg | | Vial | 3000 | | | | | | | | |
| 417. | Ultiva Injection 2mg | | Vial | 500 | | | | | | | | |
| 418. | Tear Naturale II Eye Drops | | 15ml | 600 | | | | | | | | |
| 419. | Venofer 100mg/5ml | | Vial | 12000 | | | | | | | | |
| Note: (i) Colu | mn 7[b] Custom Duties and Impo | ort Taxes paid should be | supported b | y document | ary evidence | ·. | Total Ten- Currency: In figures: In words: | : | | - - | | |

Name of Tenderer [insert complete name of Tenderer] Signature of Tenderer [signature of person signing the Tender] Date [insert date]

^{* [}For previously imported Goods, the quoted price shall be distinguishable from the original import value of these Goods declared to customs and shall include any rebate or mark-up of the local agent or representative and all local costs except import duties and taxes, which have been and/or have to be paid by the Procuring Entity. For clarity the Tenderers are asked to quote the price including import duties, and additionally to provide the import duties and the price net of import duties which is the difference of those values.]

PRICE SCHEDULE: GOODS MANUFACTURED IN KENYA

| KENYA | A | | | | | (Group | A and B | Tender | s) | | | Date: | | |
|---------------------|---|----------|--|-------------------|-----------------|---|--|---|-----------------------------|------------------------|---|--------------------------------|---|---|
| | | | | | | Curren | cies in ac | cordanc | e with l | ITT 1 | 5 | ITT | | No: |
| | | | | | | | | | | | | Alternati | ve | No: |
| | | | | | | | | | | | | Page N° | | of |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | | | 8 | 9 | 10 | 11 | 12 | 13 |
| Produ ct code | Product | Strength | Dosage form | Unit pack size | Qty. offered | Unit pr [a] Ex- factor y Ex- wareh ouse Ex- showr oom Off the shelf | [b] Inlan d transp ,, insura nce & other local costs incide ntal to delive | [c] Othe r incid ent- al costs as defin ed in the SCC | Tota l unit pric e [a+b +c] | To tal pri ce | Sale s and other taxes paya ble if contr act is awar ded | Name of manufa cturer | Phar ma- copo eial stan dard | Local input in the cost as % of exfactor y price in column 7[a] |
| | ITEM DESCRIPTION/CONTRACT PACKAGE | PACK | ESTIMAT ED ANNUAL CONSUM PTION | | | | ry | | | | | | | |
| | ANTIBIOTICS | | | | | | | | | | | | | |
| 1. | Africef 1gm | | | Vial | 30,000 | | | | | | | | | |
| 2. | Africef SB 1.5gm | | | Vial | 30,000 | | | | | | | | | |
| 5 3. | Amoxicillin/Clavulanic Acid Syrup 457mg/5ml | | | 70ml Bottle | 3710 | | | | | | | | | |

| 4. | Ampicillin/Sulbactum Injection 1.5g | Vial | 5000 | | | | | |
|-----|---|---------|--------|--|--|--|--|--|
| 5. | Ceftaroline Injection 600mg | Vial | 3000 | | | | | |
| 6. | Cefoperazone/Sulbactam Injection 2g | Vial | 3000 | | | | | |
| 7. | Clarithromycin Injection 500mg | Ampoule | 40000 | | | | | |
| 8. | Clindamycin Capsule 300mg | 1x10s | 20000 | | | | | |
| 9. | Colistin Injection 1MU | Vial | 100 | | | | | |
| 10. | Gemifloxacin Capsule 320mg | 1x5 | 3000 | | | | | |
| 11. | Merado 1 gm | Vial | 30,000 | | | | | |
| 12. | Minocycline Injection 100mg | Vial | 300 | | | | | |
| 13. | Telavancin Injection 250mg | Vial | 300 | | | | | |
| 14. | Vancomycin Capsule 250mg | 2x10s | 300 | | | | | |
| | ANTIFUNGALS | | | | | | | |
| 15. | Clotrimazole Vaginal Tablet 500mg | 1x1s | 3000 | | | | | |
| 16. | Micafungin Injection 50mg | Vial | 100 | | | | | |
| 17. | Flucytosine Capsule 500mg | 1x30s | 200 | | | | | |
| 18. | Flucytosine Injection 2.5g/250ml | Vial | 200 | | | | | |
| 19. | Posaconazole Tablet Delayed Release 100mg | 1x100s | 300 | | | | | |
| 20. | Posaconazole Injection 300mg | Vial | 200 | | | | | |
| 21. | Luliconazole cream 1% | 30gm | 1200 | | | | | |
| | ANTIRHEUMATIC DRUGS | | | | | | | |

| 22. | Everolimus Tablet 0.25mg | 1x10s | 6000 | | | | | |
|-----|--|------------|--------|--|--|--|--|--|
| 23. | Everolimus Tablet 0.5mg | 1x10s | 6000 | | | | | |
| 24. | Everolimus 10mg | 1x10s | 6000 | | | | | |
| 25. | Everolimus Tablet 1mg | 1x10s | 15000 | | | | | |
| 26. | Tofacitinib Citrate Tablet 5mg | Tablet | 6000 | | | | | |
| | GASTROINTESTINAL DRUGS | | | | | | | |
| 27. | Chlolestyramine Satchet 4gm | Satchet | 6000 | | | | | |
| 28. | Domperidone Syrup 5mg/5mls | Bottle | 6000 | | | | | |
| 29. | Dexlansoprazole 30mg | 1x10 | 6000 | | | | | |
| 30. | Emitino 8mg | 1x10 | 6000 | | | | | |
| 31. | Sodium Phosphates Enema 100ml | Bottle | 3000 | | | | | |
| 32. | Glycerin Infant Suppositories | Suppositor | 1000 | | | | | |
| 33. | Anusol Cream | 25g | 10000 | | | | | |
| 34. | B- Complex/Carnitine/Lysine/Cyproheptadine Orotate Syrup | 250ml | 3000 | | | | | |
| 35. | Ondansetron Tablet 8mg | 1x10s | 100000 | | | | | |
| 36. | Hyoscine-N-Butyl Bromide/Paracetamol Tablet 10mg/500mg | 1x100s | 1000 | | | | | |
| 37. | Otilonium Bromide Tablet 40mg | 1x100s | 1000 | | | | | |
| 38. | Polyethylene Glycol with Electrolytes for Oral Solution Satchet 118g | Satchet | 1000 | | | | | |
| 39. | Rabeprazole Sodium/Itopride Sustained Release Tablet 20mg/150mg | 1x10s | 2000 | | | | | |

| 40. | Rabeprazole/Clarithromycin/Amoxicillin 20/500/1000 mg | Kit | 1000 | | | | | |
|-----|--|--------|------|--|--|--|--|--|
| 41. | Octreotide Long Acting Release Injection 30mg | Vial | 500 | | | | | |
| 42. | Sulfasalazine Tablet 500mg | 1x10s | 50 | | | | | |
| 43. | Senna Tablet 7.5mg | 1x100s | 3000 | | | | | |
| | ANTIDIABETIC | | | | | | | |
| 44. | Diazoxide Suspension 50mg/ml | Bottle | 50 | | | | | |
| 45. | Empagliflozin Tablet 25mg | 1x28s | 8000 | | | | | |
| 46. | Empaglifozin/Metformin Tablet IR 12.5mg/500mg | 1x60s | 4000 | | | | | |
| 47. | Empaglifozin/Metformin Tablet IR 12.5mg/1000mg | 1x60s | 3000 | | | | | |
| 48. | Empaglifozin/Metformin Tablet IR 5mg/500mg | 1x60s | 3000 | | | | | |
| 49. | Empaglifozin/Metformin Tablet IR 5mg/1000mg | 1x60s | 3000 | | | | | |
| 50. | Pioglitazone/Metformin Tablet 15mg/500mg | 1x28s | 3000 | | | | | |
| 51. | Pioglitazone/Metformin Tablet 15mg/850mg | 1x28s | 3000 | | | | | |
| 52. | Human Insulin Long Acting Basal (Glargine) Injection, 100IU/ml | Vial | 800 | | | | | |
| 53. | Human Insulin, Long Acting Basal (Glargine) Injection, Pre-filled Pen, 100IU/ml, 3ml | VIal | 800 | | | | | |
| 54. | Human Insulin, Premixed (Ultra-Short Acting + Intermediate Acting) Injection | Vial | 600 | | | | | |
| 55. | Human Insulin, Ultra Short Acting Injection 100IU/ml | Vial | 600 | | | | | |
| 56. | Novorapid, Pen Fill 3ml | VIal | 200 | | | | | |
| 57. | Novomix Pen 100IU/ml | Vial | 200 | | | | | |

| 58. | Levemir Pen 100Units/ml 3ml | Vial | 200 | | | | | |
|-----|--|--------------------|-------|--|--|--|--|--|
| 59. | Repaglinide Tablet 0.5mg | 1x100s | 500 | | | | | |
| | ANALGESICS/ANTIPYRETICS | | | | | | | |
| 60. | Celecoxib /Paracetamol Tablet 200mg/500mg | 1x10s | 10000 | | | | | |
| 61. | Celecoxib/Paracetamol/Chlorzoxazone Tablet 200mg/325mg/250mg | 1x10s | 10000 | | | | | |
| 62. | Celecoxib /Paracetamol Tablet 200mg/325mg | 1x10s | 6000 | | | | | |
| 63. | Erenumab Pre Filled Syringe Injection 70mg | Pre- Filled Pen | 100 | | | | | |
| 64. | S-Etodolac/Paracetamol Tablet 400mg/325mg | 1x10s | 6000 | | | | | |
| 65. | Ibuprofen Injection 20mg | Vial | 5000 | | | | | |
| 66. | Paracetamol/Ibuprofen Injection 1000mg/300mg | Vial | 10000 | | | | | |
| 67. | Ibuprofen/Paracetamol Suspension 125mg/100mg | 100mls | 20000 | | | | | |
| 68. | Lornoxicam Injection 8mg | Vial | 6000 | | | | | |
| 69. | Morphine Powder 100g | 100g | 100 | | | | | |
| 70. | Morphine Oral Liquid 10mg/ml | 100mls | 2000 | | | | | |
| 71. | Morphine Tablet 30mg | 1x60 | 60000 | | | | | |
| 72. | Naproxen/Esomeprazole 500mg/20mg | 1x10 | 1200 | | | | | |
| 73. | Oxycodone Tablet IR 5mg | 1x10 | 4000 | | | | | |
| 74. | Probenecid Tablet 250mg | 1x100s | 1000 | | | | | |
| 75. | Tramadol/Paracetamol Tablet 37.5mg/325mg | 1x20s | 50000 | | | | | |
| | RESPIRATORY DRUGS | | | | | | | |

| 76. | Beclomethasone Inhaler 200mcg/Dose | Inhaler | 100 | | | | | |
|-----|--|---------|-------|--|--|--|--|--|
| | Beclomethasone/Salbutamol Inhaler | minater | 100 | | | | | |
| 77. | 50/100mg | Inhaler | 100 | | | | | |
| 78. | Budesonide Inhaler 200mcg | Inhaler | 100 | | | | | |
| 79. | Caffeine Citrate Injection 10mg/ml | Vial | 11000 | | | | | |
| 80. | Formoterol/Budesonide Inhaler 4.5mcg/160mcg per Dose | Inhaler | 1000 | | | | | |
| 81. | Formoterol/Budesonide Inhaler 6mcg/100mcg per Dose | Inhaler | 1000 | | | | | |
| 82. | Glycopyrronium Bromide Injection 200mcg | Vial | 4000 | | | | | |
| 83. | Ipratropium Inhaler 20mcg/Dose (200 Doses) | Inhaler | 300 | | | | | |
| 84. | Ipratropium/ Salbutamol Inhaler 20mcg/100mcg per Dose | Inhaler | 300 | | | | | |
| 85. | Ipratropium/Levosalbutamol Inhaler 20mcg/50mcg per Dose | Inhaler | 300 | | | | | |
| 86. | Ipratropium/Salbutamol Nebulizer 500mcg/2.5mg | Respule | 30000 | | | | | |
| 87. | Levosalbutamol Syrup 1mg/5mls | Bottle | 3000 | | | | | |
| 88. | Nintendanib Capsule 150mg | 1x10s | 400 | | | | | |
| 89. | Prostaglandin E1 Injection 500mcg | Vial | 20 | | | | | |
| 90. | Salbutamol Injection 500mcg/ml | Vial | 100 | | | | | |
| 91. | Salmeterol/Fluticasone Inhaler 25/50mcg per Dose | Inhaler | 100 | | | | | |
| 92. | Salmeterol/Fluticasone Inhaler 50/100mcg per Dose | Inhaler | 100 | | | | | |
| 93. | Tiotropium Bromide Respimat Inhaler 2.5 mcg/dose | Inhaler | 300 | | | | | |
| 94. | Pirfenidone Tablets 200mg | 1x100s | 100 | | | | | |
| | CARDIOVASCULAR/ RENAL | | | | | | | |

| | | | | | | | | |
|------|--|--------|----------|------|------|------|------|--|
| 95. | Apixaban Tablet 2.5mg | 1x10s | 1000 | | | | | |
| 96. | Aliskiren Tablet 150mg | 1x30s | 1000 | | | | | |
| 97. | Alteplase Injection 100mg | vial | 20 | | | | | |
| 98. | Alteplase Injection 50mg | vial | 20 | | | | | |
| 99. | Amiodarone Injection 150mg | Ampoi | ule 1200 | | | | | |
| 100. | Amlodipine/Hydrochlorothiazide Tablet 5mg/12.5mg | 1x100s | s 10000 | | | | | |
| 101. | Amlodipine/Indapamide Tablet 5mg/1.25mg | 1x30s | 900 | | | | | |
| 102. | Bempedoic acid 180mg | 1x30s | 1200 | | | | | |
| 103. | Bempedoic acid/Ezetimibe 180mg/10mg | 1x30s | 1200 | | | | | |
| 104. | S-Amlodipine Tablet 5mg | 1x100s | s 1000 | | | | | |
| 105. | S-Amlodipine Tablet 2.5mg | 1x100s | s 2000 | | | | | |
| 106. | Calcium Polystyrene Sulphonate Satchet 15g | Satche | t 1000 | | | | | |
| 107. | Cardioplegia Solution | Vial | 100 | | | | | |
| 108. | Chlorthalidone Tablet 12.5mg | 1x100s | s 1000 | | | | | |
| 109. | Chlorthalidone Tablet 6.25mg | 1x100s | s 1000 | | | | | |
| 110. | Cilnidipine Tablet 5mg | 1x10s | 5000 | | | | | |
| 111. | Clonidine Tablet 0.1mg | 1x10s | 500 | | | | | |
| 112. | Clopidogrel Tablet 75mg | 1x10s | 1000 | | | | | |
| 113. | Dabapoietin Alfa Injection 25mcg | Vial | 1000 | | | | | |
| 114. | Dabapoietin Alfa Injection 40mcg | Vial | 1000 | | | | | |

| 115. | Desmopressin Nasal Spray 10mcg/spray | Spray | 50 | | | | | |
|------|--|---------|------|--|--|--|--|--|
| 116. | Desmopressin Tablet 0.1mg | 1x100s | 100 | | | | | |
| 117. | Digoxin Injection 500mcg | Ampoule | 100 | | | | | |
| 118. | Diltiazem Gel 2% | Tube | 100 | | | | | |
| 119. | Diltiazem Injection 5mg/ml | Vial | 100 | | | | | |
| 120. | Doxazocin Tablet 2mg | 1x10s | 100 | | | | | |
| 121. | Esmolol Injection 100mg | Vial | 100 | | | | | |
| 122. | Glyceryl Trinitrate Injection 50mg Vial | Vial | 50 | | | | | |
| 123. | Hydrochlorothiazide Tablet 12.5mg | 1x100s | 5000 | | | | | |
| 124. | Isoproterenol (Isoprenaline) Injection 2mg | Vial | 100 | | | | | |
| 125. | Isosorbide Dinitrate Tablet 20mg | 1x10s | 100 | | | | | |
| 126. | Isosorbide Mononitrate Tablet 60mg | 1x10s | 100 | | | | | |
| 127. | Milrinone Injection 10mg Vial | Vial | 200 | | | | | |
| 128. | Nicardipine Injection 25mg Vial | Vial | 200 | | | | | |
| 129. | Perindopril/Amlodipine Tablet 5mg/5mg | 1x10s | 300 | | | | | |
| 130. | Perindopril/Amlodipine Tablet 5mg/10mg | 1x10s | 300 | | | | | |
| 131. | Perindopril/Amlodipine/Indapamide 5mg/5mg/1.25mg | 1x10s | 300 | | | | | |
| 132. | Perindopril/Amlodipine/Indapamide 10mg/10mg/2.5mg | 1x10s | 400 | | | | | |
| 133. | Phenoxybenzamine Capsule 10mg | 1x10s | 200 | | | | | |
| 134. | Phenylephrine Injection 10mg/Ml | Vial | 100 | | | | | |

| 135. | Prazocin Tablet 1mg | 1x10s | 100 | | | | | |
|------|---|---------|-------|--|--|--|--|--|
| 136. | Sildenafil PFOL 10mg/ml | Bottle | 100 | | | | | |
| 137. | Sodium Nitroprusside Injection 50mg | Vial | 100 | | | | | |
| 138. | Sodium Polysytrene Sulphonate 450g | Tin | 100 | | | | | |
| 139. | Terazocin Tablet 2mg | 1x10s | 100 | | | | | |
| 140. | Torsemide/Eplerenone Tablet 10mg/25mg | 1x30s | 3000 | | | | | |
| 141. | Vasopressin Injection 20 units/ml | Vial | 150 | | | | | |
| 142. | Warfarin Tablet 1mg | 1x10s | 10000 | | | | | |
| 143. | Warfarin Tablet 3 mg | 1x10s | 10000 | | | | | |
| 144. | Warfarin Tablet 5mg | 1x10s | 10000 | | | | | |
| | ANAESTHESIA AND CRITICAL CARE | | | | | | | |
| 145. | Botulinum Toxin Injection | Vial | 10 | | | | | |
| 146. | Dantrolene Injection 20mg | Vial | 10 | | | | | |
| 147. | Etomidate Injection 20mg | Vial | 500 | | | | | |
| 148. | Glycopyrronium Injection 200mcg/ml | Ampoule | 3000 | | | | | |
| 149. | Glycopyrronium + Neostigmine Injection 500mcg/2.5mg | Ampoule | 1000 | | | | | |
| 150. | Lignocaine Topical spray 2% | Spray | 300 | | | | | |
| 151. | Tetracaine Topical spray 2% | Spray | 300 | | | | | |
| 152. | Lignocaine/Adrenaline Injection 2%/1:200000 vial | Vial | 300 | | | | | |
| 153. | Pyridostigmine Tablet 60mg | 1x10 | 500 | | | | | |

| 154. | Pyridostigmine Oral solution 60mg/5ml, 240ml | 240ml | 100 | | | | | |
|------|--|---------|-------|--|--|--|--|--|
| 155. | Pyridostigmine Injection 10mg | vial | 100 | | | | | |
| 156. | Remifentanyl Injection 2mg | Vial | 500 | | | | | |
| 157. | Rocuronium Bromide Injection 10mg | Vial | 500 | | | | | |
| 158. | Vecuronium Bromide Injection 10mg | Vial | 200 | | | | | |
| | REPRODUCTIVE HEALTH | | | | | | | |
| 159. | Carboprost Tromethamine Injection 250mcg | Vial | 10 | | | | | |
| 160. | Danazol Capsule 50mg | 1x10s | 300 | | | | | |
| 161. | Ergometrine Injection 500mcg | Vial | 100 | | | | | |
| 162. | Human Menopausal Gonadotrophin (HMG) Injection 75 IU | Vial | 10 | | | | | |
| 163. | Terbutaline Injection 2.5mg | Vial | 10 | | | | | |
| 164. | Terbutaline Injection 0.5mg | Vial | 10 | | | | | |
| | VITAMINS/SUPPLEMENTS | | | | | | | |
| 165. | Sodium Chloride Tablet 600mg | 1x500s | 5000 | | | | | |
| 166. | Potassium Chloride Tab 600mg | 1x100s | 5000 | | | | | |
| 167. | Calcium Citrate/Vitamin D3/Magnesium sulphate, Zinc Sulphate Syrup 250mg/100IU 200ml | 1x10s | 4000 | | | | | |
| 168. | Collajoint Satchet | Satchet | 3000 | | | | | |
| 169. | Vitamin A Capsule 100,000 i.u. | 1x100s | 10000 | | | | | |
| 170. | Vitamin D3 Capsule or Tablet 60000iu | 1x10s | 2000 | | | | | |

| 171. | Vitamin C Tablet 1g | 1x10s | 3000 | | | | | |
|------|---|----------|------|--|--|--|--|--|
| 172. | Nanocalcium 500mg/ Vit D3 | 1x10 | 1200 | | | | | |
| | DERMATOLOGICALS | | | | | | | |
| 173. | Adapalene Gel 1% | 15g | 400 | | | | | |
| 174. | Calcium dobesilate cream | 30g | 200 | | | | | |
| 175. | Calamine Lotion 100-200ml | 100ml | 1000 | | | | | |
| 176. | Caustic Pencil 40% | Pencil | 100 | | | | | |
| 177. | Collagenase clostriopeptidase A + Proteases Ointment 1.2units + 0.24 units (15g) | 15g | 300 | | | | | |
| 178. | Crotamiton Cream 10% | 30g | 300 | | | | | |
| 179. | Desonide cream | 15g | 200 | | | | | |
| 180. | Dexpanthenol Cream 5% | 20g | 300 | | | | | |
| 181. | Dithranol Paste 2% | 30g | 300 | | | | | |
| 182. | Ketoconazole Shampoo 2% | 100ml | 500 | | | | | |
| 183. | Miconazole cream 2% | 30g | 400 | | | | | |
| 184. | Podophyllin Resin Solution 15% | 15ml | 200 | | | | | |
| 185. | Sertaconazole Cream 2% | 20g | 300 | | | | | |
| 186. | Salicylic acid Cream or ointment 2% | 50g | 100 | | | | | |
| 187. | Sun screen SPF >50% | 50ml | 1000 | | | | | |
| 188. | Tretinoin Cream 0.05% | 30g | 300 | | | | | |
| 189. | Imiquimoid Cream 5% | Satchets | 1000 | | | | | |

| 190. | Zinc Hyaluronate Gel | 15 | 5g | 300 | | | | | |
|------|--|----|--------|-----|--|--|--|--|--|
| 191. | Zinc Oxide Paste | 50 |)0g | 200 | | | | | |
| 192. | White soft Paraffin (Petroleum Jelly) | 10 |)0g | 300 | | | | | |
| | COMPOUNDING VEHICLES | | | | | | | | |
| 193. | Distilled Water | Во | ottle | 200 | | | | | |
| 194. | Simple Syrup | В | ottle | 200 | | | | | |
| 195. | Aqueous cream | В | ottle | 200 | | | | | |
| | OPTHALMOLOGY DRUGS | | | | | | | | |
| 196. | Aflibercept Injection 2mg | V | ial | 50 | | | | | |
| 197. | Azelastine Eye Drops 0.05% | 5r | nl | 200 | | | | | |
| 198. | Bimatoprost Eye drops 0.01% | 5r | nl | 100 | | | | | |
| 199. | Bimatoprost Eye drops 0.03% | 5r | nl | 100 | | | | | |
| 200. | Bimatoprost/Timolol Eye drops 0.03%/0.5% | 5r | ml | 100 | | | | | |
| 201. | Brimonidine/Timolol Eye drops 0.2%/0.5% | 5r | nl | 100 | | | | | |
| 202. | Diclofenac Opthalmic Solution 0.1% | 5r | nl | 200 | | | | | |
| 203. | Fluorescein Test Strip 0.6 mg | 5r | nl | 10 | | | | | |
| 204. | Ganciclovir Intraocular Implant | In | nplant | 10 | | | | | |
| 205. | Hypertonic Saline Eye Drops 5% | 5r | nl | 100 | | | | | |
| 206. | Moxifloxacin Eye Drops 0.5% | 5r | nl | 300 | | | | | |
| 207. | Natamycin Eye Drops 5% | 5r | nl | 200 | | | | | |

| | | | | | | | | |
|------|---|------|-------|------|------|------|--|--|
| 208. | Pilocarpine Eye Drops 4% | 5ml | 100 | | | | | |
| 209. | Proparacaine Opthalmic Solution 0.5% | 5ml | 100 | | | | | |
| 210. | Polyacrylic Acid Eye Gel 0.2% | 5ml | 100 | | | | | |
| 211. | Ranibizumab Injection 6mg/ml, | 5ml | 100 | | | | | |
| 212. | Ranibizumab Injection 10mg/ml, | 5ml | 100 | | | | | |
| 213. | Riboflavin Solution 0.1% (with Dextran) | 5ml | 100 | | | | | |
| 214. | Riboflavin Solution 0.1% (without Dextran) | 5ml | 100 | | | | | |
| 215. | Epinastine Eye Drops 0.5mg/ml | 5ml | 100 | | | | | |
| 216. | Sodium Cromoglycate Eye Drops 2% | 5ml | 100 | | | | | |
| 217. | Sodium Hyaluronate Eye Drops 1% Preservative free | 5ml | 800 | | | | | |
| 218. | Tetracaine Eye Drops 0.5% | 5ml | 100 | | | | | |
| 219. | Tobramycin 0.3%/Dexamethasone 0.1% | 5ml | 150 | | | | | |
| 220. | Timolol Eye Drops 0.5% | 5ml | 150 | | | | | |
| 221. | Tropicamide Eye Drops 1% | 5ml | 100 | | | | | |
| 222. | Tryptan Blue Intracameral Solution 0.06% | 5ml | 200 | | | | | |
| 223. | Voriconazole Powder for eye drops 1% | 5ml | 100 | | | | | |
| | ANTIMALARIALS | | | | | | | |
| 224. | Artemether/Lumefantrine Tablet 80/480mg | 1x6 | 10000 | | | | | |
| 225. | Artemether/Lumefantrine Tablet 20/120mg (dispersible) | 1x6 | 10000 | | | | | |
| 226. | Dihydroartemesinin/Piperaquine Tablet 20/160mg | 1x24 | 2000 | | | | | |

| 227. | Proguanil Tablet 100mg | 1x10s | 1000 | | | | | |
|------|---|--------|-------|--|--|--|--|--|
| | NEUROLOGICAL AND PSYCHOTHERAPEUTIC DRUGS | | | | | | | |
| 228. | Baclofen Tablet 5mg | 1x10s | 20000 | | | | | |
| 229. | Benztropine Injection 2mg/2ml | Vial | 100 | | | | | |
| 230. | Biperiden injection 5mg | Vial | 200 | | | | | |
| 231. | Biperiden Tablet 2mg | 1x10s | 300 | | | | | |
| 232. | Bupropion Tablet 150mg | 1x10s | 2000 | | | | | |
| 233. | Carbidopa/Levodopa Tablet 100mg/10mg | 1x10s | 1000 | | | | | |
| 234. | Carbidopa/Levodopa Tablet 250/25mg | 1x10s | 900 | | | | | |
| 235. | Citicoline Tablet 500mg | 1x10s | 300 | | | | | |
| 236. | Clomipramine Capsule 25mg | 1x10s | 200 | | | | | |
| 237. | Clozapine Tablet 100mg (scored) | 1x10s | 400 | | | | | |
| 238. | Clozapine Tablet 25mg (scored) | 1x10s | 400 | | | | | |
| 239. | Disalfirum Tablet 200mg | 1x100s | 200 | | | | | |
| 240. | Flupenthixol Decanoate Injection 40mg | Vial | 1000 | | | | | |
| 241. | Flupenthixol Decanoate Injection 20mg | Vial | 1000 | | | | | |
| 242. | Gabapentin Tablet 300mg | 1x10s | 500 | | | | | |
| 243. | Haloperidol Accuphase Injection 5mg | Vial | 500 | | | | | |
| 244. | Haloperidol Oral Solution 2mg/ml | 100ml | 200 | | | | | |
| 245. | Lithium Carbonate MR Tablet 200mg | 1x100s | 300 | | | | | |

| 246. | Lorazepam Tablet 1mg | 1 | 1x100s | 300 | | | | | |
|------|-------------------------------------|---|--------|-------|--|--|--|--|--|
| 247. | Lorazepam Injection 4mg/ml | 7 | Vial | 300 | | | | | |
| 248. | Meclizine Tablet 12.5mg | 1 | 1x100s | 200 | | | | | |
| 249. | Melatonin Tablet 10 mg | 1 | 1x100s | 1000 | | | | | |
| 250. | Memantine Tablet 5 mg | 1 | 1x10s | 200 | | | | | |
| 251. | Metadoxine 500mg | 1 | 1x30 | 6000 | | | | | |
| 252. | Methylphenidate Tablet 10mg | 1 | 1x10s | 300 | | | | | |
| 253. | Naltrexone Tablet 50mg | 1 | 1x10s | 400 | | | | | |
| 254. | Nicotine Chewing gum 2mg | (| Gum | 600 | | | | | |
| 255. | Nicotine Chewing gum 4mg | (| Gum | 600 | | | | | |
| 256. | Nicotine Transdermal Patch 21mg/24h | I | Patch | 1000 | | | | | |
| 257. | Nicotine Transdermal Patch 14mg/24h | I | Patch | 1000 | | | | | |
| 258. | Nicotine Transdermal Patch 7mg/24h | F | Patch | 1000 | | | | | |
| 259. | Olanzapine Tablet 20mg | 1 | 1x100s | 60000 | | | | | |
| 260. | Olanzapine Tablet 15mg | 1 | 1x100s | 60000 | | | | | |
| 261. | Olanzapine Injection 10mg | V | Vial | 500 | | | | | |
| 262. | Oxcarbazepine 60mg/ml | 1 | 100ml | 300 | | | | | |
| 263. | Oxcarbazepine Tablet 150mg | 1 | 1x50 | 1000 | | | | | |
| 264. | Oxcarbazepine Tablet 300mg | 1 | 1x50 | 1000 | | | | | |
| 265. | Phenobarbital Syrup 20mg/ml | 1 | 100ml | 500 | | | | | |

| 266. | Phenytoin Tablet 50 mg | 1x100s | 6000 | | | | | |
|------|--|--------|-------|--|--|--|--|--|
| 267. | Pramipexole tab scored 180mcg base | 1x100 | 120 | | | | | |
| 268. | Pramipexole Tab 700mcg base | 1x30 | 100 | | | | | |
| 269. | Pregabalin Tablet 150mg | 1x10s | 300 | | | | | |
| 270. | Pregabalin/Methylcobalamin Tablet 75mg/750mcg | 1x10s | 600 | | | | | |
| 271. | Pyridostigmine Tablet 60mg | 1x30s | 900 | | | | | |
| 272. | Rivastigmine Capsules 1.5mg | 1x30s | 900 | | | | | |
| 273. | Riluzole Tablet 50mg | 1x56 | 600 | | | | | |
| 274. | Sodium Valproate Tablet 750mg | 5x10s | 9000 | | | | | |
| 275. | Topiramate Tablets 25mg | 1x10s | 1000 | | | | | |
| 276. | Vigabatrin Tablet 500mg | 1x100s | 500 | | | | | |
| | STEROIDS/ ANTIHISTAMINES | | | | | | | |
| 277. | Bilastine Tablet 20mg | 1x50s | 15000 | | | | | |
| 278. | Chlorpheniramine Syrup 2mg/5mls | 100ml | 1000 | | | | | |
| 279. | Rupatadine Syrup 5mg/5ml 60ml | 100mls | 2000 | | | | | |
| 280. | Methyl Prednisolone Sodium Acetate Injection 40mg | Vial | 400 | | | | | |
| 281. | Triamcinolone Injection 40mg | Vial | 400 | | | | | |
| | THYROID AND PARATHYROID DRUGS | | | | | | | |
| 282. | Cinacalcet Tablet 30mg | 1x10s | 2000 | | | | | |
| 283. | Methimazole Tablet 5mg | 1x10s | 2000 | | | | | |

| 284. | Iodine 5% (Lugol's Iodine) | 60ml | 100 | | | | | |
|------|---|---------|------|--|--|--|--|--|
| 285. | Propylthiouracil Tablet 50mcg | 1x56s | 1200 | | | | | |
| | ANTIDOTES | | | | | | | |
| 286. | Acetylcysteine Injection 200mg/ml | Ampoule | 100 | | | | | |
| 287. | Fomepizole Injection 1.5g | Vial | 100 | | | | | |
| 288. | Deferoxamine Injection 500mg | Vial | 50 | | | | | |
| 289. | Edetate Calcium Disodium Injection 1g/5ml | Vial | 50 | | | | | |
| 290. | Dimercaprol Injection 100mg | Vial | 50 | | | | | |
| 291. | Flumazenil Injection 1mg | Ampoule | 50 | | | | | |
| 292. | Succimer Capsules 100mg | 1x10s | 50 | | | | | |
| 293. | Physostigmine Injection 2mg | Ampoule | 50 | | | | | |
| 294. | Glucagon Injection 1mg | Vial | 50 | | | | | |
| 295. | Penicillamine Capsules 250mg | 1x10s | 50 | | | | | |
| 296. | Pralidoxime Injection 1g | Vial | 2400 | | | | | |
| 297. | Protamine Sulphate Injection 50mg | Ampoule | 1000 | | | | | |
| | VACCINES and IMMUNOGLOBULINS | | | | | | | |
| 298. | Antithymocyte globulin (rabbit) | Vial | 200 | | | | | |
| 299. | Hepatitis A Vaccine | Vial | 100 | | | | | |
| 300. | E.N.T. | | | | | | | |
| 301. | Liquid Paraffin 100% Nasal Drops | 100ml | 300 | | | | | |

| 302. | Hydrogen Peroxide Ear Drops 3% | 10ml | 100 | | | | | |
|------|--|--------|------|--|--|--|--|--|
| 303. | Sodium Chloride Nasal Drops B.P. 0.9% W/V | 10ml | 3000 | | | | | |
| 304. | Lignocaine Nasal Spray 10mg/Metered dose | Spray | 300 | | | | | |
| | DENTAL | | | | | | | |
| 305. | Chlorhexidine Mouth Gel 1% | 15g | 500 | | | | | |
| 306. | Teething gel 15g | 15g | 1000 | | | | | |
| 307. | Triamcinolone Dental Paste 0.1% | 5g | 200 | | | | | |
| 308. | Miconazole Oral Gel | 40g | 300 | | | | | |
| | HEMATOLOGY/ONCOLOGY DRUGS | | | | | | | |
| 309. | 6 Mercaptopurine Tablet 50mg | 1x10s | 3000 | | | | | |
| 310. | Abatacept PFI 250mg | Vial | 100 | | | | | |
| 311. | Abiraterone 500mg | 1x60 | 1200 | | | | | |
| 312. | All-Trans-Retinoic-Acid (ATRA) Tablet 10mg | 1x100s | 20 | | | | | |
| 313. | Arsenic Trioxide Infusion 1mg/ml | Vial | 100 | | | | | |
| 314. | Azathioprine Injection 100mg | Vial | 100 | | | | | |
| 315. | Busulphan Tablet 2mg | 1x100s | 30 | | | | | |
| 316. | Cabazitaxel Injection 60mg | Vial | 100 | | | | | |
| 317. | Carfilzomib Injection 60mg | Vial | 100 | | | | | |
| 318. | Chlorambucil Tablet 2mg | 1x25s | 250 | | | | | |
| 319. | Cyclophosphamide Tablet 25mg | 1x10s | 1000 | | | | | |

| 320. | Dacarbazine Injection 200mg | Vial | 2500 | | | | | |
|------|-------------------------------------|-----------|------|--|--|--|---|--|
| 321. | Danazol Capsule 100mg | 1x30s | 100 | | | | | |
| 322. | Daratumumab Injection 400mg | Vial | 100 | | | | | |
| 323. | Dasatinib Tablets 100mg | 1x60 | 100 | | | | | |
| 324. | Daunorubicin Injection 50mg | Vial | 200 | | | | | |
| 325. | Eculizumab Injection 300mg | Vial | 50 | | | | | |
| 326. | Eltrombopag Tablet 50mg | 2x7s | 100 | | | | | |
| 327. | Etoposide Capsule 100mg | 1x12 | 100 | | | | | |
| 328. | Fludarabine Injection 50mg | Vial | 500 | | | | | |
| 329. | Folinic Acid Injection 50mg | Vial | 5000 | | | | | |
| 330. | Folinic Acid Tablet 15mg | 1x10s | 500 | | | | | |
| 331. | Hydroxyurea Capsule 250mg | 1x10s | 300 | | | | | |
| 332. | Ibrutinib Capsule 140mg | 1x90s | 400 | | | | | |
| 333. | Idarubicin Injection 20mg | Vial | 100 | | | | | |
| 334. | Infliximab Injection 100mg | Vial | 50 | | | | | |
| 335. | L-Asparaginase Injection 10000 I.U. | Vial | 400 | | | | | |
| 336. | Lenalidomide Capsule 10mg | 1x10s | 400 | | | | _ | |
| 337. | Leuprolide Injection 11.25mg | Injection | 300 | | | | | |
| 338. | Melphalan PFI 50mg | Vial | 100 | | | | | |
| 339. | Melphalan Tablet 2mg | 1x25s | 100 | | | | | |

| 340. | Methotrexate Injection (pre-filled injection) 25mg/ml, 0.4ml | Vial | 200 | | | | | |
|------|--|-------|---------|--|--|--|--|--|
| 341. | Methotrexate Injection 1g | Vial | 3000 | | | | | |
| 342. | Mitomycin C Injection 10mg | Vial | 100 | | | | | |
| 343. | Mitoxantrone Injection 20mg | Vial | 400 | | | | | |
| 344. | NAB Paclitaxel Injection 100mg | Vial | 500 | | | | | |
| 345. | Osimertinib film coated Tablet 80mg | 1x30 | 900 900 | | | | | |
| 346. | Palbociclib Capsule 100mg | 1x21 | s 300 | | | | | |
| 347. | Palbociclib Capsule 150mg | 1x21 | s 300 | | | | | |
| 348. | Palbociclib capsule 125mg | 1x21 | s 300 | | | | | |
| 349. | Palbociclib Capsule 75mg | 1x21 | s 300 | | | | | |
| 350. | Pazopanib Tablet 200mg | 1x10 | os 400 | | | | | |
| 351. | Pazopanib Tablet 400mg | 1x10 | os 500 | | | | | |
| 352. | PEG Asparaginase Injection 3750IU | Vial | 100 | | | | | |
| 353. | PEG Filgrastim Prefilled Syringe 6mg | Syrir | nge 200 | | | | | |
| 354. | Pemetredex Injection 500mg | Vial | 100 | | | | | |
| 355. | Pomalidomide Capsule 1mg | 1x21 | s 490 | | | | | |
| 356. | Procarbazine Capsule 50mg | 1x10 | 00s 100 | | | | | |
| 357. | Rasburicase Injection 1.5mg | Vial | 300 | | | | | |
| 358. | Regorafenib Tablet 40mg | 1x28 | Ss 100 | | | | | |
| 359. | Ruxolitinib Tablet 10mg | 1x24 | s 300 | | | | | |

| 360. | Ruxolitinib Tablet 20mg | 1x24s | 300 | | | | | |
|------|---|---------|------|--|--|--|--|--|
| 361. | Ruxolitinib Tablet 5mg | 1x24s | 300 | | | | | |
| 362. | Sorafenib Tablet 200mg | 1x120 | 300 | | | | | |
| 363. | Sunitinib Capsule 50mg | 1x28s | 200 | | | | | |
| 364. | Tacrolimus Injection 5mg | Vial | 100 | | | | | |
| 365. | Tioguanine SODF 40mg | Vial | 100 | | | | | |
| 366. | Topotecan Injection 2.5mg | Vial | 100 | | | | | |
| 367. | Venetoclax Tablet 100mg | 1x120 | 100 | | | | | |
| 368. | Vinorelbine Injection 10mg | Vial | 100 | | | | | |
| | MONOCLONAL ANTIBODIES | | | | | | | |
| 369. | Pembrolizumab Injection 100mg | Vial | 30 | | | | | |
| | UROLOGY DRUGS | | | | | | | |
| 370. | Dutasteride Capsule 0.5mg | 1x10s | 3000 | | | | | |
| 371. | Finasteride/Tamsulosin Capsule 400mcg/5mg | 1x10s | 3000 | | | | | |
| 372. | Mirabegron 50mg | 1x10 | 1200 | | | | | |
| 373. | Mirabegron/Solifenacin 25mg/5mg | 1x10 | 1200 | | | | | |
| 374. | Oxybutynin Tablet 5mg | 1x100s | 1500 | | | | | |
| 375. | Papaverine Injection 60mg | Ampoule | 300 | | | | | |
| 376. | Tolterodine Capsule 2mg | 1x14s | 3000 | | | | | |
| 377. | NUTRACEUTICALS | | | | | | | |

| 378. | Infant formula with iron for term babies- Bidders to bring samples | 400g | 1000 | | | | | |
|------|--|----------------|------|--|--|--|--|--|
| 379. | Infant formula with iron for premature babies-Bidders to bring samples | 400g | 800 | | | | | |
| 380. | Human Breast milk fortifier for premature babies and low birth weight infants fed on breast milk- Bidders to bring samples | 1gm x24 | 600 | | | | | |
| 381. | Human Breast milk fortifier for preterm and low birth weight infants fed on breast milk-Bidders to bring samples | 1gmx 72 | 600 | | | | | |
| 382. | Amino acids Solution for IV infusion 5% for pediatrics | 250mls | 1000 | | | | | |
| 383. | Fat-soluble vitamins (for infants and children) Solution for IV infusion | 10mls | 800 | | | | | |
| 384. | Specialized sip feed for hepatic patients Liquid | 200mls | 800 | | | | | |
| 385. | Specialized hypercaloric liquid formula feed Liquid | 500mls | 600 | | | | | |
| 386. | Low fat formula Powder | 200- 500gms | 800 | | | | | |
| 387. | Specialized Renal formula enriched with vitamins and minerals in Powder form for renal patients | 21gmx 6 | 1000 | | | | | |
| 388. | Nutritional complete feed enriched with MCT and BCAA for hepatic patients | 25gmx6 | 1000 | | | | | |
| 389. | Specialized Semi-elemental peptide formula in Powder form | 400gms | 600 | | | | | |
| 390. | Therapeutic diet feed (F-75) PFOL (for approx. 600mL) Standard formula | 400gms | 1500 | | | | | |
| 391. | Therapeutic diet feed (F-75) PFOL Standard formula | 400gms | 400 | | | | | |
| 392. | Breastfeeding stimulator in granules or powder form for lactating mothers | 250gm | 700 | | | | | |
| 393. | Specialized semi-elemental peptide formula in powder form | 400g | 600 | | | | | |
| | ORIGINAL AND BRANDED DRUGS | | | | | | | |
| 394. | Andolex C Spray | 30mls | 2400 | | | | | |

| 395. | Biogaia tablets | 1x30s | 3000 | | | | | |
|------|--|---------|------|--|--|--|--|--|
| 396. | Coloprep Bowel Preparation Kit 2x177ml | Bottle | 500 | | | | | |
| 397. | Cytotec Tablet 200mg | 1x10s | 3000 | | | | | |
| 398. | Epimax Baby and Junior Cream 400g | Bottle | 300 | | | | | |
| 399. | Epimax Plus Adult Cream 400g | Bottle | 300 | | | | | |
| 400. | Flarex Eye Drops | 5ml | 600 | | | | | |
| 401. | Heparin Rotex Injection 25000 I.U. | Vial | 3000 | | | | | |
| 402. | Herceptin 600mg/5ml | Vial | 2400 | | | | | |
| 403. | Herceptin 440mg | Vial | 2400 | | | | | |
| 404. | Infacol Colic Relief Drops 55ml | Bottle | 300 | | | | | |
| 405. | Keppra Tablet 250mg | 1x30s | 2000 | | | | | |
| 406. | Lantus Solostar Injection 100U/ml | Syringe | 500 | | | | | |
| 407. | Mabthera 500mg/50ml | Vial | 1200 | | | | | |
| 408. | Marcaine Heavy Injection 0.5% | Vial | 2000 | | | | | |
| 409. | Marcain Injection 0.5% | Vial | 2000 | | | | | |
| 410. | Movicol Pediatric Oral Solution 6.9g | Satchet | 500 | | | | | |
| 411. | Survanta 25mg/ml | Vial | 3000 | | | | | |
| 412. | Syntocinon Injection 10mg | Vial | 3000 | | | | | |
| 413. | Ultiva Injection 2mg | Vial | 500 | | | | | |
| 414. | Tear Naturale II Eye Drops | 15ml | 600 | | | | | |

| 415. | Venofer 100mg/5ml | | | Vial | 12000 | | | | | | | |
|------|--|--|--|------|-------|--|--|--|-----------------------------|---------|--------|------------|
| | | | | | | | | | Total Currer In figu In wor | ures: _ | Tender | Price: |
| | Name of Tenderer [insert complete name of Tenderer] Signature of Tenderer [signature of person signing the Tender] Date [insert date] In the capacity of: [insert: title or other appropriate designation] | | | | | | | | | | | |

| ru | TENDER SECURIT 1-[Option 1-Demand Dank Guarantee] |
|-----|--|
| Bei | neficiary: |
| Re | quest forTenders No: |
| Da | te: |
| TE | NDER GUARANTEE No.: |
| Gu | arantor: |
| 1. | We have been informed that (here inafter called "the Applicant") has submitted or will submit to the Beneficiary its Tender (here inafter called" the Tender") for the execution of |
| | under Request for Tenders No("the ITT"). |
| 2. | Furthermore, we understand that, according to the Beneficiary's conditions, Tenders must be supported by a Tender guarantee. |
| 3. | At the request of the Applicant, we, as Guarantor, hereby irrevocably undertake to pay the Beneficiary any sum or sums not exceeding in total an amount of() upon receipt by us of the Beneficiary's complying demand, supported by the Beneficiary's statement, whether in the demand itself or a separate signed document accompanying or identifying the demand, stating that either the Applicant: |
| (a) | has withdrawn its Tender during the period of Tender validity set forth in the Applicant's Letter of Tender ("the Tender Validity Period"), or any extension thereto provided by the Applicant; or |
| b) | having been notified of the acceptance of its Tender by the Beneficiary during the Tender Validity Period or any extension there to provided by the Applicant, (i) has failed to execute the contract agreement, or (ii) has failed to furnish the Performance. |
| 4. | This guarantee will expire: (a) if the Applicant is the successful Tenderer, upon our receipt of copies of the contract agreement signed by the Applicant and the Performance Security and, or (b) if the Applicant is not the successful Tenderer, upon the earlier of (i) our receipt of a copy of the Beneficiary's notification to the Applicant of the results of the Tendering process; or (ii) thirty days after the end of the Tender Validity Period. |
| 5. | Consequently, any demand for payment under this guarantee must be received by us at the office indicated above onor before that date. |
| | [signature(s)] |
| | [DiStrain C(D)] |

Note: All italicized text is for use in preparing this form and shall be deleted from the final product.

FORMAT OF TENDER SECURITY [Option 2–Insurance Guarantee]

| TENI | DER GUARANTEE No.: | - | |
|------|---|--|---|
| 1. | dated [Date of submission | tenderer] (hereinafter called "the tender on of tender] for the | d/or description of the tender] |
| 2. | Company] having our registered | se presents that WE | e Guarantor"), are bound unto uring Entity") in the sum of and truly to be made to the said |
| | Sealed with the Common Seal of | f the said Guarantor thisday of 20 | <u>_</u> |
| 3. | NOW, THEREFORE, THE CO | ONDITION OF THIS OBLIGATION is suc | h that if the Applicant: |
| | | ler during the period of Tender validity Tender Validity Period"), or any extensi- | |
| | Validity Period or any Contract agreement; or (| the acceptance of its Tender by the Procuri extension thereto provided by the Princip (ii) has failed to furnish the Performance rers ("ITT") of the Procuring Entity's Tender | al; (i) failed to execute the Security, in accordance with |
| | upon receipt of the Procuring substantiate its demand, provid | to immediately pay to the Procuring Entity Entity's first written demand, without the led that in its demand the Procuring Entity any of the above events, specifying which | Procuring Entity having to shall state that the demand |
| 4. | copies of the contract agreement if the Applicant is not the such | a) if the Applicant is the successful Terent signed by the Applicant and the Perfoccessful Tenderer, upon the earlier of (i) of the Applicant of the results of the Tendering der Validity Period. | rmance Security and, or (b) our receipt of a copy of the |
| 5. | Consequently, any demand for indicated above on or before the | r payment under this guarantee must be rhat date. | received by us at the office |
| | [Date] | [Signature of the Guarantor] | |
| | [Witness] | [Seal] | |

Note: All italicized text is for use in preparing this form and shall be deleted from the final product.

TENDER - SECURING DECLARATION FORM

| [TheBiddershallcompletethisForminaccordancewiththeinstructionsindicated] | | | | | | | |
|--|--|--|--|--|--|--|--|
| Date:[insert date (as day, month and year) of Tender Submission] | | | | | | | |
| Tende | er No.:[insert number of tendering process] | | | | | | |
| То: | [insert complete name of Purchaser] | | | | | | |
| I/We, | , the undersigned, declare that: | | | | | | |
| 1. | I/We understand that, according to your conditions, bids must be supported by a Tender-Securing Declaration. | | | | | | |
| 2. | I/We accept that I/ we will automatically be suspended from being eligible for tendering in any contract with the Purchaser for the period of time of [insert number of months or years]starting on [insert date], if we are in breach of our obligation(s) under the bid conditions, because we—(a) have withdrawn our tender during the period of tender validity specified by us in the Tendering Data Sheet; or(b) having been notified of the acceptance of our Bid by the Purchaser during the period of bid validity,(i)fail or refuse to execute the Contract, if required, or(ii) fail or refuse to furnish the Performance Security, in accordance with the instructions to tenders. | | | | | | |
| 3. | I/We understand that this Tender Securing Declaration shall expire if we are not the successful Tenderer(s),upon the earlier of: | | | | | | |
| | a) ourreceiptofacopyofyournotificationofthenameofthesuccessfulTenderer;or | | | | | | |
| | b) thirty days after the expiration of our Tender. | | | | | | |
| 4. | I/We understand that if I am/we are/in a Joint Venture, the Tender Securing Declaration must be in the name of the Joint Venture that submits the bid, and the Joint Venture has not been legally constitute d at the time of bidding, the Tender Securing Declaration shall be in the names of all future partners as named in the letter of intent. | | | | | | |
| Signe | ed: | | | | | | |
| Capa | city / title (director or partner or sole proprietor, etc.) | | | | | | |
| Name | 2: | | | | | | |
| Duly | authorized to sign the bid for and on behalf of: [insert complete name of Tenderer] | | | | | | |
| Dated on | | | | | | | |
| Seal | or stamp | | | | | | |

MANUFACTURER'S AUTHORIZATION

[The Tenderer shall require the Manufacturer to fill in this Form in accordance with the instructions indicated. This Form of authorization should be on the letterhead of the Manufacturer and should be signed by a person with the proper authority to sign documents that are binding on the Manufacturer. The Tenderer shall include it in its Tender, if so indicated in the TDS.]

| Date:[insert date (as day, month and year) of Tender submission] |
|--|
| ITT No.:[insert number of tendering process] |
| AlternativeNo.:[insertidentificationNoifthisisaTenderforanalternative] |
| To:[insertcompletenameofProcuringEntity] |
| WHEREAS |
| We [insert complete name of Manufacturer], who are official manufacturers of [insert type of goods manufactured], having factories at [insert full address of Manufacturer's factories], do hereby authorize [insert complete name of Tenderer] to submit a Tender the purpose of which is to provide the following Goods, manufactured by us[insert name and or brief description of the Goods], and to subsequently negotiate and sign the Contract. |
| We here by extend our full guarantee and warranty in accordance with Clause 28 of the General Conditions of Contract, with respect to the Goods offered by the above firm. |
| Signed:[insert signature(s)of authorized representative(s) of the Manufacturer] |
| Name:[insert complete name(s)of authorized representative(s)of the |
| Manufacturer] Title:[insert title] |
| Dated onday of,[insert date of signing] |

SPECIMEN CERTIFICATE OFA PHARMACEUTICAL PRODUCT

Certificate of a Pharmaceutical Product¹

| | | e conforms to the format recommended by the World Health Organization (general instructions and otes attached). |
|-------|--|---|
| No. o | of certification | ate: |
| Expo | orting (cer | tifying) country: |
| Impo | orting (rec | questing) country: |
| 1. | Name a | and dosage form of product: |
| | ••••• | Active ingredients ² and amount(s) per unit dose. ³ |
| | | |
| | | |
| | For cor | mplete qualitative composition including excipients, see attached.4 |
| Is | this prod | uct licensed to be placed on the market for use in the exporting country yes/no (key in as appropriate) |
| | the | product actually on the market in the exporting country? yes/no/unknown (key in as appropriate) If answer to 1.2 is yes, continue with section 2A and omit section 2B. If the answer to 1.2 is no, omit ion 2A and continue with section 2B. |
| | 2A.1 | Number of product license ⁷ and date of issue: |
| | 2A.2 | Product-license holder(name and address): |
| | | |
| | | |
| | 2A.3 2A.3.1 mare: ⁹ 2 2A.5 | Status of product-license holder: ⁸ a/b/c (key in appropriate category as defined in note 8) For categories b and c the name and address of the manufacturer producing the dosage for 2A.4 Is Summary Basis of Approval appended ¹⁰ yes/no (key in as appropriate) Is the attached, officially approved product information complete and consonant with the license ¹¹ yes/no/not provided (key in as appropriate) |
| | 2A.6 | Applicant for certificate, if different from license holder (name and |
| | address | 2):122B.1 Applicant for certificate(name and address): |

Status of applicant: a/b/c (key in appropriate category as defined in note 8)

2B.2

| | 2 B .2.1 | For categories band c the name and address of the manufacturer producing the dosage for mare: |
|----|-----------------|---|
| | | |
| | | |
| | 2B.3 | Why is marketing authorization lacking? |
| | | Not required/not requested/under consideration/ refused (key in as |
| | appropr | iate) 2B.4 Remarks: ¹³ |
| i. | | e certifying authority arrange for period inspection of the manufacturing plant in which the dosage produced? |
| | Yes /no | not applicable 14 (key in as |
| | appropr | iate) If no or not applicable proceed |
| | to quest | ion ⁴ . |
| |] | Periodicity of routine inspections(years): |
| | | Has the manufacture of this type of dosage form been |
| | i | inspected? yes/no(key in as appropriate) |
| | | Do the facilities and operations conform to GMP as recommended by the World Health |
| | (| Organization ¹⁵ yes/no/notapplicable16(key in as appropriate) |
| | | e information submitted by the applicant satisfy the certifying authority on all aspects of the cture of the product? ¹¹ |
| | yes/no(l | xey in as |
| | appropr | iate) If no, explain: |
| | | |
| | | |
| | A .d.u.a.a | |
| | | of certifying authority: |
| | | ne number: Fax number: |
| | Name o | f authorized person: |
| | Signatu | re: |
| | Stamp a | nd date: |
| | | |
| | | |

General instructions

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notes

- ¹ This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
- 2 Use whenever possible international nonproprietary names (INNs) or national nonproprietary names
- .3 The formula (complete composition) of the dosage form should be given on the certificate or be appended
- .4Details of quantitative composition are preferred, but their provision is subject to the agreement of the product-license holder
- .5When applicable, append details of any restriction applied to the sale, distribution, or administration of the product that is specified in the product license. 6Sections 2A and 2B are mutually exclusive.
- ⁷*Indicate*, when applicable, if the license is provisional or if the product has not yet been approved.
- 8 Specify whether the person responsible for placing the product on the market:
- a) Manufactures the dosage form;
- b) Packages and/or labels a dosage form manufactured by an independent company; or
- c) Is involved in none of the above.
- ⁹This information can be provided only with the consent of the product-license holder or, in the case of non-registered products, the applicant. Non completion of this Section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product license. If the production site is changed, the license must be updated or it will cease to be valid.
- ¹⁰This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed. ¹¹This refers to product information approved by the competent national regulatory authority, such as a Summary of Product Characteristics (SPC).
- ¹²In this circumstance, permission for issuing the certificate is required from the product-license holder. This permission must be provided to the authority by the applicant.
- ¹³Please indicate the reason that the applicant has provided for not requesting registration:
- a) The product has been developed exclusively for the treatment of conditions-particularly tropical diseases-not endemic in the country of export.
- b) The product has been reformulated with a view to improving its stability under tropical conditions.
- c) The product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import.
- ${\it d)} \quad The product has been reformulated to meet a different maximum dos a gelimit for an active in gredient.$
- e) Any other reason, please specify.
- ¹⁴Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
- ¹⁵The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No.823,1992, Annex1). Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No.822,1992, Annex1).
- 16 This section is to be completed when the product-license holder or applicant conforms to status(b) or(c) as described in note7above. It is of particular importance
- when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

PART 2 - SUPPLYREQUIREMENTS

SECTION VII - SCHEDULE OF REQUIREMENTS

CONTENTS

Notes for Preparing the Schedule of Requirements

- 1. List of Goods and Delivery Schedule
- 2. Technical Specifications

Sample Technical Specifications Pharmaceuticals

Sample Technical Specification Vaccines

Sample Technical Specifications Condoms

3. Inspections and Tests

NOTES FOR PREPARING THE SCHEDULE OF REQUIREMENTS

The Schedule of Requirements shall be included in the tendering document by the Procuring Entity, and shall cover, at a minimum, a description of the goods and services to be supplied and the delivery schedule.

The objective of the Schedule of Requirements is to provide sufficient information to enable Tenderers to prepare their Tenders efficiently and accurately, in particular, the Price Schedule, for which a form is provided in Section IV. In addition, the Schedule of Requirements, together with the Price Schedule, should serve as a basis in the event of quantity variation at the time of award of contract pursuant to ITT 42.1.

The date or period for delivery should be carefully specified, taking into account (a)the implications of delivery terms stipulated in the Instructions to Tenderers pursuant to the *Incoterms* rules (i.e., EXW, or CIP, FOB, FCA terms-that "delivery" takes place when goods are delivered **to the carriers**), and (b) the date prescribed here in from which the Procuring Entity's delivery obligations start (i.e., notice of award, contract signature, opening or confirmation of the Form of credit).

L LIST OF GOODS AND DELIVERY SCHEDULE

[The Procuring Entity shall fill in this table, with the exception of the column "Tenderer's offered Delivery date" to be filled by the Tenderer]

| Line Item | Description of Goods | Quantity | Physical unit | Final (Project Site) Destination as specified in TDS | Delivery (as per Incoterms) Date | | |
|-----------|--|----------------|--|--|----------------------------------|-------------------------|---|
| N° | | | | | Earliest Delivery Date | Latest Delivery Date | Tenderer's offered Delivery date [to be provided by the Tenderer] |
| | ITEM DESCRIPTION/CONTRACT PACKAGE | PACK | ESTIMATED ANNUAL CONSUMPT ION | | | | |
| | ANTIBIOTICS | Vial | 30,000 | | | | |
| 1. | Africef 1gm | Vial | 30,000 | | | | |
| 2. | Africef SB 1.5gm | 70ml Bottle | 3710 | | | | |
| 3. | Amoxicillin/Clavulanic Acid Syrup 457mg/5ml | Vial | 5000 | | | | |
| 4. | Ampicillin/Sulbactum Injection 1.5g | Vial | 3000 | | | | |
| 5. | Ceftaroline Injection 600mg | Vial | 3000 | | | | |
| 6. | Cefoperazone/Sulbactam Injection 2g | Ampoule | 40000 | | | | |
| 7. | Clarithromycin Injection 500mg | 1x10s | 20000 | | | | |
| 8. | Clindamycin Capsule 300mg | Vial | 100 | | | | |
| 9. | Colistin Injection 1MU | 1x5 | 3000 | | | | |
| 10. | Gemifloxacin Capsule 320mg | Vial | 30,000 | | | | |
| 11. | Merado 1 gm | Vial | 300 | | | | |
| 12. | Minocycline Injection 100mg | Vial | 300 | | | | |
| 13. | Telavancin Injection 250mg | 2x10s | 300 | | | | |
| 14. | Vancomycin Capsule 250mg | | | | | | |
| | ANTIFUNGALS | 1x1s | 3000 | | | | |
| 15. | Clotrimazole Vaginal Tablet 500mg | Vial | 100 | | | | |

| 16. | Micafungin Injection 50mg | 1x30s | 200 | | |
|-----|--|-----------------|--------|--|--|
| 17. | Flucytosine Capsule 500mg | Vial | 200 | | |
| 18. | Flucytosine Injection 2.5g/250ml | 1x100s | 300 | | |
| 19. | Posaconazole Tablet Delayed Release 100mg | Vial | 200 | | |
| 20. | Posaconazole Injection 300mg | 30gm | 1200 | | |
| 21. | Luliconazole cream 1% | | | | |
| | ANTIRHEUMATIC DRUGS | 1x10s | 6000 | | |
| 22. | Everolimus Tablet 0.25mg | 1x10s | 6000 | | |
| 23. | Everolimus Tablet 0.5mg | 1x10s | 6000 | | |
| 24. | Everolimus 10mg | 1x10s | 15000 | | |
| 25. | Everolimus Tablet 1mg | Tablet | 6000 | | |
| 26. | Tofacitinib Citrate Tablet 5mg | | | | |
| | GASTROINTESTINAL DRUGS | Satchet | 6000 | | |
| 27. | Chlolestyramine Satchet 4gm | Bottle | 6000 | | |
| 28. | Domperidone Syrup 5mg/5mls | 1x10 | 6000 | | |
| 29. | Dexlansoprazole 30mg | 1x10 | 6000 | | |
| 30. | Emitino 8mg | Bottle | 3000 | | |
| 31. | Sodium Phosphates Enema 100ml | Suppositor y | 1000 | | |
| 32. | Glycerin Infant Suppositories | 25g | 10000 | | |
| 33. | Anusol Cream | 250ml | 3000 | | |
| 34. | B- Complex/Carnitine/Lysine/Cyproh eptadine Orotate Syrup | 1x10s | 100000 | | |
| 35. | Ondansetron Tablet 8mg | 1x100s | 1000 | | |
| 36. | Hyoscine-N-Butyl Bromide/Paracetamol Tablet 10mg/500mg | 1x100s | 1000 | | |
| 37. | Otilonium Bromide Tablet 40mg | Satchet | 1000 | | |
| 38. | Polyethylene Glycol with Electrolytes for Oral Solution Satchet 118g | 1x10s | 2000 | | |
| 39. | Rabeprazole Sodium/Itopride Sustained Release Tablet 20mg/150mg | Kit | 1000 | | |
| 40. | Rabeprazole/Clarithromycin/Amo xicillin 20/500/1000 mg | Vial | 500 | | |

| 41. | Octreotide Long Acting Release Injection 30mg | 1x10s | 50 | | |
|-----|---|--------------------|-------|--|--|
| 42. | Sulfasalazine Tablet 500mg | 1x100s | 3000 | | |
| 43. | Senna Tablet 7.5mg | | | | |
| 44. | ANTIDIABETIC | Bottle | 50 | | |
| 45. | Diazoxide Suspension 50mg/ml | 1x28s | 8000 | | |
| 46. | Empagliflozin Tablet 25mg | 1x60s | 4000 | | |
| 47. | Empaglifozin/Metformin Tablet IR 12.5mg/500mg | 1x60s | 3000 | | |
| 48. | Empaglifozin/Metformin Tablet IR 12.5mg/1000mg | 1x60s | 3000 | | |
| 49. | Empaglifozin/Metformin Tablet IR 5mg/500mg | 1x60s | 3000 | | |
| 50. | Empaglifozin/Metformin Tablet IR 5mg/1000mg | 1x28s | 3000 | | |
| 51. | Pioglitazone/Metformin Tablet 15mg/500mg | 1x28s | 3000 | | |
| 52. | Pioglitazone/Metformin Tablet 15mg/850mg | Vial | 800 | | |
| 53. | Human Insulin Long Acting Basal (Glargine) Injection, 100IU/ml | VIal | 800 | | |
| 54. | Human Insulin, Long Acting Basal (Glargine) Injection, Pre- filled Pen, 100IU/ml, 3ml | Vial | 600 | | |
| 55. | Human Insulin, Premixed (Ultra- Short Acting + Intermediate Acting) Injection | Vial | 600 | | |
| 56. | Human Insulin, Ultra Short Acting Injection 100IU/ml | VIal | 200 | | |
| 57. | Novorapid, Pen Fill 3ml | Vial | 200 | | |
| 58. | Novomix Pen 100IU/ml | Vial | 200 | | |
| 59. | Levemir Pen 100Units/ml 3ml | 1x100s | 500 | | |
| 60. | Repaglinide Tablet 0.5mg | | | | |
| 61. | ANALGESICS/ANTIPYRETICS | 1x10s | 10000 | | |
| 62. | Celecoxib /Paracetamol Tablet 200mg/500mg | 1x10s | 10000 | | |
| 63. | Celecoxib/Paracetamol/Chlorzoxa zone Tablet 200mg/325mg/250mg | 1x10s | 6000 | | |
| 64. | Celecoxib /Paracetamol Tablet 200mg/325mg | Pre- Filled Pen | 100 | | |
| 65. | Erenumab Pre Filled Syringe Injection 70mg | 1x10s | 6000 | | |

| 66. | S-Etodolac/Paracetamol Tablet 400mg/325mg | Vial | 5000 | | |
|-----|--|---------|-------|--|--|
| 67. | Ibuprofen Injection 20mg | Vial | 10000 | | |
| 68. | Paracetamol/Ibuprofen Injection 1000mg/300mg | 100mls | 20000 | | |
| 69. | Ibuprofen/Paracetamol Suspension 125mg/100mg | Vial | 6000 | | |
| 70. | Lornoxicam Injection 8mg | 100g | 100 | | |
| 71. | Morphine Powder 100g | 100mls | 2000 | | |
| 72. | Morphine Oral Liquid 10mg/ml | 1x60 | 60000 | | |
| 73. | Morphine Tablet 30mg | 1x10 | 1200 | | |
| 74. | Naproxen/Esomeprazole 500mg/20mg | 1x10 | 4000 | | |
| 75. | Oxycodone Tablet IR 5mg | 1x100s | 1000 | | |
| 76. | Probenecid Tablet 250mg | 1x20s | 50000 | | |
| 77. | Tramadol/Paracetamol Tablet 37.5mg/325mg | | | | |
| 78. | RESPIRATORY DRUGS | Inhaler | 100 | | |
| 79. | Beclomethasone Inhaler 200mcg/Dose | Inhaler | 100 | | |
| 80. | Beclomethasone/Salbutamol Inhaler 50/100mg | Inhaler | 100 | | |
| 81. | Budesonide Inhaler 200mcg | Vial | 11000 | | |
| 82. | Caffeine Citrate Injection 10mg/ml | Inhaler | 1000 | | |
| 83. | Formoterol/Budesonide Inhaler 4.5mcg/160mcg per Dose | Inhaler | 1000 | | |
| 84. | Formoterol/Budesonide Inhaler 6mcg/100mcg per Dose | Vial | 4000 | | |
| 85. | Glycopyrronium Bromide Injection 200mcg | Inhaler | 300 | | |
| 86. | Ipratropium Inhaler 20mcg/Dose (200 Doses) | Inhaler | 300 | | |
| 87. | Ipratropium/ Salbutamol Inhaler 20mcg/100mcg per Dose | Inhaler | 300 | | |
| 88. | Ipratropium/Levosalbutamol Inhaler 20mcg/50mcg per Dose | Respule | 30000 | | |
| 89. | Ipratropium/Salbutamol Nebulizer 500mcg/2.5mg | Bottle | 3000 | | |
| 90. | Levosalbutamol Syrup 1mg/5mls | 1x10s | 400 | | |
| 91. | Nintendanib Capsule 150mg | Vial | 20 | | |

| 92. | Prostaglandin E1 Injection 500mcg | Vial | 100 | | |
|------|---|---------|-------|--|--|
| 93. | Salbutamol Injection 500mcg/ml | Inhaler | 100 | | |
| 94. | Salmeterol/Fluticasone Inhaler 25/50mcg per Dose | Inhaler | 100 | | |
| 95. | Salmeterol/Fluticasone Inhaler 50/100mcg per Dose | Inhaler | 300 | | |
| 96. | Tiotropium Bromide Respimat Inhaler 2.5 mcg/dose | 1x100s | 100 | | |
| 97. | Pirfenidone Tablets 200mg | | | | |
| 98. | CARDIOVASCULAR/ RENAL | 1x10s | 1000 | | |
| 99. | Apixaban Tablet 2.5mg | 1x30s | 1000 | | |
| 100. | Aliskiren Tablet 150mg | vial | 20 | | |
| 101. | Alteplase Injection 100mg | vial | 20 | | |
| 102. | Alteplase Injection 50mg | Ampoule | 1200 | | |
| 103. | Amiodarone Injection 150mg | 1x100s | 10000 | | |
| 104. | Amlodipine/Hydrochlorothiazide Tablet 5mg/12.5mg | 1x30s | 900 | | |
| 105. | Amlodipine/Indapamide Tablet 5mg/1.25mg | 1x30s | 1200 | | |
| 106. | Bempedoic acid 180mg | 1x30s | 1200 | | |
| 107. | Bempedoic acid/Ezetimibe 180mg/10mg | 1x100s | 1000 | | |
| 108. | S-Amlodipine Tablet 5mg | 1x100s | 2000 | | |
| 109. | S-Amlodipine Tablet 2.5mg | Satchet | 1000 | | |
| 110. | Calcium Polystyrene Sulphonate Satchet 15g | Vial | 100 | | |
| 111. | Cardioplegia Solution | 1x100s | 1000 | | |
| 112. | Chlorthalidone Tablet 12.5mg | 1x100s | 1000 | | |
| 113. | Chlorthalidone Tablet 6.25mg | 1x10s | 5000 | | |
| 114. | Cilnidipine Tablet 5mg | 1x10s | 500 | | |
| 115. | Clonidine Tablet 0.1mg | 1x10s | 1000 | | |
| 116. | Clopidogrel Tablet 75mg | Vial | 1000 | | |
| 117. | Dabapoietin Alfa Injection 25mcg | Vial | 1000 | | |
| 118. | Dabapoietin Alfa Injection 40mcg | Spray | 50 | | |
| 119. | Desmopressin Nasal Spray 10mcg/spray | 1x100s | 100 | | |
| 120. | Desmopressin Tablet 0.1mg | Ampoule | 100 | | |

| 121. | Digoxin Injection 500mcg | Tube | 100 | | |
|------|--|--------|-------|--|--|
| 122. | Diltiazem Gel 2% | Vial | 100 | | |
| 123. | Diltiazem Injection 5mg/ml | 1x10s | 100 | | |
| 143 | Doxazocin Tablet 2mg | Vial | 100 | | |
| 144. | Esmolol Injection 100mg | Vial | 50 | | |
| 145. | Glyceryl Trinitrate Injection 50mg Vial | 1x100s | 5000 | | |
| 146. | Hydrochlorothiazide Tablet 12.5mg | Vial | 100 | | |
| 147. | Isoproterenol (Isoprenaline) Injection 2mg | 1x10s | 100 | | |
| 148. | Isosorbide Dinitrate Tablet 20mg | 1x10s | 100 | | |
| 149. | Isosorbide Mononitrate Tablet 60mg | Vial | 200 | | |
| 150. | Milrinone Injection 10mg Vial | Vial | 200 | | |
| 151. | Nicardipine Injection 25mg Vial | 1x10s | 300 | | |
| 152. | Perindopril/Amlodipine Tablet 5mg/5mg | 1x10s | 300 | | |
| 153. | Perindopril/Amlodipine Tablet 5mg/10mg | 1x10s | 300 | | |
| 154. | Perindopril/Amlodipine/Indapami de 5mg/5mg/1.25mg | 1x10s | 400 | | |
| 155. | Perindopril/Amlodipine/Indapami de 10mg/10mg/2.5mg | 1x10s | 200 | | |
| 156. | Phenoxybenzamine Capsule 10mg | Vial | 100 | | |
| 157. | Phenylephrine Injection 10mg/Ml | 1x10s | 100 | | |
| 158. | Prazocin Tablet 1mg | Bottle | 100 | | |
| 159. | Sildenafil PFOL 10mg/ml | Vial | 100 | | |
| 160. | Sodium Nitroprusside Injection 50mg | Tin | 100 | | |
| 161. | Sodium Polysytrene Sulphonate 450g | 1x10s | 100 | | |
| 162. | Terazocin Tablet 2mg | 1x30s | 3000 | | |
| 163. | Torsemide/Eplerenone Tablet 10mg/25mg | Vial | 150 | | |
| 164. | Vasopressin Injection 20 units/ml | 1x10s | 10000 | | |
| 165. | Warfarin Tablet 1mg | 1x10s | 10000 | | |
| 166. | Warfarin Tablet 3 mg | 1x10s | 10000 | | |
| 167. | Warfarin Tablet 5mg | | | | |

| 168. | ANAESTHESIA AND CRITICAL CARE | Vial | 10 | | |
|------|--|---------|-------|------|--|
| 169. | Botulinum Toxin Injection | Vial | 10 | | |
| 170. | Dantrolene Injection 20mg | Vial | 500 | | |
| 171. | Etomidate Injection 20mg | Ampoule | 3000 | | |
| 172. | Glycopyrronium Injection 200mcg/ml | Ampoule | 1000 | | |
| 173. | Glycopyrronium + Neostigmine Injection 500mcg/2.5mg | Spray | 300 | | |
| 174. | Lignocaine Topical spray 2% | Spray | 300 | | |
| 175. | Tetracaine Topical spray 2% | Vial | 300 | | |
| 176. | Lignocaine/Adrenaline Injection 2%/1:200000 vial | 1x10 | 500 | | |
| 177. | Pyridostigmine Tablet 60mg | 240ml | 100 | | |
| 178. | Pyridostigmine Oral solution 60mg/5ml, 240ml | vial | 100 | | |
| 179. | Pyridostigmine Injection 10mg | Vial | 500 | | |
| 180. | Remifentanyl Injection 2mg | Vial | 500 | | |
| 181. | Rocuronium Bromide Injection 10mg | Vial | 200 | | |
| 182. | Vecuronium Bromide Injection 10mg | | | | |
| 183. | REPRODUCTIVE HEALTH | Vial | 10 | | |
| 184. | Carboprost Tromethamine Injection 250mcg | 1x10s | 300 | | |
| 185. | Danazol Capsule 50mg | Vial | 100 | | |
| 186. | Ergometrine Injection 500mcg | Vial | 10 | | |
| 187. | Human Menopausal Gonadotrophin (HMG) Injection 75 IU | Vial | 10 | | |
| 188. | Terbutaline Injection 2.5mg | Vial | 10 | | |
| 189. | Terbutaline Injection 0.5mg | | | | |
| 190. | VITAMINS/SUPPLEMENTS | 1x500s | 5000 | | |
| 191. | Sodium Chloride Tablet 600mg | 1x100s | 5000 | | |
| 192. | Potassium Chloride Tab 600mg | 1x10s | 4000 | | |
| 193. | Calcium Citrate/Vitamin D3/Magnesium sulphate, Zinc Sulphate Syrup 250mg/100IU 200ml | Satchet | 3000 | | |
| 194. | Collajoint Satchet | 1x100s | 10000 | | |

| 195. | Vitamin A Capsule 100,000 i.u. | 1x10s | 2000 | | |
|------|--|----------|------|--|--|
| 196. | Vitamin D3 Capsule or Tablet 60000iu | 1x10s | 3000 | | |
| 197. | Vitamin C Tablet 1g | 1x10 | 1200 | | |
| 198. | Nanocalcium 500mg/ Vit D3 | | | | |
| 199. | DERMATOLOGICALS | 15g | 400 | | |
| 200. | Adapalene Gel 1% | 30g | 200 | | |
| 201. | Calcium dobesilate cream | 100ml | 1000 | | |
| 202. | Calamine Lotion 100-200ml | Pencil | 100 | | |
| 203. | Caustic Pencil 40% | 15g | 300 | | |
| 204. | Collagenase clostriopeptidase A + Proteases Ointment 1.2units + 0.24 units (15g) | 30g | 300 | | |
| 205. | Crotamiton Cream 10% | 15g | 200 | | |
| 206. | Desonide cream | 20g | 300 | | |
| 207. | Dexpanthenol Cream 5% | 30g | 300 | | |
| 208. | Dithranol Paste 2% | 100ml | 500 | | |
| 209. | Ketoconazole Shampoo 2% | 30g | 400 | | |
| 210. | Miconazole cream 2% | 15ml | 200 | | |
| 211. | Podophyllin Resin Solution 15% | 20g | 300 | | |
| 212. | Sertaconazole Cream 2% | 50g | 100 | | |
| 213. | Salicylic acid Cream or ointment 2% | 50ml | 1000 | | |
| 214. | Sun screen SPF >50% | 30g | 300 | | |
| 215. | Tretinoin Cream 0.05% | Satchets | 1000 | | |
| 216. | Imiquimoid Cream 5% | 15g | 300 | | |
| 217. | Zinc Hyaluronate Gel | 500g | 200 | | |
| 218. | Zinc Oxide Paste | 100g | 300 | | |
| 219. | White soft Paraffin (Petroleum Jelly) | | | | |
| 220. | COMPOUNDING VEHICLES | Bottle | 200 | | |
| 221. | Distilled Water | Bottle | 200 | | |
| 222. | Simple Syrup | Bottle | 200 | | |
| 223. | Aqueous cream | | | | |
| 224. | OPTHALMOLOGY DRUGS | Vial | 50 | | |
| 225. | Aflibercept Injection 2mg | 5ml | 200 | | |

| 226. | Azelastine Eye Drops 0.05% | 5ml | 100 | | |
|------|--|---------|-------|--|--|
| 227. | Bimatoprost Eye drops 0.01% | 5ml | 100 | | |
| 228. | Bimatoprost Eye drops 0.03% | 5ml | 100 | | |
| 229. | Bimatoprost/Timolol Eye drops 0.03%/0.5% | 5ml | 100 | | |
| 230. | Brimonidine/Timolol Eye drops 0.2%/0.5% | 5ml | 200 | | |
| 231. | Diclofenac Opthalmic Solution 0.1% | 5ml | 10 | | |
| 232. | Fluorescein Test Strip 0.6 mg | Implant | 10 | | |
| 233. | Ganciclovir Intraocular Implant | 5ml | 100 | | |
| 234. | Hypertonic Saline Eye Drops 5% | 5ml | 300 | | |
| 235. | Moxifloxacin Eye Drops 0.5% | 5ml | 200 | | |
| 236. | Natamycin Eye Drops 5% | 5ml | 100 | | |
| 237. | Pilocarpine Eye Drops 4% | 5ml | 100 | | |
| 238. | Proparacaine Opthalmic Solution 0.5% | 5ml | 100 | | |
| 239. | Polyacrylic Acid Eye Gel 0.2% | 5ml | 100 | | |
| 240. | Ranibizumab Injection 6mg/ml, | 5ml | 100 | | |
| 241. | Ranibizumab Injection 10mg/ml, | 5ml | 100 | | |
| 242. | Riboflavin Solution 0.1% (with Dextran) | 5ml | 100 | | |
| 243. | Riboflavin Solution 0.1% (without Dextran) | 5ml | 100 | | |
| 244. | Epinastine Eye Drops 0.5mg/ml | 5ml | 100 | | |
| 245. | Sodium Cromoglycate Eye Drops 2% | 5ml | 800 | | |
| 246. | Sodium Hyaluronate Eye Drops 1% Preservative free | 5ml | 100 | | |
| 247. | Tetracaine Eye Drops 0.5% | 5ml | 150 | | |
| 248. | Tobramycin 0.3%/Dexamethasone 0.1% | 5ml | 150 | | |
| 249. | Timolol Eye Drops 0.5% | 5ml | 100 | | |
| 250. | Tropicamide Eye Drops 1% | 5ml | 200 | | |
| 251. | Tryptan Blue Intracameral Solution 0.06% | 5ml | 100 | | |
| 252. | Voriconazole Powder for eye drops 1% | | | | |
| 253. | ANTIMALARIALS | 1x6 | 10000 | | |

| 254. | Artemether/Lumefantrine Tablet 80/480mg | 1x6 | 10000 | | |
|------|---|--------|-------|--|--|
| 255. | Artemether/Lumefantrine Tablet 20/120mg (dispersible) | 1x24 | 2000 | | |
| 256. | Dihydroartemesinin/Piperaquine Tablet 20/160mg | 1x10s | 1000 | | |
| 257. | Proguanil Tablet 100mg | | | | |
| 258. | NEUROLOGICAL AND PSYCHOTHERAPEUTIC DRUGS | 1x10s | 20000 | | |
| 259. | Baclofen Tablet 5mg | Vial | 100 | | |
| 260. | Benztropine Injection 2mg/2ml | Vial | 200 | | |
| 261. | Biperiden injection 5mg | 1x10s | 300 | | |
| 262. | Biperiden Tablet 2mg | 1x10s | 2000 | | |
| 263. | Bupropion Tablet 150mg | 1x10s | 1000 | | |
| 264. | Carbidopa/Levodopa Tablet 100mg/10mg | 1x10s | 900 | | |
| 265. | Carbidopa/Levodopa Tablet 250/25mg | 1x10s | 300 | | |
| 266. | Citicoline Tablet 500mg | 1x10s | 200 | | |
| 267. | Clomipramine Capsule 25mg | 1x10s | 400 | | |
| 268. | Clozapine Tablet 100mg (scored) | 1x10s | 400 | | |
| 269. | Clozapine Tablet 25mg (scored) | 1x100s | 200 | | |
| 270. | Disalfirum Tablet 200mg | Vial | 1000 | | |
| 271. | Flupenthixol Decanoate Injection 40mg | Vial | 1000 | | |
| 272. | Flupenthixol Decanoate Injection 20mg | 1x10s | 500 | | |
| 273. | Gabapentin Tablet 300mg | Vial | 500 | | |
| 274. | Haloperidol Accuphase Injection 5mg | 100ml | 200 | | |
| 275. | Haloperidol Oral Solution 2mg/ml | 1x100s | 300 | | |
| 276. | Lithium Carbonate MR Tablet 200mg | 1x100s | 300 | | |
| 277. | Lorazepam Tablet 1mg | Vial | 300 | | |
| 278. | Lorazepam Injection 4mg/ml | 1x100s | 200 | | |
| 279. | Meclizine Tablet 12.5mg | 1x100s | 1000 | | |
| 280. | Melatonin Tablet 10 mg | 1x10s | 200 | | |
| 281. | Memantine Tablet 5 mg | 1x30 | 6000 | | |

| 282. | Metadoxine 500mg | 1x10s | 300 | | |
|------|---|--------|-------|--|--|
| 283. | Methylphenidate Tablet 10mg | 1x10s | 400 | | |
| 284. | Naltrexone Tablet 50mg | Gum | 600 | | |
| 285. | Nicotine Chewing gum 2mg | Gum | 600 | | |
| 286. | Nicotine Chewing gum 4mg | Patch | 1000 | | |
| 287. | Nicotine Transdermal Patch 21mg/24h | Patch | 1000 | | |
| 288. | Nicotine Transdermal Patch 14mg/24h | Patch | 1000 | | |
| 289. | Nicotine Transdermal Patch 7mg/24h | 1x100s | 60000 | | |
| 290. | Olanzapine Tablet 20mg | 1x100s | 60000 | | |
| 291. | Olanzapine Tablet 15mg | Vial | 500 | | |
| 292. | Olanzapine Injection 10mg | 100ml | 300 | | |
| 293. | Oxcarbazepine 60mg/ml | 1x50 | 1000 | | |
| 294. | Oxcarbazepine Tablet 150mg | 1x50 | 1000 | | |
| 295. | Oxcarbazepine Tablet 300mg | 100ml | 500 | | |
| 296. | Phenobarbital Syrup 20mg/ml | 1x100s | 6000 | | |
| 297. | Phenytoin Tablet 50 mg | 1x100 | 120 | | |
| 298. | Pramipexole tab scored 180mcg base | 1x30 | 100 | | |
| 299. | Pramipexole Tab 700mcg base | 1x10s | 300 | | |
| 300. | Pregabalin Tablet 150mg | 1x10s | 600 | | |
| 301. | Pregabalin/Methylcobalamin Tablet 75mg/750mcg | 1x30s | 900 | | |
| 302. | Pyridostigmine Tablet 60mg | 1x30s | 900 | | |
| 303. | Rivastigmine Capsules 1.5mg | 1x56 | 600 | | |
| 304. | Riluzole Tablet 50mg | 5x10s | 9000 | | |
| 305. | Sodium Valproate Tablet 750mg | 1x10s | 1000 | | |
| 306. | Topiramate Tablets 25mg | 1x100s | 500 | | |
| 307. | Vigabatrin Tablet 500mg | | | | |
| 308. | STEROIDS/ ANTIHISTAMINES | 1x50s | 15000 | | |
| 309. | Bilastine Tablet 20mg | 100ml | 1000 | | |
| 310. | Chlorpheniramine Syrup 2mg/5mls | 100mls | 2000 | | |
| 311. | Rupatadine Syrup 5mg/5ml 60ml | Vial | 400 | | |

| 312. | Methyl Prednisolone Sodium Acetate Injection 40mg | Vial | 400 | | |
|------|--|---------|------|--|--|
| 313. | Triamcinolone Injection 40mg | | | | |
| 314. | THYROID AND PARATHYROID DRUGS | 1x10s | 2000 | | |
| 315. | Cinacalcet Tablet 30mg | 1x10s | 2000 | | |
| 316. | Methimazole Tablet 5mg | 60ml | 100 | | |
| 317. | Iodine 5% (Lugol's Iodine) | 1x56s | 1200 | | |
| 318. | Propylthiouracil Tablet 50mcg | | | | |
| 319. | ANTIDOTES | Ampoule | 100 | | |
| 320. | Acetylcysteine Injection 200mg/ml | Vial | 100 | | |
| 321. | Fomepizole Injection 1.5g | Vial | 50 | | |
| 322. | Deferoxamine Injection 500mg | Vial | 50 | | |
| 323. | Edetate Calcium Disodium Injection 1g/5ml | Vial | 50 | | |
| 324. | Dimercaprol Injection 100mg | Ampoule | 50 | | |
| 325. | Flumazenil Injection 1mg | 1x10s | 50 | | |
| 326. | Succimer Capsules 100mg | Ampoule | 50 | | |
| 327. | Physostigmine Injection 2mg | Vial | 50 | | |
| 328. | Glucagon Injection 1mg | 1x10s | 50 | | |
| 329. | Penicillamine Capsules 250mg | Vial | 2400 | | |
| 330. | Pralidoxime Injection 1g | Ampoule | 1000 | | |
| 331. | Protamine Sulphate Injection 50mg | | | | |
| 332. | VACCINES and IMMUNOGLOBULINS | Vial | 200 | | |
| 333. | Antithymocyte globulin (rabbit) | Vial | 100 | | |
| 334. | Hepatitis A Vaccine | | | | |
| 335. | E.N.T. | 100ml | 300 | | |
| 336. | Liquid Paraffin 100% Nasal Drops | 10ml | 100 | | |
| 337. | Hydrogen Peroxide Ear Drops 3% | 10ml | 3000 | | |
| 338. | Sodium Chloride Nasal Drops B.P. 0.9% W/V | Spray | 300 | | |
| 339. | Lignocaine Nasal Spray 10mg/Metered dose | | | | |
| 340. | DENTAL | 15g | 500 | | |
| 341. | Chlorhexidine Mouth Gel 1% | 15g | 1000 | | |

| 342. | Teething gel 15g | 5g | 200 | | |
|------|--|-----------|------|--|--|
| 343. | Triamcinolone Dental Paste 0.1% | 40g | 300 | | |
| 344. | Miconazole Oral Gel | | | | |
| 345. | HEMATOLOGY/ONCOLOGY DRUGS | 1x10s | 3000 | | |
| 346. | 6 Mercaptopurine Tablet 50mg | Vial | 100 | | |
| 347. | Abatacept PFI 250mg | 1x60 | 1200 | | |
| 348. | Abiraterone 500mg | 1x100s | 20 | | |
| 349. | All-Trans-Retinoic-Acid (ATRA) Tablet 10mg | Vial | 100 | | |
| 350. | Arsenic Trioxide Infusion 1mg/ml | Vial | 100 | | |
| 351. | Azathioprine Injection 100mg | 1x100s | 30 | | |
| 352. | Busulphan Tablet 2mg | Vial | 100 | | |
| 353. | Cabazitaxel Injection 60mg | Vial | 100 | | |
| 354. | Carfilzomib Injection 60mg | 1x25s | 250 | | |
| 355. | Chlorambucil Tablet 2mg | 1x10s | 1000 | | |
| 356. | Cyclophosphamide Tablet 25mg | Vial | 2500 | | |
| 357. | Dacarbazine Injection 200mg | 1x30s | 100 | | |
| 358. | Danazol Capsule 100mg | Vial | 100 | | |
| 359. | Daratumumab Injection 400mg | 1x60 | 100 | | |
| 360. | Dasatinib Tablets 100mg | Vial | 200 | | |
| 361. | Daunorubicin Injection 50mg | Vial | 50 | | |
| 362. | Eculizumab Injection 300mg | 2x7s | 100 | | |
| 363. | Eltrombopag Tablet 50mg | 1x12 | 100 | | |
| 364. | Etoposide Capsule 100mg | Vial | 500 | | |
| 365. | Fludarabine Injection 50mg | Vial | 5000 | | |
| 366. | Folinic Acid Injection 50mg | 1x10s | 500 | | |
| 367. | Folinic Acid Tablet 15mg | 1x10s | 300 | | |
| 368. | Hydroxyurea Capsule 250mg | 1x90s | 400 | | |
| 369. | Ibrutinib Capsule 140mg | Vial | 100 | | |
| 370. | Idarubicin Injection 20mg | Vial | 50 | | |
| 371. | Infliximab Injection 100mg | Vial | 400 | | |
| 372. | L-Asparaginase Injection 10000 I.U. | 1x10s | 400 | | |
| 373. | Lenalidomide Capsule 10mg | Injection | 300 | | |

| 374. | Leuprolide Injection 11.25mg | Vial | 100 | | |
|------|--|---------|------|--|--|
| 375. | Melphalan PFI 50mg | 1x25s | 100 | | |
| 376. | Melphalan Tablet 2mg | Vial | 200 | | |
| 377. | Methotrexate Injection (pre-filled injection) 25mg/ml, 0.4ml | Vial | 3000 | | |
| 378. | Methotrexate Injection 1g | Vial | 100 | | |
| 379. | Mitomycin C Injection 10mg | Vial | 400 | | |
| 380. | Mitoxantrone Injection 20mg | Vial | 500 | | |
| 381. | NAB Paclitaxel Injection 100mg | 1x30s | 900 | | |
| 382. | Osimertinib film coated Tablet 80mg | 1x21s | 300 | | |
| 383. | Palbociclib Capsule 100mg | 1x21s | 300 | | |
| 384. | Palbociclib Capsule 150mg | 1x21s | 300 | | |
| 385. | Palbociclib capsule 125mg | 1x21s | 300 | | |
| 386. | Palbociclib Capsule 75mg | 1x10s | 400 | | |
| 387. | Pazopanib Tablet 200mg | 1x10s | 500 | | |
| 388. | Pazopanib Tablet 400mg | Vial | 100 | | |
| 389. | PEG Asparaginase Injection 3750IU | Syringe | 200 | | |
| 390. | PEG Filgrastim Prefilled Syringe 6mg | Vial | 100 | | |
| 391. | Pemetredex Injection 500mg | 1x21s | 490 | | |
| 392. | Pomalidomide Capsule 1mg | 1x100s | 100 | | |
| 393. | Procarbazine Capsule 50mg | Vial | 300 | | |
| 394. | Rasburicase Injection 1.5mg | 1x28s | 100 | | |
| 395. | Regorafenib Tablet 40mg | 1x24s | 300 | | |
| 396. | Ruxolitinib Tablet 10mg | 1x24s | 300 | | |
| 397. | Ruxolitinib Tablet 20mg | 1x24s | 300 | | |
| 398. | Ruxolitinib Tablet 5mg | 1x120 | 300 | | |
| 399. | Sorafenib Tablet 200mg | 1x28s | 200 | | |
| 400. | Sunitinib Capsule 50mg | Vial | 100 | | |
| 401. | Tacrolimus Injection 5mg | Vial | 100 | | |
| 402. | Tioguanine SODF 40mg | Vial | 100 | | |
| 403. | Topotecan Injection 2.5mg | 1x120 | 100 | | |
| 404. | Venetoclax Tablet 100mg | Vial | 100 | | |

| 405. | Vinorelbine Injection 10mg | | | | |
|------|---|----------------|------|--|--|
| 406. | MONOCLONAL ANTIBODIES | Vial | 30 | | |
| 407. | Pembrolizumab Injection 100mg | | | | |
| 408. | UROLOGY DRUGS | 1x10s | 3000 | | |
| 409. | Dutasteride Capsule 0.5mg | 1x10s | 3000 | | |
| 410. | Finasteride/Tamsulosin Capsule 400mcg/5mg | 1x10 | 1200 | | |
| 411. | Mirabegron 50mg | 1x10 | 1200 | | |
| 412. | Mirabegron/Solifenacin 25mg/5mg | 1x100s | 1500 | | |
| 413. | Oxybutynin Tablet 5mg | Ampoule | 300 | | |
| 414. | Papaverine Injection 60mg | 1x14s | 3000 | | |
| 415. | Tolterodine Capsule 2mg | | | | |
| 416. | NUTRACEUTICALS | 400g | 1000 | | |
| 417. | Infant formula with iron for term babies-Bidders to bring samples | 400g | 800 | | |
| 418. | Infant formula with iron for premature babies-Bidders to bring samples | 1gm x24 | 600 | | |
| 419. | Human Breast milk fortifier for premature babies and low birth weight infants fed on breast milk- Bidders to bring samples | 1gmx 72 | 600 | | |
| 420. | Human Breast milk fortifier for preterm and low birth weight infants fed on breast milk- Bidders to bring samples | 250mls | 1000 | | |
| 421. | Amino acids Solution for IV infusion 5% for pediatrics | 10mls | 800 | | |
| 422. | Fat-soluble vitamins (for infants and children) Solution for IV infusion | 200mls | 800 | | |
| 423. | Specialized sip feed for hepatic patients Liquid | 500mls | 600 | | |
| 424. | Specialized hypercaloric liquid formula feed Liquid | 200- 500gms | 800 | | |
| 425. | Low fat formula Powder | 21gmx 6 | 1000 | | |
| 426. | Specialized Renal formula enriched with vitamins and minerals in Powder form for renal patients | 25gmx6 | 1000 | | |

| 427. | Nutritional complete feed enriched with MCT and BCAA for hepatic patients | 400gms | 600 | | |
|------|--|---------|------|--|--|
| 428. | Specialized Semi-elemental peptide formula in Powder form | 400gms | 1500 | | |
| 429. | Therapeutic diet feed (F-75) PFOL (for approx. 600mL) Standard formula | 400gms | 400 | | |
| 430. | Therapeutic diet feed (F-75) PFOL Standard formula | 250gm | 700 | | |
| 431. | Breastfeeding stimulator in granules or powder form for lactating mothers | 400g | 600 | | |
| 432. | Specialized semi-elemental peptide formula in powder form | | | | |
| 433. | ORIGINAL AND BRANDED DRUGS | 30mls | 2400 | | |
| 434. | Andolex C Spray | 1x30s | 3000 | | |
| 435. | Biogaia tablets | Bottle | 500 | | |
| 436. | Coloprep Bowel Preparation Kit 2x177ml | 1x10s | 3000 | | |
| 437. | Cytotec Tablet 200mg | Bottle | 300 | | |
| 438. | Epimax Baby and Junior Cream 400g | Bottle | 300 | | |
| 439. | Epimax Plus Adult Cream 400g | 5ml | 600 | | |
| 440. | Flarex Eye Drops | Vial | 3000 | | |
| 441. | Heparin Rotex Injection 25000 I.U. | Vial | 2400 | | |
| 442. | Herceptin 600mg/5ml | Vial | 2400 | | |
| 443. | Herceptin 440mg | Bottle | 300 | | |
| 444. | Infacol Colic Relief Drops 55ml | 1x30s | 2000 | | |
| 445. | Keppra Tablet 250mg | Syringe | 500 | | |
| 446. | Lantus Solostar Injection 100U/ml | Vial | 1200 | | |
| 447. | Mabthera 500mg/50ml | Vial | 2000 | | |
| 448. | Marcaine Heavy Injection 0.5% | Vial | 2000 | | |
| 449. | Marcain Injection 0.5% | Satchet | 500 | | |
| 450. | Movicol Pediatric Oral Solution 6.9g | Vial | 3000 | | |
| 451. | Survanta 25mg/ml | Vial | 3000 | | |
| 452. | Syntocinon Injection 10mg | Vial | 500 | | |

| 453. | Ultiva Injection 2mg | 15ml | 600 | | |
|------|----------------------------|------|-------|--|--|
| 454. | Tear Naturale II Eye Drops | Vial | 12000 | | |
| 455. | Venofer 100mg/5ml | | | | |

1. TECHNICAL SPECIFICATIONS

The purpose of the Technical Specifications (TS), is to define the technical characteristics of the Goods and Related Services required by the Procuring Entity. The Procuring Entity shall prepare the detailed TS take into account that:

- The TS constitute the benchmarks against which the Procuring Entity will verify the technical responsiveness of Tenders and subsequently evaluate the Tenders. Therefore, well-defined TS will facilitate preparation of responsive Tenders by Tenderers, as well as examination, evaluation, and comparison of the Tenders by the Procuring Entity.
- Technical Specifications shall be fully descriptive of the requirements in respect of, but not limited to, the following:
 - a) Standards of materials and workmanship required for the production and manufacturing of the Goods.
 - b) Detailed tests required (type and number).
 - c) Other Related Services required to achieve full delivery/completion.
 - d) Detailed activities to be performed by the Supplier, and participation of the Procuring Entity there on.
 - e) List of detailed functional guarantees covered by the Warranty and the specification of the liquidated damages to be applied in the event that such guarantees are not met.

A set of precise and clear specifications is a prerequisite for Tenderer stores pond realistically and competitively to the requirements of the Procuring Entity without qualifying their Tenders. The sample text provided in this section should serve as guidance only. This text is not intended to be used verbatim since technical specifications specific to each procurement should be drafted by the Procuring Entity for inclusion in the tendering document. In the context of international competitive procurement process among qualified firms, the specifications must be drafted to permit the widest possible The technical specifications establish the requirements for good manufacturing practices (GMPs), pharmacopeial standards, nomenclature, and description required for each product, shelf life and package expiration date parameters, labeling instructions, packaging instructions, GMP and quality assurance certificates required, and other evidence of product quality to be submitted with the Tender and with each shipment. Only if this is done will the objectives of economy, efficiency, and fairness in procurement be realized, responsiveness of Tenders be ensured, and the subsequent task of Tender evaluation facilitated.

Specific pharmacopeia standards should be listed for each product; if any of a range of standards is adequate (British Pharmacopoeia, United States Pharmacopoeia, European Pharmacopoeia, or International Pharmacopoeia), this should be noted. If special packaging or labeling is required for a subset of products, this should be indicated on the schedule of requirements (see above), but a generic statement of packaging and labeling applied to all products should be included in the general technical specifications. Instructions about labeling (contents and language)and package inserts can be included in the technical specifications, unless there are specific requirements for each batch or schedule of requirement.

Technical Specifications

[Text of Technical Specifications to be inserted in the tendering document by the Procuring Entity, as applicable]

TECHNICAL SPECIFICATIONS:

TECHNICAL SPECIFICATIONS:

TECHNICAL SPECIFICATIONS: PHARMACEUTICALS CONDOMS

VACCINES

SAMPLE TECHNICAL SPECIFICATIONS PHARMACEUTICALS

1. Product and Package Specifications

- 1.1 The Goods to be purchased by the Procuring Entity under this Invitation to Tender are included in the Procuring Entity's *current* national essential drugs list or national formulary. The required packing standards and labeling must meet the latest requirements of the World Health Organization (WHO) good manufacturing practices (GMP) standards in all respects. (These standards are contained in "Good Practices in the Manufacture and Quality Control of Drugs.")
- 1.2 Product specifications indicate dosage form (e.g., tablet, *capsules*, *dry syrup*, liquid, *ointment*, injectable, emulsion, suspension, etc.) and the drug content (exact number of mg *or international units*[IU] or %v/v, w/w or v/w acceptable range). The Goods should conform to standards specified in the following compendia: [The Procuring Entity should specify an acceptable pharmacopoeia standard from one of the following: The *British Pharmacopoeia*, the *United States Pharmacopoeia*, the *French Pharmacopoeia*, the *International Pharmacopoeia*, or the *European Pharmacopoeia*, the latter particularly for raw materials.] *The standards will be the latest edition unless otherwise stated by the Procuring Entity or other if applicable*. In case the pharmaceutical product is not included in the specified compendium, *but included in the Procuring Entity's national essential drug list, the Procuring Entity should clearly indicate acceptable limits and the Supplier, upon award of the Contract, must provide the reference standards and testing protocols to allow for quality control testing.*
- 1.3 Not only the pharmaceutical item, but also the packaging and labeling components (e.g., bottles, closures, and *labeling*) should also meet specifications suitable for distribution, storage, and use in a climate similar to that prevailing in Kenya. All packaging must be properly sealed and tamper-proof, *and packaging components must meet the latest compendium standards and be approved for pharmaceutical packaging by the manufacturer's national regulatory authority(RA). The Procuring Entity should specify any additional special requirements.*
- 1.4 All labeling and packaging inserts shall be in the language requested by the Procuring Entity or English if not otherwise stated.
- 1.5 Goods requiring refrigeration or freezing *or those that should not fall below a certain minimum temperature* or stability must specifically indicate storage requirements on labels and containers and be shipped in special containers to ensure stability in transit from point of shipment to port of entry.
- 1.6 Upon award, the successful Supplier shall, on demand, provide a translated version in the language of the Tender of the prescriber's information for any specific goods the Procuring Entity may request.

2. Labeling Instructions

- 2.1 The label of the primary container for each pharmaceutical and vaccine product shall meet the W210 GMP standard and include:
 - a) The international all nonproprietary name (INN) or generic name prominently displayed and above the brand name, where a brand name has been given. Brand names should not be bolder or larger than the generic name;
 - b) dosage or m, e.g., tablet, ampoule, syrup, etc.;
 - c) the active ingredient" per unit, dose, tablet or capsule, etc.";
 - d) the applicable pharmacopoeial standard;
 - e) the Procuring Entity's logo and code number and any specific color coding if required;
 - f) content per pack;
 - g) instructions for use;
 - h) specials to rage requirements;
 - i) batch number;
 - j) date of manufacture and date of expiry (in clear language, not code);

- k) name and address of manufacture;
- 1) any additional cautionary statement.
- 2.2 The outer case or carton should also display the above information.

3. Case Identification

- 3.1 All cases should prominently indicate the following:
 - a) Procuring Entity's line and code numbers;
 - b) The generic name of the product;
 - c) The dosage form(tablet, ampoule, syrup);
 - d) Date of manufacture and expiry(in clear language not code);
 - e) Batch number;
 - f) Quantity per case;
 - g) Special instructions for storage;
 - h) Name and address of manufacture;
 - i) Any additional cautionary statements.
- 3.2 No case should contain pharmaceutical products from more than one batch.

4. Unique Identifiers

4.1 The Procuring Entity shall have the right to request the Supplier to imprint a logo, if the quantity so justifies it, on the *labels of the containers* used for packaging and in certain do sage forms, such as tablets, *and ampoules* and this will be in the Technical Specifications. The design *and detail will be clearly indicated at the time of Tendering, and confirmation of the design of such logo shall be provided to the Supplier at the time of contract award.*

5. Standards of Quality Control for Supply

- 5.1 The successful Supplier will be required to furnish to the Procuring Entity:
 - a) With each consignment, and for each item a WHO certificate of quality control test results concerning quantitative assay, chemical analysis, sterility, pyrogen contentuni formity, microbial limit, and other tests, as applicable to the Goodsbeing supplied and the manufacturer's certificate of analysis.
 - b) As say methodology of any or all tests if requested.
 - c) Evidence of bio-availability and/or bio-equivalence for certain critical Goods upon request. *This information would be supplied on a strictly confidential basis only.*
 - d) Evidence of basis for expiration dating and other stability data concerning the commercial final package upon request.
- 5.2 The Supplier will also be required to provide the Procuring Entity with access to its manufacturing facilities to inspect the compliance with the GMP requirements and quality control mechanisms.

SAMPLE TECHNICAL SPECIFICATION VACCINES

1. Product Qualification Requirements

Option A

- 1.1 The Goods to be purchased by the Procuring Entity under this Invitation to Tender must be produced under the control of a recognized, well-functioning National Control Authority (NCA) for biological, which performs all six critical functions as defined by the World Health Organization(WHO):
 - a) Licensing based on published set of requirements
 - b) Surveillance of vaccine field performance
 - c) System of lot release for vaccines
 - d) Use of laboratory when needed
 - e) Regular inspections for good manufacturing practices(GMP)
 - f) Evaluation of clinical performance Or state the following:

Option B

- 1.1 The Goods under this Invitation to Tender should be purchased from WHO-approved sources only.
- 1.2 The Goods to be purchased by the Procuring Entity under this Invitation to Tender must be produced in accordance with the GMP recommendations of WHO for biological products.
- 1.3 The Goods to be purchased by the Procuring Entity under this Invitation to Tender must be registered by the National Control Authority (NCA) of Kenya.

2. Product Specifications

- 2.1 Dosage form (e.g.: oral or injectable; liquid or freeze dried with sterile diluent packed separately, etc.).
- 2.2 Type (e.g.: "live attenuated," "manufactured from purified inactivated (...) obtained from human plasma or manufactured using recombinant DNA technology," etc.).
- 2.3 Administration (e.g.: "intended for intramuscular injection," etc.).
- 2.4 Description of intended use (e.g.: "immunization of new born infants," etc.).
- 2.5 Dosage size (if not restrictive), or expected immune genic reaction (e.g.: each dose shall contain that amount of Hbs ag-protein with micrograms/ml specified by the manufacturer for new born dosage, that when given as part of a primary immunization series[3doses] is capable of producing specific humoral anti-body [anti-HBs] at a level of at least10milliinternationalunitsin>-90 percent of recipients," etc.).
- 2.6 Dose package (e.g.: "5 infant dose sterile glass vials," etc.).
- 2.7 Filling volume (e.g.: "final product should contain 15% overfill," etc.).
- 2.8 Closures (e.g.: "vaccine vials shall befitted with closures that conform to ISO standard 8362-2").
- 2.9 Storage temperature (e.g.: "2–8 degrees C. Do not freeze," or as appropriate, etc.).
- 2.10 The product should remain stable up to the indicated test expiry date if kept according to the required storage temperature.
- 2.11 Standards (e.g.: "The vaccine should conform to standards established by Kenya or, where no standard has been adopted, meet current requirements published by the WHO Expert Committee on Biological Standardization, or requirements of an established body of equivalent stature such as the *U.S. Pharmacopoeia*, the British Pharmacopoeia, the French Pharmacopoeia, or the International Pharmacopoeia").

3. Labeling Requirements

- 3.1 Each vial or ampoule shall carry the manufacturer's standard label in the language of Kenya, if available at no extra charge; otherwise, the label shall be in English.
- 3.2 Each vial or ampoule label shall state the following:
 - a) Name of the vaccine;

- b) Name of the manufacturer;
- c) Place of manufacture;
- d) Lot number;
- e) composition;
- f) concentration;
- g) dose mode for administration;
- h) expiration date;
- i) storage temperature;
- i) any other information that is appropriate.
- 3.3 All labeling shall with stand immersion in water and remain intact.

4. Packing Requirements

- 4.1 *Inner boxes:* Inner Boxes shall contain no more than (*number*) individual vials/ampoules and shall be constructed of sturdy white cardboard outfitted with individual segments for protecting and separating each vial/ampoules.
- 4.2 Printed materials: Each inner box shall contain at least (number) manufacturer's standard package inserts in the language of Kenya if available at no extra charge; otherwise, package insert shall be in English.
- 4.3 Over packing: Inner boxes shall be over packed so that the vaccine remains refrigerated as designated in Clause 2.9. The over packing must be suitable for export handling and be in accordance with WHO Expanded Program of Immunization (EPI) Guidelines on International Packaging and Shipping of Vaccines including all measures needed to maintain required temperatures for seventy-two (72) hours. It must have adequate insulation and sufficient refrigerant to ensure that the warmest storage temperature of the vaccine does not rise above that designated in Sub-Clause 2.9 when exposed to continuous outside temperature of +43 degrees C, nor fall below that specified of-20 degrees C during transit and for a period of at least twenty-four (24) hours after arrival at the airport destination. Additional cushioning shall be provided sufficient to protect the vials/ampoules from breakage during transit and handling.
- 4.4 Exterior shipping cartons: Product and printed materials, packaged as described above, shall be packed in weather-resistant, triple-wall corrugated fiberboard cartons with a bursting test strength of not less than 1,900k Pa. The overall dimensions of the exterior shipping cartons should be such that the product does not become damaged during transportation and storage.

No shipping carton should contain vaccine from more than one lot.

- 4.5 Cold chain monitor cards: Each insulated shipping container must include appropriate temperature-monitoring devices designated by the Procuring Entity.
 - a) At least two suitable cold chain monitor cards, as approved by the Procuring Entity, shall be packed in each transport case of vaccine.
 - b) Freezewatchindicatorsshallbeincludedineachtransportcaseatthedirection of Procuring Entity.

5. Marking Requirements

- 5.1 All containers and invoices must bear the following information:
 - a) The name of the vaccine;
 - b) Expiration date of the vaccine;
 - c) Appropriate storage temperature.
- 5.2 *Inner boxes:* The inner boxes containing vaccine vials or ampoules shall be marked with the following information in a clearly legible manner that is acceptable to the Procuring Entity:
 - d) Generic name and trade name of the vaccine;
 - e) Manufacturer's name and trade registered address;
 - f) Manufacturer's national registration number;
 - g) Lot or batch number;

- h) Composition and concentration;
 i) Number of vials contained in box;
 j) Expiration date (month and year in clear language, not code);
 k) Instructions for storage and handling;
 l) Place of manufacture (Made in_____).
- 5.3 Exterior Shipping Cartons: The following information shall be stenciled or labeled on the exterior shipping cartons on two opposing sides in bold letters at least 30 mm high with waterproof ink in a clearly legible manner that is acceptable to the Procuring Entity.
 - m) Generic name and trade name of the vaccine;
 - n) Lot or batch number;
 - o) Expiration date (month and year in clear language, not code);
 - p) Manufacturer's name and registered address;
 - q) Manufacturer's national registration number;
 - r) Destination airport and routing;
 - s) Consignee's name and address in full;
 - t) Consignee contact name and telephone number;
 - u) Number of vials or ampoules contained in the carton;
 - v) Gross weight of each cart on (in kg);
 - w) Carton# of ;
 - x) Instructions for storage and handling;
 - y) Contract number;
 - z) Place of manufacture (Made in).

6. Quality Control for Supply

- 6.1 All goods must:
 - a) meettherequirementsofmanufacturinglegislationandregulationofvaccinesinthecountryoforigin;
 - b) meetinternationallyrecognizedstandardsforsafety,efficacy,andquality;
 - c) conform to all the specifications and related documents contain here in;
 - d) befitforthepurposesexpresslymadeknowntotheSupplierbytheProcuringEntity;
 - e) be free from defects in workmanship and materials; and
 - f) be certified by competent authority in the manufacturer's country according to resolution WHA28-65(2), of the WHO release certificate.
- 6.2 The Supplier will be required to furnish to the Procuring Entity with each consignment;
 - a) AcertificateofqualitycontrolandtestresultsinconformitywiththeWHOreleasecertificate.
 - b) Assay methodology of any or all tests if required.
 - c) Evidence of basis for expiration dating and other stability data concerning the commercial final package upon request.
- 6.3 Pre-shipment inspection and testing: The Supplier will be required to provide the Procuring Entity or his representative with access to the product as packed for shipment at the sellers' factory and/or warehouse at a mutually agreeable time prior to shipment of the product.
 - a) The Procuring Entity may inspect and sample, or cause to be sampled, such product.
 - b) The Procuring Entity may cause independent laboratory testing to be performed as deemed necessary to ensure that the Goods con form to prescribed requirements.

The testing laboratory shall be of the Procuring Entity's choice and suitably equipped and qualified to conduct quality control test on biological products.

SAMPLETECHNICALSPECIFICATIONSCONDOMS

CONDOMS

1. Product and Package Specifications

- 1.1 The Goods must conform to the manufacturer's current standards for condoms and specified in line with the ISO 4074 Standard for Latex Rubber Condoms.
- 1.2 The specifications for the Goods shall indicate critical factors, i.e., bursting volume and pressure, freedom from holes, width and length, thickness, lubricant quality, and viscosity.
- 1.3 The Goods and packaging and labeling components shall meet the standards specified in the latest WHO specification, including batch-by-batch independent quality control laboratory tests.
- 1.4 Condomsshouldbeshippedinspecialcontainerstoensurestabilityintransitfrompointofshipmenttoport/air port of entry and point of destination for CIP deliveries. Any special temperature requirements must be designed to meet the climatic conditions prevailing in Kenya, and the Procuring Entity should advise the Supplier of any particular requirements.

2. Labeling

- $2.1 \quad The primary packs hould be labeled in accordance with the latest WHO specifications and include:\\$
 - a) Manufacturer's name;
 - b) Batch number (printed at the time of packaging);
 - c) Month and year of expiry; and
 - d) Any other information as requested by the Procuring Entity.
- 2.2 The secondary packing, i.e., the inner box, should be labeled in accordance with the latest WHO specifications and include:
 - e) Batch number;
 - f) Month and year of manufacture (including the words: Date of Manufacture/month/year);
 - g) Manufacturer's name and registered address;
 - h) Nominal width expressed in millimeters;
 - i) Number of condoms in box;
 - j) Instructions for storage; and
 - k) Month and year of expiry.

3. Packaging Specification

3.1 All exterior shipping cartons and packaging must comply with the latest WHO specification for packaging of condoms.

4. Case Identification

- 4.1 All cases should predominantly indicate the following:
 - a) Batch number;
 - b) Monthandyearofmanufacture(includingthewords:DateofManufacture/month/year);
 - c) Name and address of supplier;
 - d) Nominal width expressed in millimeters;
 - e) Number contained in the carton;
 - f) Instructions for storage and handling; and
 - g) Month and year of expiry.

5. Lot Traceability

- 5.1 All exterior shipping cartons for each batch should be assembled and shipped together to facilitate the monitoring of batch quality during shipping and storage.
- 5.2 Both codes should be used on exterior shipping cartons, color coded for ease of identification if requested by the Procuring Entity.

6. Unique Identifiers

6.1 The Procuring Entity will have the right to request the Supplier to imprint, provided the quantity justifies it, a logo on the packaging of the condoms. The design and details will be clearly indicated at the time of Tendering and shall be provided to the Supplier at the time of contract award.

7. Standards of Quality Control for Supply

7.1 The Supplier will be required to provide the Procuring Entity with access to its manufacturing facilities to inspect compliance with the GMP requirements and quality control mechanisms.

8. Quality Control Testing

- 8.1 a) The Supplier shall be required to carry out testing of a proposed shipment in line with the WHO specification, and the size of sample will be calculated by reference to ISO2859-1.
 - b) With each consignment the Supplier must provide a certificate of quality control test results in conformity with the WHO specifications and in accordance with the general sampling levels appropriate to each feature as necessary.

3. INSPECTIONS ANDTESTS

The following inspections and tests shall be performed: [insert list of inspections and tests].

PART 3 - CONTRACT

SECTION VIII - GENERAL CONDITIONS OF CONTRACT

1. Definitions

- 1.1 The following words and expressions shall have the meanings here by assigned to them:
 - (a) "Completion" means the fulfillment of the Related Services by the Supplier in accordance with the terms and conditions set forth in the Contract.
 - (b) "Contract Documents" means the documents listed in the Contract Agreement, including any amendments thereto.
 - (c) "Contract Price" means the price payable to the Supplier as specified in the Contract Agreement, subject to such additions and adjustments thereto or deductions therefrom, as may be made pursuant to the Contract.
 - (d) "Contract" means the Contract Agreement entered into between the Procuring Entity and the Supplier, together with the Contract Documents referred to therein, including all attachments, appendices, and all documents incorporated by reference therein.
 - (e) "Day" means calendar day. "GCC "means the General Conditions of Contract.
 - (f) "Goods" means all of the pharmaceuticals including nutritional supplement and oral and injectable forms of contraception, vaccines, and condoms Supplier is required to supply to the Procuring Entity under the Contract.
 - (g) "Laws" means all national legislation, statutes, ordinances, and regulations and by-laws of any legally constituted public authority.
 - (h) "Letter of Acceptance" means the letter of formal acceptance, signed by the contractor. Procuring Entity, including any annexed memoranda comprising agreements between and signed by both Parties.
 - (i) "Procuring Entity" means the Entity named in the Special Conditions of Contract. "Procuring Entity" means the entity purchasing the Goods and Related Services, as specified in the SCC.
 - (j) "Public Procurement Regulatory Authority (PPRA)" shall mean the agency responsible in Kenya for regulating and monitoring the public procurement unction
 - (k) "Registration Certificate" means the certificate of registration or other documents in lieu thereof establishing that the Goods supplied under the Contract are registered for use in Kenya in accordance with the Applicable Law.
 - (l) "Related Services" means the services incidental to the supply of the goods, such as insurance, installation, training and initial maintenance and other such obligations of the Supplier under the Contract.
 - (m) "Supplier" means the person, private or government entity, or a combination of the above, who's Tender to perform the Contract has been accepted by the Procuring Entity and is named as such in the Contract Agreement.
 - (n) "The Project Site," where applicable, means the place named in the SCC.
 - (o) SCC" means the Special Conditions of Contract.

2. Contract Documents

- 1.1 Subject to the order of precedence set forth in the Contract Agreement, all documents forming the Contract (and all parts thereof) are intended to be correlative, complementary, and mutually explanatory. The Contract Agreement shall be read as a whole. The documents forming the Contract shall be interpreted in the following order of priority:
 - a) The Contract Agreement,
 - b) The Letter of Acceptance,

- c) The Special Conditions-Part A,
- d) The Special Conditions-Part B
- e) The General Conditions of Contract
- f) The Form of Tender,
- g) The Specifications and Schedules of the Drawings(if any),and
- h) The Schedules of Requirements and any other documents forming part of the Contract.

3. Fraud and Corruption

- 3.1 The Procuring Entity requires compliance with anti-corruption laws and guidelines and its prevailing sanctions policies and procedures as set forth in Laws of Kenya.
- 3.2 The Procuring Entity requires the Supplier to disclose any commissions or fees that may have been paid or are to be paid to agents or any other party with respect to the Tendering process or execution of the Contract. The information disclosed must include at least the name and address of the agent or other party, the amount and currency, and the purpose of the commission, gratuity or fee.

4. Interpretation

4.1 If the context so requires it, singular means plural and vice versa.

4.2 Incoterms

- a) Unless inconsistent with any provision of the Contract, the meaning of any trade term and the rights and obligations of parties there under shall be as prescribed by Incoterms specified in the SCC.
- b) The terms EXW, CIP, FCA, CFR and other similar terms, when used, shall be governed by the rules prescribed in the current edition of Incoterms specified in the SCC and published by the International Chamber of Commerce in Paris, France.

4.3 Entire Agreement

The Contract constitutes the entire agreement between the Procuring Entity and the Supplier and supersedes all communications, negotiations and agreements (whether written or oral) of the parties with respect there to made prior to the date of Contract.

4.4 Amendment

No amend mentor other variation of the Contract shall be valid unless it is in writing, is dated, expressly refers to the Contract, and is signed by a duly authorized representative of each party thereto.

4.5 Non waiver

- a) Subject to GCC Sub-Clause4.5 (b)below, no relaxation, forbearance, delay, or indulgence by either party in enforcing any of the terms and conditions of the Contractor the granting of time by either party to the other shall prejudice, affect, or restrict the rights of that party under the Contract, neither shall any waiver by either party of any breach of Contract operate as waiver of any subsequent or continuing breach of Contract.
- b) Any waiver of a party's rights, powers, or remedies under the Contract must be in writing, dated, and signed by an authorized representative of the party granting such waiver, and must specify the right and the extent to which it is being waived.

4.6 Severability

If any provision or condition of the Contract is prohibited or rendered in valid or unenforceable, such prohibition, invalidity or unenforceability shall not affect the validity or enforceability of any other provisions and conditions of the Contract.

5. Language

5.1 The Contract as well as all correspondence and documents relating to the Contract exchanged by the Supplier and the Procuring Entity, shall be written in the English language. Supporting documents and printed literature

that are part of the Contract may be in another language provided they are accompanied by an accurate translation of the relevant passages in the English language, in which case, for purposes of interpretation of the Contract, this translation shall govern.

5.2 The Supplier shall bear all costs of translation to the governing language and all risks of the accuracy of such translation, for documents provided by the Supplier.

6. Joint Venture, Consortium or Association

6.1 If the Supplier is a joint venture, consortium, or association, all of the parties shall be jointly and severally liable totheProcuringEntityforthefulfillmentoftheprovisionsoftheContractandshalldesignateonepartytoactas a leader with authority to bind the joint venture, consortium, or association. The composition or the constitution of the joint venture, consortium, or association shall not be altered without the prior consent of the Procuring Entity.

7. Eligibility

- 7.1 The Supplier and its Subcontractors shall have the nationality of an eligible country. A Supplier or Subcontract or shall be deemed to have the nationality of a country if it is a citizen or constituted, incorporated, or registered, and operates in conformity with the provisions of the laws of that country.
- 7.2 All Goods and Related Services to be supplied under the Contract shall have their origin in Eligible Countries. For the purpose of this Clause, origin means the country where the goods have been grown, mined, cultivated, produced, manufactured, or processed; or through manufacture, processing, or assembly, another commercially recognized article results that differs substantially in its basic characteristics from its components.

8. Notices

- 8.1 Any notice given by one party to the other pursuant to the Contract shall be in writing to the address specified **in the SCC.** The term "in writing" means communicated in written form with proof of receipt.
- 8.2 A notice shall be effective when delivered or on the notice's effective date, whichever is later.

9. Governing Law

- 9.1 The Contract shall be governed by and interpreted in accordance with the laws of Kenya.
- 9.2 Throughout the execution of the Contract, the Supplier shall comply with the import of goods and services prohibitions in Kenya when
 - a) As a matter of law or official regulations, Kenya prohibits commercial relations with that country; or
 - b) by an act of compliance with a decision of the United Nations Security Council taken under Chapter VII of the Charter of the United Nations, Kenya a prohibits any import of goods from that country or any payments to any country, person, or entity in that country.

10. Settlement of Disputes

- 10.1 The Procuring Entity and the Supplier shall make every effort to resolve amicably by direct negotiation any disagreement or dispute arising between them under or in connection with the Contract.
- 10.1.1 If, after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the Procuring Entity or the Supplier may give notice to the other party of its intention to commence arbitration, as herein after provided, as to the matter in dispute, and no arbitration in respect of this matter may be commenced unless such notice is given. Any dispute or difference in respect of which a notice of intention to commence arbitration has been given in accordance with this Clause shall be finally settled by arbitration. Arbitration may be commenced prior to or after delivery of the Goods under the Contract.
- 10.2 Arbitration proceedings shall be conducted as follows:
- 10.2.1 Any claim or dispute between the Parties arising out of or in connection with the Contract not settled amicably in accordance with Sub-Clause10.1shall be finally settled by arbitration.

- 10.2.2 No arbitration proceedings shall be commenced on any claim or dispute where notice of a claim or dispute has not been given by the applying party within thirty days of the occurrence or discovery of the matter or issue giving rise to the dispute.
- 10.2.3 Notwithstanding the issue of a notice as stated above, the arbitration of such a claim or dispute shall not commence unless an attempt has in the first instance been made by the parties to settle such claim or dispute amicably with or without the assistance of third parties. Proof of such attempt shall be required.
- 10.2.4 The Arbitrator shall, without prejudice to the generality of his powers, have powers to direct such measurements, computations, or valuations as may in his opinion be desirable in order to determine the rights of the parties and assess and award any sums which ought to have been the subject of or included in any due payments.
- 10.2.5 Neither Party shall be limited in the proceedings before the arbitrators to the evidence, or to the reasons for the dispute given in its notice of a claim or dispute.
- 10.2.6 Arbitration may be commenced prior to or after delivery of the goods. The obligations of the Parties shall not be altered by reason of any arbitration being conducted during the progress of the delivery of goods.
- 10.2.7 The terms of the remuneration of each or all the members of Arbitration shall be mutually agreed upon by the Parties when agreeing the terms of appointment. Each Party shall be responsible for paying one-half of this remuneration.
- 10.3 Arbitration Proceedings
- 10.3.1 Arbitration proceedings with both national suppliers will be conducted in accordance with the Arbitration Laws of Kenya. In case of any claim or dispute, such claim or dispute shall be notified in writing by either party to the other with are quest to submit it to arbitration and to concur in the appointment of an Arbitrator with in thirty days of the notice. The dispute shall be referred to the arbitration and final decision of a person or persons to be agreed between the parties. Failing agreement to concur in the appointment of an Arbitrator, the Arbitrator shall be appointed, on the request of the applying party, by the Chairman or Vice Chairman of any of the following professional institutions;
 - i) Kenya National Chamber of Commerce
 - ii) Chartered Institute of Arbitrators (Kenya Branch)
 - iii) The Law Society of Kenya
- 10.3.2 The institution written to first by the aggrieved party shall take precedence overall other institutions.
- 10.4 Arbitration with Foreign Suppliers
- 10.4.1 Arbitration with foreign suppliers shall be conducted in accordance with the arbitration rules of the United Nations Commission on International Trade Law (UNCITRAL); or with proceedings administered by the International Chamber of Commerce (ICC) and conducted under the ICC Rules of Arbitration; by one or more arbitrators appointed in accordance with said arbitration rules.
- 10.4.2 The place of arbitration shall be a location specified in the SCC; and the arbitration shall be conducted in the language for communications defined in Sub-Clause 1.4 [Law and Language].
- 10.5 Alternative Arbitration Proceedings
- 10.5.1 Alternatively, the Parties may refer the matter to the Nairobi Centre for International Arbitration (NCIA) which offers a neutral venue for the conduct of national and international arbitration with commitment to providing institutional support to the arbitral process.

11. Inspections and Audit by the PPRA

11.1 The Supplier shall keep, and shall make all reasonable efforts to cause its Subcontractors and subconsultants to keep, accurate and systematic accounts and records in respect of the Goods in such form and details as will clearly identify relevant time changes and costs.

11.2 Pursuant to paragraph 2.2e. of Appendix to the General Conditions the Supplier shall permit and shall cause its subcontractors and sub-consultants to permit, PPRA and/or persons appointed by the PPRA to inspect the Site and/or the accounts and records relating to the procurement process, selection and/ or contract execution, and to have such accounts and records audited by auditors appointed by the PPRA. The Supplier's and its Subcontractors' and sub-consultants' attention is drawn to Sub-Clause 3.1 which provides, inter alia, that acts intended to materially impede the exercise of the PPRA's inspection and audit rights constitute a prohibited practice subject to contract termination.

12. Scope of Supply

12.1 The Goods and Related Services to be supplied shall be as specified in the Schedule of Requirements.

13. Delivery and Documents

13.1 Subject to GCC Sub-Clause 33.1, the Delivery of the Goods and Completion of the Related Services shall be in accordance with the Delivery and Completion Schedule specified in the Schedule of Requirements. The details of shipping and other documents to be furnished by the Supplier are specified in the SCC.

14. Supplier's Responsibilities

14.1 The Supplier shall supply all the Goods and Related Services included in the Scope of Supply in accordance with GCCC lause 12, and the Delivery and Completion Schedule, as per GCCC lause 13.

15 Contract Price

15.1 Prices charged by the Supplier for the Goods supplied and the Related Services performed under the Contract shall not vary from the prices quoted by the Supplier in its Tender, with the exception of any price adjustments authorized in the SCC.

16. Terms of Payment

- 16.1 The Contract Price, including any Advance Payments, if applicable, shall be paid as specified in the SCC.
- 16.2 The Supplier's Invitation to payment shall be made to the Procuring Entity in writing, accompanied by invoices describing, as appropriate, the Goods delivered and Related Services performed, and by the documents submitted pursuant to GCCClause13 and upon fulfillment of all other obligations stipulated in the Contract.
- 16.3 Payments shall be made promptly by the Procuring Entity, but in no case later than sixty (60) days after submission of an invoice or Invitation to payment by the Supplier, and after the Procuring Entity has accepted it.
- 16.4 The currencies in which payments shall be made to the Supplier under this Contract shall be those in which the Tender price is expressed.
- 16.5 In the event that the Procuring Entity fails to pay the Supplier any payment by its due date or within the period set forth **in the SCC**, the Procuring Entity shall pay to the Supplier interest on the amount of such delayed payment at the rate shown **in the SCC**, for the period of delay until payment has been made in full, whether before or after judgment t or arbitrage award.

17. Taxes and Duties

- 17.1 For goods manufactured outside Kenya, the Supplier shall be entirely responsible for all taxes, stamp duties, license fees, and other such levies imposed outside Kenya.
- 17.2 For goods Manufactured within Kenya, the Supplier shall be entirely responsible for all taxes, duties, license fees, etc., incurred until delivery of the contracted Goods to the Procuring Entity.
- 17.3 If any tax exemptions, reductions, allowances or privileges may be available to the Supplier in Kenya, the Procuring Entity shall use its Lowest efforts to enable the Supplier to benefit from any such tax savings to the maximum allowable extent.

18. Performance Security

- 18.1 If required as specified in the SCC, the Supplier shall, within twenty-eight (28) days of the notification of contract award, provide a Performance Security for the performance of the Contract in the amount specified in the SCC.
- 18.2 The proceeds of the Performance Security shall be payable to the Procuring Entity as compensation for any loss resulting from the Supplier's failure to complete its obligations under the Contract.
- 18.3 As specified in the SCC, the Performance Security, if required, shall be denominated in the currency (ies) of the Contract, or in a freely convertible currency acceptable to the Procuring Entity; and shall be in one of the format stipulated by the Procuring Entity in the SCC, or in another form at acceptable to the Procuring Entity.
- 18.4 The Performance Security shall be discharged by the Procuring Entity and returned to the Supplier not later than twenty-eight (28) days following the date of Completion of the Supplier's performance obligations under the Contract, including any warranty obligations, unless specified otherwise in the SCC.

19. Certification of Goods in Accordance with Laws of Kenya

- 19.1 If required under the Applicable Law, Goods supplied under the Contract shall be registered for use in Kenya. The Procuring Entity undertakes to cooperate with the Supplier to facilitate registration of the Goods for use in Kenya as specified in the SCC.
- 19.2 Unless otherwise specified **in the SCC**, the Contract shall become effective on the date("the Effective Date") that the Supplier receives written notification from the relevant authority in Kenya that the Goods have been registered for use in Kenya.
- 19.3 If thirty (30) days, or such longer period specified **in the SCC**, elapse from the date of Contract signing and the Contract has not become effective pursuant to Sub-Clause 19.2 above, then either party may, by not less than seven (7) days' written notice to the other party, declare this Contract null and void. In such event, the Supplier's Performance Security shall be promptly returned.

20. Confidential Information

- 20.1 The Procuring Entity and the Supplier shall keep confidential and shall not, without the written consent of the other party hereto, divulge to any third party any documents, data, or other information furnished directly or indirectly by the other party hereto in connection with the Contract, whether such information has been furnished prior to, during or following completion or termination of the Contract. Notwithstanding the above, the Supplier may furnish to its Subcontractor such documents, data, and other information it receives from the Procuring Entity to the extent required for the Subcontractor to perform its work under the Contract, in which event the Supplier shall obtain from such Subcontractor an undertaking of confidentiality similar to that imposed on the Supplier under GCC Clause 20.
- 20.2 The Procuring Entity shall not use such documents, data, and other information received from the Supplier for any purposes unrelated to the contract. Similarly, the Supplier shall not use such documents, data, and other information received from the Procuring Entity for any purpose other than the performance of the Contract.
- 20.3 The obligation of a party under GCC Sub-Clauses20.1 and 20.2 above, however, shall not apply to information that:
 - a) the Procuring Entity or Supplier need to share with the PPRA or other institutions participating in the financing of the Contract;
 - b) now or here after enters the public domain through no fault of that party;
 - c) can be proven to have been possessed by that party at the time of disclosure and which was not previously obtained, directly or indirectly, from the other party; or
 - d) otherwise lawfully becomes available to that party from a third party that has no obligation of confidentiality.
- 20.4 The above provisions of GCC Clause 20 shall not in any way modify any undertaking of confidentiality given by either of the parties here to prior to the date of the Contract in respect of the Supply or any part thereof.

20.5 The provisions of GCC Clause 20 shall survive completion or termination, for whatever reason, of the Contract.

21. Subcontracting

- 21.1 The Supplier shall notify the Procuring Entity in writing of all subcontracts awarded under the Contract if not already specified in the Tender. Such notification, in the original Tender or later shall not relieve the Supplier from any of its obligations, duties, responsibilities, or liability under the Contract.
- 21.2 Subcontracts shall comply with the provisions of GCC Clauses 3 and 7.

22. Specifications and Standards

22.1 The Goods supplied under this Contract shall conform to technical specifications and standards mentioned in Section VII, Schedule of Requirements and, when no applicable standard is mentioned, to the authoritative standards appropriate to the Goods' country of origin. Such standards shall be the latest issued by the concerned institution.

23. Packing and Documents

- 23.1 The Supplier shall provide such packing of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the Contract. During transit, the packing shall be sufficient to withstand, without limitation, rough handling and exposure to extreme temperatures, salt and precipitation, and open storage. Packing case size and weights shall take into consideration, where appropriate, the remoteness of the goods' final destination and the absence of heavy handling facilities at all points in transit.
- 23.2 The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified **in the SCC**, and in any other instructions ordered by the Procuring Entity.

24. Insurance

24.1 Unless otherwise specified **in the SCC**, **the** Goods supplied under the Contract shall be fully insured-in a freely convertible currency from an eligible country—against loss or damage incidental to manufacture or acquisition, transportation, storage, and delivery, in accordance with the applicable Incoterms or in the manner specified in the **SCC**.

25. Transportation and Incidental Services

- 25.1 Unless otherwise specified **in the SCC**, responsibility for arranging transportation of the Goods shall be in accordance with the specified Incoterms.
- 25.2 The Supplier may be required to provide any or all of the following services, including additional services, if any, specified **in SCC:**
 - a) Performance or supervision of on-site assembly and/or start-up of the supplied Goods;
 - b) Furnishing of tools required for assembly and/or maintenance of the supplied Goods;
 - c) furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied Goods;
 - d) performance or supervision or maintenance and/or repair of the supplied Goods, for a period of time agreed by the parties, provided that this service shall not relieve the Supplier of any warranty obligations under this Contract; and
 - e) training of the Procuring Entity's personnel, at the Supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied Goods.
- 25.3 Prices charged by the Supplier for incidental services, if not included in the Contract Price for the Goods, shall be agreed upon in advance by the parties and shall not exceed the prevailing rates charged to other parties by the Supplier for similar services

26. Inspections and Tests

26.1 The Supplier shall at its own expense and at no cost to the Procuring Entity carry out all such tests and/or inspections of the Goods and Related Services as are specified in the SCC.

- 26.2 The inspections and tests may be conducted on the premises of the Supplier or the manufacturer, at point of delivery, and /or at the Goods' final destination, or in another place in Kenya as specified **in the SCC.** Subject to GCCSub-Clause26.3, if conducted on the premises of the Supplier or the manufacturer, all reasonable facilities and assistance, including access to production data, shall be furnished to the inspectors at no charge to the Procuring Entity.
- 26.3 The Procuring Entity or its designated representative shall be entitled to attend the tests and/or inspections referred to in GCC Sub-Clause 26.2, provided that the Procuring Entity bear all of its own costs and expenses incurred in connection with such attendance including, but not limited to, all traveling and board and lodging expenses.
- 26.4 Whenever the Supplier is ready to carry out any such test and inspection, it shall give a reasonable advance notice, including the place and time, to the Procuring Entity. The Supplier shall obtain from any relevant third party or manufacturer any necessary permission or consent to enable the Procuring Entity or its designated representative to attend the test and/or inspection.
 - a) Said inspection and testing is for the Procuring Entity's account. In the event that inspection and testing is required prior to dispatch, the Goods shall not be shipped unless a satisfactory inspection and quality control report has been issued in respect of those Goods.
 - b) The Supplier may have an independent quality test conducted on a batch ready for shipment. The cost of such tests will be borne by the Supplier.
 - c) Upon receipt of the Goods at place of final destination, the Procuring Entity's representative shall inspect the Goods or part of the Goods to ensure that they conform to the condition of the Contract and advise the Procuring Entity that the Goods were received in apparent good order. The Procuring Entity will issue an Acceptance Certificate to the Supplier in respect of such Goods (or part of Goods). The Acceptance Certificate shall be issued within ten (10) days of receipt of the Goods or part of Goods at place of final destination.
- 26.5 Where the Supplier contests the validity of the rejection by the Procuring Entity or his representative, of any inspection as required by 26.4 above conducted before shipment or at ultimate destination, whether based on product or packing grounds, a sample drawn jointly by the Supplier and Procuring Entity or his or her representative and authenticated by both, will be forwarded for umpire analysis within four weeks of the time the Supplier contests to an independent agency mutually agreed by the Procuring Entity and Supplier. The umpire's finding, which will be promptly obtained, will be final and binding on both parties. The cost of umpire analysis will be borne by the losing party;
- 26.6 The Procuring Entity may require the Supplier to carry out any test and/or inspection not required by the Contract but deemed necessary to verify that the characteristics and performance of the Goods comply with the technical specifications codes and standards under the Contract, provided that the Supplier's reasonable costs and expenses incurred in the carrying out of such test and/or inspection shall be added to the Contract Price. Further, if such test and/or inspection impedes the progress of manufacturing and/or the Supplier's performance of its other obligations under the Contract, due allowance will be made in respect of the Delivery Dates and Completion Dates and the other obligations so affected.
- 26.7 The Supplier shall provide the Procuring Entity with a report of the results of any such test and/or inspection.
- 26.8 The Procuring Entity may reject any Goods or any part there of that fail to pass any test and/or inspection or do not conform to the specifications. The Supplier shall either rectify or replace such rejected Goods or parts thereof or make alterations necessary to meet the specifications at no cost to the Procuring Entity, and shall repeat the test and/or inspection, at no cost to the Procuring Entity, upon giving a notice pursuant to GCC Sub- Clause 26.4.
- 26.9 The Supplier agrees that neither the execution of attest and/or inspection of the Goods or any part thereof, nor the attendance by the Procuring Entity or its representative, nor the issue of any report pursuant to GCC Sub-Clause 26.7, shall release the Supplier from any warranties or other obligations under the Contract.

27. Liquidated Damages

27.1 Except as provided under GCC Clause 32, if the Supplier fails to deliver any or all of the Goods by the Date (s) of delivery or perform the Related Services within the period specified in the Contract, the Procuring Entity may without prejudice to all its other remedies under the Contract, deduct from the Contract Price, as liquidated damages, a sum equivalent to the percentage specified in the SCC of the delivered price of the

delayed Goods or unperformed Services for each week or part thereof of delay until actual delivery or performance, up to a maximum deduction of the percentage specified **in the SCC.** Once the maximum is reached, the Procuring Entity may terminate the Contract pursuant to GCCClause35.

28. Warranty

28.1 All goods must be of fresh manufacture and must bear the dates of manufacture and expiry.

The Supplier further warrants that all Goods supplied under the Contract will have remaining a minimum of five-sixths (5/6) of the specified shelf life upon delivery at port/airport of entry for goods with a shelf life of more than two years and three-fourths (3/4) for goods with shelf life of two years or less, unless otherwise specified **in the SCC**; have "overages" within the ranges set forth in the Technical Specifications, where applicable; are not subject to recall by the applicable regulatory authority due to unacceptable quality or an adverse drug reaction; and in every other respect willfully comply in all respects with the Technical Specifications and with the conditions laid down in the Contract.

- 28.2 The Procuring Entity shall have the right to make claims under the above warranty for three months after the Goods have been delivered to the final destination indicated in the Contract. Upon receipt of a written notice from the Procuring Entity, the Supplier shall, with all reasonable speed, replace the defective Goods without cost to the Procuring Entity. The Supplier will be entitled to remove, at his own risk and cost, the defective Goods once the replacement Goods have been delivered.
- 28.3 In the event of a dispute by the Procuring Entity, a counter-analysis will be carried out on the manufacturer's retained samples by an independent neutral laboratory agreed by both the Procuring Entity and the Supplier. If the counter-analysis confirms the defect, the cost of such analysis will be borne by the Supplier as well as the replacement and disposal of the defective goods. In the event of the independent analysis confirming the quality of the product, the Procuring Entity will meet all costs for such analysis.
- 28.4 If, after being notified that the defect has been confirmed pursuant to GCC Sub-Clause 28.2 above, the Supplier fails to replace the defective Goods within the period specified **in the SCC** the Procuring Entity may proceed to take such remedial action as may be necessary, including removal and disposal, at the Supplier's risk and expense and without prejudice to any other rights that the Procuring Entity may have against the Supplier under the Contract. The Procuring Entity will also be entitled to claim for storage in respect of the defective Goods for the period following notification and deduct the sum from payments due to the Supplier under this Contract. *Recalls*. In the event any of the Goods are recalled, the Supplier shall notify the Procuring Entity within fourteen (14) Days, providing full details of the reason for the recall and promptly replace, at its own cost, the items covered by the recall with Goods that fully meet the requirements of the Technical Specification and arrange for collection or destruction of any defective Goods. If the Supplier fails to fulfill its recall obligation promptly, the Procuring Entity will, at the Supplier's expense, carry out the recall.

29. Patent Indemnity

- 29.1 The Supplier shall, subject to the Procuring Entity's compliance with GCC Sub-Clause 29.2, indemnify and hold harmless the Procuring Entity and its employees and officers from and against any and all suits, actions or administrative proceedings, claims, demands, losses, damages, costs, and expenses of any nature, including attorney's fees and expenses, which the Procuring Entity may suffer as a result of any infringement or alleged infringement of any patent, utility model, registered design ,trade mark, copyright, or other intellectual property right registered or otherwise existing at the date of the Contract by reason of:
 - a) The installation of the Goods by the Supplier or the use of the Goods in the country where the Site is located; and
 - b) the sale in any country of the products produced by the Goods. Such indemnity shall not cover any use of the Goods or any part thereof other than for the purpose indicated by or to be reasonably inferred from the Contract, neither any infringement resulting from the use of the Goods or any part thereof, or any products produced there by in association or combination with any other equipment, plant, or materials not supplied by the Supplier, pursuant to the Contract.
- 29.2 If any proceedings are brought or any claim is made against the Procuring Entity arising out of the matters referred to in GCC Sub-Clause 29.1, the Procuring Entity shall promptly give the Supplier a notice thereof, and the Supplier may at its own expense and in the Procuring Entity's name conduct such proceedings or claim and any negotiations for the settlement of any such proceedings or claim.

- 29.3 If the Supplier fails to notify the Procuring Entity within twenty-eight (28) days after receipt of such notice that it intends to conduct any such proceedings or claim, then the Procuring Entity shall be free to conduct the same on its own behalf.
- 29.4 The Procuring Entity shall, at the Supplier's request, afford all available assistance to the Supplier in conducting such proceedings or claim, and shall be reimbursed by the Supplier for all reasonable expenses incurred in so doing.
- 29.5 The Procuring Entity shall indemnify and hold harmless the Supplier and its employees, officers, and Subcontractors from and against any and all suits, actions or administrative proceedings, claims, demands, losses, damages, costs, and expenses of any nature, including attorney's fees and expenses, which the Supplier may suffer as a result of any infringement or alleged infringement of any patent, utility model, registered design, trademark, copyright, or other intellectual property right registered or otherwise existing at the date of the Contract arising out of or in connection with any design, data, drawing, specification, or other documents or materials provided or designed by or on behalf of the Procuring Entity.

30 Limitation of Liability

- 31.1 Except in cases of criminal negligence or willful misconduct, and in the case of infringement pursuant to Clause 29,
 - a) the Supplier shall not be liable to the Procuring Entity, whether in contract, tort, or otherwise, for any indirect or consequential loss or damage, loss of use, loss of production, or loss of profits or interest costs, provided that this exclusion shall not apply to any obligation of the Supplier to pay liquidated damages to the Procuring Entity and
 - b) the aggregate liability of the Supplier to the Procuring Entity, whether under the Contract, in tort or otherwise, shall not exceed the total Contract Price, provided that this limitation shall not apply to the cost of repairing or replacing defective equipment, or to any obligation of the supplier to indemnify the Procuring Entity with respect to patent infringement.

31. Change in Laws and Regulations

31.1 Unless otherwise specified in the Contract, if after the date of 30 days prior to date of Tender submission, any law, regulation, ordinance, order or bylaw having the force of law is enacted, promulgated, abrogated, or changed in the place of Kenya where the Site is located (which shall be deemed to include any change in interpretation or application by the competent authorities) that subsequently affects the Delivery Date and/or the Contract Price, then such Delivery Date and/or Contract Price shall be correspondingly increased or decreased, to the extent that the Supplier has there by been affected in the performance of any of its obligations under the Contract. Notwithstanding the foregoing, such additional or reduced cost shall not be separately paid or credited if the same has already been accounted for in the price adjustment provisions where applicable, in accordance with GCCClause15.

32. Force Majeure

- 32.1 The Supplier shall not be liable for forfeiture of its Performance Security, liquidated damages, or termination for default if and to the extent that it's delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure.
- 32.2 For purposes of this Clause, "Force Majeure" means an event or situation beyond the control of the Supplier that is not foreseeable, is unavoidable, and its origin is not due to negligence or lack of care on the part of the Supplier. Such events may include, but not be limited to, acts of the Procuring Entity in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight embargoes.
- 32.3 If a Force Majeure situation arises, the Supplier shall promptly notify the Procuring Entity in writing of such condition and the cause there of. Unless otherwise directed by the Procuring Entity in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.

33. Change Orders and Contract Amendments

- 33.1 The Procuring Entity may at any time order the Supplier through notice in accordance GCC Clause 8, to make changes within the general scope of the Contract in any one or more of the following:
 - a) drawings, designs, or specifications, where Goods to be furnished under the Contract are to be specifically manufactured for the Procuring Entity;
 - b) the method of shipment or packing;
 - c) the place of delivery; and
 - d) the Related Services to be provided by the Supplier.
- 33.2 If any such change causes an increase or decrease in the cost of, or the time required for, the Supplier's performance of any provisions under the Contract, an equitable adjustment shall be made in the Contract Price or in the Delivery/Completion Schedule, or both, and the Contract shall accordingly be amended. Any claims by the Supplier for adjustment under this Clause must be asserted within twenty-eight (28) days from the date of the Supplier's receipt of the Procuring Entity's change order.
- 33.3 Prices to be charged by the Supplier for any Related Services that might be needed but which were not included in the Contract shall be agreed upon in advance by the parties and shall not exceed the prevailing rates charged to other parties by the Supplier for similar services.
- 33.4 Subject to the above, no variation in or modification of the terms of the Contract shall be made except by written amendment signed by the parties. This includes, if specified **in the SCC**, any variation to the contract resulting from a value engineering proposal agreed between the parties.

34. Extensions of Time

- 34.1 If at any time during performance of the Contract, the Supplier or its sub-contractors should encounter conditions impeding timely delivery of the Goods or completion of Related Services pursuant to GCC Clause 13, the Supplier shall promptly notify the Procuring Entity in writing of the delay, its likely duration, and its cause. As soon as practicable after receipt of the Supplier's notice, the Procuring Entity shall evaluate the situation and may at its discretion extend the Supplier's time for performance, in which case the extension shall be ratified by the parties by amendment of the Contract.
- 34.2 Except in case of Force Majeure, as provided under GCCClause32, a delay by the Supplier in the performance of its Delivery and Completion obligations shall render the Supplier liable to the imposition of liquidated damages pursuant to GCC Clause 27, unless an extension of time is agreed upon, pursuant to GCC Sub-Clause 34.1.

35. Termination

35.1 Termination for Default

- a) The Procuring Entity, without prejudice to any other remedy for breach of Contract, by written notice of default sent to the Supplier, may terminate the Contract in whole or in part:
 - i) if the Supplier fails to deliver any or all of the Goods within the period specified in the Contract, or within any extension thereof granted by the Procuring Entity pursuant to GCCClause34;
 - ii) if the Supplier fails to perform any other obligation under the Contract; or
 - iii) if the Supplier, in the judgment of the Procuring Entity has engaged in Fraud and Corruption, as defined in paragraph 2.2a of the Appendix to the GCC, in competing for or in executing the Contract.
- b) In the event the Procuring Entity terminates the Contract in whole or in part, pursuant to GCC Clause 35.1(a), the Procuring Entity may procure, upon such terms and in such manner as it deems appropriate, Goods or Related Services similar to those undelivered or not per formed, and the Supplier shall be liable to the Procuring Entity for any additional costs for such similar Goods or Related Services. However, the Supplier shall continue performance of the Contract to the extent not terminated.

35.2 Termination for Insolvency.

c) The Procuring Entity may at any time terminate the Contract by giving notice to the Supplier if the Supplier becomes bankrupt or otherwise insolvent. In such event, termination will be without compensation to the supplier, provided that such termination will not prejudice or affect any right of action or remedy that has accrued or will accrue thereafter to the Procuring Entity.

35.3 Termination for Convenience.

- d) The Procuring Entity, by notice sent to the Supplier, may terminate the Contract, in whole or in part, at any time for its convenience. The notice of termination shall specify that termination is for the Procuring Entity's convenience, the extent to which performance of the Supplier under the Contract is terminated, and the date upon which such termination becomes effective.
- e) The Goods that are complete and ready for shipment within twenty-eight (28) days after the Supplier's receipt of notice of termination shall be accepted by the Procuring Entity at the Contract terms and prices. For the remaining Goods, the Procuring Entity may elect:
 - i) To have any portion completed and delivered at the Contract terms and prices; and/or
 - ii) to cancel the remainder and pay to the Supplier an agreed amount for partially completed Goods and Related Services and for materials and parts previously procured by the Supplier.

36. Assignment

36.1 Neither the Procuring Entity nor the Supplier shall assign, in whole or in part, their obligations under this Contract, except with prior written consent of the other party.

37. Export Restriction

Notwithstanding any obligation under the Contract to complete all export formalities, any export restrictions attributable to the Procuring Entity, to Kenya or to the use of the products/goods, systems or services to be supplied, which arise from trade regulations from a country supplying those products/goods, systems or services, and which substantially impede the Supplier from meeting its obligations under the Contract, shall release the Supplier from the obligation to provide deliveries or services, always provided, however, that the Supplier can demonstrate to the satisfaction of the Procuring Entity that it has completed all formalities in a timely manner, including applying for permits, authorizations and licenses necessary for the export of the products/goods, systems or services under the terms of the Contract. Termination of the Contract on this basis shall be for the Procuring Entity's convenience pursuant to Sub-Clause35.3.

APPENDIX TO GENERAL CONDITIONS

Section IX-Special Conditions of Contract The following Special Conditions of Contract (SCC) shall supplement and/ or amend the General Conditions of Contract (GCC). Whenever there is a conflict, the provisions here in shall prevail over those in the GCC.

[The Procuring Entity shall select insert the appropriate wording using the samples below or other acceptable wording, and delete the text in italics]

| Number of GC Clause | Amendments of, and Supplements to, Clauses in the General Conditions of Contract | | | | | | |
|------------------------|---|--|--|--|--|--|--|
| GCC 1.1(i) | The Procuring Entity is: [Insert complete legal name of the Procuring Entity] | | | | | | |
| GCC 1.1 (n) | The Project Site(s)/Final Destination(s) is/are: [Insert name(s) and detailed information on the location(s) of the site(s)] | | | | | | |
| GCC 4.2 (a) | The meaning of the trade terms shall be as prescribed by Incoterms. If the meaning of any trade term and the rights and obligations of the parties thereunder shall not be as prescribed by Incoterms, they shall be as prescribed by: [exceptional; refer to other internationally accepted trade terms] | | | | | | |
| GCC 4.2 (b) | The version edition of Incoterms shall be [insert date of current edition] | | | | | | |
| GCC 5.1 | The language shall be: [insert the name of the language] | | | | | | |
| GCC 8.1 | For <u>notices</u> , the Procuring Entity's address shall be: | | | | | | |
| | Postal address (full postal address) Physical Address (full Location Address- insert city, street name, Building name floor number, room number) Telephone: [include telephone number, including country and city codes] Electronic mail address: [insert e-mail address, if applicable] | | | | | | |
| GCC 10.2 | The rules of procedure for arbitration proceedings pursuant to GCC Clause 10.2 shall be as follows: | | | | | | |
| | [The tendering document should contain one clause to be retained in the event of a Contract with a foreign Supplier and one clause to be retained in the event of a Contract with a Supplier who is a national of Kenya. At the time of finalizing the Contract, the respective applicable clause should be retained in the Contract. The following explanatory note should therefore be inserted as a header to GCC 10.2 in the tendering document. | | | | | | |
| | "Clause 10.2 (a) shall be retained in the case of a Contract with a foreign Supplier and clause 10.2 (b) shall be retained in the case of a Contract with a national of Kenya."] | | | | | | |
| | (a) Contract with foreign Supplier: | | | | | | |
| | [For contracts entered into with foreign suppliers, International commercial arbitration may have practical advantages over other dispute settlement methods. Among the rules to govern the arbitration proceedings, the Procuring Entity may wish to consider the United Nations Commission on International Trade Law (UNCIAL) Arbitration Rules of 1976, the Rules of Conciliation and Arbitration of the International Chamber of Commerce (ICC), the Rules of the London Court of International Arbitration or the Rules of Arbitration Institute of the Stockholm Chamber of Commerce.] | | | | | | |
| | If the Procuring Entity chooses the UNCITRAL Arbitration Rules, the following sample clause should be inserted: | | | | | | |
| | GCC 10.2 (a)—Any dispute, controversy or claim arising out of or relating to this Contract, or breach, termination or invalidity thereof, shall be settled by arbitration in accordance with the UNCITRAL Arbitration | | | | | | |

| Number of GC Clause | Amendments of, and Supplements to, Clauses in the General Conditions of Contract | | | | | |
|------------------------|--|--|--|--|--|--|
| | Rules as at present in force. | | | | | |
| | If the Procuring Entity chooses the Rules of ICC, the following sample clause should be inserted: | | | | | |
| | GCC 10.2 (a)—All disputes arising in connection with the prese Contract shall be finally settled under the Rules of Conciliation ar Arbitration of the International Chamber of Commerce by one or mo arbitrators appointed in accordance with said Rules. | | | | | |
| | If the Procuring Entity chooses the Rules of Arbitration Institute of Stockholm Chamber of Commerce, the following sample clause should be inserted: | | | | | |
| | GCC 10.2 (a)—Any dispute, controversy or claim arising out of or in connection with this Contract, or the breach termination or invalidity thereof, shall be settled by arbitration in accordance with the Rules of the Arbitration Institute of the Stockholm Chamber of Commerce. | | | | | |
| | If the Procuring Entity chooses the Rules of the London Court of International Arbitration, the following clause should be inserted: | | | | | |
| | GCC 10.2 (a)—Any dispute arising out of or in connection with this Contract, including any question regarding its existence, validity or termination shall be referred to and finally resolved by arbitration under the Rules of the London Court of International Arbitration, which rules are deemed to be incorporated by reference to this clause. | | | | | |
| | (b) Contracts with Supplier national of Kenya: | | | | | |
| | In the case of a dispute between the Procuring Entity and a Supplier who is a national of Kenya, the dispute shall be referred to adjudication or arbitration in accordance with the laws of Kenya. | | | | | |
| GCC 10.4.2 | The place of arbitration shall be(specify City and Country). | | | | | |
| GCC 13.1 | Sample provision | | | | | |
| | For Goods supplied from abroad: | | | | | |
| | Upon shipment, the Supplier shall notify the Procuring Entity and the insurance company in writing the full details of the shipment including Contract number, description of the Goods, quantity, date and place of shipment, mode of transportation, and estimated date of arrival at place of destination. In the event of Goods sent by airfreight, the Supplier shall notify the Procuring Entity a minimum of forty-eight (48) hours ahead of dispatch, the name of the carrier, the flight number, the expected time of arrival, and the waybill number. The Supplier shall fax and then send by courier the following documents to the Procuring Entity, with a copy to the insurance company: | | | | | |
| | (i) three originals and two copies of the Supplier's invoice, showing Procuring Entity as <i>[enter correct description of Procuring Entity for customs purposes]</i> ; the Contract number, Goods description, quantity, unit price, and total amount. Invoices must be signed in original, stamped, or sealed with the company stamp/seal; | | | | | |
| | (ii) one original and two copies of the negotiable, clean, on-board through bill of lading marked "freight prepaid" and showing Procuring Entity as [enter correct name of Procuring Entity for customs purposes] and Notify Party as stated in the Contract, with delivery through to final destination as per the Schedule of Requirements and two copies of non-negotiable bill of lading, or three copies of railway consignment note, road consignment note, truck or air waybill, or multimodal transport document, marked "freight prepaid" and showing delivery through to final destination as per the Schedule of Requirements; | | | | | |

| Number of GC Clause | Amendments of, and Supplements to, Clauses in the General Conditions of Contract | | | | |
|------------------------|---|--|--|--|--|
| | (iii) four copies of the packing list identifying contents of each package; | | | | |
| | (iv) copy of the Insurance Certificate, showing the Procuring Entity as the beneficiary; | | | | |
| | (v) one original of the manufacturer's or Supplier's Warranty Certificate covering all items supplied; | | | | |
| | (vi) one original of the Supplier's Certificate of Origin covering all items supplied; | | | | |
| | (vii) original copy of the Certificate of Inspection furnished to Supplier by the nominated inspection agency and six copies (where inspection is required); | | | | |
| | (viii) any other procurement-specific documents required for delivery/paymen purposes. | | | | |
| | For Goods from within Kenya: | | | | |
| | Upon or before delivery of the Goods, the Supplier shall notify the Procuring Entity in writing and deliver the following documents to the Procuring Entity: | | | | |
| | two originals and two copies of the Supplier's invoice, showing Procuring Entity, the Contract number, Goods' description, quantity, uni price, and total amount. Invoices must be signed in original and stamped or sealed with the company stamp/seal; | | | | |
| | (ii) two copies of delivery note, railway consignment notes, road consignment note, truck or air waybill, or multimodal transport documen showing Procuring Entity as [enter correct name of Procuring Entity for customs purposes] and delivery through to final destination as stated in the Contract; | | | | |
| | (iii) copy of the Insurance Certificate, showing the Procuring Entity as the beneficiary; | | | | |
| | (iv) four copies of the packing list identifying contents of each package; | | | | |
| | (v) one original of the manufacturer's or Supplier's Warranty certificate covering all items supplied; | | | | |
| | (vi) one original of the Supplier's Certificate of Origin covering all items supplied; | | | | |
| | (vii) original copy of the Certificate of Inspection furnished to Supplier by the nominated inspection agency and six copies (where inspection is required) | | | | |
| | (viii) other procurement-specific documents required for delivery/paymen purposes. | | | | |
| | The above documents shall be received by the Procuring Entity before arrival of the Goods and, if not received, the Supplier will be responsible for an consequent expenses. | | | | |
| GCC 15.1 | The prices charged for the Goods supplied and the related Services performed [inser "shall" or "shall not," as appropriate] be adjustable. | | | | |
| | If prices are adjustable, the following method shall be used to calculate the price adjustment [see attachment to these SCC for a sample Price Adjustment Formula] | | | | |
| GCC 16.1 | Sample provision | | | | |
| | GCC 16.1—The method and conditions of payment to be made to the Supplier under this Contract shall be as follows: | | | | |
| | | | | | |

| Number of GC Clause | , | | | | |
|------------------------|--|--|--|--|--|
| | Payment for Goods supplied from abroad: | | | | |
| | Payment of foreign currency portion shall be made in () [currency of the Contract Price] in the following manner: (i) Advance Payment: Ten (10) percent of the Contract Price shall be paid within thirty (30) days of signing of the Contract, and upon submission of claim and a bank guarantee for equivalent amount valid until the Goods are delivered and in the form provided in the tendering document or another form acceptable to the Procuring Entity. | | | | |
| | | | | | |
| | (ii) On Shipment: Eighty (80) percent of the Contract Price of the Goods shipped shall be paid through irrevocable confirmed Form of credit opened in favor of the Supplier in a bank in its country, upon submission of documents specified in GCC Clause 12. | | | | |
| | (iii) On Acceptance: Ten (10) percent of the Contract Price of Goods received shall be paid within thirty (30) days of receipt of the Goods upon submission of claim supported by the acceptance certificate issued by the Procuring Entity. | | | | |
| | Payment of local currency portion shall be made in | | | | |
| | thin thirty (30) days of presentation of claim supported by a certificate from the Procuring Entity declaring that the Goods have been delivered and that all other contracted Services have been performed. | | | | |
| | Payment for Goods and Services supplied from within Kenya: | | | | |
| | Payment for Goods and Services supplied from within Kenya shall be made in[currency], as follows: | | | | |
| | (i) Advance Payment: Ten (10) percent of the Contract Price shall be paid within thirty (30) days of signing of the Contract against a simple receipt and a bank guarantee for the equivalent amount and in the form provided in the tendering document or another form acceptable to the Procuring Entity. | | | | |
| | (ii) On Delivery: Eighty (80) percent of the Contract Price shall be paid on receipt of the Goods and upon submission of the documents specified in GCC Clause 13. | | | | |
| | (iii) On Acceptance: The remaining ten (10) percent of the Contract Price shall be paid to the Supplier within thirty (30) days after the date of the acceptance certificate for the respective delivery issued by the Procuring Entity. | | | | |
| GCC 16.5 | The payment-delay period after which the Procuring Entity shall pay interest to the supplier shall be [insert number] days. | | | | |
| | The interest rate that shall be applied is [insert number] % | | | | |
| GCC 18.1 | A Performance Security [insert "shall" or "shall not" be required] | | | | |
| | [If a Performance Security is required, insert "the amount of the Performance Security shall be: [insert amount] | | | | |
| | [The amount of the Performance Security is usually expressed as a percentage of the Contract Price. The percentage varies according to the Procuring Entity's perceived risk and impact of non-performance by the Supplier. A 10% percentage is used under normal circumstances] | | | | |

| Number of GC Clause | Amendments of, and Supplements to, Clauses in the General Conditions of Contract | | | |
|------------------------|--|--|--|--|
| GCC 18.3 | If required, the Performance Security shall be in the form of: [insert "a Demand Guarantee" or "a Performance Bond"] | | | |
| | If required, the Performance security shall be denominated in [insert "a freel convertible currency acceptable to the Procuring Entity" or "the currencies of payment of the Contract, in accordance with their portions of the Contract Price"] | | | |
| GCC 18.4 | Discharge of the Performance Security shall take place: [insert date if different from the one indicated in sub clause GCC 18.4] | | | |
| GCC19.1 | The registration and other certification necessary to prove registration in Kenya is [insert: details of registration and other certification necessary to prove registration in Kenya.] | | | |
| GCC19.2 | The Effective Date of the Contract is [insert: date of Contract signing if EITHER: (i) the Goods have already been registered at the time of Contracting signing OR (ii) registration of the Goods is not a requirement under the Applicable Law. Otherwise, delete and insert "NOT USED."] | | | |
| GCC19.3 | The time period shall be [insert: a number greater than 30] days. [If not used, delete and insert "NOT USED."] | | | |
| GCC 23.2 | The packing, marking and documentation within and outside the packages shall be: [insert in detail the type of packing required, the markings in the packing and all documentation required] | | | |
| GCC 24.1 | he insurance coverage shall be as specified in the Incoterms. | | | |
| | If not in accordance with Incoterms, insurance shall be as follows: | | | |
| | [insert specific insurance provisions agreed upon, including coverage, currency and amount] | | | |
| GCC 25.1 | Responsibility for transportation of the Goods shall be as specified in the Incoterms. | | | |
| | If not in accordance with Incoterms, responsibility for transportations shall be as follows: [insert "The Supplier is required under the Contract to transport the Goods to a specified place of final destination within Kenya, defined as the Project Site, transport to such place of destination in Kenya, including insurance and storage, as shall be specified in the Contract, shall be arranged by the Supplier, and related costs shall be included in the Contract Price"; or any other agreed upon trade terms (specify the respective responsibilities of the Procuring Entity and the Supplier)] | | | |
| GCC 25.2 | Incidental services to be provided are: | | | |
| | [Selected services covered under GCC Clause 25.2 and/or other should be specified with the desired features. The price quoted in the Tender price or agreed with the selected Supplier shall be included in the Contract Price.] | | | |
| GCC 26.1 | The inspections and tests shall be: [insert nature, frequency, procedures for carrying out the inspections and tests] | | | |
| GCC 26.2 | The Inspections and tests shall be conducted at: [insert name(s) of location(s)] | | | |
| GCC 27.1 | The liquidated damage shall be: [insert number] % per week | | | |
| GCC 27.1 | The maximum amount of liquidated damages shall be: [insert number] % | | | |
| GCC 28.1 | [Insert any alternative warranty requirements or indicate: "No changes to GCC 28.1"] | | | |
| GCC 28.4 | The period for replacement shall be: [insert number] days. | | | |
| | | | | |

| Number of GC Clause | Amendments of, and Supplements to, Clauses in the General Conditions of Contract | | | | |
|------------------------|---|--|--|--|--|
| GCC 33.4 | [Value engineering may be included if it has been specified] | | | | |
| | Value Engineering: | | | | |
| | The Supplier may, at any time, submit to the Procuring Entity a written value engineering proposal that seeks to yield any benefits to the Procuring Entity, without sacrificing the necessary functions or quality of the Goods or Related Services. | | | | |
| | The value engineering proposal shall be prepared at the cost of the Supplier. If the value engineering proposal is approved by the Procuring Entity and results in a reduction of the Contract Price, the amount to be paid to the Supplier shall be a percentage [insert appropriate percentage. The percentage is normally up to 50%] of the amount of the reduction in the Contract Price. | | | | |

.

Special Conditions of Contract

PHARMACEUTICALS

(Additional Clauses)

The below data should be included in the Special Conditions of Contract used in tendering document for the procurement of pharmaceuticals.

| GCC 13.1 | For Goods supplied from abroad: |
|----------|---|
| | (ix) One original of the Certificate of Pharmaceutical Product as recommended by the WHO for each of the items supplied. |
| | (x) Certificate of quality control test results in conformity with the World Health Organization "Certification Scheme on the Quality of Pharmaceutical Products Moving in International Trade" stating quantitative assays, chemical analysis, sterility, pyrogen content, uniformity, microbial limit, and other tests as appropriate to the Goods. |
| | (xi) Original copy of the certificate of weight issued by the port authority/licensed authority and six copies. |

Special Conditions of Contract

VACCINES

(Additional Clauses)

| The below data si | hould be included in the Special Conditions of Contract for the procurement of vaccines. | | | |
|-------------------|---|--|--|--|
| GCC 13.1 | For Goods supplied from abroad: | | | |
| | (ix) one copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped. | | | |
| | (x) Certificate of quality control test results in conformity with the World Health Organization "Certification Scheme on the Quality of Pharmaceutical Products Moving in International Trade" stating quantitative assays, chemical analysis, sterility, pyrogen content, uniformity, microbial limit, and other tests as appropriate to the Goods. | | | |
| | (xi) Original copy of the certificate of weight issued by the port authority/licensed authority and six copies. | | | |
| | For Goods from within Kenya: | | | |
| | (x) one copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped. | | | |
| GCC 28.1 | [Sample clauses] | | | |
| | The Procuring Entity reserves the right to request evidence of bio-availability and/or bio-equivalence data and/or evidence of the basis for expiration dating and other stability data concerning the Goods to verify shelf life claimed for the Goods. | | | |
| | If an adverse event following immunization (AEFI) occurs in Kenya and the cause of such | | | |

event cannot be immediately established, the Procuring Entity will, with all urgency and in accordance with the procedures laid down by the NCA of Kenya, take steps to advise the Supplier in order that an investigation may be launched immediately. If the vaccine has been supplied through an agency of the United Nations, the most current procedures laid down by the WHO for such situations will be used.

Special Conditions of Contract

CONDOMS

| The below data should be included in the Special Conditions of Contract for the procurement of condoms. | | | | | | |
|---|--|--|--|--|--|--|
| GCC 13.1 | For Goods supplied from abroad: | | | | | |
| | (ix) original copy of quality control tests for each consignment as stated in SCC 26 hereafter. | | | | | |
| | (x) original copy of the certificate of inspection furnished to Supplier by nominated inspection agency and six copies [where separate inspection is required]. | | | | | |
| | For Goods from within Kenya: | | | | | |
| | (ix) certificate of in-house analysis. | | | | | |
| GCC 26.4 | (d) The Supplier shall test batches of Goods ready for shipment in accordance with the WHO specification. The size of the sample for testing will be calculated by reference to ISO2859-1. With each consignment, the Supplier must provide a certificate of quality control test results in conformity with the standards laid down in ISO 2859-1 and in accordance with the general sampling levels appropriate to each feature as necessary. The Supplier will bear the cost of such tests. | | | | | |

Attachment: Price Adjustment Formula

If in accordance with GCC 15.1, prices shall be adjustable, the following method shall be used to calculate the price adjustment:

- 15.1 Prices payable to the Supplier, as stated in the Contract, shall be subject to adjustment during performance of the Contract to reflect changes in the cost of labor and material components in accordance with the formula:
 - a) No price adjustment shall be payable on the portion of the Contract Price paid to the Supplier as advance payment.

SECTION X - CONTRACT FORMS

This Section contains forms which, once completed, will form part of the Contract. The forms for Performance Security and Advance Payment Security, when required, shall only be completed by the successful Tenderer after Contract award.

Table of Forms

Notification of Intention to Award

Request for Review

Letter of Award

Contract Agreement

Performance Security

Advance Payment Security

Beneficial Ownership Disclosure Form

1. NOTIFICATION OF INTENTION TO AWARD

| [This Notification of Intention to Award shall be sent to each Tenderer that submitted a Tender.] |
|--|
| [Send this Notification to the Tenderer's Authorized Representative named in the Tenderer Information Form] |
| For the attention of Tenderer's Authorized Representative Name:[insert Authorized |
| Representative's name] |
| Address:[insert Authorized Representative's Address] Telephone/Fax |
| numbers:[insert Authorized Representative's telephone/fax numbers] |
| Email Address:[insert Authorized Representative's email address] |
| [IMPORTANT: insert the date that this Notification is transmitted to Tenderers. The Notification must be sent to all Tenderers simultaneously. This means on the same date and as close to the same time as possible.] |
| DATE OF TRANSMISSION : This Notification is sent by:[email/fax] on [date] (local time) |
| Notification of Intention to Award Procuring Entity:[insert the name of the Procuring Entity] |
| Contract title:[insert the name of the contract] |
| ITT No:[insert ITT reference number from Procurement Plan] |

This Notification of Intention to Award (Notification) notifies you of our decision to award the above contract. The transmission of this Notification begins the Standstill Period. During the Standstill Period you may:

- a) Request a debriefing in relation to the evaluation of your Tender, and/or
- b) Submit a Procurement-related Complaint in relation to the decision to award the contract.

1) The successful Tenderer

| Name: | [insert name of successful Tenderer] | | |
|--|--|--|--|
| Address: [insert address of the successful Tenderer] | | | |
| Contract price: | [insert contract price of the successful Tender] | | |

2) **Other Tenderers [INSTRUCTIONS:** insert names of all Tenderers that submitted a Tender. If the Tender's price was evaluated include the evaluated price as well as the Tender price as readout.]

| Name of Tenderer | Tender price | Evaluated Tender price (if applicable) |
|------------------|-----------------------|--|
| [insert name] | [insert Tender price] | [insert evaluated price] |
| [insert name] | [insert Tender price] | [insert evaluated price] |
| [insert name] | [insert Tender price] | [insert evaluated price] |
| [insert name] | [insert Tender price] | [insert evaluated price] |
| [insert name] | [insert Tender price] | [insert evaluated price] |

3) Reason/s why your Tender was unsuccessful

[INSTRUCTIONS: State the reason/s why this Tenderer's Tender was unsuccessful. Do NOT include: (a) a point by point comparison with another Tenderer's Tender or (b) information that is marked confidential by the Tenderer in its Tender.]

4) How to request a debriefing

DEADLINE: The deadline to request a debriefing expires at midnight on [insert date] (local time).

You may request a debriefing in relation to the results of the evaluation of your Tender. If you decide to request a debriefing your written request must be made within three (3) Business Days of receipt of this Notification of Intention to Award.

Provide the contract name, reference number, name of the Tenderer, contact details; and address the Invitation to debriefing as follows:

Attention:[insert full name of person, if

applicable | Title | position: [insert

title/position] Agency: [insert name of Procuring

Entity | Email address: [insert email

address] Fax number:[insert fax number]delete if

not used

If your Invitation to a debriefing is received within the 3 Business Days deadline, we will provide the debriefing within five (5) Business Days of receipt of your request. If we are un able to provide the debriefing within this period, the Standstill Period shall be extended by five (5) Business Days after the date that the debriefing is provided. If this happens, we will notify you and confirm the date that the extended Standstill Period will end.

The debriefing may be in writing, by phone, video conference call or in person. We shall promptly advise you in writing how the debriefing will take place and confirm the date and time.

If the deadline to request a debriefing has expired, you may still request a de briefing. In this case, we will provide the debriefing as soon as practicable, and normally no later than fifteen (15) Business Days from the date of publication of the Contract Award Notice.

5) How to make a complaint

Period: Procurement-related Complaint challenging the decision to award shall be submitted by midnight, [insert date] (local time).

Provide the contract name, reference number, name of the Tenderer, contact details; and address the Procurement-related Complaint as follows:

Attention:[insert full name of person, if applicable] Title/position: [insert title/position] Agency: [insert name of Procuring Entity] Email address: [insert email address] Fax number:[insert fax number]delete if not used

At this point in the procurement process, you may submit a Procurement-related Complaint challenging the decision to award the contract. You do not need to have requested, or received, a debriefing before making this complaint. Your complaint must be submitted within the Standstill Period and received by us before the Standstill Period ends.

Further information:

Further information: For more information refer to the Public Procurement and Disposals Act 2015 and its Regulations available from the Website info@ppra.go.ke or complaints@ppra.go.ke provides a useful explanation of the process, as well as a sample Form of complaint.

In summary, there are four essential requirements:

- 1. You must be an 'interested party'. In this case, that means a Tenderer who submit ted a Tender in this tendering process, and is the recipient of a Notification of Intention to Award.
- 2 The complaint can only challenge the decision to award the contract.
- 3. You must submit the complaint with in the period stated above.
- 4. You must include, in your complaint, all of the information required by the Procurement Regulations (as described in Annex III).

6) Standstill Period

DEADLINE: The Standstill Period is due to end at midnight on [insert date] (local time).

The Stand still Period lasts ten (10) Business Days after the date of transmission of this Notification of Intention to Award. The Standstill Period may be extended as stated in Section 4 above.

If you have any questions regarding this Notification please do not hesitate to contact us.

On behalf of the Procuring Entity:

| Signature: | | |
|-----------------|--|------|
| Namas | | |
| Title/position: | | |
| Telephone: | | |
| Email: | | |

2. REQUEST FOR REVIEW

FORM FOR REVIEW(r.203(1))

| PUBLIC PROCUREMENT ADMINISTRATIVE REVIEW BOARD |
|---|
| APPLICATION NOOF20 |
| BETWEEN |
| APPLICANT |
| AND |
| RESPONDENT (Procuring Entity) |
| Request for review of the decision of the |
| REQUEST FOR REVIEW |
| I/We |
| 1. |
| 2. |
| By this memorandum, the Applicant requests the Board for an order/orders that: |
| 1. |
| 2. |
| SIGNED(Applicant) Dated onday of/20 |
| FOR OFFICIAL USE ONLY Lodged with the Secretary Public Procurement Administrative Review Board onday of20 |
| SIGNED |

Board Secretary

3. LETTER OF AWARD

Attachment: Contract Agreement

| [letterhead paper of the Procuring Entity] [date] To:[name and address of the Supplier] |
|--|
| Subject: Notification of Award Contract No |
| This is to notify you that your Tender dated |
| You are requested to furnish the Performance Security within 30days in accordance with the Conditions of Contract, using for that purpose the of the Performance Security Form included in Section X, Contract Forms, of the tendering document. |
| Authorized Signature: |
| Name and Title of |
| Signatory: Name of |
| Agency: |
| |

4. CONTRACTAGREEMENT

[The successful Tenderer shall fill in this form in accordance with the instructions indicated]

THIS AGREEMENT made the [insert: number] day of [insert: month], [insert: year].

BETWEEN

- 1) [insert complete name of Procuring Entity], a [insert description of type of legal entity, for example, an agency of the Ministry of... of the Government of Kenya, or corporation in Kenya and having its principal place of business at [insert address of Procuring Entity] (hereinafter called "the Procuring Entity"), of the one part, and
- 2) [insert name of Supplier], a corporation incorporated under the laws of [insert: country of Supplier] and having its principal place of business at [insert: address of Supplier] (herein after called "the Supplier"), of the other part:

WHEREAS the Procuring Entity invited Tenders for certain Goods and ancillary services, viz., [insert brief description of Goods and Services] and has accepted a Tender by the Supplier for the supply of those Goods and Services.

The Procuring Entity and the Supplier agree as follows:

- 1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to the min the Contract documents referred to.
- 2 The following documents shall be deemed to form and be read and construed as part of this Agreement. This Agreement shall prevail overall other contract documents.
 - a) The Form of Acceptance
 - b) The Form of Tender
 - c) the Addenda Nos. (if any)
 - d) Special Conditions of Contract
 - e) General Conditions of Contract
 - f) The Specification (including Schedule of Requirements and Technical Specifications)
 - g) the completed Schedules (including Price Schedules)
 - h) any other document listed in GCC as forming part of the Contract
- 3. In consideration of the payments to be made by the Procuring Entity to the Supplier as specified in this Agreement, the Supplier hereby covenants with the Procuring Entity to provide the Goods and Services and to remedy defects therein conformity in all respects with the provisions of the Contract.
- 4. The Procuring Entity here by covenants to pay the Supplier in consideration of the provision of the Goods and Services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with the laws of *Kenya* on the day, month and year indicated

above. For and on behalf of the Procuring Entity

Signed: _____ [insert signature] in the capacity of [insert title or other appropriate designation] in the presence of [insert identification of official witness] For and on behalf of the Supplier

Signed: [insert signature of authorized representative(s) of the Supplier] in the capacity of [insert title or other appropriate designation] in the presence of [insert identification of official witness]

5. PERFORMANCE SECURITY

product.

| Bank Guarantee [The bank, as requested by the successful Tenderer, shall fill in this form in accordance with |
|--|
| the instructions indicated] [Guarantor letterhead or SWIFT identifier code] Beneficiary: |
| [insert name and Address of Procuring Entity] |
| Date:[Insert date of issue] |
| PERFORMANCE GUARANTEE No.:[Insert guarantee reference number] |
| Guarantor:[Insert name and address of place of issue, unless indicated in the letterhead] |
| We have been informed that |
| Furthermore, we understand that, according to the conditions of the Contract, a performance guarantee is required. |
| At the request of the Applicant, we as Guarantor, hereby irrevocably undertake to pay the Beneficiary any sum or sums not exceeding in total amount of |
| This guarantee shall expire, no later than the |
| This guarantee is subject to the Uniform Rules for Demand Guarantees (URDG) 2010 Revision, ICC Publication No.758, except that the supporting statement under Article 15(a) is here by excluded. |
| [Signature] |
| Note: All italicized text (including foot notes) is for use in preparing this form and shall be deleted from the final |

 $^{^1} The Guarant or shall insert an amount representing the percentage of the Accepted Contract Amount specified in the Form of Acceptance, and denominated either in the currency (ies) of the Contract or a freely convertible currency acceptable to the Beneficiary.$

²Insert the date twenty-eight days after the expected completion date as described in GC Clause 18.4. The Procuring Entity should note that in the event of an extension of this date for completion of the Contract, the ProcuringEntitywouldneedtorequestanextensionofthisguaranteefromtheGuarantor.Suchrequest must be in writing and must be made prior to the expiration date established in the guarantee. In preparing this guarantee, the Procuring Entity might consider adding the following text to the form, at the endofthepenultimateparagraph: "TheGuarantoragreestoaone-timeextensionofthisguaranteeforaperiodnotto exceed[sixmonths][oneyear], in response to the Beneficiary's written Invitation to such extension, such request to be presented to the Guarantor before the expiry of the guarantee."

6. ADVANCE PAYMENT SECURITY

| [Guar | antor letter head or SWI | FT identifier cod | e] | | | | |
|--|--|---|--|---|---|-------------------------------|------------------------------------|
| Benef | iciary: | [In | sert name and | Address of Procu | ring Entity] | | |
| Date:. | | [Insert da | te of issue] | | | | |
| ADV | ANCE PAYMENT | GUARANTEE | No.: | [Insert | guarantee | reference | number] |
| Guara | ntor:[Inser | t name and addre | ess of place of i | ssue, unless indic | ated in the let | tter head] | |
| namewith 1 | of the joint venture insert reference the Beneficiary, for the Goods and related Serv | e] (here in afterneence number of execution of | ter called "tl | ne Applicant") nated[insert name of | has entered | into Con[ir | tract No. isert date] |
| | ermore, we understand t t amount in figures] () [in | | | | | | |
| in wo | e request of the Applican not exceeding in total an rds] upon receipt by us er in the demand itself of that the Applicant: | amount of of the Beneficia | [insert of ary's complying | <i>amount in figures</i> g demand suppor | (ted by the B |) [inse eneficiary's | ert amount statement, |
| a) | Has used the advance pa | yment for purpos | es other than to | oward delivery of | Goods; or | | |
| | has failed to repay the ac which the Applicant has | | n accordance w | ith the Contract c | conditions, spe | ecifying the | amount |
| Benef | nand under this guaranted iciary's bank stating that nt number | t the advance pa | yment referred | to above has be | en credited to | o the Applic | cant on its |
| repaid preser certific (90) p day] o | naximum amount of this l by the Applicant as someted to us. This guarant cate indicating that ninety percent of the Accepted day of | specified in copiee shall expire, y Contract Amount [insert month], 2 | es of interim at the latest, u t, has been cer [insert year], | statements or pa ipon our receipt tified for paymen whichever is ear | ayment certification of a copy of t, or on the lier. Consequent | icates which f the interin | n shall be n payment [insert |
| [Signa | nture] | | | | | | |

Note: All italicized text (including foot notes) is for use in preparing this form and shall be deleted from the final product.

 $[\]overline{}$ The Guarantor shall insert an amount representing the amount of the advance payment and denominated either in the currency (ies) of the advance payment as specified in the Contract, or in a freely convertible currency acceptable to the Procuring Entity.

7. BENEFICIAL OWNERSHIP DISCLOSURE FORM (Amended and issued pursuant to PPRA CIRCULAR No. 02/2022)

INSTRUCTIONS TO TENDERERS: DELETE THIS BOX ONCE YOU HAVE COMPLETED THE FORM

This Beneficial Ownership Disclosure Form ("Form") is to be completed by the successful tenderer pursuant to Regulation 13 (2A) and 13 (6) of the Companies (Beneficial Ownership Information) Regulations, 2020. In case of joint venture, the tenderer must submit a separate Form for each member. The beneficial ownership information to be submitted in this Form shall be current as of the date of its submission.

For the purposes of this Form, a Beneficial Owner of a Tenderer is any natural person who ultimately owns or controls the legal person (tenderer) or arrangements or a natural person on whose behalf a transaction is conducted, and includes those persons who exercise ultimate effective control over a legal person (Tenderer) or arrangement.

| Tender Reference No.: | | _[insert identification |
|---|--------------------------------------|---|
| no] Name of the Tender Title/Descripti | on: | _[insert name of the |
| assignment] to: | [insert complete name of Procuring E | Entity] |
| In response to the requirement in your additional information on beneficial ow options that are not applicable] | | date of notification of award] to furnish one option as applicable and delete the |

I) We here by provide the following beneficial ownership information.

Details of beneficial ownership

| | Details of all Beneficial Owners | % of shares a person holds in the company Directly or indirectly | % of voting rights a person holds in the company | Whether a person directly or indirectly holds a right to appoint or remove a member of the board of directors of the company or an equivalent governing body of the Tenderer (Yes / No) | Whether a person directly or indirectly exercises significant influence or control over the Company (tenderer) (Yes / No) |
|----|--|--|--|--|--|
| | Full Name | Directly | Directly | 1. Having the right to appoint a majority of | 1. Exercises significant |
| 1. | National identity card number or Passport number | of shares | rights Indirectly % of voting rights | the board of the directors or an equivalent governing | influence or control over the Company body of the Company (tenderer) |
| | Personal Identification Number (where applicable) | Indirectly % of shares | | body of the Tenderer: YesNo 2. Is this right held directly or indirectly?: | |
| | Nationality | | | | 2. Is this influence |
| | Date of birth [dd/mm/yyyy] | | | Direct | or control exercised directly or |
| | Postal address | | | Indirect | indirectly? |
| | Residential address | | | • | Direct |
| | Telephone number | | | | - 4 |
| | Email address | | | | Indirect |
| | Occupation or profession | | | | |

| | Details of all Beneficial Owners | % of shares a person holds in the company Directly or indirectly | % of voting rights a person holds in the company | Whether a person directly or indirectly holds a right to appoint or remove a member of the board of directors of the company or an equivalent governing body of the Tenderer (Yes / No) | Whether a person directly or indirectly exercises significant influence or control over the Company (tenderer) (Yes / No) |
|-----------|--|---|--|--|--|
| 2. | Full Name National identity card number or Passport number Personal Identification Number (where applicable) Nationality(ies) Date of birth [dd/mm/yyyy] Postal address Residential address Telephone number Email address Occupation or profession | Directly % of shares Indirectly % of shares | Directly % of voting rights Indirectly % of voting rights | 1. Having the right to appoint a majority of the board of the directors or an equivalent governing body of the Tenderer: YesNo 2. Is this right held directly or indirectly?: Direct | 1. Exercises significant influence or control over the Company body of the Company (tenderer) YesNo 2. Is this influence or control exercised directly or indirectly? Direct |
| 3. e.t | | | | | |

- II) Am fully aware that beneficial ownership information above shall be reported to the Public Procurement Regulatory Authority together with other details in relation to contract awards and shall be maintained in the Government Portal, published and made publicly available pursuant to Regulation 13(5) of the Companies (Beneficial Ownership Information) Regulations, 2020.(Notwithstanding this paragraph Personally Identifiable Information in line with the Data Protection Act shall not be published or made public). Note that Personally Identifiable Information (PII) is defined as any information that can be used to distinguish one person from another and can be used to deanonymize previously anonymous data. This information includes National identity card number or Passport number, Personal Identification Number, Date of birth, Residential address, email address and Telephone number.
- III) In determining who meets the threshold of who a beneficial owner is, the Tenderer must consider a natural person who in relation to the company:
 - (a) holds at least ten percent of the issued shares in the company either directly or indirectly;
 - (b) exercises at least ten percent of the voting rights in the company either directly or indirectly;
 - (c) holds a right, directly or indirectly, to appoint or remove a director of the company; or
 - (d) exercises significant influence or control, directly or indirectly, over the company.
- IV) What is stated to herein above is true to the best of my knowledge, information and belief.

| Name of the Tenderer: | *[insert | complete name | of the | Tenderer] | |
|-----------------------|----------|---------------|--------|-----------|--|
| 0 | | • | | | |

| Name of the person duly authorized to sign the Tender on behalf of the Tenderer: ** [insert complete name of |
|--|
| person duly authorized to sign the Tender] |
| Designation of the person signing the Tender: [insert complete title of the person signing the |
| Tender] |
| Signature of the person named above: |
| shown above] |
| Date this |

Bidder Official Stamp